PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
17392131-5	2007	Corosolic acid suppressed the differentiation of 3T3-L1 pre-adipocytes and down-regulated the expression of PPAR-gamma and C/EBP-alpha mRNA (p<0.01, vs control group).	corosolic acid	0-14	CCAAT enhancer binding protein alpha	Homo sapiens	123-134
17148654-8	2007	In 5-aza-2"-deoxycytosine/trichostatin-treated NCI-H441 cells, overexpression of C/EBPdelta, a lung-enriched C/EBP, led to additional increases in CYP2A13 expression, whereas C/EBPdelta knockdown by small interference RNA suppressed CYP2A13 expression, findings that confirm a role for C/EBP in CYP2A13 regulation.	5-aza-2"-deoxycytosine	3-25	CCAAT enhancer binding protein alpha	Homo sapiens	81-86
17148654-8	2007	In 5-aza-2"-deoxycytosine/trichostatin-treated NCI-H441 cells, overexpression of C/EBPdelta, a lung-enriched C/EBP, led to additional increases in CYP2A13 expression, whereas C/EBPdelta knockdown by small interference RNA suppressed CYP2A13 expression, findings that confirm a role for C/EBP in CYP2A13 regulation.	5-aza-2"-deoxycytosine	3-25	CCAAT enhancer binding protein alpha	Homo sapiens	109-114
17148654-8	2007	In 5-aza-2"-deoxycytosine/trichostatin-treated NCI-H441 cells, overexpression of C/EBPdelta, a lung-enriched C/EBP, led to additional increases in CYP2A13 expression, whereas C/EBPdelta knockdown by small interference RNA suppressed CYP2A13 expression, findings that confirm a role for C/EBP in CYP2A13 regulation.	trichostatin A	26-38	CCAAT enhancer binding protein alpha	Homo sapiens	81-86
17148654-8	2007	In 5-aza-2"-deoxycytosine/trichostatin-treated NCI-H441 cells, overexpression of C/EBPdelta, a lung-enriched C/EBP, led to additional increases in CYP2A13 expression, whereas C/EBPdelta knockdown by small interference RNA suppressed CYP2A13 expression, findings that confirm a role for C/EBP in CYP2A13 regulation.	trichostatin A	26-38	CCAAT enhancer binding protein alpha	Homo sapiens	109-114
17392131-6	2007	Corosolic acid promotes the 3H-glucose uptaking, suppresses the differentiation and downregulates the expression of PPAR-gamma and C/EBP-alpha mRNA in 3T3-L1 adipocytes.	corosolic acid	0-14	CCAAT enhancer binding protein alpha	Homo sapiens	131-142
16888802-4	2007	Instead, we find that PGF2alpha inhibits adipocyte differentiation via a calcineurin-dependent mechanism that acts to prevent the expression of the critical pro-adipogenic transcription factors PPARgamma and C/EBPalpha.	Dinoprost	22-31	CCAAT enhancer binding protein alpha	Homo sapiens	208-218
17982260-5	2007	Treatment of skeletal muscle cells with an inhibitor of connexin function, 18alpha-glycyrrhetinic acid (AGRA), resulted in a reduction in the number of MyoD-positive cells and complete inhibition of myotube formation, concomitantly with an increase in the number of C/EBPalpha-positive cells.	18alpha-glycyrrhetinic acid	75-102	CCAAT enhancer binding protein alpha	Homo sapiens	266-276
17217039-10	2007	The activation of both pathways of transcriptional regulation by the myeloid lineage-specific transcription factor C/EBPalpha (CCAAT/enhancer-binding protein-alpha), and posttranscriptional regulation by miR-223 appears essential for granulocytic differentiation and clinical response of acute promyelocytic leukemia (APL) blasts to all-trans retinoic acid (ATRA).	Tretinoin	343-356	CCAAT enhancer binding protein alpha	Homo sapiens	115-125
17217039-10	2007	The activation of both pathways of transcriptional regulation by the myeloid lineage-specific transcription factor C/EBPalpha (CCAAT/enhancer-binding protein-alpha), and posttranscriptional regulation by miR-223 appears essential for granulocytic differentiation and clinical response of acute promyelocytic leukemia (APL) blasts to all-trans retinoic acid (ATRA).	Tretinoin	358-362	CCAAT enhancer binding protein alpha	Homo sapiens	115-125
17208590-5	2007	Budesonide completely inhibited C/EBPalpha and beta expression; formoterol increased C/EBPalpha expression (2-fold).	Budesonide	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
17208590-5	2007	Budesonide completely inhibited C/EBPalpha and beta expression; formoterol increased C/EBPalpha expression (2-fold).	Formoterol Fumarate	64-74	CCAAT enhancer binding protein alpha	Homo sapiens	85-95
17208590-12	2007	Budesonide inhibited C/EBPalpha and beta expression, upregulated C/EBPdelta (3.2-fold), and had no effect on C/EBPepsilon.	Budesonide	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	21-31
17208590-13	2007	Formoterol upregulated C/EBPalpha expression (3-fold) but not the other C/EBPs.	Formoterol Fumarate	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	23-33
17208590-16	2007	Budesonide and formoterol modulate C/EBP expression in a drug- and disease-specific pattern.	Budesonide	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	35-40
17208590-16	2007	Budesonide and formoterol modulate C/EBP expression in a drug- and disease-specific pattern.	Formoterol Fumarate	15-25	CCAAT enhancer binding protein alpha	Homo sapiens	35-40
17082780-7	2006	A chromatin immunoprecipitation assay revealed occupancy of the human C/EBPalpha promoter in vivo by Max and Myc under cellular settings and by C/EBPalpha and Max under retinoic acid induced granulocytic differentiation.	Tretinoin	169-182	CCAAT enhancer binding protein alpha	Homo sapiens	70-80
17261502-3	2007	CD33 expression in the Liu01 cell line, a subclone of U266 cells, and in vitamin D3-treated ILKM3 cells, correlated with a monocytoid morphology featuring convoluted nuclei and with increased C/EBPalpha expression.	Cholecalciferol	73-83	CCAAT enhancer binding protein alpha	Homo sapiens	192-202
16971443-7	2006	Purified Zta C171S bound AP-1 sites similar to wild-type Zta, but it was incapable of binding several degenerate Zta sites, including a consensus C/EBP site.	zta	9-12	CCAAT enhancer binding protein alpha	Homo sapiens	146-151
17079688-4	2006	The expression of GATA-2 instructed C/EBPalpha-expressing GMPs to commit exclusively into the eosinophil lineage, while it induced basophil and/or mast cell lineage commitment if C/EBPalpha was suppressed at the GMP stage.	guanosine 5'-monophosphorothioate	58-61	CCAAT enhancer binding protein alpha	Homo sapiens	36-46
16971443-8	2006	Zta truncation mutations reveal that residues N terminal to the B-ZIP (amino acids 156 to 178) confer C/EBP binding capacity to the otherwise AP-1-restricted DNA recognition function.	zta	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	102-107
16918696-7	2006	In contrast, ATRA-induced expression of PU.1, C/EBPalpha, C/EBPbeta and IRF-1 was unaffected.	Tretinoin	13-17	CCAAT enhancer binding protein alpha	Homo sapiens	46-56
16857754-7	2006	Exposing ST-13 adipocytes to A23187 also led to losses of endogenous PPARgamma and C/EBPalpha.	Calcimycin	29-35	CCAAT enhancer binding protein alpha	Homo sapiens	83-93
16740979-0	2006	17 beta-estradiol stimulates resistin gene expression in 3T3-L1 adipocytes via the estrogen receptor, extracellularly regulated kinase, and CCAAT/enhancer binding protein-alpha pathways.	Estradiol	3-17	CCAAT enhancer binding protein alpha	Homo sapiens	140-176
16740979-6	2006	Although E2 was shown to increase activities of the estrogen receptor (ER) and MAPK kinase 1 and the association of nuclear ER alpha and CCAAT/enhancer binding protein-alpha with the resistin gene promoter, signaling was demonstrated to be blocked by pretreatment with either ICI182780 or PD98059.	Fulvestrant	276-285	CCAAT enhancer binding protein alpha	Homo sapiens	137-173
16807249-5	2006	Furthermore, our studies demonstrate that activation of p38 stimulates phosphorylation of CCAAT/enhancer-binding protein alpha (C/EBPalpha) at serine 21 and increases its transactivation activity in the context of PEPCK gene transcription.	Serine	143-149	CCAAT enhancer binding protein alpha	Homo sapiens	90-126
16878996-2	2006	Specifically, the cAMP response element-binding protein (CREB) interacts with the cAMP response element (CRE) DNA site with high affinity, while it binds the CAAT/enhancer-binding protein (CEBP) DNA site with low affinity.	Cyclic AMP	18-22	CCAAT enhancer binding protein alpha	Homo sapiens	158-187
16878996-2	2006	Specifically, the cAMP response element-binding protein (CREB) interacts with the cAMP response element (CRE) DNA site with high affinity, while it binds the CAAT/enhancer-binding protein (CEBP) DNA site with low affinity.	Cyclic AMP	18-22	CCAAT enhancer binding protein alpha	Homo sapiens	189-193
16737972-10	2006	Ethanol down-regulated hepcidin promoter activity and the DNA binding activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha) but not beta.	Ethanol	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	82-118
16737972-10	2006	Ethanol down-regulated hepcidin promoter activity and the DNA binding activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha) but not beta.	Ethanol	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	120-130
16807249-5	2006	Furthermore, our studies demonstrate that activation of p38 stimulates phosphorylation of CCAAT/enhancer-binding protein alpha (C/EBPalpha) at serine 21 and increases its transactivation activity in the context of PEPCK gene transcription.	Serine	143-149	CCAAT enhancer binding protein alpha	Homo sapiens	128-138
16600022-5	2006	RESULTS: C/EBPalpha represses the IGFBP1 thymine-rich insulin response element (TIRE), but mutation of T222 or T226 of C/EBPalpha to non-phosphorylatable alanines has no effect on C/EBPalpha activity in liver cells (towards the TIRE or a consensus C/EBP binding sequence).	Alanine	154-162	CCAAT enhancer binding protein alpha	Homo sapiens	119-129
16737972-11	2006	Interestingly, the antioxidants vitamin E and N-acetylcysteine abolished both the alcohol-mediated down-regulation of C/EBPalpha binding activity and hepcidin expression in the liver and the up-regulation of duodenal divalent metal transporter 1.	Vitamin E	32-41	CCAAT enhancer binding protein alpha	Homo sapiens	118-128
16737972-11	2006	Interestingly, the antioxidants vitamin E and N-acetylcysteine abolished both the alcohol-mediated down-regulation of C/EBPalpha binding activity and hepcidin expression in the liver and the up-regulation of duodenal divalent metal transporter 1.	Acetylcysteine	46-62	CCAAT enhancer binding protein alpha	Homo sapiens	118-128
16737972-11	2006	Interestingly, the antioxidants vitamin E and N-acetylcysteine abolished both the alcohol-mediated down-regulation of C/EBPalpha binding activity and hepcidin expression in the liver and the up-regulation of duodenal divalent metal transporter 1.	Alcohols	82-89	CCAAT enhancer binding protein alpha	Homo sapiens	118-128
16737972-12	2006	Collectively, these findings indicate that alcohol metabolism-mediated oxidative stress regulates hepcidin transcription via C/EBPalpha, which in turn leads to increased duodenal iron transport.	Alcohols	43-50	CCAAT enhancer binding protein alpha	Homo sapiens	125-135
16737972-12	2006	Collectively, these findings indicate that alcohol metabolism-mediated oxidative stress regulates hepcidin transcription via C/EBPalpha, which in turn leads to increased duodenal iron transport.	Iron	179-183	CCAAT enhancer binding protein alpha	Homo sapiens	125-135
16608438-4	2006	ChIP (chromatin immunoprecipitation) assays revealed that in vivo binding of C/EBPalpha to the region markedly decreases upon incubation with ATRA, whereas ATRA treatment marginally increases the recruitment of C/EBPbeta.	Tretinoin	142-146	CCAAT enhancer binding protein alpha	Homo sapiens	77-87
16226872-4	2006	Electrophoretic mobility shift assay (EMSA) using an oligonucleotide for the c/EBP consensus binding sequence showed that c/EBPalpha was activated in ATRA-treated HL-60/Vect cells but not in HL-60/FAK cells, indicating that c/EBPalpha activation by ATRA was impaired in HL-60/FAK cells.	Oligonucleotides	53-68	CCAAT enhancer binding protein alpha	Homo sapiens	77-82
16226872-4	2006	Electrophoretic mobility shift assay (EMSA) using an oligonucleotide for the c/EBP consensus binding sequence showed that c/EBPalpha was activated in ATRA-treated HL-60/Vect cells but not in HL-60/FAK cells, indicating that c/EBPalpha activation by ATRA was impaired in HL-60/FAK cells.	Oligonucleotides	53-68	CCAAT enhancer binding protein alpha	Homo sapiens	122-132
16226872-4	2006	Electrophoretic mobility shift assay (EMSA) using an oligonucleotide for the c/EBP consensus binding sequence showed that c/EBPalpha was activated in ATRA-treated HL-60/Vect cells but not in HL-60/FAK cells, indicating that c/EBPalpha activation by ATRA was impaired in HL-60/FAK cells.	Tretinoin	150-154	CCAAT enhancer binding protein alpha	Homo sapiens	77-82
16226872-4	2006	Electrophoretic mobility shift assay (EMSA) using an oligonucleotide for the c/EBP consensus binding sequence showed that c/EBPalpha was activated in ATRA-treated HL-60/Vect cells but not in HL-60/FAK cells, indicating that c/EBPalpha activation by ATRA was impaired in HL-60/FAK cells.	Tretinoin	150-154	CCAAT enhancer binding protein alpha	Homo sapiens	122-132
16226872-4	2006	Electrophoretic mobility shift assay (EMSA) using an oligonucleotide for the c/EBP consensus binding sequence showed that c/EBPalpha was activated in ATRA-treated HL-60/Vect cells but not in HL-60/FAK cells, indicating that c/EBPalpha activation by ATRA was impaired in HL-60/FAK cells.	Tretinoin	150-154	CCAAT enhancer binding protein alpha	Homo sapiens	224-234
16226872-4	2006	Electrophoretic mobility shift assay (EMSA) using an oligonucleotide for the c/EBP consensus binding sequence showed that c/EBPalpha was activated in ATRA-treated HL-60/Vect cells but not in HL-60/FAK cells, indicating that c/EBPalpha activation by ATRA was impaired in HL-60/FAK cells.	Tretinoin	249-253	CCAAT enhancer binding protein alpha	Homo sapiens	77-82
16226872-4	2006	Electrophoretic mobility shift assay (EMSA) using an oligonucleotide for the c/EBP consensus binding sequence showed that c/EBPalpha was activated in ATRA-treated HL-60/Vect cells but not in HL-60/FAK cells, indicating that c/EBPalpha activation by ATRA was impaired in HL-60/FAK cells.	Tretinoin	249-253	CCAAT enhancer binding protein alpha	Homo sapiens	122-132
16226872-5	2006	In addition, the association of retinoblastoma protein (pRb) and c/EBPalpha after treatment with ATRA was seen in HL-60/Vect cells but not in HL-60/FAK cells.	Tretinoin	97-101	CCAAT enhancer binding protein alpha	Homo sapiens	65-75
16226872-7	2006	Finally, the introduction of FAK siRNA into HL-60/FAK cells resulted in the recovery of sensitivity to ATRA-induced differentiation, confirming that the inhibition of HL-60/FAK differentiation resulted from both the induction of pRb hyperphosphorylation and the inhibition of association of pRb and c/EBPalpha.	Tretinoin	103-107	CCAAT enhancer binding protein alpha	Homo sapiens	299-309
16677282-10	2006	Norepinephrine elevated C/EBPalpha DNA binding activity, but cortisol did not increase the activity.	Norepinephrine	0-14	CCAAT enhancer binding protein alpha	Homo sapiens	24-34
16608438-7	2006	In conclusion, we propose a novel model for down-regulation of the albumin gene, in which ATRA triggers an increase in the translation of C/EBPbeta-LIP that antagonizes C/EBP transactivators by interacting with their binding sites in the albumin promoter.	Tretinoin	90-94	CCAAT enhancer binding protein alpha	Homo sapiens	138-143
16600022-5	2006	RESULTS: C/EBPalpha represses the IGFBP1 thymine-rich insulin response element (TIRE), but mutation of T222 or T226 of C/EBPalpha to non-phosphorylatable alanines has no effect on C/EBPalpha activity in liver cells (towards the TIRE or a consensus C/EBP binding sequence).	Alanine	154-162	CCAAT enhancer binding protein alpha	Homo sapiens	119-129
16600022-8	2006	Meanwhile C/EBPalpha activity in 3T3 L1 preadipocytes was enhanced by mutation of T222/T226 and/or S230 to alanine residues.	Alanine	107-114	CCAAT enhancer binding protein alpha	Homo sapiens	10-20
16357103-9	2006	VDR and C/EBP-alpha associated endogenously as a DNA-dependent, coimmunoprecipitable complex, which was detected at a markedly higher level in 1,25-(OH)2D3-treated cells.	Calcitriol	143-155	CCAAT enhancer binding protein alpha	Homo sapiens	8-19
16813147-7	2006	It was found that cAMP and cAMP-dependent transcription factors C/EBP (CAAT/enhancer binding protein) induced long-term changes in sensory inputs from chemoreceptors of the head part of snail in L-RP11 neurons, while proteinkinase C and proteinkinase C-dependent transcription factor SRF are involved in long-term regulation of synaptic inputs from mechanoreceptors of the head part of snail in the neurons.	Cyclic AMP	18-22	CCAAT enhancer binding protein alpha	Homo sapiens	64-69
16813147-7	2006	It was found that cAMP and cAMP-dependent transcription factors C/EBP (CAAT/enhancer binding protein) induced long-term changes in sensory inputs from chemoreceptors of the head part of snail in L-RP11 neurons, while proteinkinase C and proteinkinase C-dependent transcription factor SRF are involved in long-term regulation of synaptic inputs from mechanoreceptors of the head part of snail in the neurons.	Cyclic AMP	18-22	CCAAT enhancer binding protein alpha	Homo sapiens	71-100
16813147-7	2006	It was found that cAMP and cAMP-dependent transcription factors C/EBP (CAAT/enhancer binding protein) induced long-term changes in sensory inputs from chemoreceptors of the head part of snail in L-RP11 neurons, while proteinkinase C and proteinkinase C-dependent transcription factor SRF are involved in long-term regulation of synaptic inputs from mechanoreceptors of the head part of snail in the neurons.	Cyclic AMP	27-31	CCAAT enhancer binding protein alpha	Homo sapiens	64-69
16813147-7	2006	It was found that cAMP and cAMP-dependent transcription factors C/EBP (CAAT/enhancer binding protein) induced long-term changes in sensory inputs from chemoreceptors of the head part of snail in L-RP11 neurons, while proteinkinase C and proteinkinase C-dependent transcription factor SRF are involved in long-term regulation of synaptic inputs from mechanoreceptors of the head part of snail in the neurons.	Cyclic AMP	27-31	CCAAT enhancer binding protein alpha	Homo sapiens	71-100
16357103-10	2006	These results provide the first example of the essential role of the interaction in cis between C/EBP-alpha and VDR in directing 1,25-(OH)2D3-induced expression of a VDR target gene.	Calcitriol	129-141	CCAAT enhancer binding protein alpha	Homo sapiens	96-107
16537832-4	2006	C/EBPalpha promoter methylation was assessed using bisulfite sequencing, combined bisulfite restriction analysis, methylation-specific polymerase chain reaction, and Southern blotting.	hydrogen sulfite	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
16875555-10	2006	The expression level of C/EBPalpha gene of NB4/VEGF-C cells on ATRA treatment was only 1/32 that of NB4/pcDNA3.1 cells.	Tretinoin	63-67	CCAAT enhancer binding protein alpha	Homo sapiens	24-34
16537832-4	2006	C/EBPalpha promoter methylation was assessed using bisulfite sequencing, combined bisulfite restriction analysis, methylation-specific polymerase chain reaction, and Southern blotting.	hydrogen sulfite	82-91	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
16537832-8	2006	MeCP2 and MBD binding to the upstream C/EBPalpha promoter was detected in C/EBPalpha-nonexpressing cell lines; USF binding was detected in C/EBPalpha-expressing cell lines; however, in C/EBPalpha-nonexpressing cell lines USF binding was detected only after trichostatin A and 5-aza-dC treatment.	trichostatin A	257-271	CCAAT enhancer binding protein alpha	Homo sapiens	38-48
16537832-8	2006	MeCP2 and MBD binding to the upstream C/EBPalpha promoter was detected in C/EBPalpha-nonexpressing cell lines; USF binding was detected in C/EBPalpha-expressing cell lines; however, in C/EBPalpha-nonexpressing cell lines USF binding was detected only after trichostatin A and 5-aza-dC treatment.	Azacitidine	276-281	CCAAT enhancer binding protein alpha	Homo sapiens	38-48
16427606-9	2006	H2O2 treatment decreased the expression levels of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein (C/EBPalpha), but had no effect on HIF-1alpha, whereas hypoxia stabilized HIF-1alpha and decreased expression of C/EBPalpha, but not PPARgamma.	Hydrogen Peroxide	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	147-157
16427606-9	2006	H2O2 treatment decreased the expression levels of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein (C/EBPalpha), but had no effect on HIF-1alpha, whereas hypoxia stabilized HIF-1alpha and decreased expression of C/EBPalpha, but not PPARgamma.	Hydrogen Peroxide	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	259-269
16414987-3	2006	Induction of the lytic cycle in EBV-positive AGS/BX1 cells with phorbol ester and sodium butyrate treatment led to a transient stimulation of C/EBPbeta expression and a prolonged increase in C/EBPalpha expression.	Phorbol Esters	64-77	CCAAT enhancer binding protein alpha	Homo sapiens	191-201
16377306-8	2006	2-Aminopurine (2-AP), an inhibitor of eIF2alpha kinases, could overcome the apoptotic effect of AICAR, abolishing the reduction of PPARgamma and C/EBPalpha and the lipolytic properties of AMPK.	2-Aminopurine	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	145-155
16377306-8	2006	2-Aminopurine (2-AP), an inhibitor of eIF2alpha kinases, could overcome the apoptotic effect of AICAR, abolishing the reduction of PPARgamma and C/EBPalpha and the lipolytic properties of AMPK.	2-Aminopurine	15-19	CCAAT enhancer binding protein alpha	Homo sapiens	145-155
16754199-8	2006	Our results indicate that de novo ceramide produced by TNF-alpha-induced insulin resistance on GLUT4 gene expression in brown adipocytes by interfering C/EBP-alpha expression, a transcription factor essential for the expression of GLUT4.	Ceramides	34-42	CCAAT enhancer binding protein alpha	Homo sapiens	152-163
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	polyhistidine	79-92	CCAAT enhancer binding protein alpha	Homo sapiens	5-20
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	polyhistidine	79-92	CCAAT enhancer binding protein alpha	Homo sapiens	5-15
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	Serine	97-103	CCAAT enhancer binding protein alpha	Homo sapiens	5-20
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	Serine	97-103	CCAAT enhancer binding protein alpha	Homo sapiens	5-15
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	Threonine	104-113	CCAAT enhancer binding protein alpha	Homo sapiens	5-20
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	Threonine	104-113	CCAAT enhancer binding protein alpha	Homo sapiens	5-15
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	Proline	114-121	CCAAT enhancer binding protein alpha	Homo sapiens	5-20
16440369-4	2006	This C/EBPalpha-HNF6 transcriptional synergy required both the N-terminal HNF6 polyhistidine and serine/threonine/proline box sequences, as well as the C/EBPalpha AD1/AD2 sequences, the latter of which are known to recruit the CREB binding protein (CBP) transcriptional coactivator.	Proline	114-121	CCAAT enhancer binding protein alpha	Homo sapiens	5-15
16467360-6	2006	Normal synthesis of surfactant lipids and proteins, including SP-A, SP-B, SP-C, SP-D, ABCA3 (a lamellar body associated protein) and FAS (precursor of fatty acid synthesis) were dependent upon expression of the C/EBPalpha in respiratory epithelial cells.	Fatty Acids	151-161	CCAAT enhancer binding protein alpha	Homo sapiens	211-221
16414987-3	2006	Induction of the lytic cycle in EBV-positive AGS/BX1 cells with phorbol ester and sodium butyrate treatment led to a transient stimulation of C/EBPbeta expression and a prolonged increase in C/EBPalpha expression.	Butyric Acid	82-97	CCAAT enhancer binding protein alpha	Homo sapiens	191-201
16311219-4	2005	However, in the state of obesity, where adipose tissue shows elevated storage of triglycerides, many lipogenic genes that are essential for adipose cell function including PPARgamma, SREBP-1c, CCAAT-enhancer binding protein alpha and stearoyl-CoA desaturase-1 are downregulated, apparently due to desensitization of the very same crucial nutrient sensors.	Triglycerides	81-94	CCAAT enhancer binding protein alpha	Homo sapiens	193-229
16433737-3	2006	AIM: To investigate mechanisms underlying alcohol-induced disturbances in iron homeostasis by measuring the expression of hepcidin and C/EBPalpha mRNA using in vivo and in vitro models of alcoholic liver injury.	Alcohols	42-49	CCAAT enhancer binding protein alpha	Homo sapiens	135-145
16325577-3	2005	The two factors compete for binding to the miR-223 promoter: NFI-A maintains miR-223 at low levels, whereas its replacement by C/EBPalpha, following retinoic acid (RA)-induced differentiation, upregulates miR-223 expression.	Tretinoin	149-162	CCAAT enhancer binding protein alpha	Homo sapiens	127-137
16325577-3	2005	The two factors compete for binding to the miR-223 promoter: NFI-A maintains miR-223 at low levels, whereas its replacement by C/EBPalpha, following retinoic acid (RA)-induced differentiation, upregulates miR-223 expression.	Tretinoin	164-166	CCAAT enhancer binding protein alpha	Homo sapiens	127-137
16433737-12	2006	CONCLUSION: The down-regulation of hepcidin and C/EBPalpha gene expression shown in vivo implies disturbed iron sensing contributing to the hepatosiderosis seen in alcoholic liver disease, possibly by mechanisms involving the IL-6 signaling cascade.	Iron	107-111	CCAAT enhancer binding protein alpha	Homo sapiens	48-58
16321657-0	2005	C/EBP and Cdx family factors regulate liver fatty acid binding protein transgene expression in the small intestinal epithelium.	Fatty Acids	44-54	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
16008523-0	2005	Arsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding protein.	arsenite	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	122-152
16008523-8	2005	Point mutations of the putative Elk-1 site and the C/EBP (CCAAT/enhancer-binding protein) site within this region were able to reduce the stimulatory effect of arsenite, indicating that Elk-1 and C/EBP are involved in transcriptional regulation of the RTP801 gene by arsenite.	arsenite	160-168	CCAAT enhancer binding protein alpha	Homo sapiens	51-56
16008523-8	2005	Point mutations of the putative Elk-1 site and the C/EBP (CCAAT/enhancer-binding protein) site within this region were able to reduce the stimulatory effect of arsenite, indicating that Elk-1 and C/EBP are involved in transcriptional regulation of the RTP801 gene by arsenite.	arsenite	160-168	CCAAT enhancer binding protein alpha	Homo sapiens	58-88
16008523-8	2005	Point mutations of the putative Elk-1 site and the C/EBP (CCAAT/enhancer-binding protein) site within this region were able to reduce the stimulatory effect of arsenite, indicating that Elk-1 and C/EBP are involved in transcriptional regulation of the RTP801 gene by arsenite.	arsenite	160-168	CCAAT enhancer binding protein alpha	Homo sapiens	196-201
16008523-8	2005	Point mutations of the putative Elk-1 site and the C/EBP (CCAAT/enhancer-binding protein) site within this region were able to reduce the stimulatory effect of arsenite, indicating that Elk-1 and C/EBP are involved in transcriptional regulation of the RTP801 gene by arsenite.	arsenite	267-275	CCAAT enhancer binding protein alpha	Homo sapiens	51-56
16008523-8	2005	Point mutations of the putative Elk-1 site and the C/EBP (CCAAT/enhancer-binding protein) site within this region were able to reduce the stimulatory effect of arsenite, indicating that Elk-1 and C/EBP are involved in transcriptional regulation of the RTP801 gene by arsenite.	arsenite	267-275	CCAAT enhancer binding protein alpha	Homo sapiens	58-88
16008523-8	2005	Point mutations of the putative Elk-1 site and the C/EBP (CCAAT/enhancer-binding protein) site within this region were able to reduce the stimulatory effect of arsenite, indicating that Elk-1 and C/EBP are involved in transcriptional regulation of the RTP801 gene by arsenite.	arsenite	267-275	CCAAT enhancer binding protein alpha	Homo sapiens	196-201
16008523-9	2005	Furthermore, a gel mobility-shift assay demonstrated that arsenite was able to mount the rapid formation of a protein complex that bound the arsenic-responsive region as well as the C/EBP-containing sequence.	arsenite	58-66	CCAAT enhancer binding protein alpha	Homo sapiens	182-187
16008523-12	2005	Therefore these studies indicate that RTP801 is a transcriptional target of arsenic in human keratinocytes, and that arsenic and ROS production are linked to Elk-1 and C/EBP in the transcriptional control.	Reactive Oxygen Species	129-132	CCAAT enhancer binding protein alpha	Homo sapiens	168-173
16106045-0	2005	Ceramide- and ERK-dependent pathway for the activation of CCAAT/enhancer binding protein by interleukin-1beta in hepatocytes.	Ceramides	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	58-88
16106045-4	2005	In this study, we investigate the role of ceramide in the IL-1beta regulation of C/EBP in primary hepatocytes.	Ceramides	42-50	CCAAT enhancer binding protein alpha	Homo sapiens	81-86
16106045-5	2005	The C/EBP DNA binding activity was found to increase in a dose-dependent manner after stimulation with IL-1beta and exogenous addition of C2-ceramide or treatment with SMase.	N-acetylsphingosine	138-149	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
15985551-5	2005	Ex vivo and in vitro experiments with C/EBPbeta show that phosphorylation of Thr-188 by mitogen-activating protein kinase "primes" C/EBPbeta for subsequent phosphorylation on Ser-184 and Thr-179 by glycogen synthase kinase 3beta, acquisition of DNA-binding function, and transactivation of the C/EBPalpha and PPARgamma genes.	Threonine	77-80	CCAAT enhancer binding protein alpha	Homo sapiens	294-304
15928042-0	2005	C/EBPalpha functionally and physically interacts with GABP to activate the human myeloid IgA Fc receptor (Fc alphaR, CD89) gene promoter.	gabp	54-58	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
15928042-7	2005	This is the first report demonstrating both physical and functional interactions between GABP and C/EBPalpha and will provide new insights into the molecular basis of myeloid gene expression.	gabp	89-93	CCAAT enhancer binding protein alpha	Homo sapiens	98-108
16393856-6	2005	The role of C/EBP activation by PD98059 in repressing CYP1A1 induction was supported by the observation that a dominant-negative mutant C/EBP abolished the ability of PD98059 to suppress 3-MC induction of CYP1A1.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	32-39	CCAAT enhancer binding protein alpha	Homo sapiens	12-17
16393856-6	2005	The role of C/EBP activation by PD98059 in repressing CYP1A1 induction was supported by the observation that a dominant-negative mutant C/EBP abolished the ability of PD98059 to suppress 3-MC induction of CYP1A1.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	32-39	CCAAT enhancer binding protein alpha	Homo sapiens	136-141
16393856-6	2005	The role of C/EBP activation by PD98059 in repressing CYP1A1 induction was supported by the observation that a dominant-negative mutant C/EBP abolished the ability of PD98059 to suppress 3-MC induction of CYP1A1.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	167-174	CCAAT enhancer binding protein alpha	Homo sapiens	12-17
16393856-6	2005	The role of C/EBP activation by PD98059 in repressing CYP1A1 induction was supported by the observation that a dominant-negative mutant C/EBP abolished the ability of PD98059 to suppress 3-MC induction of CYP1A1.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	167-174	CCAAT enhancer binding protein alpha	Homo sapiens	136-141
16393856-6	2005	The role of C/EBP activation by PD98059 in repressing CYP1A1 induction was supported by the observation that a dominant-negative mutant C/EBP abolished the ability of PD98059 to suppress 3-MC induction of CYP1A1.	Methylcholanthrene	187-191	CCAAT enhancer binding protein alpha	Homo sapiens	12-17
16393856-6	2005	The role of C/EBP activation by PD98059 in repressing CYP1A1 induction was supported by the observation that a dominant-negative mutant C/EBP abolished the ability of PD98059 to suppress 3-MC induction of CYP1A1.	Methylcholanthrene	187-191	CCAAT enhancer binding protein alpha	Homo sapiens	136-141
16061473-8	2005	GW501516 also increased EP4 promoter activity through effects on the region between -1555 and -992 bp in the EP4 promoter, and mutation of the CCAAT/enhancer-binding protein (C/EBP) site in this region abrogated the effect of GW501516.	GW 501516	226-234	CCAAT enhancer binding protein alpha	Homo sapiens	175-180
16061473-9	2005	GW501516 increased not only the binding activity of C/EBP to the NF-IL6 site in the EP4 promoter, which was prevented by the inhibitor of PI3-K, but also increased C/EBPbeta protein in a dose- and PPARbeta/delta-dependent manner.	GW 501516	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	52-57
15935329-1	2005	We recently showed that moderate hypoxia and hypoxia-mimetic agents CoCl(2) and desferrioxamine (DFO) induce differentiation of acute myeloid leukemic cells via hypoxia-inducible factor-1alpha (HIF-1alpha) that interacts with and increases the transcriptional activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for granulocytic differentiation.	cocl	68-72	CCAAT enhancer binding protein alpha	Homo sapiens	272-308
15935329-1	2005	We recently showed that moderate hypoxia and hypoxia-mimetic agents CoCl(2) and desferrioxamine (DFO) induce differentiation of acute myeloid leukemic cells via hypoxia-inducible factor-1alpha (HIF-1alpha) that interacts with and increases the transcriptional activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for granulocytic differentiation.	cocl	68-72	CCAAT enhancer binding protein alpha	Homo sapiens	310-320
15935329-1	2005	We recently showed that moderate hypoxia and hypoxia-mimetic agents CoCl(2) and desferrioxamine (DFO) induce differentiation of acute myeloid leukemic cells via hypoxia-inducible factor-1alpha (HIF-1alpha) that interacts with and increases the transcriptional activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for granulocytic differentiation.	Deferoxamine	80-95	CCAAT enhancer binding protein alpha	Homo sapiens	272-308
15935329-1	2005	We recently showed that moderate hypoxia and hypoxia-mimetic agents CoCl(2) and desferrioxamine (DFO) induce differentiation of acute myeloid leukemic cells via hypoxia-inducible factor-1alpha (HIF-1alpha) that interacts with and increases the transcriptional activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for granulocytic differentiation.	Deferoxamine	80-95	CCAAT enhancer binding protein alpha	Homo sapiens	310-320
15935329-1	2005	We recently showed that moderate hypoxia and hypoxia-mimetic agents CoCl(2) and desferrioxamine (DFO) induce differentiation of acute myeloid leukemic cells via hypoxia-inducible factor-1alpha (HIF-1alpha) that interacts with and increases the transcriptional activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for granulocytic differentiation.	Deferoxamine	97-100	CCAAT enhancer binding protein alpha	Homo sapiens	272-308
15935329-1	2005	We recently showed that moderate hypoxia and hypoxia-mimetic agents CoCl(2) and desferrioxamine (DFO) induce differentiation of acute myeloid leukemic cells via hypoxia-inducible factor-1alpha (HIF-1alpha) that interacts with and increases the transcriptional activity of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for granulocytic differentiation.	Deferoxamine	97-100	CCAAT enhancer binding protein alpha	Homo sapiens	310-320
15935329-3	2005	Furthermore, DFO also increased C/EBPalpha expression rapidly but transiently, which was inhibited by metavanadate.	Deferoxamine	13-16	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
15935329-3	2005	Furthermore, DFO also increased C/EBPalpha expression rapidly but transiently, which was inhibited by metavanadate.	Vanadates	102-114	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
15935329-4	2005	Taken together, these findings provide further evidence for the role of HIF-1alpha and C/EBPalpha in DFO-induced leukemic cell differentiation.	Deferoxamine	101-104	CCAAT enhancer binding protein alpha	Homo sapiens	87-97
15987634-5	2005	Indeed, anandamide induced triglyceride droplet accumulation and the expression of PPARgamma responsive genes such as CCAAT enhancer binding protein alpha (C-EBPalpha), aP2, PerilipinA and Acrp30.	anandamide	8-18	CCAAT enhancer binding protein alpha	Homo sapiens	118-154
15987634-5	2005	Indeed, anandamide induced triglyceride droplet accumulation and the expression of PPARgamma responsive genes such as CCAAT enhancer binding protein alpha (C-EBPalpha), aP2, PerilipinA and Acrp30.	anandamide	8-18	CCAAT enhancer binding protein alpha	Homo sapiens	156-166
16393856-4	2005	PD98059 treatment inhibited 3-MC-induced AhR binding to the XRE, but increased protein binding to the CYP1A1 C/EBP binding site.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	109-114
16433072-5	2005	C/EBP was inactivated using oligonucleotides specifically binding to these proteins.	Oligonucleotides	28-44	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
15985551-5	2005	Ex vivo and in vitro experiments with C/EBPbeta show that phosphorylation of Thr-188 by mitogen-activating protein kinase "primes" C/EBPbeta for subsequent phosphorylation on Ser-184 and Thr-179 by glycogen synthase kinase 3beta, acquisition of DNA-binding function, and transactivation of the C/EBPalpha and PPARgamma genes.	Serine	175-178	CCAAT enhancer binding protein alpha	Homo sapiens	294-304
15985551-5	2005	Ex vivo and in vitro experiments with C/EBPbeta show that phosphorylation of Thr-188 by mitogen-activating protein kinase "primes" C/EBPbeta for subsequent phosphorylation on Ser-184 and Thr-179 by glycogen synthase kinase 3beta, acquisition of DNA-binding function, and transactivation of the C/EBPalpha and PPARgamma genes.	Threonine	187-190	CCAAT enhancer binding protein alpha	Homo sapiens	294-304
15902299-0	2005	Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha.	Deferoxamine	0-15	CCAAT enhancer binding protein alpha	Homo sapiens	144-180
15902299-6	2005	Furthermore, the inducible expression of chromosome translocation t(8;21)-generated leukemogenic AML1-ETO fusion gene attenuated DFO-induced differentiation of U937 cells with the decrease of CCAAT/enhancer-binding protein alpha (C/EBP alpha), a critical factor for granulocytic differentiation.	Deferoxamine	129-132	CCAAT enhancer binding protein alpha	Homo sapiens	192-228
15902299-6	2005	Furthermore, the inducible expression of chromosome translocation t(8;21)-generated leukemogenic AML1-ETO fusion gene attenuated DFO-induced differentiation of U937 cells with the decrease of CCAAT/enhancer-binding protein alpha (C/EBP alpha), a critical factor for granulocytic differentiation.	Deferoxamine	129-132	CCAAT enhancer binding protein alpha	Homo sapiens	230-241
15886297-9	2005	Chromatin immunoprecipitation showed increased acetylated histone H3 bound to both Tig1 and C/ebpalpha genes after treatment with 5-aza-2"-deoxycytidine and/or suberoylanilide bishydroxamide.	Decitabine	130-152	CCAAT enhancer binding protein alpha	Homo sapiens	92-102
15647458-5	2005	The effects of FSH and cAMP analogue on the distribution of CEBP isoforms were evaluated in primary cultures of porcine granulosa cells.	Cyclic AMP	23-27	CCAAT enhancer binding protein alpha	Homo sapiens	60-64
15647458-8	2005	In transfected granulosa cells, FSH and cAMP analogue stimulated a CEBP consensus sequence-reporter construct that was blocked by H89.	Cyclic AMP	40-44	CCAAT enhancer binding protein alpha	Homo sapiens	67-71
15854165-11	2005	We have also shown that: (i) reporter constructs containing the AGT gene promoter with nucleoside A at -217 have increased promoter activity on transient transfection; and (ii) the CCAAT box enhancer binding protein (C/EBP) family of transcription factors and glucocorticoid receptor (GR) bind preferentially to this region of the promoter when nucleoside A is present at -217.	nucleoside a	87-99	CCAAT enhancer binding protein alpha	Homo sapiens	181-215
15854165-11	2005	We have also shown that: (i) reporter constructs containing the AGT gene promoter with nucleoside A at -217 have increased promoter activity on transient transfection; and (ii) the CCAAT box enhancer binding protein (C/EBP) family of transcription factors and glucocorticoid receptor (GR) bind preferentially to this region of the promoter when nucleoside A is present at -217.	nucleoside a	87-99	CCAAT enhancer binding protein alpha	Homo sapiens	217-222
15854165-11	2005	We have also shown that: (i) reporter constructs containing the AGT gene promoter with nucleoside A at -217 have increased promoter activity on transient transfection; and (ii) the CCAAT box enhancer binding protein (C/EBP) family of transcription factors and glucocorticoid receptor (GR) bind preferentially to this region of the promoter when nucleoside A is present at -217.	nucleoside a	345-357	CCAAT enhancer binding protein alpha	Homo sapiens	181-215
15854165-11	2005	We have also shown that: (i) reporter constructs containing the AGT gene promoter with nucleoside A at -217 have increased promoter activity on transient transfection; and (ii) the CCAAT box enhancer binding protein (C/EBP) family of transcription factors and glucocorticoid receptor (GR) bind preferentially to this region of the promoter when nucleoside A is present at -217.	nucleoside a	345-357	CCAAT enhancer binding protein alpha	Homo sapiens	217-222
15772366-8	2005	PP1 reduced DON-induced increases in nuclear levels and binding activities of several transcription factors (NF-kappaB, AP-1, and C/EBP), which corresponded to decreases in TNF-alpha production, caspase-3 activation, and apoptosis.	deoxynivalenol	12-15	CCAAT enhancer binding protein alpha	Homo sapiens	130-135
15886297-9	2005	Chromatin immunoprecipitation showed increased acetylated histone H3 bound to both Tig1 and C/ebpalpha genes after treatment with 5-aza-2"-deoxycytidine and/or suberoylanilide bishydroxamide.	suberoylanilide bishydroxamide	160-190	CCAAT enhancer binding protein alpha	Homo sapiens	92-102
15812237-6	2005	Indeed, both NaBu and IL-1beta led to increased recruitment of NF-kappa B p65, C/EBPbeta, and C/EBP delta, and decreased NF-kappa B p50 and C/EBP alpha DNA-binding to the proximal SAA2 promoter, as assessed by chromatin immunoprecipitation assays.	sethoxydim	13-17	CCAAT enhancer binding protein alpha	Homo sapiens	140-151
15777798-7	2005	DNA Affinity Precipitation Assays (DAPA) and chromatin immunoprecipitation demonstrated that the binding of C/EBPalpha and beta to the C/EBP site decreased upon treatment with RA.	2'-deoxyadenylyl-(3'-5')-2'-deoxyadenosine	35-39	CCAAT enhancer binding protein alpha	Homo sapiens	108-118
15777798-7	2005	DNA Affinity Precipitation Assays (DAPA) and chromatin immunoprecipitation demonstrated that the binding of C/EBPalpha and beta to the C/EBP site decreased upon treatment with RA.	2'-deoxyadenylyl-(3'-5')-2'-deoxyadenosine	35-39	CCAAT enhancer binding protein alpha	Homo sapiens	108-113
15777798-7	2005	DNA Affinity Precipitation Assays (DAPA) and chromatin immunoprecipitation demonstrated that the binding of C/EBPalpha and beta to the C/EBP site decreased upon treatment with RA.	Tretinoin	176-178	CCAAT enhancer binding protein alpha	Homo sapiens	108-118
15777798-7	2005	DNA Affinity Precipitation Assays (DAPA) and chromatin immunoprecipitation demonstrated that the binding of C/EBPalpha and beta to the C/EBP site decreased upon treatment with RA.	Tretinoin	176-178	CCAAT enhancer binding protein alpha	Homo sapiens	108-113
15686465-2	2005	Isopentenyladenine (IPA), a potent cytokinin, significantly induced the expression of CCAAT/enhancer-binding protein (C/EBP)delta, but not C/EBP alpha protein, whereas all-trans retinoic acid, a well-known inducer of granulocytic differentiation, induced C/EBP alpha but not C/EBP delta protein.	N(6)-(delta(2)-isopentenyl)adenine	20-23	CCAAT enhancer binding protein alpha	Homo sapiens	139-150
15604115-2	2005	Recent reports suggested that CCAAT enhancer binding protein (C/EBP) binding to the PEPCK cAMP response element (CRE) plays a role in Dex induction and that insulin-induces inhibitory forms of C/EBPbeta to inhibit transcription.	Cyclic AMP	90-94	CCAAT enhancer binding protein alpha	Homo sapiens	30-60
15604115-2	2005	Recent reports suggested that CCAAT enhancer binding protein (C/EBP) binding to the PEPCK cAMP response element (CRE) plays a role in Dex induction and that insulin-induces inhibitory forms of C/EBPbeta to inhibit transcription.	Cyclic AMP	90-94	CCAAT enhancer binding protein alpha	Homo sapiens	62-67
15604115-2	2005	Recent reports suggested that CCAAT enhancer binding protein (C/EBP) binding to the PEPCK cAMP response element (CRE) plays a role in Dex induction and that insulin-induces inhibitory forms of C/EBPbeta to inhibit transcription.	Dexamethasone	134-137	CCAAT enhancer binding protein alpha	Homo sapiens	30-60
15604115-2	2005	Recent reports suggested that CCAAT enhancer binding protein (C/EBP) binding to the PEPCK cAMP response element (CRE) plays a role in Dex induction and that insulin-induces inhibitory forms of C/EBPbeta to inhibit transcription.	Dexamethasone	134-137	CCAAT enhancer binding protein alpha	Homo sapiens	62-67
15629151-0	2005	C/EBPalpha reverses the anti-adipogenic effects of the HIV protease inhibitor nelfinavir.	Nelfinavir	78-88	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
15629151-4	2005	Forced expression of the adipogenic transcription factor C/EBPalpha rescues some of the anti-adipogenic effects of nelfinavir.	Nelfinavir	115-125	CCAAT enhancer binding protein alpha	Homo sapiens	57-67
15629151-5	2005	These results suggest that nelfinavir may mediate an anti-adipogenic effect by antagonizing expression of C/EBPalpha.	Nelfinavir	27-37	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
15751966-7	2005	Furthermore, a gel mobility shift assay revealed that MMS was able to initiate rapid formation of a protein complex that bound the C/EBP site of the promoter.	Methyl Methanesulfonate	54-57	CCAAT enhancer binding protein alpha	Homo sapiens	131-136
15713621-7	2005	TSA treatment increased the acetylation of the transcription factors Sp1 and C/EBPalpha and decreased their binding as well as the binding of CBP and HDAC2 to the bcl-2 promoters.	trichostatin A	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	77-87
15713621-8	2005	Mutation of Sp1 and C/EBPalpha binding sites reduced the TSA-induced repression of bcl-2 promoter activity.	trichostatin A	57-60	CCAAT enhancer binding protein alpha	Homo sapiens	20-30
15686465-2	2005	Isopentenyladenine (IPA), a potent cytokinin, significantly induced the expression of CCAAT/enhancer-binding protein (C/EBP)delta, but not C/EBP alpha protein, whereas all-trans retinoic acid, a well-known inducer of granulocytic differentiation, induced C/EBP alpha but not C/EBP delta protein.	N(6)-(delta(2)-isopentenyl)adenine	0-18	CCAAT enhancer binding protein alpha	Homo sapiens	255-266
15686465-2	2005	Isopentenyladenine (IPA), a potent cytokinin, significantly induced the expression of CCAAT/enhancer-binding protein (C/EBP)delta, but not C/EBP alpha protein, whereas all-trans retinoic acid, a well-known inducer of granulocytic differentiation, induced C/EBP alpha but not C/EBP delta protein.	N(6)-(delta(2)-isopentenyl)adenine	20-23	CCAAT enhancer binding protein alpha	Homo sapiens	255-266
15572670-6	2004	N-Methyl-N"-nitro-N-nitrosoguanidine, etoposide, and bleomycin also induced C/EBPalpha.	Methylnitronitrosoguanidine	0-36	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
15388792-5	2005	We also show that HNF4alpha, C/EBPalpha, and C/EBPbeta are constitutively bound to the endogenous Glc6Pase gene, whereas CREB and CREB-binding protein (CBP) will be bound to the gene upon stimulation by cAMP.	Cyclic AMP	203-207	CCAAT enhancer binding protein alpha	Homo sapiens	29-39
15578880-4	2004	OBJECTIVE: To determine if the substitution of Ara-C for cytosine in double-stranded oligonucleotides that contain 4 specific transcription factor binding sites (TATA, GATA, C/EBP, and AP-2alpha) alters transcription factor binding to their respective DNA binding elements.	Oligonucleotides	85-101	CCAAT enhancer binding protein alpha	Homo sapiens	174-179
15572670-6	2004	N-Methyl-N"-nitro-N-nitrosoguanidine, etoposide, and bleomycin also induced C/EBPalpha.	Etoposide	38-47	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
15572670-6	2004	N-Methyl-N"-nitro-N-nitrosoguanidine, etoposide, and bleomycin also induced C/EBPalpha.	Bleomycin	53-62	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
15572670-7	2004	UVB-induced C/EBPalpha was accompanied by an increase in p53 protein and caffeine, an inhibitor of ataxia-telangiectasia-mutated kinase, and ataxia-telangiectasia-mutated and Rad3-related kinase inhibited UVB-induced increases in both C/EBPalpha and p53.	Caffeine	73-81	CCAAT enhancer binding protein alpha	Homo sapiens	12-22
15528329-7	2004	Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP.	Prostaglandins E	119-122	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
15528329-7	2004	Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP.	Cyclic AMP	127-131	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
15528329-7	2004	Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP.	Ionomycin	137-146	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
15528329-7	2004	Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP.	Cyclic AMP	152-156	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
15466360-5	2004	We show that amlodipine-dependent activation of p21(Waf1/Cip1) involves the action of the glucocorticoid receptor (GR) and C/EBP-alpha.	Amlodipine	13-23	CCAAT enhancer binding protein alpha	Homo sapiens	123-134
15577645-4	2004	However, stavudine and zidovudine altered the lipid phenotype, decreasing the lipid content and expression of markers involved in lipid metabolism, namely C/EBPalpha, peroxisome proliferator-activated receptor gamma, adipocyte lipid binding protein 2, fatty acid synthase and acetyl-coenzyme A carboxylase.	Stavudine	9-18	CCAAT enhancer binding protein alpha	Homo sapiens	155-250
15577645-4	2004	However, stavudine and zidovudine altered the lipid phenotype, decreasing the lipid content and expression of markers involved in lipid metabolism, namely C/EBPalpha, peroxisome proliferator-activated receptor gamma, adipocyte lipid binding protein 2, fatty acid synthase and acetyl-coenzyme A carboxylase.	Zidovudine	23-33	CCAAT enhancer binding protein alpha	Homo sapiens	155-250
15466360-7	2004	Amlodipine-induced p21(Waf1/Cip1) promoter activity and expression were abrogated by C/EBP-alpha antisense oligonucleotide or by the GR antagonist RU486.	Amlodipine	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	85-96
15466360-7	2004	Amlodipine-induced p21(Waf1/Cip1) promoter activity and expression were abrogated by C/EBP-alpha antisense oligonucleotide or by the GR antagonist RU486.	Oligonucleotides	107-122	CCAAT enhancer binding protein alpha	Homo sapiens	85-96
15466360-8	2004	Amlodipine-dependent inhibition of cell proliferation was partially reversed by RU486 at 10(-8) M (58%+/-29%), antisense oligonucleotides targeting C/EBP-alpha (91%+/-26%), or antisense mRNAs targeting p21(Waf1/Cip1) (96%+/-32%, n=6); scrambled antisense oligonucleotides or those directed against C/EBP-beta were ineffective.	Amlodipine	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	148-159
15466360-8	2004	Amlodipine-dependent inhibition of cell proliferation was partially reversed by RU486 at 10(-8) M (58%+/-29%), antisense oligonucleotides targeting C/EBP-alpha (91%+/-26%), or antisense mRNAs targeting p21(Waf1/Cip1) (96%+/-32%, n=6); scrambled antisense oligonucleotides or those directed against C/EBP-beta were ineffective.	Oligonucleotides	121-137	CCAAT enhancer binding protein alpha	Homo sapiens	148-159
15187114-8	2004	This appears to be a general mechanism because simvastatin also augments LPS-dependent activation of the TNF-alpha promoter, perhaps because the TNF-alpha promoter has C/EBP and AP-1 binding sites in a similar configuration to the IL-12p40 promoter.	Simvastatin	47-58	CCAAT enhancer binding protein alpha	Homo sapiens	168-173
15295049-10	2004	C/EBPalpha antisense oligonucleotides or the glucocorticoid-receptor inhibitor mifepristone reversed the antiproliferative effect of glucocorticoids in bronchial smooth-muscle cells from subjects without asthma.	Oligonucleotides	21-37	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
15136298-7	2004	NF-kappaB and C/EBP DNA binding were increased after LPS treatment compared with control, an effect inhibited by cotreatment with NAL.	N-acetylcysteine lysinate	130-133	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
15339442-6	2004	Salidroside suppressed the differentiation of 3T3-L1 pre-adipocytes and down-regulated the expression of PPAR-gamma and C/EBP-alpha mRNA (P < 0.01, vs control group).	rhodioloside	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	120-131
15078966-4	2004	Glutathione S-transferase affinity assays with mutant ZTA proteins revealed that the basic DNA binding domain and the key leucine zipper residues required for homodimerization are all required for the interaction with C/EBPalpha.	Glutathione	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	218-228
15078966-8	2004	Reporter assays revealed that cotransfected C/EBPalpha activated the ZTA promoter even more effectively than cotransfected ZTA.	zta	69-72	CCAAT enhancer binding protein alpha	Homo sapiens	44-54
15044435-6	2004	We now show that EGCG activation of this pathway results in increased CCAAT/enhancer-binding protein (C/EBPalpha and C/EBPbeta) factor level and increased complex formation at the hINV promoter C/EBP DNA binding site.	epigallocatechin gallate	17-21	CCAAT enhancer binding protein alpha	Homo sapiens	102-112
15044435-6	2004	We now show that EGCG activation of this pathway results in increased CCAAT/enhancer-binding protein (C/EBPalpha and C/EBPbeta) factor level and increased complex formation at the hINV promoter C/EBP DNA binding site.	epigallocatechin gallate	17-21	CCAAT enhancer binding protein alpha	Homo sapiens	102-107
15044435-10	2004	This is associated with inhibition of the EGCG-dependent increase in C/EBP factor level and C/EBP factor binding to the hINV promoter.	epigallocatechin gallate	42-46	CCAAT enhancer binding protein alpha	Homo sapiens	69-74
15044435-10	2004	This is associated with inhibition of the EGCG-dependent increase in C/EBP factor level and C/EBP factor binding to the hINV promoter.	epigallocatechin gallate	42-46	CCAAT enhancer binding protein alpha	Homo sapiens	92-97
15044435-12	2004	The curcumin-dependent suppression of C/EBP factor level is inhibited by treatment with the proteasome inhibitor MG132, suggesting that the proteasome function is required for curcumin action.	Curcumin	4-12	CCAAT enhancer binding protein alpha	Homo sapiens	38-43
15044435-12	2004	The curcumin-dependent suppression of C/EBP factor level is inhibited by treatment with the proteasome inhibitor MG132, suggesting that the proteasome function is required for curcumin action.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	113-118	CCAAT enhancer binding protein alpha	Homo sapiens	38-43
15044435-12	2004	The curcumin-dependent suppression of C/EBP factor level is inhibited by treatment with the proteasome inhibitor MG132, suggesting that the proteasome function is required for curcumin action.	Curcumin	176-184	CCAAT enhancer binding protein alpha	Homo sapiens	38-43
15044435-13	2004	We conclude that curcumin and EGCG produce opposing effects on involucrin gene expression via regulation of C/EBP factor function.	Curcumin	17-25	CCAAT enhancer binding protein alpha	Homo sapiens	108-113
15044435-13	2004	We conclude that curcumin and EGCG produce opposing effects on involucrin gene expression via regulation of C/EBP factor function.	epigallocatechin gallate	30-34	CCAAT enhancer binding protein alpha	Homo sapiens	108-113
15339442-7	2004	CONCLUSION: Salidroside promotes the 3H-glucose uptaking, suppresses the differentiation and down-regulates the expression of PPAR-gamma and C/EBP-alpha mRNA in 3T3-L1 adipocytes.	rhodioloside	12-23	CCAAT enhancer binding protein alpha	Homo sapiens	141-152
15107404-4	2004	In this paper, we present evidence that the activation of the PI3K/Akt pathway in liver tumor cells blocks the growth inhibitory activity of C/EBPalpha through the PP2A-mediated dephosphorylation of C/EBPalpha on Ser 193, leading to a failure of C/EBPalpha to interact with and inhibit cdks and E2F.	Serine	213-216	CCAAT enhancer binding protein alpha	Homo sapiens	141-151
15003822-5	2004	On the other hand, granulocyte differentiation by Fes was mediated through activation of CCAAT/enhancer-binding protein alpha (C/EBP-alpha) and STAT3, two transcription factors that are critical for granulocytic differentiation.	Iron	50-53	CCAAT enhancer binding protein alpha	Homo sapiens	89-125
15107404-4	2004	In this paper, we present evidence that the activation of the PI3K/Akt pathway in liver tumor cells blocks the growth inhibitory activity of C/EBPalpha through the PP2A-mediated dephosphorylation of C/EBPalpha on Ser 193, leading to a failure of C/EBPalpha to interact with and inhibit cdks and E2F.	Serine	213-216	CCAAT enhancer binding protein alpha	Homo sapiens	199-209
15107404-4	2004	In this paper, we present evidence that the activation of the PI3K/Akt pathway in liver tumor cells blocks the growth inhibitory activity of C/EBPalpha through the PP2A-mediated dephosphorylation of C/EBPalpha on Ser 193, leading to a failure of C/EBPalpha to interact with and inhibit cdks and E2F.	Serine	213-216	CCAAT enhancer binding protein alpha	Homo sapiens	199-209
15047839-3	2004	The cellular CCAAT/enhancer-binding protein alpha (C/EBP alpha) is induced in TPA-treated PEL cells and contributes to transactivation of the promoters for all of these genes through both direct binding and cooperative interactions with RTA and RAP targeted to upstream C/EBP sites.	Tetradecanoylphorbol Acetate	78-81	CCAAT enhancer binding protein alpha	Homo sapiens	13-49
15047839-3	2004	The cellular CCAAT/enhancer-binding protein alpha (C/EBP alpha) is induced in TPA-treated PEL cells and contributes to transactivation of the promoters for all of these genes through both direct binding and cooperative interactions with RTA and RAP targeted to upstream C/EBP sites.	Tetradecanoylphorbol Acetate	78-81	CCAAT enhancer binding protein alpha	Homo sapiens	51-62
15003822-5	2004	On the other hand, granulocyte differentiation by Fes was mediated through activation of CCAAT/enhancer-binding protein alpha (C/EBP-alpha) and STAT3, two transcription factors that are critical for granulocytic differentiation.	Iron	50-53	CCAAT enhancer binding protein alpha	Homo sapiens	127-138
14704358-4	2004	We have engineered C2C12 cells for dual-regulated expression of human C/EBP-alpha and BMP-2 to enable independent transcription control of both differentiation factors using clinically licensed antibiotics of the streptogramin (pristinamycin) and tetracycline (tetracycline) classes.	Tetracycline	261-273	CCAAT enhancer binding protein alpha	Homo sapiens	70-81
14605006-6	2004	During adipogenic differentiation, down-regulation in the mRNA levels of PPARgamma and CCAAT/enhancer-binding protein-alpha at d 3 and decreased lipoprotein lipase and adipsin mRNA levels at d 21 were observed after genistein treatment.	Genistein	216-225	CCAAT enhancer binding protein alpha	Homo sapiens	87-123
14691721-5	2004	We found C/EBP-alpha and C/EBP-beta expression in the villous syncytiotrophophoblast (ST) and the extravillous (intermediate) trophoblast (EVT), but it was absent from the villous cytotrophoblast (CT).	EVT	139-142	CCAAT enhancer binding protein alpha	Homo sapiens	9-20
14753708-0	2004	Effect of the detergent Tween-20 on the DNA affinity chromatography of Gal4, C/EBPalpha, and lac repressor with observations on column regeneration.	Polysorbates	24-32	CCAAT enhancer binding protein alpha	Homo sapiens	77-87
14753708-3	2004	Higher amounts of lac repressor, the Green Fluorescent Protein fusions with CAAT enhancer binding protein (C/EBPalpha) and Gal4, elute from the columns when 0.1% Tween-20 is added to the mobile phase.	Lactose	18-21	CCAAT enhancer binding protein alpha	Homo sapiens	107-117
14753708-3	2004	Higher amounts of lac repressor, the Green Fluorescent Protein fusions with CAAT enhancer binding protein (C/EBPalpha) and Gal4, elute from the columns when 0.1% Tween-20 is added to the mobile phase.	Polysorbates	162-170	CCAAT enhancer binding protein alpha	Homo sapiens	107-117
14753708-7	2004	Mg2+ or EDTA in the mobile phase gave similar chromatography for C/EBP; since EDTA protects columns from DNases, its inclusion in the mobile phase is preferred.	magnesium ion	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	65-70
14753708-7	2004	Mg2+ or EDTA in the mobile phase gave similar chromatography for C/EBP; since EDTA protects columns from DNases, its inclusion in the mobile phase is preferred.	Edetic Acid	8-12	CCAAT enhancer binding protein alpha	Homo sapiens	65-70
14704358-4	2004	We have engineered C2C12 cells for dual-regulated expression of human C/EBP-alpha and BMP-2 to enable independent transcription control of both differentiation factors using clinically licensed antibiotics of the streptogramin (pristinamycin) and tetracycline (tetracycline) classes.	Pristinamycin	228-241	CCAAT enhancer binding protein alpha	Homo sapiens	70-81
14704358-4	2004	We have engineered C2C12 cells for dual-regulated expression of human C/EBP-alpha and BMP-2 to enable independent transcription control of both differentiation factors using clinically licensed antibiotics of the streptogramin (pristinamycin) and tetracycline (tetracycline) classes.	Tetracycline	247-259	CCAAT enhancer binding protein alpha	Homo sapiens	70-81
14720509-6	2004	Increased levels of the transcription factor C/EBP were found in nuclear extracts from cells exposed to sucrose for 12 h, relative to matched controls suggesting regulation of gene expression following sucrose-induced vacuolation may be coordinated, at least in part, by the transcription factor C/EBP.	Sucrose	104-111	CCAAT enhancer binding protein alpha	Homo sapiens	45-50
14720509-6	2004	Increased levels of the transcription factor C/EBP were found in nuclear extracts from cells exposed to sucrose for 12 h, relative to matched controls suggesting regulation of gene expression following sucrose-induced vacuolation may be coordinated, at least in part, by the transcription factor C/EBP.	Sucrose	104-111	CCAAT enhancer binding protein alpha	Homo sapiens	296-301
14720509-6	2004	Increased levels of the transcription factor C/EBP were found in nuclear extracts from cells exposed to sucrose for 12 h, relative to matched controls suggesting regulation of gene expression following sucrose-induced vacuolation may be coordinated, at least in part, by the transcription factor C/EBP.	Sucrose	202-209	CCAAT enhancer binding protein alpha	Homo sapiens	45-50
14720509-6	2004	Increased levels of the transcription factor C/EBP were found in nuclear extracts from cells exposed to sucrose for 12 h, relative to matched controls suggesting regulation of gene expression following sucrose-induced vacuolation may be coordinated, at least in part, by the transcription factor C/EBP.	Sucrose	202-209	CCAAT enhancer binding protein alpha	Homo sapiens	296-301
14517214-7	2003	Using high density oligonucleotide microarrays, the gene expression profile of KCL22 cells stably transfected with C/EBPalpha was compared with that of empty vector, and we identified genes not previously known to be regulated by C/EBPalpha.	Oligonucleotides	19-34	CCAAT enhancer binding protein alpha	Homo sapiens	115-125
14701740-4	2004	This inhibition is mediated by extracellular signal-regulated kinases 1 and/or 2 (ERK1/2), which interact with C/EBPalpha through an FXFP docking site and phosphorylate serine 21.	Serine	169-175	CCAAT enhancer binding protein alpha	Homo sapiens	111-121
14701740-5	2004	As a consequence of C/EBPalpha phosphorylation, induction of granulocyte differentiation by C/EBPalpha or retinoic acid is inhibited.	Tretinoin	106-119	CCAAT enhancer binding protein alpha	Homo sapiens	20-30
12941938-3	2003	Given that oltipraz activates C/EBPbeta for gene transactivation and that the putative C/EBP binding site is located in the CYP1A1 promoter region, this study investigated the effect of oltipraz on CYP1A1 induction by 3-methylcholanthrene (3-MC).	oltipraz	11-19	CCAAT enhancer binding protein alpha	Homo sapiens	30-35
12941938-10	2003	Oltipraz enhanced protein binding to the C/EBP binding site in the gene promoter and the binding complex comprised of C/EBPbeta and partly C/EBPdelta.	oltipraz	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	41-46
12842822-9	2003	Electromobility shift assay and supershifts showed that the transcription factors bound to the Gln-responsive element in the GAPDH promoter are C/EBPalpha and -delta.	Glutamine	95-98	CCAAT enhancer binding protein alpha	Homo sapiens	144-165
14522018-4	2003	We have previously found that an oligonucleotide containing a kappaB site diminished binding of C/EBPbeta to the C/EBP site, suggesting that unidentified Rel proteins present in Hep3B nuclei facilitate the formation of C/EBPbeta-complexes.	Oligonucleotides	33-48	CCAAT enhancer binding protein alpha	Homo sapiens	96-101
14572618-6	2003	Surprisingly, either PDTC or DMTU inhibited the binding of TNFalpha-enhanced C/EBP complexes to the consensus site directly adjacent to the NFkappaB site.	1,3-dimethylthiourea	29-33	CCAAT enhancer binding protein alpha	Homo sapiens	77-82
12941938-11	2003	Overexpression of dominant-negative mutant C/EBP significantly abolished the ability of oltipraz to suppress 3-MC-inducible CYP1A1 and the CYP1A1 reporter gene expression.	oltipraz	88-96	CCAAT enhancer binding protein alpha	Homo sapiens	43-48
12941938-11	2003	Overexpression of dominant-negative mutant C/EBP significantly abolished the ability of oltipraz to suppress 3-MC-inducible CYP1A1 and the CYP1A1 reporter gene expression.	Methylcholanthrene	109-113	CCAAT enhancer binding protein alpha	Homo sapiens	43-48
14523996-3	2003	We tested the effect of SA on the activity of CCAAT/enhancer binding protein (C/EBP), activating protein-1 (AP-1), and CRE binding proteins in IL-1beta-treated Caco-2 cells.	sodium arsenite	24-26	CCAAT enhancer binding protein alpha	Homo sapiens	46-76
14523996-3	2003	We tested the effect of SA on the activity of CCAAT/enhancer binding protein (C/EBP), activating protein-1 (AP-1), and CRE binding proteins in IL-1beta-treated Caco-2 cells.	sodium arsenite	24-26	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
14522018-7	2003	Depletion of Rel proteins from Hep3B nuclei led to decreased formation of C/EBPbeta-complexes on a CRP promoter-derived oligonucleotide that contained only the intact C/EBP binding site but not the nonconsensus kappaB site.	Oligonucleotides	120-135	CCAAT enhancer binding protein alpha	Homo sapiens	74-79
12915572-6	2003	Furthermore, chromatin immunoprecipitation assay results showed that the endogenous C/EBPalpha, RTA, and RAP proteins all associate with RTA promoter sequences in tetradecanoyl phorbol acetate-induced primary effusion lymphoma (PEL) cells.	Tetradecanoylphorbol Acetate	163-192	CCAAT enhancer binding protein alpha	Homo sapiens	84-94
12783878-7	2003	Preferential luciferase activity was observed in SKN-MC concomitant with differential DNA binding activity to several responsive elements, including CREB, Oct-1, C/EBP, and Brn-2.	skn-mc	49-55	CCAAT enhancer binding protein alpha	Homo sapiens	162-167
12865412-0	2003	Keratinocyte growth factor and the transcription factors C/EBP alpha, C/EBP delta, and SREBP-1c regulate fatty acid synthesis in alveolar type II cells.	Fatty Acids	105-115	CCAAT enhancer binding protein alpha	Homo sapiens	57-68
12637525-9	2003	Our data demonstrate that the cyclic stretch of HASMC causes the increased production of IL-8 by activating the AP-1 and C/EBP transcription factors through the activation of ERK1/2 and p38 kinase signaling pathways.	hasmc	48-53	CCAAT enhancer binding protein alpha	Homo sapiens	121-126
12641495-0	2003	Insulin and dexamethasone induce GLUT4 gene expression in foetal brown adipocytes: synergistic effect through CCAAT/enhancer-binding protein alpha.	Dexamethasone	12-25	CCAAT enhancer binding protein alpha	Homo sapiens	110-146
12641495-4	2003	Dexamethasone induces the expression of CCAAT/enhancer-binding protein (C/EBP) alpha, insulin promotes myocyte enhancer factor-2 DNA-binding activity and both combined produces a significant increase in C/EBPalpha DNA-binding activity.	Dexamethasone	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	72-84
12641495-4	2003	Dexamethasone induces the expression of CCAAT/enhancer-binding protein (C/EBP) alpha, insulin promotes myocyte enhancer factor-2 DNA-binding activity and both combined produces a significant increase in C/EBPalpha DNA-binding activity.	Dexamethasone	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	203-213
12641495-6	2003	Our results show that the synergism between insulin and glucocorticoids on glucose uptake is a consequence of the activation of the GLUT4 promoter by the transcription factor C/EBPalpha.	Glucose	75-82	CCAAT enhancer binding protein alpha	Homo sapiens	175-185
12522006-1	2003	Monocytic differentiation of 32DPKCdelta cells in response to activation of protein kinase C delta (PKCdelta) by phorbol 12-myristate 13-acetate (PMA) was inhibited by exogenous CCAAT/enhancer binding protein alpha-estradiol receptor (C/EBPalpha-ER), which impeded morphologic maturation and induction of macrosialin mRNA.	Tetradecanoylphorbol Acetate	146-149	CCAAT enhancer binding protein alpha	Homo sapiens	235-245
12493739-5	2003	We show that the level of basal as well as cAMP-stimulated IL-10 transcription depends on the expression of C/EBP alpha and beta and their binding to three motifs in the promoter/enhancer region.	Cyclic AMP	43-47	CCAAT enhancer binding protein alpha	Homo sapiens	108-119
12522006-1	2003	Monocytic differentiation of 32DPKCdelta cells in response to activation of protein kinase C delta (PKCdelta) by phorbol 12-myristate 13-acetate (PMA) was inhibited by exogenous CCAAT/enhancer binding protein alpha-estradiol receptor (C/EBPalpha-ER), which impeded morphologic maturation and induction of macrosialin mRNA.	Tetradecanoylphorbol Acetate	113-144	CCAAT enhancer binding protein alpha	Homo sapiens	235-245
12727880-7	2003	Treatment with histone deacetylase inhibitors replaced the effects of steroid treatment on preadipocyte differentiation and C/EBPalpha expression, while overexpression of HDAC1 abrogated the stimulatory effects of steroid.	Steroids	70-77	CCAAT enhancer binding protein alpha	Homo sapiens	124-134
15199473-5	2003	Expression of other genes, such as inducible nitric oxide synthase and interleukin-4, may be inhibited by aspirin and salicylate by a C/EBP-dependent mechanism.	Aspirin	106-113	CCAAT enhancer binding protein alpha	Homo sapiens	134-139
15199473-5	2003	Expression of other genes, such as inducible nitric oxide synthase and interleukin-4, may be inhibited by aspirin and salicylate by a C/EBP-dependent mechanism.	Salicylates	118-128	CCAAT enhancer binding protein alpha	Homo sapiens	134-139
12406909-5	2003	Induction of C/EBPalpha function in primary human CD34(+) cells, by the addition of beta-estradiol, leads to granulocytic differentiation and inhibits erythrocyte differentiation.	Estradiol	84-98	CCAAT enhancer binding protein alpha	Homo sapiens	13-23
12406909-6	2003	Using Affymetrix (Santa Clara, CA) oligonucleotide arrays we have identified C/EBPalpha target genes in primary human hematopoietic cells, including granulocyte-specific genes that are involved in hematopoietic differentiation and inhibitor of differentiation 1 (Id1), a transcriptional repressor known to interfere with erythrocyte differentiation.	Oligonucleotides	35-50	CCAAT enhancer binding protein alpha	Homo sapiens	77-87
12493739-6	2003	The C/EBP5 motif, which is located between the TATA-box and the translation start point, is essential for the C/EBP-mediated constitutive and most of the cAMP-stimulated expression as its mutation nearly abolished IL-10 promoter activity.	Cyclic AMP	154-158	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
12477864-14	2003	A chromatin immunoprecipitation assay showed that all three proteins associated specifically with RAP promoter DNA in vivo and that, when C/EBPalpha was removed from a tetradecanoyl phorbol acetate-treated JSC-1 primary effusion lymphoma cell lysate, the levels of association of RTA and RAP with the RAP promoter were reduced 3- and 13-fold, respectively.	Tetradecanoylphorbol Acetate	168-197	CCAAT enhancer binding protein alpha	Homo sapiens	138-148
12637982-0	2003	Thiazolidinediones (PPARgamma ligands) increase IRS-1, UCP-2 and C/EBPalpha expression, but not transdifferentiation, in L6 muscle cells.	Thiazolidinediones	0-18	CCAAT enhancer binding protein alpha	Homo sapiens	65-75
12637982-12	2003	Activation of C/EBPalpha by TZD could be necessary but it is not sufficient to account for the increased IRS-1 expression.	Thiazolidinediones	28-31	CCAAT enhancer binding protein alpha	Homo sapiens	14-24
12837037-7	2003	In terms of main findings, dexamethasone induces expression of both HNF4 and C/EBPalpha, essential transcription factors for hepatocyte differentiation.	Dexamethasone	27-40	CCAAT enhancer binding protein alpha	Homo sapiens	77-87
12502863-0	2003	CCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle.	zta	52-55	CCAAT enhancer binding protein alpha	Homo sapiens	0-36
12524255-9	2003	Gel shift assay revealed that C/EBP proteins can bind the -393C/T polymorphic site.	Tetrahydrocortisone	54-57	CCAAT enhancer binding protein alpha	Homo sapiens	30-35
12502863-11	2003	Similarly, ZTA alone had little effect on the p21 promoter in transient reporter gene assays, but in the presence of cotransfected C/EBPalpha, ZTA enhanced the level of C/EBPalpha activation.	zta	143-146	CCAAT enhancer binding protein alpha	Homo sapiens	131-141
12477864-16	2003	Binding to C/EBPalpha occurred within the N-terminal DNA binding domain of RTA, and deletion of a 17-amino-acid basic motif of RTA abolished both the C/EBPalpha and DNA binding activities as well as all RTA transactivation and the cooperativity with C/EBPalpha.	17-amino-acid	98-111	CCAAT enhancer binding protein alpha	Homo sapiens	150-160
12502863-11	2003	Similarly, ZTA alone had little effect on the p21 promoter in transient reporter gene assays, but in the presence of cotransfected C/EBPalpha, ZTA enhanced the level of C/EBPalpha activation.	zta	143-146	CCAAT enhancer binding protein alpha	Homo sapiens	169-179
12502863-14	2003	Overall, we conclude that C/EBPalpha is essential for at least one pathway of ZTA-induced G(1) arrest during EBV lytic-cycle DNA replication and that this process involves a physical piggyback interaction between ZTA and C/EBPalpha leading to greatly enhanced C/EBPalpha and p21 levels through both transcriptional and posttranslational mechanisms.	zta	78-81	CCAAT enhancer binding protein alpha	Homo sapiens	26-36
12502863-14	2003	Overall, we conclude that C/EBPalpha is essential for at least one pathway of ZTA-induced G(1) arrest during EBV lytic-cycle DNA replication and that this process involves a physical piggyback interaction between ZTA and C/EBPalpha leading to greatly enhanced C/EBPalpha and p21 levels through both transcriptional and posttranslational mechanisms.	zta	78-81	CCAAT enhancer binding protein alpha	Homo sapiens	221-231
12502863-0	2003	CCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle.	zta	69-72	CCAAT enhancer binding protein alpha	Homo sapiens	0-36
12502863-5	2003	Double-label immunofluorescence assays (IFA) performed with Ad-ZTA-infected HF cells revealed that only ZTA-positive cells induced the expression of both endogenous C/EBPalpha and p21 and blocked the progression into S phase, as detected by a lack of incorporation of bromodeoxyuridine.	zta	104-107	CCAAT enhancer binding protein alpha	Homo sapiens	165-175
12502863-7	2003	Mechanistically, the ZTA protein proved to directly interact with C/EBPalpha by coimmunoprecipitation in EBV-Akata cells and with DNA-bound C/EBPalpha in electrophoretic mobility shift assay experiments, and the in vitro interaction domain encompassed the basic leucine zipper domain of ZTA.	zta	21-24	CCAAT enhancer binding protein alpha	Homo sapiens	66-76
12502863-7	2003	Mechanistically, the ZTA protein proved to directly interact with C/EBPalpha by coimmunoprecipitation in EBV-Akata cells and with DNA-bound C/EBPalpha in electrophoretic mobility shift assay experiments, and the in vitro interaction domain encompassed the basic leucine zipper domain of ZTA.	zta	21-24	CCAAT enhancer binding protein alpha	Homo sapiens	140-150
12502863-8	2003	ZTA also specifically protected C/EBPalpha from degradation in a protein stability assay with a non-EBV-induced Akata cell proteasome extract.	zta	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
12502863-9	2003	Furthermore, both C/EBPalpha and ZTA were found to specifically associate with the C/EBPalpha promoter in chromatin immunoprecipitation assays, but the interaction with ZTA appeared to be mediated by C/EBPalpha because it was abolished by clearing with anti-C/EBPalpha antibody.	zta	33-36	CCAAT enhancer binding protein alpha	Homo sapiens	83-93
12502863-9	2003	Furthermore, both C/EBPalpha and ZTA were found to specifically associate with the C/EBPalpha promoter in chromatin immunoprecipitation assays, but the interaction with ZTA appeared to be mediated by C/EBPalpha because it was abolished by clearing with anti-C/EBPalpha antibody.	zta	33-36	CCAAT enhancer binding protein alpha	Homo sapiens	83-93
12502863-9	2003	Furthermore, both C/EBPalpha and ZTA were found to specifically associate with the C/EBPalpha promoter in chromatin immunoprecipitation assays, but the interaction with ZTA appeared to be mediated by C/EBPalpha because it was abolished by clearing with anti-C/EBPalpha antibody.	zta	33-36	CCAAT enhancer binding protein alpha	Homo sapiens	83-93
12502863-9	2003	Furthermore, both C/EBPalpha and ZTA were found to specifically associate with the C/EBPalpha promoter in chromatin immunoprecipitation assays, but the interaction with ZTA appeared to be mediated by C/EBPalpha because it was abolished by clearing with anti-C/EBPalpha antibody.	zta	169-172	CCAAT enhancer binding protein alpha	Homo sapiens	18-28
12502863-14	2003	Overall, we conclude that C/EBPalpha is essential for at least one pathway of ZTA-induced G(1) arrest during EBV lytic-cycle DNA replication and that this process involves a physical piggyback interaction between ZTA and C/EBPalpha leading to greatly enhanced C/EBPalpha and p21 levels through both transcriptional and posttranslational mechanisms.	zta	78-81	CCAAT enhancer binding protein alpha	Homo sapiens	221-231
12502863-14	2003	Overall, we conclude that C/EBPalpha is essential for at least one pathway of ZTA-induced G(1) arrest during EBV lytic-cycle DNA replication and that this process involves a physical piggyback interaction between ZTA and C/EBPalpha leading to greatly enhanced C/EBPalpha and p21 levels through both transcriptional and posttranslational mechanisms.	zta	213-216	CCAAT enhancer binding protein alpha	Homo sapiens	26-36
12477864-16	2003	Binding to C/EBPalpha occurred within the N-terminal DNA binding domain of RTA, and deletion of a 17-amino-acid basic motif of RTA abolished both the C/EBPalpha and DNA binding activities as well as all RTA transactivation and the cooperativity with C/EBPalpha.	17-amino-acid	98-111	CCAAT enhancer binding protein alpha	Homo sapiens	150-160
12145290-7	2002	Finally, we show that interleukin-6 treatment in the presence or absence of overexpressed C/EBPbeta increased the promoter activities of reporter constructs containing nucleoside A at -217 compared with reporter constructs containing nucleoside G at -217.	nucleoside a	168-180	CCAAT enhancer binding protein alpha	Homo sapiens	90-99
12095417-3	2002	We found that genistein blocked the DNA binding and transcriptional activity of CCAAT/enhancer-binding protein beta (C/EBPbeta) during differentiation by promoting the expression of C/EBP homologous protein, a dominant-negative member of the C/EBP family.	Genistein	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	117-122
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	U 0126	82-87	CCAAT enhancer binding protein alpha	Homo sapiens	274-286
12270934-2	2002	Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2).	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	91-98	CCAAT enhancer binding protein alpha	Homo sapiens	274-286
12237288-2	2002	Because both the CRE-binding protein and several C/EBP isoforms can to bind to the CRE with similar affinity, a variety of transcription factor bindings arrays in the cAMP response unit are possible that may affect the protein kinase A (PKA) responsivity of the promoter.	Cyclic AMP	167-171	CCAAT enhancer binding protein alpha	Homo sapiens	49-54
12410800-10	2002	The functional significance of the C/EBP site as indicated by the immunohistochemical result was that in HASMCs anti-C/EBPbeta reactivity was shifted from the cytoplasm to the nuclei.	hasmcs	105-111	CCAAT enhancer binding protein alpha	Homo sapiens	35-40
12161447-9	2002	Importantly, the RDM is similar to the recognition sequence for attachment of the ubiquitin-like protein, small ubiquitin-like modifier-1 (SUMO-1), and the conserved lysine residue of each C/EBP RDM served as an attachment site for SUMO-1.	Lysine	166-172	CCAAT enhancer binding protein alpha	Homo sapiens	189-194
12071851-3	2002	The addition of exogenous N-acetylsphingosine (C2-ceramide) or increasing endogenous ceramide levels inhibited the expression of C/EBPalpha and PPARgamma, and blocked adipocyte development.	Ceramides	50-58	CCAAT enhancer binding protein alpha	Homo sapiens	129-139
11997389-3	2002	Previously, we have identified a thyroid hormone response element in the PEPCK promoter and demonstrated that C/EBP proteins bound to the P3(I) site are participants in the induction of PEPCK gene expression by thyroid hormone and cAMP.	Cyclic AMP	231-235	CCAAT enhancer binding protein alpha	Homo sapiens	110-115
11997389-5	2002	We also demonstrate that several conserved amino acids in the transactivation domain of C/EBP(alpha) and C/EBPbeta are required for the stimulation of basal gene expression and identify amino acids within C/EBPbeta that participate in the cAMP induction of the PEPCK gene.	Cyclic AMP	239-243	CCAAT enhancer binding protein alpha	Homo sapiens	88-100
12071851-3	2002	The addition of exogenous N-acetylsphingosine (C2-ceramide) or increasing endogenous ceramide levels inhibited the expression of C/EBPalpha and PPARgamma, and blocked adipocyte development.	N-acetylsphingosine	26-45	CCAAT enhancer binding protein alpha	Homo sapiens	129-139
12071851-3	2002	The addition of exogenous N-acetylsphingosine (C2-ceramide) or increasing endogenous ceramide levels inhibited the expression of C/EBPalpha and PPARgamma, and blocked adipocyte development.	N-acetylsphingosine	47-58	CCAAT enhancer binding protein alpha	Homo sapiens	129-139
12115737-5	2002	When Caco-2 cells were treated with IL-1beta in the presence of the MAPK inhibitor, PD-98059, IL-6 mRNA and protein levels were reduced by the same concentrations of PD-98059 that inhibited C/EBP DNA binding activity in previous studies.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	166-174	CCAAT enhancer binding protein alpha	Homo sapiens	190-195
11978798-9	2002	Transfection with a dominant negative AP-1 construct or mutation of the AP-1, GATA, or C/EBP sites in the -272-bp IL-8 promoter construct blocked induction by nickel.	Nickel	159-165	CCAAT enhancer binding protein alpha	Homo sapiens	87-92
12074569-0	2002	Involvement of CCAAT/enhancer-binding protein alpha in haptoglobin gene expression by all-trans-retinoic acid.	Tretinoin	86-109	CCAAT enhancer binding protein alpha	Homo sapiens	15-51
12074569-4	2002	Western blot analysis showed that treatment with ATRA increased C/EBPalpha and beta expression, but decreased that of C/EBPdelta.	Tretinoin	49-53	CCAAT enhancer binding protein alpha	Homo sapiens	64-74
12074569-6	2002	Furthermore, when ATRA-dependent Hp induction was inhibited by sodium butyrate or auranofin, induction of C/EBPalpha, but not C/EBPbeta, was also diminished.	Tretinoin	18-22	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
12074569-6	2002	Furthermore, when ATRA-dependent Hp induction was inhibited by sodium butyrate or auranofin, induction of C/EBPalpha, but not C/EBPbeta, was also diminished.	Butyric Acid	63-78	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
12086590-8	2002	The counteracting effects of USF2 and C/EBPbeta observed on the RIIbeta promoter is in accordance with the hypothesis that C/EBP and USF play opposite roles in regulation of glucose metabolism.	Glucose	174-181	CCAAT enhancer binding protein alpha	Homo sapiens	38-43
11994385-5	2002	In this study, we disrupted several potential sequences and found that mutations of a -211/-197-bp cAMP-response element (CRE) and a -317/-304-bp C/EBP binding site abolished both baseline and cAMP-induced promoter II activity.	Cyclic AMP	193-197	CCAAT enhancer binding protein alpha	Homo sapiens	146-151
11825899-7	2002	In SK-N-MC cells, which display constitutive, high expression of IGF-I on use of the major promoter, a large amount of C/EBP beta binding was observed with the C/EBP site in the basal state.	sk-n-mc	3-10	CCAAT enhancer binding protein alpha	Homo sapiens	119-124
11825899-10	2002	These observations suggest that the increase of C/EBP beta binding to the C/EBP site, which is in part mediated via activation of RSK, can primarily explain the TPA responsiveness of the IGF-I gene promoter.	Tetradecanoylphorbol Acetate	161-164	CCAAT enhancer binding protein alpha	Homo sapiens	48-53
11825899-4	2002	A CCAAT/enhancer-binding protein (C/EBP) binding site located at +22 to +30 was bound by C/EBP beta in a TPA-dependent manner and was solely responsible for the TPA responsiveness.	Tetradecanoylphorbol Acetate	105-108	CCAAT enhancer binding protein alpha	Homo sapiens	2-32
11825899-4	2002	A CCAAT/enhancer-binding protein (C/EBP) binding site located at +22 to +30 was bound by C/EBP beta in a TPA-dependent manner and was solely responsible for the TPA responsiveness.	Tetradecanoylphorbol Acetate	105-108	CCAAT enhancer binding protein alpha	Homo sapiens	34-39
11825899-4	2002	A CCAAT/enhancer-binding protein (C/EBP) binding site located at +22 to +30 was bound by C/EBP beta in a TPA-dependent manner and was solely responsible for the TPA responsiveness.	Tetradecanoylphorbol Acetate	161-164	CCAAT enhancer binding protein alpha	Homo sapiens	2-32
11825899-4	2002	A CCAAT/enhancer-binding protein (C/EBP) binding site located at +22 to +30 was bound by C/EBP beta in a TPA-dependent manner and was solely responsible for the TPA responsiveness.	Tetradecanoylphorbol Acetate	161-164	CCAAT enhancer binding protein alpha	Homo sapiens	34-39
12016158-5	2002	Using transient transfections with reporter constructs, we showed that the transcription factors activator protein-1 (AP-1) and NF-kB were increased in HCT 116 cells, in a dose-dependent fashion, by DCA COX-2 promoter activity was also induced by DCA and using mutant COX-2 promoter plasmids, we showed that the ability of DCA to induce promoter activity was partly dependent upon a functional NF-kB and C/EBP site, and completely dependent on a functional c-AMP response element site.	Deoxycholic Acid	199-202	CCAAT enhancer binding protein alpha	Homo sapiens	404-409
11994385-6	2002	Ectopic expression of C/EBPalpha increased both baseline and cAMP-dependent promoter II activity significantly in endometriotic cells, whereas ectopic expression of C/EBPbeta or C/EBPdelta abolished promoter II activity in both untreated and cAMP-treated endometriotic stromal cells.	Cyclic AMP	61-65	CCAAT enhancer binding protein alpha	Homo sapiens	22-32
11958950-2	2002	In this study, we investigated the effect of NAL upon oxidant-mediated interleukin (IL)-8 release and the activation of the redox-sensitive transcription factors AP-1, NF-kappaB, and C/EBP in a human alveolar epithelial cell line (A549).	N-acetylcysteine lysinate	45-48	CCAAT enhancer binding protein alpha	Homo sapiens	183-188
11861917-4	2002	Thermal denaturation in 150 mM KCl indicates that the CREB B-ZIP domain binds all the DNA sequences, with highest affinity for the CRE site, followed by the PAR (5"-TAACGTTA-3"), C/EBP (5"-TTGCGCAA-3") and AP-1 (5"-TGAGTCA-3") sites.	Potassium Chloride	31-34	CCAAT enhancer binding protein alpha	Homo sapiens	179-184
11911941-5	2002	Interestingly, a number of other gene promoters that are activated in response to cAMP also contain binding sites for C/EBP, and these binding sites are often located within the region of the promoter that is responsible for mediating the acute responsiveness to cAMP.	Cyclic AMP	82-86	CCAAT enhancer binding protein alpha	Homo sapiens	118-123
11911941-5	2002	Interestingly, a number of other gene promoters that are activated in response to cAMP also contain binding sites for C/EBP, and these binding sites are often located within the region of the promoter that is responsible for mediating the acute responsiveness to cAMP.	Cyclic AMP	263-267	CCAAT enhancer binding protein alpha	Homo sapiens	118-123
11861917-5	2002	The addition of 10 mM MgCl2 diminished DNA binding to the CRE and PAR DNA sequences and abolished binding to the C/EBP and AP-1 DNA sequences, resulting in more sequence-specific DNA binding.	Magnesium Chloride	22-27	CCAAT enhancer binding protein alpha	Homo sapiens	113-118
11812925-8	2002	Because C/EBP alpha is important in the expression of certain keratinocyte-specific genes, the negative effect of arsenic on C/EBP alpha might also contribute to the development of skin cancer.	Arsenic	114-121	CCAAT enhancer binding protein alpha	Homo sapiens	125-136
11751971-0	2002	Prostaglandin E(2)-mediated activation of HIV-1 long terminal repeat transcription in human T cells necessitates CCAAT/enhancer binding protein (C/EBP) binding sites in addition to cooperative interactions between C/EBPbeta and cyclic adenosine 5"-monophosphate response element binding protein.	Dinoprostone	0-18	CCAAT enhancer binding protein alpha	Homo sapiens	113-143
11779194-9	2002	The effects of the proteasome inhibitors on C/EBP were inhibited by treating the cells with quercetin, a substance known to block the heat shock response.	Quercetin	92-101	CCAAT enhancer binding protein alpha	Homo sapiens	44-49
11751971-0	2002	Prostaglandin E(2)-mediated activation of HIV-1 long terminal repeat transcription in human T cells necessitates CCAAT/enhancer binding protein (C/EBP) binding sites in addition to cooperative interactions between C/EBPbeta and cyclic adenosine 5"-monophosphate response element binding protein.	Dinoprostone	0-18	CCAAT enhancer binding protein alpha	Homo sapiens	145-150
11751971-3	2002	We report in this work that the nuclear transcription factor CCAAT/enhancer binding protein (C/EBP) is also important for PGE(2)-dependent up-regulation of HIV-1 LTR-driven gene activity.	Dinoprostone	122-128	CCAAT enhancer binding protein alpha	Homo sapiens	61-91
11751971-3	2002	We report in this work that the nuclear transcription factor CCAAT/enhancer binding protein (C/EBP) is also important for PGE(2)-dependent up-regulation of HIV-1 LTR-driven gene activity.	Dinoprostone	122-128	CCAAT enhancer binding protein alpha	Homo sapiens	93-98
11160683-2	2001	Additionally, sequence variation at C/EBP site I, which lies immediately upstream of the distal nuclear factor kappa B site and immediately downstream of a binding site for activating transcription factor (ATF)/cyclic AMP response element binding protein (CREB), has been shown to affect HIV-1 long terminal repeat (LTR) activity.	Cyclic AMP	211-221	CCAAT enhancer binding protein alpha	Homo sapiens	36-41
11673276-7	2001	However, there was also significant but less dramatic inhibition of cloprostenol stimulation by mutation of C/EBP and CRE in the Cox-2 promoter, and mutation of all three elements eliminated cloprostenol induction of this promoter.	Cloprostenol	68-80	CCAAT enhancer binding protein alpha	Homo sapiens	108-113
11682632-3	2001	However, the molecular mechanisms by which LIF and prostacyclin-induced signals are propagated to the nucleus and the transcription factors mediating ERK and cAMP-induced C/EBP gene expression were unknown.	Cyclic AMP	158-162	CCAAT enhancer binding protein alpha	Homo sapiens	171-176
11476938-0	2001	Characterization of domains in C/EBPalpha that mediate its constitutive and cAMP-inducible activities.	Cyclic AMP	76-80	CCAAT enhancer binding protein alpha	Homo sapiens	31-41
11476938-1	2001	Structure/function analysis of CCAAT/enhancer binding proteins (C/EBP) alpha and beta have shown that they possess both constitutive and cAMP inducible activities.	Cyclic AMP	137-141	CCAAT enhancer binding protein alpha	Homo sapiens	64-76
11476938-2	2001	Three regions conserved between C/EBPalpha and beta were identified which lie within the cAMP inducible domains of each protein.	Cyclic AMP	89-93	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
11403491-3	2001	Columns having a discrete DNA sequence bound by cytidylic-adenylic-adenylic-thymidylic oligonucleotide (CAAT) enhancer binding protein (C/EBP) yields significantly more green fluorescent protein-C/EBP (GFP-C/EBP) fusion protein than a concatemeric DNA column made from five tandem repeats of the same DNA sequence.	Oligonucleotides	87-102	CCAAT enhancer binding protein alpha	Homo sapiens	136-141
11317672-10	2001	During early stages of adipocyte differentiation, dexamethasone induced the expression of the transcription factors PPAR gamma (peroxisome proliferator activated receptor gamma) and C/EBP alpha (CCAAT/enhancer binding protein alpha) while inhibiting the expression of the inhibitor of DNA binding Id2.	Dexamethasone	50-63	CCAAT enhancer binding protein alpha	Homo sapiens	182-193
11317672-10	2001	During early stages of adipocyte differentiation, dexamethasone induced the expression of the transcription factors PPAR gamma (peroxisome proliferator activated receptor gamma) and C/EBP alpha (CCAAT/enhancer binding protein alpha) while inhibiting the expression of the inhibitor of DNA binding Id2.	Dexamethasone	50-63	CCAAT enhancer binding protein alpha	Homo sapiens	195-231
11317672-11	2001	CONCLUSION/INTERPRETATION: The effect of dexamethasone on human adipocyte differentiation is not mediated by reduction of TNF-alpha expression but more likely by regulation of the expression of nuclear factors such as PPAR gamma, CEBP alpha and Id2.	Dexamethasone	41-54	CCAAT enhancer binding protein alpha	Homo sapiens	230-240
11160296-4	2001	Depletion of free Rel proteins by pretreatment of nuclear extracts with a kappaB consensus oligonucleotide markedly decreased formation of C/EBP complexes, indicating that Rel proteins are required for formation of such complexes.	Oligonucleotides	91-106	CCAAT enhancer binding protein alpha	Homo sapiens	139-144
11182553-3	2001	Addition of 100 microM oleic acid (C18:1) for 5 days increased differentiation and the mRNA levels for PPARgamma, C/EBPalpha, LPL and aP2.	Oleic Acid	23-33	CCAAT enhancer binding protein alpha	Homo sapiens	114-124
11182553-9	2001	Taken together, these results indicate that selected fatty acids modulate porcine adipocyte differentiation and transcripts for adipocyte differentiation-related proteins such as PPARgamma, C/EBPalpha, LPL and aP2.	Fatty Acids	53-64	CCAAT enhancer binding protein alpha	Homo sapiens	190-200
11682632-6	2001	Expression of dominant negative forms of CREB dramatically reduced the LIF- and prostacyclin-stimulated C/EBP beta and C/EBP delta expression.	Epoprostenol	80-92	CCAAT enhancer binding protein alpha	Homo sapiens	104-109
18498477-4	2001	These results indicate that retinol per se inhibits the adipo-conversion of human preadipocytes and suggest that the mechanisms of this antiadipogenic action implies at least in part inhibition of C/EBP transcriptional activity.	Vitamin A	28-35	CCAAT enhancer binding protein alpha	Homo sapiens	197-202
11160296-2	2001	Accordingly, we employed EMSA to investigate possible cooperation between p50 and C/EBP proteins using an oligonucleotide probe (-63/-41) derived from the CRP promoter and containing both C/EBP and p50 binding sites.	Oligonucleotides	106-121	CCAAT enhancer binding protein alpha	Homo sapiens	82-87
10567568-5	1999	Accordingly, GSK3 phosphorylates the predicted region of C/EBPalpha on threonine in vitro, and GSK3 uses C/EBPalpha as a substrate in vivo.	Threonine	71-80	CCAAT enhancer binding protein alpha	Homo sapiens	57-67
11253404-2	2001	The incubation of the CNS with serotonin that imitates the effects of conditioning or stimulation of adenylate cyclase with forscolin also increase the DNA-binding activity of C/EBP.	Serotonin	31-40	CCAAT enhancer binding protein alpha	Homo sapiens	176-181
11253404-2	2001	The incubation of the CNS with serotonin that imitates the effects of conditioning or stimulation of adenylate cyclase with forscolin also increase the DNA-binding activity of C/EBP.	forscolin	124-133	CCAAT enhancer binding protein alpha	Homo sapiens	176-181
11253404-4	2001	However, a slight increase in the cAMP-induced influence on the activation of C/EBP transcription factors was observed during a combined action of phorbol ester and serotonin.	Cyclic AMP	34-38	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
11253404-4	2001	However, a slight increase in the cAMP-induced influence on the activation of C/EBP transcription factors was observed during a combined action of phorbol ester and serotonin.	Phorbol Esters	147-160	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
11253404-4	2001	However, a slight increase in the cAMP-induced influence on the activation of C/EBP transcription factors was observed during a combined action of phorbol ester and serotonin.	Serotonin	165-174	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
11253404-5	2001	The more substantial cAMP-induced rise in DNA-binding activity of C/EBP family transcription factors was observed during increase in the intracellular Ca2+ concentration (incubation of the CNS with calcium ionophor A23187 and forscolin).	Cyclic AMP	21-25	CCAAT enhancer binding protein alpha	Homo sapiens	66-71
11253404-5	2001	The more substantial cAMP-induced rise in DNA-binding activity of C/EBP family transcription factors was observed during increase in the intracellular Ca2+ concentration (incubation of the CNS with calcium ionophor A23187 and forscolin).	Calcium	198-205	CCAAT enhancer binding protein alpha	Homo sapiens	66-71
11253404-5	2001	The more substantial cAMP-induced rise in DNA-binding activity of C/EBP family transcription factors was observed during increase in the intracellular Ca2+ concentration (incubation of the CNS with calcium ionophor A23187 and forscolin).	forscolin	226-235	CCAAT enhancer binding protein alpha	Homo sapiens	66-71
11253404-6	2001	Thus, the convergence of Ca2+ and cAMP-dependent regulating signals that reflect the interaction of different modal stimuli during learning can produce the intensification of formation of the C/EBP transcription complexes.	Cyclic AMP	34-38	CCAAT enhancer binding protein alpha	Homo sapiens	192-197
11085926-7	2000	Our data support a model in which cAMP agonists increase CREB activity and stimulate PEPCK gene transcription, a process that is enhanced by E1a through the phosphorylation of C/EBPalpha.	Cyclic AMP	34-38	CCAAT enhancer binding protein alpha	Homo sapiens	176-186
11101056-9	2000	In contrast, ritonavir attenuated the differentiation-induced increase in CEBPalpha and PPARgamma.	Ritonavir	13-22	CCAAT enhancer binding protein alpha	Homo sapiens	74-83
11042264-3	2000	The cAMP response element (CRE)-1 site within the proximal promoter region mediated the HBx-induced transactivation of the PEPCK gene through C/EBP alpha and ATF-2.	Cyclic AMP	4-8	CCAAT enhancer binding protein alpha	Homo sapiens	142-153
10970794-0	2000	Thapsigargin suppresses phorbol ester-dependent human involucrin promoter activity by suppressing CCAAT-enhancer-binding protein alpha (C/EBPalpha) DNA binding.	Thapsigargin	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	98-134
10970794-0	2000	Thapsigargin suppresses phorbol ester-dependent human involucrin promoter activity by suppressing CCAAT-enhancer-binding protein alpha (C/EBPalpha) DNA binding.	Thapsigargin	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	136-146
10970794-0	2000	Thapsigargin suppresses phorbol ester-dependent human involucrin promoter activity by suppressing CCAAT-enhancer-binding protein alpha (C/EBPalpha) DNA binding.	Phorbol Esters	24-37	CCAAT enhancer binding protein alpha	Homo sapiens	98-134
10970794-0	2000	Thapsigargin suppresses phorbol ester-dependent human involucrin promoter activity by suppressing CCAAT-enhancer-binding protein alpha (C/EBPalpha) DNA binding.	Phorbol Esters	24-37	CCAAT enhancer binding protein alpha	Homo sapiens	136-146
10748164-3	2000	Studies in HepG2 cells showed that binding of AP-1 and CAAT/enhancer-binding protein (C/EBP) to AC is required for induction by cAMP, but insulin did not inhibit cAMP-induced PEPCK expression in HepG2 cells.	Actinium	96-98	CCAAT enhancer binding protein alpha	Homo sapiens	55-84
10748164-3	2000	Studies in HepG2 cells showed that binding of AP-1 and CAAT/enhancer-binding protein (C/EBP) to AC is required for induction by cAMP, but insulin did not inhibit cAMP-induced PEPCK expression in HepG2 cells.	Actinium	96-98	CCAAT enhancer binding protein alpha	Homo sapiens	86-91
10748164-3	2000	Studies in HepG2 cells showed that binding of AP-1 and CAAT/enhancer-binding protein (C/EBP) to AC is required for induction by cAMP, but insulin did not inhibit cAMP-induced PEPCK expression in HepG2 cells.	Cyclic AMP	128-132	CCAAT enhancer binding protein alpha	Homo sapiens	55-84
10748164-3	2000	Studies in HepG2 cells showed that binding of AP-1 and CAAT/enhancer-binding protein (C/EBP) to AC is required for induction by cAMP, but insulin did not inhibit cAMP-induced PEPCK expression in HepG2 cells.	Cyclic AMP	128-132	CCAAT enhancer binding protein alpha	Homo sapiens	86-91
10834576-4	2000	Seeding and plating in dexamethasone (DEX) + FBS from d 0 to 3 markedly increased the proportions and numbers of preadipocytes and C/EBPalpha-reactive cells compared to seeding and plating in FBS, d 0 to 3.	Dexamethasone	23-36	CCAAT enhancer binding protein alpha	Homo sapiens	131-141
10834576-4	2000	Seeding and plating in dexamethasone (DEX) + FBS from d 0 to 3 markedly increased the proportions and numbers of preadipocytes and C/EBPalpha-reactive cells compared to seeding and plating in FBS, d 0 to 3.	Dexamethasone	38-41	CCAAT enhancer binding protein alpha	Homo sapiens	131-141
10834576-5	2000	The number of C/EBPalpha- and C/EBPbeta-reactive cells and preadipocyte reactivity for C/EBPbeta decreased with insulin or DEX treatment, d 3 to 6, following FBS, d 0 to 3.	Dexamethasone	123-126	CCAAT enhancer binding protein alpha	Homo sapiens	14-31
10834576-6	2000	However, insulin + DEX treatment, d 3 to 6, maintained the number of C/EBPalpha-reactive cells and either maintained or increased preadipocyte reactivity for C/EBPalpha and C/EBPbeta.	Dexamethasone	19-22	CCAAT enhancer binding protein alpha	Homo sapiens	69-79
10834576-6	2000	However, insulin + DEX treatment, d 3 to 6, maintained the number of C/EBPalpha-reactive cells and either maintained or increased preadipocyte reactivity for C/EBPalpha and C/EBPbeta.	Dexamethasone	19-22	CCAAT enhancer binding protein alpha	Homo sapiens	158-168
10706790-1	2000	Oligonucleotides bound by the CAAT enhancer binding protein (C/EBP), the lactose repressor, and Gal4 were chemically coupled to cyanogen bromide-activated Sepharose and the temperature dependence of transcription factor chromatography was characterized.	Oligonucleotides	0-16	CCAAT enhancer binding protein alpha	Homo sapiens	30-59
10706790-1	2000	Oligonucleotides bound by the CAAT enhancer binding protein (C/EBP), the lactose repressor, and Gal4 were chemically coupled to cyanogen bromide-activated Sepharose and the temperature dependence of transcription factor chromatography was characterized.	Oligonucleotides	0-16	CCAAT enhancer binding protein alpha	Homo sapiens	61-66
10706790-1	2000	Oligonucleotides bound by the CAAT enhancer binding protein (C/EBP), the lactose repressor, and Gal4 were chemically coupled to cyanogen bromide-activated Sepharose and the temperature dependence of transcription factor chromatography was characterized.	Cyanogen Bromide	128-144	CCAAT enhancer binding protein alpha	Homo sapiens	30-59
10706790-1	2000	Oligonucleotides bound by the CAAT enhancer binding protein (C/EBP), the lactose repressor, and Gal4 were chemically coupled to cyanogen bromide-activated Sepharose and the temperature dependence of transcription factor chromatography was characterized.	Cyanogen Bromide	128-144	CCAAT enhancer binding protein alpha	Homo sapiens	61-66
10706790-1	2000	Oligonucleotides bound by the CAAT enhancer binding protein (C/EBP), the lactose repressor, and Gal4 were chemically coupled to cyanogen bromide-activated Sepharose and the temperature dependence of transcription factor chromatography was characterized.	Sepharose	155-164	CCAAT enhancer binding protein alpha	Homo sapiens	30-59
10706790-1	2000	Oligonucleotides bound by the CAAT enhancer binding protein (C/EBP), the lactose repressor, and Gal4 were chemically coupled to cyanogen bromide-activated Sepharose and the temperature dependence of transcription factor chromatography was characterized.	Sepharose	155-164	CCAAT enhancer binding protein alpha	Homo sapiens	61-66
10706790-4	2000	As temperature was increases, less salt was required to elute C/EBP, more salt was required to elute lac repressor, while Gal4 showed a biphasic dependency with the amount of salt first decreasing between 4 and 19 degrees C and then increasing above 19 degrees C. This temperature dependence is not due to protein or DNA unfolding but rather is a property of complex formation.	Salts	35-39	CCAAT enhancer binding protein alpha	Homo sapiens	62-67
11134336-7	2001	In addition to Zta, we found that two other b-zip proteins, NF-E2 and C/EBPalpha, strongly stimulated nucleosomal HAT activity.	zta	15-18	CCAAT enhancer binding protein alpha	Homo sapiens	70-80
11085926-4	2000	This result was supported by experiments in which expression of dominant-negative CREB and/or C/EBP proteins repressed E1a- and cAMP-stimulated transcription from the PEPCK gene promoter.	Cyclic AMP	128-132	CCAAT enhancer binding protein alpha	Homo sapiens	94-99
11085926-5	2000	In reconstitution experiments using a Gal4-responsive promoter, E1a enhanced cAMP-stimulated transcription when chimaeric Gal4-CREB and Gal4-C/EBPalpha were co-expressed.	Cyclic AMP	77-81	CCAAT enhancer binding protein alpha	Homo sapiens	141-151
10942517-6	2000	Sequence analysis by GCG identifies multiple recognition sites for the AP-1 and C/EBP transcription factors.	gallocatechin gallate	21-24	CCAAT enhancer binding protein alpha	Homo sapiens	80-85
10854692-6	2000	Since alpha- and beta-isoforms of C/EBP are liver-enriched, this may provide the molecular basis for the liver-specific responsiveness to cAMP.	Cyclic AMP	138-142	CCAAT enhancer binding protein alpha	Homo sapiens	34-39
10854692-8	2000	However, the non-consensus CRE in the PEPCK promoter also binds C/EBP proteins with high affinity, and C/EBPalpha can functionally substitute for CREB in this cAMP response unit while C/EBPbeta cannot.	Cyclic AMP	159-163	CCAAT enhancer binding protein alpha	Homo sapiens	103-113
10567568-7	1999	Treatment of 3T3-L1 adipocytes with the phosphatidylinositol 3-kinase inhibitor wortmannin results in phosphorylation of C/EBPalpha, whereas treatment with the GSK3 inhibitor lithium results in dephosphorylation of C/EBPalpha.	Wortmannin	80-90	CCAAT enhancer binding protein alpha	Homo sapiens	121-131
10567568-7	1999	Treatment of 3T3-L1 adipocytes with the phosphatidylinositol 3-kinase inhibitor wortmannin results in phosphorylation of C/EBPalpha, whereas treatment with the GSK3 inhibitor lithium results in dephosphorylation of C/EBPalpha.	Wortmannin	80-90	CCAAT enhancer binding protein alpha	Homo sapiens	215-225
10567568-9	1999	Since dephosphorylation of C/EBPalpha in response to lithium is blocked by okadaic acid, strong candidates for the T222 and T226 phosphatase are protein phosphatases 1 and 2a.	Lithium	53-60	CCAAT enhancer binding protein alpha	Homo sapiens	27-37
10567568-9	1999	Since dephosphorylation of C/EBPalpha in response to lithium is blocked by okadaic acid, strong candidates for the T222 and T226 phosphatase are protein phosphatases 1 and 2a.	Okadaic Acid	75-87	CCAAT enhancer binding protein alpha	Homo sapiens	27-37
10567568-11	1999	Finally, phosphorylation of C/EBPalpha and other substrates by GSK3 may be required for adipogenesis, since treatment of differentiating preadipocytes with lithium inhibits their conversion to adipocytes.	Lithium	156-163	CCAAT enhancer binding protein alpha	Homo sapiens	28-38
10037704-3	1999	In the present study we show that a CCAAT/enhancer-binding protein (C/EBP) site in the proximal regulatory region is required for the phorbol ester response.	Phorbol Esters	134-147	CCAAT enhancer binding protein alpha	Homo sapiens	36-66
10499512-10	1999	By electrophoretic mobility shift assay, prominent gel shift complexes occurred with osteoblast nuclear extracts and 32P-labeled probes spanning the E box-, C/EBP-, and NF-1-related motifs.	Phosphorus-32	117-120	CCAAT enhancer binding protein alpha	Homo sapiens	157-164
10473624-1	1999	Two putative CCAAT/enhancer-binding protein (C/EBP) response elements were identified in the proximal promoter of the human steroidogenic acute regulatory protein (StAR) gene, which encodes a key protein-regulating steroid hormone synthesis.	Steroids	215-230	CCAAT enhancer binding protein alpha	Homo sapiens	13-43
10473624-1	1999	Two putative CCAAT/enhancer-binding protein (C/EBP) response elements were identified in the proximal promoter of the human steroidogenic acute regulatory protein (StAR) gene, which encodes a key protein-regulating steroid hormone synthesis.	Steroids	215-230	CCAAT enhancer binding protein alpha	Homo sapiens	45-50
10473624-4	1999	When the putative C/EBP response elements were mutated, individually or together, a pronounced decline in basal StAR promoter activity in human granulosa-lutein cells resulted, but the fold stimulation of promoter activity by 8-Br-cAMP was unaffected.	8-Bromo Cyclic Adenosine Monophosphate	226-235	CCAAT enhancer binding protein alpha	Homo sapiens	18-23
10438498-8	1999	Furthermore, with stably transfected cell lines, we demonstrate that the C/EBP binding site in the CD14 promoter plays a critical role for mediating TGF-beta signaling in the synergistic activation of CD14 expression by vitamin D(3) and TGF-beta during U937 differentiation.	Vitamin D	220-229	CCAAT enhancer binding protein alpha	Homo sapiens	73-78
10417323-6	1999	Further analysis of the 4574+15.6 kb DHS implicates the involvement of CCAAT-enhancer-binding protein (C/EBP), cAMP-response-element-binding protein (CREB)/activating transcription factor (ATF) and activator protein 1 (AP-1) family transcription factors at this regulatory element.	dhs	37-40	CCAAT enhancer binding protein alpha	Homo sapiens	71-101
10037704-3	1999	In the present study we show that a CCAAT/enhancer-binding protein (C/EBP) site in the proximal regulatory region is required for the phorbol ester response.	Phorbol Esters	134-147	CCAAT enhancer binding protein alpha	Homo sapiens	68-73
10037704-4	1999	Mutation of the C/EBP site results in the loss of basal and TPA-responsive activity.	Tetradecanoylphorbol Acetate	60-63	CCAAT enhancer binding protein alpha	Homo sapiens	16-21
10037704-5	1999	Gel mobility supershift analysis shows that C/EBPalpha binding to this site is increased by TPA treatment.	Tetradecanoylphorbol Acetate	92-95	CCAAT enhancer binding protein alpha	Homo sapiens	44-54
10037704-8	1999	Transfection experiments using GADD153 to create C/EBP-null conditions confirm that C/EBP factors are absolutely required for promoter activity and TPA responsiveness.	Tetradecanoylphorbol Acetate	148-151	CCAAT enhancer binding protein alpha	Homo sapiens	49-54
10037704-8	1999	Transfection experiments using GADD153 to create C/EBP-null conditions confirm that C/EBP factors are absolutely required for promoter activity and TPA responsiveness.	Tetradecanoylphorbol Acetate	148-151	CCAAT enhancer binding protein alpha	Homo sapiens	84-89
10037704-9	1999	C/EBPbeta and C/EBPdelta inhibit both TPA- and C/EBPalpha-dependent promoter activation, indicating functional differences among C/EBP family members.	Tetradecanoylphorbol Acetate	38-41	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
10037704-10	1999	These results suggest that C/EBP transcription factor activity is necessary for basal promoter activity and TPA response of the involucrin gene.	Tetradecanoylphorbol Acetate	108-111	CCAAT enhancer binding protein alpha	Homo sapiens	27-32
9668047-9	1998	This tripartite array of binding sites for CREB, C/EBP, and activator protein-1 (AP-1) factors forms a cAMP response unit that, together with the minimal promoter, can mediate both induction by cAMP and inhibition by insulin.	Cyclic AMP	103-107	CCAAT enhancer binding protein alpha	Homo sapiens	49-54
9990015-3	1999	Exposure of preadipocytes to the calpain inhibitor N-acetyl-Leu-Leu-norleucinal or overexpression of calpastatin, a specific endogenous inhibitor of calpain, blocks expression of adipocyte-specific genes, notably the CCAAT/enhancer-binding protein (C/EBP)alpha gene, and acquisition of the adipocyte phenotype.	Nitrogen	51-52	CCAAT enhancer binding protein alpha	Homo sapiens	249-260
9921275-4	1998	A gel electrophoretic mobility shift assay using wild type double-stranded oligonucleotides or modified wild type duplex oligonucleotides with 10 nucleotides inserted between HNF-4 and C/EBP alpha factor motifs showed similar retarded complexes, indicating that HNF-4 and C/EBP alpha factors interact independently of the distance between binding sites.	Oligonucleotides	121-137	CCAAT enhancer binding protein alpha	Homo sapiens	185-196
9867832-4	1999	C/EBPalpha contributes to the liver-specific expression and cAMP responsiveness of the PEPCK gene.	Cyclic AMP	60-64	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
9668047-9	1998	This tripartite array of binding sites for CREB, C/EBP, and activator protein-1 (AP-1) factors forms a cAMP response unit that, together with the minimal promoter, can mediate both induction by cAMP and inhibition by insulin.	Cyclic AMP	194-198	CCAAT enhancer binding protein alpha	Homo sapiens	49-54
9406848-6	1997	Increased CRH promoter activity following phorbol ester treatment was inhibited by a dominant negative NF-IL6 mutant, showing that the effects of phorbol ester were principally mediated by C/EBP.	Phorbol Esters	42-55	CCAAT enhancer binding protein alpha	Homo sapiens	189-194
9683733-8	1998	In electrophoretic mobility shift assays (EMSAs) with a 31-bp oligonucleotide representing the conserved region with homology to C/EBP alpha we could provide evidence for specific DNA/protein interactions with nuclear extracts derived from kidney and liver cell lines but not for HeLa-S3 and U937 nuclear extracts.	Oligonucleotides	62-77	CCAAT enhancer binding protein alpha	Homo sapiens	129-140
9514873-0	1998	Regulation of CCAAT/enhancer binding protein alpha (C/EBP alpha) gene expression by thiazolidinediones in 3T3-L1 adipocytes.	Thiazolidinediones	84-102	CCAAT enhancer binding protein alpha	Homo sapiens	14-50
9514873-0	1998	Regulation of CCAAT/enhancer binding protein alpha (C/EBP alpha) gene expression by thiazolidinediones in 3T3-L1 adipocytes.	Thiazolidinediones	84-102	CCAAT enhancer binding protein alpha	Homo sapiens	52-63
9514873-3	1998	Thiazolidinediones induce expression of C/EBP alpha mRNA and protein, while insulin stimulates a rapid decline in C/EBP alpha mRNA and protein.	Thiazolidinediones	0-18	CCAAT enhancer binding protein alpha	Homo sapiens	40-51
9514873-4	1998	When added in combination, thiazolidinediones block the suppression of C/EBP alpha mRNA by insulin; however, thiazolidinediones do not block the insulin-induced decline in GLUT4 mRNA, indicating that repression of C/EBP alpha mRNA is not required for insulin to suppress expression of a C/EBP alpha-responsive gene such as GLUT4.	Thiazolidinediones	27-45	CCAAT enhancer binding protein alpha	Homo sapiens	71-82
9360988-4	1997	A C/EBP-binding site within the CD11c promoter (CEBP-80) is bound by CEBPalpha in undifferentiated U937 cells and by C/EBPalpha- and C/EBPbeta-containing dimers in phorbol 12-myristate 13-acetate-differentiating cells, and its disruption decreased the CD11c promoter activity in a cell type-dependent manner.	Tetradecanoylphorbol Acetate	164-195	CCAAT enhancer binding protein alpha	Homo sapiens	69-78
9360988-4	1997	A C/EBP-binding site within the CD11c promoter (CEBP-80) is bound by CEBPalpha in undifferentiated U937 cells and by C/EBPalpha- and C/EBPbeta-containing dimers in phorbol 12-myristate 13-acetate-differentiating cells, and its disruption decreased the CD11c promoter activity in a cell type-dependent manner.	Tetradecanoylphorbol Acetate	164-195	CCAAT enhancer binding protein alpha	Homo sapiens	117-134
9614100-0	1998	Characterization of CCAAT/enhancer-binding protein alpha as a cyclic AMP-responsive nuclear regulator.	Cyclic AMP	62-72	CCAAT enhancer binding protein alpha	Homo sapiens	20-56
9614100-3	1998	For example, the cAMP responsiveness of the phosphoenolpyruvate carboxykinase gene promoter in liver requires synergism among the cAMP response element-binding protein (CREB), C/EBPalpha, and activator protein-1.	Cyclic AMP	17-21	CCAAT enhancer binding protein alpha	Homo sapiens	176-211
9614100-4	1998	In the present study, we show that C/EBPalpha can functionally substitute for CREB in this cAMP response unit, i.e. cAMP responsiveness can occur in the absence of CREB.	Cyclic AMP	91-95	CCAAT enhancer binding protein alpha	Homo sapiens	35-45
9614100-4	1998	In the present study, we show that C/EBPalpha can functionally substitute for CREB in this cAMP response unit, i.e. cAMP responsiveness can occur in the absence of CREB.	Cyclic AMP	116-120	CCAAT enhancer binding protein alpha	Homo sapiens	35-45
9614100-5	1998	This observation is physiologically relevant since both CREB and C/EBPalpha have been shown to bind with high affinity to the cAMP response element in this particular promoter.	Cyclic AMP	126-130	CCAAT enhancer binding protein alpha	Homo sapiens	65-75
9406848-6	1997	Increased CRH promoter activity following phorbol ester treatment was inhibited by a dominant negative NF-IL6 mutant, showing that the effects of phorbol ester were principally mediated by C/EBP.	Phorbol Esters	146-159	CCAAT enhancer binding protein alpha	Homo sapiens	189-194
8798413-8	1996	The physical association of NF-kappaB1(p50) with C/EBP factors was assayed by direct interaction of in vitro translated p50 proteins with C/EBPbeta or C/EBPdelta produced as glutathione S-transferase fusion proteins.	Glutathione	174-185	CCAAT enhancer binding protein alpha	Homo sapiens	49-54
9171095-2	1997	We have previously shown that the effects of TNFalphaand estradiol on the human IL-6 promoter were dependent on a region of the promoter containing a C/EBP site and a NF-kappaB site.	Estradiol	57-66	CCAAT enhancer binding protein alpha	Homo sapiens	150-155
9032283-4	1997	In studies of normal preadipocytes, RA does not prevent C/EBPbeta induction but blocks induction of PPARgamma, C/EBPalpha, and adipogenesis.	Tretinoin	36-38	CCAAT enhancer binding protein alpha	Homo sapiens	111-121
18472835-3	1997	Gel mobility shift analysis revealed that curdlan sulphate increases the DNA binding activity of NF-kappaB and C/EBP, suggesting that these transcription factors may participate in the regulatory effects of curdlan sulphate in HepG2 cells.	curdlan sulphate	207-223	CCAAT enhancer binding protein alpha	Homo sapiens	111-116
9325324-4	1997	Consistent with insulin causing dephosphorylation of C/EBPalpha through activation of phosphatidylinositol 3-kinase, addition of phosphatidylinositol 3-kinase inhibitors (e.g. wortmannin) blocks insulin-stimulated dephosphorylation of C/EBPalpha.	Wortmannin	176-186	CCAAT enhancer binding protein alpha	Homo sapiens	53-63
9325324-5	1997	In the absence of insulin, wortmannin or LY294002 enhance C/EBPalpha phosphorylation.	Wortmannin	27-37	CCAAT enhancer binding protein alpha	Homo sapiens	58-68
9325324-5	1997	In the absence of insulin, wortmannin or LY294002 enhance C/EBPalpha phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	41-49	CCAAT enhancer binding protein alpha	Homo sapiens	58-68
18472835-0	1997	Curdlan sulphate modulates protein synthesis and enhances NF-kappaB and C/EBP binding activity in HepG2 cells.	curdlan sulphate	0-16	CCAAT enhancer binding protein alpha	Homo sapiens	72-77
18472835-3	1997	Gel mobility shift analysis revealed that curdlan sulphate increases the DNA binding activity of NF-kappaB and C/EBP, suggesting that these transcription factors may participate in the regulatory effects of curdlan sulphate in HepG2 cells.	curdlan sulphate	42-58	CCAAT enhancer binding protein alpha	Homo sapiens	111-116
8680485-3	1996	Vector-directed expression of antisense C/EBP alpha RNA in preadipocytes blocked expression of C/EBP alpha, as well as adipose-specific mRNAs, and also prevented cytoplasmic triglyceride accumulation.	Triglycerides	174-186	CCAAT enhancer binding protein alpha	Homo sapiens	40-51
8626491-2	1996	Evidence has accumulated which suggests that a liver-enriched transcription factor, likely a member of the CCAAT/enhancer binding protein (C/EBP) family, is required along with other ubiquitously expressed transcription factors to mediate this liver-specific response to cAMP.	Cyclic AMP	271-275	CCAAT enhancer binding protein alpha	Homo sapiens	107-137
8626491-2	1996	Evidence has accumulated which suggests that a liver-enriched transcription factor, likely a member of the CCAAT/enhancer binding protein (C/EBP) family, is required along with other ubiquitously expressed transcription factors to mediate this liver-specific response to cAMP.	Cyclic AMP	271-275	CCAAT enhancer binding protein alpha	Homo sapiens	139-144
8626491-3	1996	In this study, we examined the ability of C/EBP to participate in the cAMP-mediated activation of phosphoenolpyruvate carboxykinase (PEPCK) gene transcription in hepatoma cells.	Cyclic AMP	70-74	CCAAT enhancer binding protein alpha	Homo sapiens	42-47
8626491-7	1996	However, only the GAL4-C/EBPalpha fusion protein demonstrated the ability to synergize with the other transcription factors bound to the PEPCK promoter which are required to mediate cAMP responsiveness.	Cyclic AMP	182-186	CCAAT enhancer binding protein alpha	Homo sapiens	23-33
8626491-8	1996	The DNA-binding domain of C/EBPalpha was not required for this activity in hepatoma cells, although in non-hepatoma cells the basic region leucine zipper domain appeared to inhibit the ability of C/EBPalpha to participate in mediating cAMP responsiveness.	Cyclic AMP	235-239	CCAAT enhancer binding protein alpha	Homo sapiens	196-206
8626491-9	1996	These results suggest that the liver-specific nature of the cAMP responsiveness of the PEPCK promoter involves the recruitment of C/EBPalpha to the cAMP response unit.	Cyclic AMP	60-64	CCAAT enhancer binding protein alpha	Homo sapiens	130-140
8626491-9	1996	These results suggest that the liver-specific nature of the cAMP responsiveness of the PEPCK promoter involves the recruitment of C/EBPalpha to the cAMP response unit.	Cyclic AMP	148-152	CCAAT enhancer binding protein alpha	Homo sapiens	130-140
8895337-5	1996	Northern analysis indicated that during differentiation, expression of the adipocyte-specific transcription factor, CCAAT enhancer binding protein-alpha, increased more rapidly in troglitazone-treated cells, but did not change in fully differentiated adipocytes.	Troglitazone	180-192	CCAAT enhancer binding protein alpha	Homo sapiens	116-152
8680485-5	1996	Using an IPTG-inducible double-vector LacSwitch C/EBP alpha expression system, it was found that differentiation can be induced without exogenous hormone inducers.	Isopropyl Thiogalactoside	9-13	CCAAT enhancer binding protein alpha	Homo sapiens	48-59
7557430-5	1995	These P1-P5 sites are highly conserved in the human pCbg, and resemble recognition sequences for HNF-1, CP-2, DBP, HNF-3 and C/EBP or NF-1L6, respectively.	S-(1,2,3,4,4-Pentachloro-1,3-butadienyl)glutathione	52-56	CCAAT enhancer binding protein alpha	Homo sapiens	125-130
8846917-3	1996	IPTG-induced C/EBPalpha caused inhibition of cell proliferation and DNA synthesis as measured by colony growth assays, cell counting, and BrdU uptake.	Isopropyl Thiogalactoside	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	13-23
7479080-3	1995	In the basic region of C/EBP position -14 is occupied by valine instead of alanine, the other four residues being identical.	Valine	57-63	CCAAT enhancer binding protein alpha	Homo sapiens	23-28
7479080-3	1995	In the basic region of C/EBP position -14 is occupied by valine instead of alanine, the other four residues being identical.	Alanine	75-82	CCAAT enhancer binding protein alpha	Homo sapiens	23-28
7479080-4	1995	Here we analyse the role of valine -14 in C/EBP-DNA complex formation.	Valine	28-34	CCAAT enhancer binding protein alpha	Homo sapiens	42-47
7479080-6	1995	We present evidence that valine -14 of C/EBP interacts more strongly with thymine 2 than with cytosine 1" of the C/EBP binding site, unlike the corresponding alanine -14 of GCN4, which exclusively contacts thymine 1" of the GCN4 binding sites.	Valine	25-31	CCAAT enhancer binding protein alpha	Homo sapiens	39-44
7479080-6	1995	We present evidence that valine -14 of C/EBP interacts more strongly with thymine 2 than with cytosine 1" of the C/EBP binding site, unlike the corresponding alanine -14 of GCN4, which exclusively contacts thymine 1" of the GCN4 binding sites.	Valine	25-31	CCAAT enhancer binding protein alpha	Homo sapiens	113-118
7479080-6	1995	We present evidence that valine -14 of C/EBP interacts more strongly with thymine 2 than with cytosine 1" of the C/EBP binding site, unlike the corresponding alanine -14 of GCN4, which exclusively contacts thymine 1" of the GCN4 binding sites.	Thymine	74-81	CCAAT enhancer binding protein alpha	Homo sapiens	39-44
7479080-6	1995	We present evidence that valine -14 of C/EBP interacts more strongly with thymine 2 than with cytosine 1" of the C/EBP binding site, unlike the corresponding alanine -14 of GCN4, which exclusively contacts thymine 1" of the GCN4 binding sites.	Cytosine	94-102	CCAAT enhancer binding protein alpha	Homo sapiens	39-44
7479080-6	1995	We present evidence that valine -14 of C/EBP interacts more strongly with thymine 2 than with cytosine 1" of the C/EBP binding site, unlike the corresponding alanine -14 of GCN4, which exclusively contacts thymine 1" of the GCN4 binding sites.	gcn4	224-228	CCAAT enhancer binding protein alpha	Homo sapiens	39-44
7959011-2	1994	The D. melanogaster transcription repressor, adult enhancer factor-1 (AEF-1), binds to AAE at a site which overlaps with a sequence recognized by the mammalian transcription factor, CCAAT/enhancer-binding protein alpha [C/EBP alpha; Falb and Maniatis, Genes Dev.	acetoacetic acid	87-90	CCAAT enhancer binding protein alpha	Homo sapiens	182-218
7959011-2	1994	The D. melanogaster transcription repressor, adult enhancer factor-1 (AEF-1), binds to AAE at a site which overlaps with a sequence recognized by the mammalian transcription factor, CCAAT/enhancer-binding protein alpha [C/EBP alpha; Falb and Maniatis, Genes Dev.	acetoacetic acid	87-90	CCAAT enhancer binding protein alpha	Homo sapiens	220-231
8003480-11	1994	The binding of C/EBP factors to element C was confirmed by competition with previously described oligonucleotide and nucleotide substitution of element C. Band shift experiments using rat liver nuclear extracts showed that element D formed one major DNA-protein complex.	Oligonucleotides	97-112	CCAAT enhancer binding protein alpha	Homo sapiens	15-20
8286417-7	1994	Four of these activities (designated as NHE-1D1-4) are competed out completely by oligonucleotides containing the binding sites of transcription factors CREB, AP3, NFY, and other CCAAT box-binding proteins (C/EBP alpha or related proteins).	Oligonucleotides	82-98	CCAAT enhancer binding protein alpha	Homo sapiens	207-212
8144615-5	1994	The NH2-terminal boundary of the TCD is longer than tryptic peptides reported from C/EBP alpha.DNA complexes.	Peptides	60-68	CCAAT enhancer binding protein alpha	Homo sapiens	83-94
7577367-6	1994	C/EBP isoforms inhibited the phorbol 12-myristate 13-acetate (PMA)-stimulated HIV-1 promoter activity in human glioblastoma U138MG and neuroblastoma SHSY5Y cells, but not in HeLa epithelial cells, and this inhibition required the NF-kappa B element.	Tetradecanoylphorbol Acetate	29-60	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
7577367-6	1994	C/EBP isoforms inhibited the phorbol 12-myristate 13-acetate (PMA)-stimulated HIV-1 promoter activity in human glioblastoma U138MG and neuroblastoma SHSY5Y cells, but not in HeLa epithelial cells, and this inhibition required the NF-kappa B element.	Tetradecanoylphorbol Acetate	62-65	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
8506317-2	1993	Using a 32P-labeled protein probe consisting of the bZip domain of C/EBP beta, we isolated a clone encoding C/EBP-related ATF (C/ATF), a bZip protein that heterodimerizes with C/EBP-like proteins but belongs to the CREB/ATF family.	Phosphorus-32	8-11	CCAAT enhancer binding protein alpha	Homo sapiens	67-72
8336711-9	1993	Frequent addition of fresh medium to the cells during the differentiation process, as well as supplementation of medium with glucose, reduced gadd153 expression without preventing C/EBP alpha expression or interfering with cellular differentiation.	Glucose	125-132	CCAAT enhancer binding protein alpha	Homo sapiens	180-191
8391636-8	1993	Furthermore, inhibition of C/EBP-binding protein(s) in HepG2 cells by transfection of C/EBP oligonucleotides suppressed the xenobiotic response.	Oligonucleotides	92-108	CCAAT enhancer binding protein alpha	Homo sapiens	27-32
8391636-8	1993	Furthermore, inhibition of C/EBP-binding protein(s) in HepG2 cells by transfection of C/EBP oligonucleotides suppressed the xenobiotic response.	Oligonucleotides	92-108	CCAAT enhancer binding protein alpha	Homo sapiens	86-91
8506317-2	1993	Using a 32P-labeled protein probe consisting of the bZip domain of C/EBP beta, we isolated a clone encoding C/EBP-related ATF (C/ATF), a bZip protein that heterodimerizes with C/EBP-like proteins but belongs to the CREB/ATF family.	Phosphorus-32	8-11	CCAAT enhancer binding protein alpha	Homo sapiens	108-113
1527059-2	1992	High-performance liquid chromatography-peptide mapping of 32P-labeled C/EBP indicated the presence of three major 32P-labeled peptides: S299 (P)RDK, AKKS277 (P)VDK, and GAAGLPGPGGS248 (P)LK.	Peptides	39-46	CCAAT enhancer binding protein alpha	Homo sapiens	70-75
8386280-6	1993	Point mutations in the RSV gag intragenic enhancer region, which blocked binding of C/EBP at two of three adjacent C/EBP sites, also reduced virus production significantly.	Glycosaminoglycans	27-30	CCAAT enhancer binding protein alpha	Homo sapiens	84-89
8386280-6	1993	Point mutations in the RSV gag intragenic enhancer region, which blocked binding of C/EBP at two of three adjacent C/EBP sites, also reduced virus production significantly.	Glycosaminoglycans	27-30	CCAAT enhancer binding protein alpha	Homo sapiens	115-120
1527059-2	1992	High-performance liquid chromatography-peptide mapping of 32P-labeled C/EBP indicated the presence of three major 32P-labeled peptides: S299 (P)RDK, AKKS277 (P)VDK, and GAAGLPGPGGS248 (P)LK.	Phosphorus-32	58-61	CCAAT enhancer binding protein alpha	Homo sapiens	70-75
1527059-2	1992	High-performance liquid chromatography-peptide mapping of 32P-labeled C/EBP indicated the presence of three major 32P-labeled peptides: S299 (P)RDK, AKKS277 (P)VDK, and GAAGLPGPGGS248 (P)LK.	Phosphorus-32	114-117	CCAAT enhancer binding protein alpha	Homo sapiens	70-75
1527059-2	1992	High-performance liquid chromatography-peptide mapping of 32P-labeled C/EBP indicated the presence of three major 32P-labeled peptides: S299 (P)RDK, AKKS277 (P)VDK, and GAAGLPGPGGS248 (P)LK.	Peptides	126-134	CCAAT enhancer binding protein alpha	Homo sapiens	70-75
1527059-3	1992	Phosphorylation of C/EBP by PKC or M-kinase resulted in an attenuation of binding to a 32P-labeled CCAAT oligodeoxynucleotide.	Phosphorus-32	87-90	CCAAT enhancer binding protein alpha	Homo sapiens	19-24
1527059-3	1992	Phosphorylation of C/EBP by PKC or M-kinase resulted in an attenuation of binding to a 32P-labeled CCAAT oligodeoxynucleotide.	ccaat oligodeoxynucleotide	99-125	CCAAT enhancer binding protein alpha	Homo sapiens	19-24
1511897-3	1992	Oligodeoxyribonucleotides corresponding to CPS site II or to the C/EBP alpha-recognition element of the ALB promoter, site D, competed with the six CPS-promoter elements in footprinting assays.	Oligodeoxyribonucleotides	0-25	CCAAT enhancer binding protein alpha	Homo sapiens	65-76
1618860-8	1992	Okadaic acid treatment (1 h, 0.5 microM) also resulted in the coordinate transcriptional repression of the C/EBP-alpha, GLUT4, and 422/aP2 genes, consistent with involvement of a kinase-phosphatase system in the regulation of these genes.	Okadaic Acid	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	107-118
1618860-10	1992	The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor.	Cycloheximide	109-122	CCAAT enhancer binding protein alpha	Homo sapiens	51-62
1547943-6	1992	Cotransfection experiments in mammalian cells reveal that C/EBP stimulates the activity of the AAE by 50-fold, and this activity can be suppressed by AEF-1.	acetoacetic acid	95-98	CCAAT enhancer binding protein alpha	Homo sapiens	58-63
2146494-1	1990	The protein sequence deduced from the open reading frame of a human placental cDNA encoding a cAMP-responsive enhancer (CRE)-binding protein (CREB-327) has structural features characteristic of several other transcriptional transactivator proteins including jun, fos, C/EBP, myc, and CRE-BP1.	Cyclic AMP	94-98	CCAAT enhancer binding protein alpha	Homo sapiens	268-273
1993067-5	1991	In addition, double stranded oligonucleotides corresponding to two of these sequences can bind C/EBP in a gel retardation assay.	Oligonucleotides	29-45	CCAAT enhancer binding protein alpha	Homo sapiens	95-100
1993067-6	1991	These two oligonucleotides can complete with each other to bind C/EBP.	Oligonucleotides	10-26	CCAAT enhancer binding protein alpha	Homo sapiens	64-69
1754374-1	1991	The A-activator binding site (AABS), present in the Xenopus A2 vitellogenin gene and several mammalian liver specifically expressed genes, interacts with different liver specific transcription factors including LFB1- and C/EBP-isobinders.	aabs	30-34	CCAAT enhancer binding protein alpha	Homo sapiens	221-226
1754374-5	1991	Competition experiments in the cell free in vitro transcription show that AABS dependent transcriptional activation is mediated by transcription factors belonging to at least two different families, the C/EBP- and the HNF3-isobinders.	aabs	74-78	CCAAT enhancer binding protein alpha	Homo sapiens	203-208
2294400-8	1990	However, site 1 could complete for binding to an oligonucleotide, previously shown to be recognized by C/EBP, in a nonreciprocal fashion.	Oligonucleotides	49-64	CCAAT enhancer binding protein alpha	Homo sapiens	103-108
11849876-8	2002	Moreover, a consensus dODN directed against CCAAT/enhancer binding protein (C/EBP), another deformation-sensitive transcription factor, did not significantly affect neointimal formation after four weeks (n = 3).	dodn	22-26	CCAAT enhancer binding protein alpha	Homo sapiens	44-74
27673564-0	2016	miR-181a Induces Macrophage Polarized to M2 Phenotype and Promotes M2 Macrophage-mediated Tumor Cell Metastasis by Targeting KLF6 and C/EBPalpha.	mir-181a	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
33232782-8	2021	Of 4,190 genes that were upregulated by cAMP, C/EBPbeta knockdown inhibited these upregulation in 2,239 genes (53.4%), indicating that they are under the regulation of C/EBPbeta.	Cyclic AMP	40-44	CCAAT enhancer binding protein alpha	Homo sapiens	46-55
33232782-8	2021	Of 4,190 genes that were upregulated by cAMP, C/EBPbeta knockdown inhibited these upregulation in 2,239 genes (53.4%), indicating that they are under the regulation of C/EBPbeta.	Cyclic AMP	40-44	CCAAT enhancer binding protein alpha	Homo sapiens	168-177
11849876-8	2002	Moreover, a consensus dODN directed against CCAAT/enhancer binding protein (C/EBP), another deformation-sensitive transcription factor, did not significantly affect neointimal formation after four weeks (n = 3).	dodn	22-26	CCAAT enhancer binding protein alpha	Homo sapiens	76-81
34883426-7	2022	Additionally, 6-shogaol down-regulated the expression of PPAR-gamma and C/EBP-alpha, while it decreased the phosphorylation of IRS-1, PI3K and AKT.	shogaol	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	72-83
34802714-6	2022	KEY FINDINGS: The effect of CDDO-Im in HUVECs can be divided into two main phases: the short early phase (0.5-3 h) with an acute FOXD1/CEBPA/JUNB-regulated pro-angiogenic response induced by xenobiotic stress, and the second anti-angiogenic step (6-24 h) with massive suppression of various angiogenesis-related processes, accompanied by the activation of cytoprotective mechanisms.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	28-32	CCAAT enhancer binding protein alpha	Homo sapiens	135-140
34667024-9	2022	SN-38 had the lowest IC50 (approximately 10 nM), and its pro-apoptotic effects were countered by knockdown of CEBPA but not of TP53 Irinotecan significantly inhibited tumor growth at well tolerated doses, induced nuclear expression of C/EBPalpha, and inhibited HIF1a expression in DDLS patient-derived and cancer cell line xenograft models.	Irinotecan	0-5	CCAAT enhancer binding protein alpha	Homo sapiens	235-245
34626776-10	2022	Furthermore, 1-deoxynojirimycin and isoquercitrin both could increase glucose uptake and promote differentiation of HepG2 cells, increase PPARgamma, C/EBPalpha and SREBP-l expression in 3T3-L1 cells, and inhibit AGEs-induced injury and apoptosis in GLUTag cells, reduce the expression of proteins related to AGEs/RAGE and p38MAPK/NF-kappaB pathway.	1-DEOXYNOJIRIMYCIN	13-31	CCAAT enhancer binding protein alpha	Homo sapiens	149-159
34626776-10	2022	Furthermore, 1-deoxynojirimycin and isoquercitrin both could increase glucose uptake and promote differentiation of HepG2 cells, increase PPARgamma, C/EBPalpha and SREBP-l expression in 3T3-L1 cells, and inhibit AGEs-induced injury and apoptosis in GLUTag cells, reduce the expression of proteins related to AGEs/RAGE and p38MAPK/NF-kappaB pathway.	isoquercitrin	36-49	CCAAT enhancer binding protein alpha	Homo sapiens	149-159
34667024-9	2022	SN-38 had the lowest IC50 (approximately 10 nM), and its pro-apoptotic effects were countered by knockdown of CEBPA but not of TP53 Irinotecan significantly inhibited tumor growth at well tolerated doses, induced nuclear expression of C/EBPalpha, and inhibited HIF1a expression in DDLS patient-derived and cancer cell line xenograft models.	Irinotecan	0-5	CCAAT enhancer binding protein alpha	Homo sapiens	110-115
34667024-9	2022	SN-38 had the lowest IC50 (approximately 10 nM), and its pro-apoptotic effects were countered by knockdown of CEBPA but not of TP53 Irinotecan significantly inhibited tumor growth at well tolerated doses, induced nuclear expression of C/EBPalpha, and inhibited HIF1a expression in DDLS patient-derived and cancer cell line xenograft models.	Irinotecan	132-142	CCAAT enhancer binding protein alpha	Homo sapiens	235-245
34667024-12	2022	These include irinotecan, which induces apoptosis of DDLS cells in a C/EBPalpha-dependent, p53-independent manner and should be clinically evaluated in patients with advanced DDLS.	Irinotecan	14-24	CCAAT enhancer binding protein alpha	Homo sapiens	69-79
34777588-9	2021	Treatment with DAPT upregulated the expression levels of CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPbeta, peroxisome proliferator-activated receptor-gamma, adiponectin and insulin-like growth factor 1, and promoted the proliferation, apoptosis, migration and lipid accumulation in HemSCs in vitro.	dapt	15-19	CCAAT enhancer binding protein alpha	Homo sapiens	89-101
34626776-13	2022	1-DNJ and QG increased glucose uptake and promoted differentiation of HepG2 cells, increased PPARgamma, C/EBPalpha and SREBP-l expression in 3T3-L1 cells, and inhibited AGEs-induced injury and apoptosis in GLUTag cells via the AGEs/RAGE and p38 MAPK/NF-kappaB pathway.	spiraeoside	10-12	CCAAT enhancer binding protein alpha	Homo sapiens	104-114
34626776-13	2022	1-DNJ and QG increased glucose uptake and promoted differentiation of HepG2 cells, increased PPARgamma, C/EBPalpha and SREBP-l expression in 3T3-L1 cells, and inhibited AGEs-induced injury and apoptosis in GLUTag cells via the AGEs/RAGE and p38 MAPK/NF-kappaB pathway.	Glucose	23-30	CCAAT enhancer binding protein alpha	Homo sapiens	104-114
34777588-9	2021	Treatment with DAPT upregulated the expression levels of CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPbeta, peroxisome proliferator-activated receptor-gamma, adiponectin and insulin-like growth factor 1, and promoted the proliferation, apoptosis, migration and lipid accumulation in HemSCs in vitro.	dapt	15-19	CCAAT enhancer binding protein alpha	Homo sapiens	103-112
34944408-7	2021	Co-treatment with hispidulin and p-synephrine also significantly inhibited adipogenic marker proteins, including Akt, mitogen-activated protein kinases, peroxisome proliferator-activated receptor gamma, CCAAT/enhancer-binding protein alpha, glucocorticoid receptor, and CCAAT/enhancer-binding protein beta.	Synephrine	33-45	CCAAT enhancer binding protein alpha	Homo sapiens	203-239
34944408-7	2021	Co-treatment with hispidulin and p-synephrine also significantly inhibited adipogenic marker proteins, including Akt, mitogen-activated protein kinases, peroxisome proliferator-activated receptor gamma, CCAAT/enhancer-binding protein alpha, glucocorticoid receptor, and CCAAT/enhancer-binding protein beta.	hispidulin	18-28	CCAAT enhancer binding protein alpha	Homo sapiens	203-239
34807506-0	2021	METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.	Cisplatin	74-83	CCAAT enhancer binding protein alpha	Homo sapiens	44-49
34831209-4	2021	We demonstrate that impairment of DNMT1 enzymatic activity by NAD-promoted ADP-ribosylation leads to demethylation and transcriptional activation of the CEBPA gene, suggesting the existence of an unknown NAD-controlled region within the locus.	NAD	62-65	CCAAT enhancer binding protein alpha	Homo sapiens	153-158
34831209-4	2021	We demonstrate that impairment of DNMT1 enzymatic activity by NAD-promoted ADP-ribosylation leads to demethylation and transcriptional activation of the CEBPA gene, suggesting the existence of an unknown NAD-controlled region within the locus.	NAD	204-207	CCAAT enhancer binding protein alpha	Homo sapiens	153-158
34831059-6	2021	TGF-beta1 upregulated C/EBP-beta in all fibroblasts, which was reduced by treprostinil in control-fibroblasts, but not in IPF-fibroblasts.	treprostinil	74-86	CCAAT enhancer binding protein alpha	Homo sapiens	22-32
34352342-9	2021	Moreover, both cladosporols downregulated mRNA and protein levels of early (C/EBPalpha and PPARgamma) and late (aP2, LPL, FASN, GLUT-4, adiponectin and leptin) differentiation markers of adipogenesis.	cladosporol	15-27	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
34676202-11	2021	In metformin-treated samples, the CEBPA, TP53 and USF1 transcription factors appeared to be involved in the regulation of several factors (SOD1, SOD2, CAT, GLRX, GSTP1) blocking ROS.	Metformin	3-12	CCAAT enhancer binding protein alpha	Homo sapiens	34-39
34721992-5	2021	In addition, BA decreased hMSC adipogenesis with the decrease in glycerol-3-phosphate dehydrogenase activity, reduced intracellular lipid accumulations, down-regulated CCAAT-enhancer-binding protein alpha, and suppressed post-transcriptional adiponectin and leptin secretion.	betulinic acid	13-15	CCAAT enhancer binding protein alpha	Homo sapiens	168-204
34676202-11	2021	In metformin-treated samples, the CEBPA, TP53 and USF1 transcription factors appeared to be involved in the regulation of several factors (SOD1, SOD2, CAT, GLRX, GSTP1) blocking ROS.	Reactive Oxygen Species	178-181	CCAAT enhancer binding protein alpha	Homo sapiens	34-39
34790046-0	2021	Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancer.	Cisplatin	37-46	CCAAT enhancer binding protein alpha	Homo sapiens	72-77
34478711-0	2021	The essential glucose transporter GLUT1 is epigenetically upregulated by C/EBPbeta and WT1 during decidualization of the endometrium.	Glucose	14-21	CCAAT enhancer binding protein alpha	Homo sapiens	73-82
34478711-8	2021	Knockdown of either C/EBPbeta or WT1 suppressed cAMP-increased GLUT1 expression and glucose uptake.	Glucose	84-91	CCAAT enhancer binding protein alpha	Homo sapiens	20-29
34478711-9	2021	cAMP treatment also increased the recruitment of C/EBPbeta and WT1 to the GLUT1 promoter region.	Cyclic AMP	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	49-58
34790046-4	2021	Here, we found that the expression of lncRNA CEBPA-DT/CEBPA/BCL2 was upregulated in cisplatin resistance OSCC cells (Cal27-CisR and HSC4-CisR) compared with their parental cells (Cal27 and HSC4).	Cisplatin	84-93	CCAAT enhancer binding protein alpha	Homo sapiens	54-59
34790046-5	2021	CEBPA-DT overexpression could upregulated both cytoplasmic and nuclear CEBPA expression.	Thymidine	6-8	CCAAT enhancer binding protein alpha	Homo sapiens	71-76
34790046-6	2021	Down-regulation of CEBPA-DT enhances cisplatin sensitivity, facilitates cell apoptosis in cisplatin-resistant OSCC cells.	Thymidine	25-27	CCAAT enhancer binding protein alpha	Homo sapiens	19-24
34790046-6	2021	Down-regulation of CEBPA-DT enhances cisplatin sensitivity, facilitates cell apoptosis in cisplatin-resistant OSCC cells.	Cisplatin	37-46	CCAAT enhancer binding protein alpha	Homo sapiens	19-24
34790046-6	2021	Down-regulation of CEBPA-DT enhances cisplatin sensitivity, facilitates cell apoptosis in cisplatin-resistant OSCC cells.	Cisplatin	90-99	CCAAT enhancer binding protein alpha	Homo sapiens	19-24
34790046-7	2021	In addition, we identified that CEBPA-DT regulates cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis.	Cisplatin	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	32-37
34790046-7	2021	In addition, we identified that CEBPA-DT regulates cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis.	Cisplatin	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	86-91
34790046-8	2021	Knockdown of CEBPA and BCL2 could alleviate the increasement of cisplatin resistance induced by CEBPA-DT overexpression.	Cisplatin	64-73	CCAAT enhancer binding protein alpha	Homo sapiens	13-18
34790046-8	2021	Knockdown of CEBPA and BCL2 could alleviate the increasement of cisplatin resistance induced by CEBPA-DT overexpression.	Thymidine	102-104	CCAAT enhancer binding protein alpha	Homo sapiens	13-18
34790046-9	2021	Our findings indicate that downregulation of lncRNA CEBPA-DT may be a potential therapy to overcome cisplatin resistance in OSCC.	Cisplatin	100-109	CCAAT enhancer binding protein alpha	Homo sapiens	52-57
34445549-6	2021	Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT enhancer binding proteins beta (C/EBPbeta), two adipogenic transcription factors, was also decreased by kaempferol and kaempferide treatment.	kaempferol	189-199	CCAAT enhancer binding protein alpha	Homo sapiens	117-126
34510484-0	2022	Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPalpha-miRNA-223 axis.	Alcohols	35-42	CCAAT enhancer binding protein alpha	Homo sapiens	120-130
34513657-1	2021	Adult acute myeloid leukemia (AML) patients with biallelic mutations of CEBPA (biCEBPA) displays a favorable clinical outcome, and is defined as a unique entity in the 2016 World Health Organization classification.	bicebpa	79-86	CCAAT enhancer binding protein alpha	Homo sapiens	72-77
34439364-7	2021	Interestingly, inhibition of the UPR regulators inositol-requiring enzyme 1 (IRE1) and c-Jun N-terminal kinase (JNK) significantly reduced thapsigargin-induced LCN2 RNA and protein expression, and luciferase promoter assays identified nuclear factor kappa B (NF-kappaB) and CCAAT binding protein (C/EBP) as critical regulators of mLCN2 transcription.	Thapsigargin	139-151	CCAAT enhancer binding protein alpha	Homo sapiens	297-302
34483915-12	2021	Correspondingly, the expression of the adipogenic genes CCAAT/enhancer-binding protein alpha (CEBPA) and PPARG was downregulated upon ALM and AST treatment.	astragalin	142-145	CCAAT enhancer binding protein alpha	Homo sapiens	56-92
34483915-12	2021	Correspondingly, the expression of the adipogenic genes CCAAT/enhancer-binding protein alpha (CEBPA) and PPARG was downregulated upon ALM and AST treatment.	astragalin	142-145	CCAAT enhancer binding protein alpha	Homo sapiens	94-99
34445549-6	2021	Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT enhancer binding proteins beta (C/EBPbeta), two adipogenic transcription factors, was also decreased by kaempferol and kaempferide treatment.	kaempferide	204-215	CCAAT enhancer binding protein alpha	Homo sapiens	117-126
34217716-10	2021	Acetylation of lysine at positions K298, K302 and K326 of C/EBP-alpha promotes its binding to Beclin1.	Lysine	15-21	CCAAT enhancer binding protein alpha	Homo sapiens	58-69
34217716-10	2021	Acetylation of lysine at positions K298, K302 and K326 of C/EBP-alpha promotes its binding to Beclin1.	Enalapril	35-39	CCAAT enhancer binding protein alpha	Homo sapiens	58-69
34217716-10	2021	Acetylation of lysine at positions K298, K302 and K326 of C/EBP-alpha promotes its binding to Beclin1.	6-nitroindazole	41-45	CCAAT enhancer binding protein alpha	Homo sapiens	58-69
34217716-10	2021	Acetylation of lysine at positions K298, K302 and K326 of C/EBP-alpha promotes its binding to Beclin1.	sodium iodide	50-54	CCAAT enhancer binding protein alpha	Homo sapiens	58-69
34439474-8	2021	NRF2 activation inhibited FFA-induced ROS production, which suppressed lipogenic transcription factors, C/EBPalpha and PPARgamma.	Fatty Acids, Nonesterified	26-29	CCAAT enhancer binding protein alpha	Homo sapiens	104-114
34193599-4	2021	To investigate the underlying mechanisms of these alcohol-induced AM derangements, we hypothesized that alcohol stimulates CCAAT/enhancer-binding protein beta (C/EBPbeta) to suppress Nox-related microRNAs (miRs), thereby enhancing AM Nox expression, oxidative stress, and phagocytic dysfunction.	Alcohols	50-57	CCAAT enhancer binding protein alpha	Homo sapiens	160-169
34344962-0	2021	Author Correction: Early induction of C/EBPbeta expression as a potential marker of steroid responsive colitis.	Steroids	84-91	CCAAT enhancer binding protein alpha	Homo sapiens	38-47
34193599-4	2021	To investigate the underlying mechanisms of these alcohol-induced AM derangements, we hypothesized that alcohol stimulates CCAAT/enhancer-binding protein beta (C/EBPbeta) to suppress Nox-related microRNAs (miRs), thereby enhancing AM Nox expression, oxidative stress, and phagocytic dysfunction.	Alcohols	104-111	CCAAT enhancer binding protein alpha	Homo sapiens	160-169
34193599-5	2021	Furthermore, we postulated that pharmacologic PPARgamma activation with pioglitazone would inhibit C/EBPbeta and attenuate alcohol-induced AM dysfunction.	Pioglitazone	72-84	CCAAT enhancer binding protein alpha	Homo sapiens	99-108
34193599-8	2021	These alcohol-induced AM derangements were abrogated by inhibition of C/EBPbeta, overexpression of miR-1264 or miR-107, or pioglitazone treatment.	Alcohols	6-13	CCAAT enhancer binding protein alpha	Homo sapiens	70-79
34156146-7	2021	Knockdown of TRRAP reduced triglyceride accumulation in HuH-7 hepatocytes, in part by reducing C/EBPalpha-mediated de novo synthesis of TGs.	Triglycerides	136-139	CCAAT enhancer binding protein alpha	Homo sapiens	95-105
34298689-5	2021	As a transcriptional factor, CEBPalpha was verified to augment OGA transcription, and further experiments demonstrated that RANBP2 enhanced the O-GlcNAc level by downregulating OGA transcription while not affecting OGT expression.	o-glcnac	144-152	CCAAT enhancer binding protein alpha	Homo sapiens	29-38
34295928-0	2021	Lacidipine Ameliorates the Endothelial Senescence and Inflammatory Injury Through CXCR7/P38/C/EBP-beta Signaling Pathway.	lacidipine	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	92-102
34295928-9	2021	Results: Our data showed that Lacidipine treatment lowered the blood pressure of SHRs accompanied by the elevation of CXCR7 expression and suppression of P38 and CCAAT/enhancer-binding protein beta (C/EBP-beta) compared with the control group.	lacidipine	30-40	CCAAT enhancer binding protein alpha	Homo sapiens	199-209
34295928-11	2021	Conclusions: Our results suggested that Lacidipine plays a protective role in EC senescence, oxidative stress, and inflammatory injury through the regulation of CXCR7/P38/C/EBP-beta signaling pathway.	lacidipine	40-50	CCAAT enhancer binding protein alpha	Homo sapiens	171-181
34183648-9	2021	Treatment with doxycycline decreased the abundance of mitochondrial encoded proteins while increasing expression of CHOP, C/EBPbeta, ClpP, and mtHsp60, markers of the mtUPR.	Doxycycline	15-26	CCAAT enhancer binding protein alpha	Homo sapiens	122-131
34211022-4	2021	We show that the small molecule inhibitors MG132 (a 26S proteasome inhibitor used to block NF-kappaB signaling) and U0126 (a MAPK Kinase inhibitor used to block CCAAT-enhancer-binding proteins C/EBP) successfully block IL-1beta and TNF-alpha mRNA expression.	U 0126	116-121	CCAAT enhancer binding protein alpha	Homo sapiens	193-198
34208730-8	2021	Examination of the NAG-1 promoter activity showed that p53, C/EBPalpha, or C/EBPdelta played a role in quercetin-induced NAG-1 expression.	Quercetin	103-112	CCAAT enhancer binding protein alpha	Homo sapiens	60-70
34064531-3	2021	The adipogenic genes, PPAR-gamma and C/EBP-alpha, were 1.5 times more highly expressed in the salt-treated groups than the non-salt-treated groups, and adipogenesis was greatly increased in Tg(+/+) WAT compared to non-transfected Tg(-/-).	Salts	94-98	CCAAT enhancer binding protein alpha	Homo sapiens	37-48
34103688-7	2022	In addition, 8-O-cAMP treatment restored C/EBP-beta expression in HK-2 cells and promoted C/EBP-beta translocation to the nucleus, where it transcriptionally upregulated SOCS3 expression, subsequently inhibiting STAT3 phosphorylation.	8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate	13-21	CCAAT enhancer binding protein alpha	Homo sapiens	41-51
34103688-7	2022	In addition, 8-O-cAMP treatment restored C/EBP-beta expression in HK-2 cells and promoted C/EBP-beta translocation to the nucleus, where it transcriptionally upregulated SOCS3 expression, subsequently inhibiting STAT3 phosphorylation.	8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate	13-21	CCAAT enhancer binding protein alpha	Homo sapiens	90-100
34117368-4	2022	Oroxylin A promoted NAG-1 transcription by regulating the acetylation of CCAAT/enhancer binding protein beta (C/EBPbeta), a transcription factor that binds to the NAG-1 promoter.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	110-119
34117368-5	2022	In terms of the underlying mechanism, oroxylin A may interact with histone deacetylase 1 (HDAC1) by forming hydrogen bonds with GLY149 residue and induce proteasome-mediated degradation of HDAC1 subsequently impairing HDAC1-mediated deacetylation of C/EBPbeta and promoting the expression of NAG-1.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	38-48	CCAAT enhancer binding protein alpha	Homo sapiens	250-259
34064531-3	2021	The adipogenic genes, PPAR-gamma and C/EBP-alpha, were 1.5 times more highly expressed in the salt-treated groups than the non-salt-treated groups, and adipogenesis was greatly increased in Tg(+/+) WAT compared to non-transfected Tg(-/-).	Salts	127-131	CCAAT enhancer binding protein alpha	Homo sapiens	37-48
35441186-4	2022	Our results showed that the existence of the galloyl moiety in the structure of polyphenols was necessary for their inhibition of adipogenic differentiation, which could help to delay cells from entering the G2/M phase as well as to hinder the MCE process in the early stage of differentiation and the downstream PPARgamma and C/EBPalpha related MAPK signaling pathway, probably via binding to IR and disturbing the alpha-helix in its conformation.	galloyl	45-52	CCAAT enhancer binding protein alpha	Homo sapiens	327-337
35623502-0	2022	Synergistic induction of IL-6 production in human bronchial epithelial cells in vitro by nickel nanoparticles and lipopolysaccharide is mediated by STAT3 and C/EBPbeta.	Nickel	89-95	CCAAT enhancer binding protein alpha	Homo sapiens	158-167
35605401-7	2022	The quercetin-treated PDGFRalpha+/CD201+ cells showed attenuated lipid accumulation and adipogenic gene expression (CEBPA and ADIPOQ) via the inhibition of CREB phosphorylation under adipocyte differentiation conditions.	Quercetin	4-13	CCAAT enhancer binding protein alpha	Homo sapiens	116-121
35526567-6	2022	Particularly, sampsonione F, one of the PPAPs dramatically suppressed adipogenesis dose-dependently in vitro, along with decreased expressions of C/EBPbeta, C/EBPalpha, PPARgamma, FABP4, and FAS.	Sampsonione F	14-27	CCAAT enhancer binding protein alpha	Homo sapiens	146-155
35526567-6	2022	Particularly, sampsonione F, one of the PPAPs dramatically suppressed adipogenesis dose-dependently in vitro, along with decreased expressions of C/EBPbeta, C/EBPalpha, PPARgamma, FABP4, and FAS.	Sampsonione F	14-27	CCAAT enhancer binding protein alpha	Homo sapiens	157-167
35441186-4	2022	Our results showed that the existence of the galloyl moiety in the structure of polyphenols was necessary for their inhibition of adipogenic differentiation, which could help to delay cells from entering the G2/M phase as well as to hinder the MCE process in the early stage of differentiation and the downstream PPARgamma and C/EBPalpha related MAPK signaling pathway, probably via binding to IR and disturbing the alpha-helix in its conformation.	Polyphenols	80-91	CCAAT enhancer binding protein alpha	Homo sapiens	327-337
35343920-0	2022	C/EBPbeta mediates anti-proliferative effects of 1,25(OH)2D on differentiated thyroid carcinoma cells.	1,25(oh)2d	49-59	CCAAT enhancer binding protein alpha	Homo sapiens	0-9
35343920-7	2022	In addition, 1,25(OH)2D3 induced phosphorylation and translocation of C/EBPbeta to the nucleus from the cytoplasm.	Calcitriol	13-24	CCAAT enhancer binding protein alpha	Homo sapiens	70-79
35343920-8	2022	However, inhibition of p38 mitogen-activated protein kinases (MAPK) abrogated 1,25(OH)2D3-induced phosphorylation and nuclear translocation of C/EBPbeta as well as 1,25(OH)2D3-suppressed DTC cell proliferation.	Calcitriol	78-89	CCAAT enhancer binding protein alpha	Homo sapiens	143-152
35343920-13	2022	In conclusions, C/EBPbeta stimulated Notch3 signaling via the p38 MAPK-dependent pathway mediates the inhibitory effect of 1,25(OH)2D on DTC cell proliferation.	1,25(oh)2d	123-133	CCAAT enhancer binding protein alpha	Homo sapiens	16-25
35367764-11	2022	Finally, our study provides evidence that ONON exerts anti-adipogenic effect by upregulation of SIRT1 and inhibition of PI3K, PPARgamma and adiponectin, while MACK induced strong inhibitory effect on adipogenesis via hampering PI3K, PPARgamma/C/EBPalpha signaling and anti-lipogenic effect through downregulation of SREBP1 and ACC.	calycosin-7-O-beta-D-glucoside	42-46	CCAAT enhancer binding protein alpha	Homo sapiens	243-253
35358514-6	2022	We found cAMP increased the recruitment of PGC-1alpha and p300 to C/EBPbeta binding sites in the promoter and enhancer regions of IGFBP1 and PRL, corresponding with increases in H3K27ac.	Cyclic AMP	9-13	CCAAT enhancer binding protein alpha	Homo sapiens	66-75
35358514-9	2022	We found cAMP increased C/EBPbeta recruitment to the novel enhancer regions of PPARGC1A.	Cyclic AMP	9-13	CCAAT enhancer binding protein alpha	Homo sapiens	24-33
35485096-6	2022	Salicin ether treatment of the adipocytes effectively suppressed rosiglitazone induced expression of FAS, C/EBPalpha, aP2, and HMG-CoA genes.	salicin	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
35485096-6	2022	Salicin ether treatment of the adipocytes effectively suppressed rosiglitazone induced expression of FAS, C/EBPalpha, aP2, and HMG-CoA genes.	Rosiglitazone	65-78	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
35485096-7	2022	Treatment of the adipocytes with salicin ether led to a prominent decrease in rosiglitazone mediated increase in aP2, CHIP, and C/EBPalpha protein expression.	salicin ether	33-46	CCAAT enhancer binding protein alpha	Homo sapiens	128-138
35485096-7	2022	Treatment of the adipocytes with salicin ether led to a prominent decrease in rosiglitazone mediated increase in aP2, CHIP, and C/EBPalpha protein expression.	Rosiglitazone	78-91	CCAAT enhancer binding protein alpha	Homo sapiens	128-138
35180468-6	2022	Exposure to LuCS induced lipid accumulation of preadipocytes via activation of CEBP/alpha signaling pathway in preadipocytes.	lucs	12-16	CCAAT enhancer binding protein alpha	Homo sapiens	79-89
35402661-13	2022	miRNA-320a inhibition significantly decreased the expression of adipogenesis-related markers: AP2, C/EBPalpha, FABP4 and PPARgamma.	mirna-320a	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	99-109
35594692-5	2022	However, during terminal adipogenesis, RA downregulated PPARgamma, C/EBPalpha and inhibited lipid accumulation.	Tretinoin	39-41	CCAAT enhancer binding protein alpha	Homo sapiens	67-77
35077804-2	2022	Here we have studied the inhibitory potential and biological effects of a synthetic analog of the natural product helenalin, a known inhibitor of C/EBPbeta.	helenalin	114-123	CCAAT enhancer binding protein alpha	Homo sapiens	146-155
35077804-3	2022	The synthetic compound inhibits C/EBPbeta by covalent binding to cysteine residues in the transactivation domain, thereby causing up-regulation of differentiation-associated genes, cell death and reduced self-renewal potential of AML cells.	Cysteine	65-73	CCAAT enhancer binding protein alpha	Homo sapiens	32-41
35077804-5	2022	Overall, our work demonstrates that the synthetic helenalin mimic acts as a covalent inhibitor of C/EBPbeta and identifies the cysteine residues in the transactivation domain of C/EBPbeta as ligandable sites.	helenalin	50-59	CCAAT enhancer binding protein alpha	Homo sapiens	98-107
35077804-5	2022	Overall, our work demonstrates that the synthetic helenalin mimic acts as a covalent inhibitor of C/EBPbeta and identifies the cysteine residues in the transactivation domain of C/EBPbeta as ligandable sites.	helenalin	50-59	CCAAT enhancer binding protein alpha	Homo sapiens	178-187
35077804-5	2022	Overall, our work demonstrates that the synthetic helenalin mimic acts as a covalent inhibitor of C/EBPbeta and identifies the cysteine residues in the transactivation domain of C/EBPbeta as ligandable sites.	Cysteine	127-135	CCAAT enhancer binding protein alpha	Homo sapiens	178-187
35077804-6	2022	The helenalin mimic can be considered a potential "lead molecule" but needs further development towards more effective C/EBPbeta inhibitors before being used as a therapeutic agent.	helenalin	4-13	CCAAT enhancer binding protein alpha	Homo sapiens	119-128
34320176-3	2022	CEBPA mutations were identified in 240 patients (5.1%), 131 CEBPAbi and 109 CEBPAsm (60 affecting the amino-terminal transactivation domains (CEBPAsmTAD) and 49 the carboxy-terminal DNA-binding or basic leucine zipper region (CEBPAsmbZIP)).	Leucine	203-210	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
35174151-14	2022	Conclusion: Differential expression profile of three aspartic acid metabolic-associated genes, ASNS, CEBPA, and CAD, can be considered as a risk model with a good evaluation effect on the prognosis of colon cancer patients.	Aspartic Acid	53-66	CCAAT enhancer binding protein alpha	Homo sapiens	101-106
35451875-5	2022	Our experiments showed that SPS exposure prolonged mechanical allodynia, increased the expression of C/EBPbeta and pro-inflammatory cytokines, and potentiated the activation of spinal microglia.	Sodium phenolsulfonate	28-31	CCAAT enhancer binding protein alpha	Homo sapiens	101-110
35096424-4	2022	We found that, at a concentration as low as one-tenth that of allyl isothiocyanate, sulforaphane reduced triacylglycerol levels, lipid-filled adipocyte quantity, and mRNA and protein levels of CCAAT-enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma).	allyl isothiocyanate	62-82	CCAAT enhancer binding protein alpha	Homo sapiens	193-229
35096424-4	2022	We found that, at a concentration as low as one-tenth that of allyl isothiocyanate, sulforaphane reduced triacylglycerol levels, lipid-filled adipocyte quantity, and mRNA and protein levels of CCAAT-enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma).	sulforaphane	84-96	CCAAT enhancer binding protein alpha	Homo sapiens	193-229
35096424-4	2022	We found that, at a concentration as low as one-tenth that of allyl isothiocyanate, sulforaphane reduced triacylglycerol levels, lipid-filled adipocyte quantity, and mRNA and protein levels of CCAAT-enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma).	sulforaphane	84-96	CCAAT enhancer binding protein alpha	Homo sapiens	231-241
35054838-5	2022	DCC dose-dependently inhibited the lipid accumulation and expression of adipogenic transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha) in hBM-MSCs induced to undergo adipogenesis.	DICYCLOHEXYLCARBODIIMIDE	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	170-206
35054838-5	2022	DCC dose-dependently inhibited the lipid accumulation and expression of adipogenic transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha) in hBM-MSCs induced to undergo adipogenesis.	DICYCLOHEXYLCARBODIIMIDE	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	208-218
33744198-9	2021	Overexpression of C/EBPbeta in MEK/ERK pathway inhibited by U0126 did not promote MKs differentiation.	U 0126	60-65	CCAAT enhancer binding protein alpha	Homo sapiens	18-27
35551662-13	2022	Antibody-Drug Conjugates (ADC) constitute the only FDA-approved immunotherapy to treat AML with Gemtuzumab Ozogamicin, a CD33-specific ADC used in CEBPalpha-mutated AML.	OZOGAMICIN	107-117	CCAAT enhancer binding protein alpha	Homo sapiens	147-156
33864839-0	2021	Polychlorinated Biphenyl Congener 180 (PCB 180) Regulates Mitotic Clonal Expansion and Enhances Adipogenesis through Modulation of C/EBPbeta SUMOylation in Preadipocytes.	polychlorinated biphenyl congener 180	0-37	CCAAT enhancer binding protein alpha	Homo sapiens	131-140
33864839-0	2021	Polychlorinated Biphenyl Congener 180 (PCB 180) Regulates Mitotic Clonal Expansion and Enhances Adipogenesis through Modulation of C/EBPbeta SUMOylation in Preadipocytes.	2,2',3,4,4',5,5'-HEPTACHLOROBIPHENYL	39-46	CCAAT enhancer binding protein alpha	Homo sapiens	131-140
33864839-8	2021	Molecular mechanistic investigation revealed that PCB 180 promoted accumulation of the C/EBPbeta protein, a key regulator that controls MCE.	2,2',3,4,4',5,5'-HEPTACHLOROBIPHENYL	50-57	CCAAT enhancer binding protein alpha	Homo sapiens	87-96
34039742-8	2021	We also found that knockdown of CRED9 in Hep3B cells caused a 57.8% reduction in H3K27ac levels at the +9kb CEBPA enhancer.	h3k27ac	81-88	CCAAT enhancer binding protein alpha	Homo sapiens	108-113
33945665-0	2021	C/EBPbeta enhances efficacy of sorafenib in hepatoblastoma.	Sorafenib	31-40	CCAAT enhancer binding protein alpha	Homo sapiens	0-9
34039010-10	2021	The results of the reviewed in vitro studies have revealed that treatment with PMFs significantly inhibits lipid accumulation in adipocytes (e.g. reduced lipid accumulation by 55-60%) and 3T3-L1 pre-adipocyte differentiation as well by decreasing the expression of PPARgamma and C/EBPalpha and also reduces the number and size of fat cells and reduced TG content in adipocytes by 45.67% and 23.10% and 16.08% for nobiletin, tangeretin and hesperetin, respectively.	pmfs	79-83	CCAAT enhancer binding protein alpha	Homo sapiens	279-289
33877329-7	2021	Furthermore, repair of the deamination product of unmethylated cytosine, which yields a U:G DNA mismatch that is normally repaired via uracil DNA glycosylase, is also inhibited by CEBPbeta binding.	Cytosine	63-71	CCAAT enhancer binding protein alpha	Homo sapiens	180-188
33979616-4	2021	Under arginine starvation, ASS1 transcription is induced by ATF4 and CEBPbeta binding to an enhancer within ASS1.	Arginine	6-14	CCAAT enhancer binding protein alpha	Homo sapiens	69-77
33979616-6	2021	Arginine starvation drives global chromatin compaction and repressive histone methylation, which disrupts ATF4/CEBPbeta binding and target gene transcription.	Arginine	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	111-119
33958723-6	2021	Ectopic expression of GFI1, a zinc-finger protein that is required for the maintenance of hematopoietic stem and progenitor cells, partially abrogated STL-induced myelomonocytic differentiation, implicating GFI1 as a relevant target of C/EBPbeta-inhibitory STLs.	Resveratrol	151-154	CCAAT enhancer binding protein alpha	Homo sapiens	236-245
34017261-0	2021	Xanthohumol Attenuated Inflammation and ECM Degradation by Mediating HO-1/C/EBPbeta Pathway in Osteoarthritis Chondrocytes.	xanthohumol	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	74-83
33945347-0	2021	Evodiamine Enhanced the Anti-Inflammation Effect of Clindamycin in the BEAS-2B Cells Infected with H5N1 and Pneumoniae D39 Through CREB-C/EBPbeta Signaling Pathway.	evodiamine	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	136-145
33945347-0	2021	Evodiamine Enhanced the Anti-Inflammation Effect of Clindamycin in the BEAS-2B Cells Infected with H5N1 and Pneumoniae D39 Through CREB-C/EBPbeta Signaling Pathway.	Clindamycin	52-63	CCAAT enhancer binding protein alpha	Homo sapiens	136-145
33945347-8	2021	Moreover, evodiamine markedly reduced TLR2,3,4 protein expression and the phosphorylated protein of C/EBPbeta and CREB.	evodiamine	10-20	CCAAT enhancer binding protein alpha	Homo sapiens	100-109
33945347-10	2021	Taken together, our results demonstrated that evodiamine enhanced the anti-inflammation effect of clindamycin in the BEAS-2B cells infected with H5N1 and pneumoniae D39 through CREB-C/EBPbeta signaling pathway.	evodiamine	46-56	CCAAT enhancer binding protein alpha	Homo sapiens	182-191
33945347-10	2021	Taken together, our results demonstrated that evodiamine enhanced the anti-inflammation effect of clindamycin in the BEAS-2B cells infected with H5N1 and pneumoniae D39 through CREB-C/EBPbeta signaling pathway.	Clindamycin	98-109	CCAAT enhancer binding protein alpha	Homo sapiens	182-191
33760042-3	2021	Along with an increase in TCA cycle intermediates, this AML-specific metabolic behavior mechanistically occurred through the increase in electron transport chain complex I activity, mitochondrial respiration, and methylation-driven CEBPalpha-induced fatty acid beta-oxidation of IDH1 mutant cells.	Trichloroacetic Acid	26-29	CCAAT enhancer binding protein alpha	Homo sapiens	232-241
33760042-3	2021	Along with an increase in TCA cycle intermediates, this AML-specific metabolic behavior mechanistically occurred through the increase in electron transport chain complex I activity, mitochondrial respiration, and methylation-driven CEBPalpha-induced fatty acid beta-oxidation of IDH1 mutant cells.	Fatty Acids	250-260	CCAAT enhancer binding protein alpha	Homo sapiens	232-241
33947580-10	2021	And the enhanced TNF-alpha and IL-6 secretion as well as cell cycle arrest by C/EBP beta overexpression were blocked by BAY11-7082 inhibitor of NF-kappaB pathway.	3-(4-methylphenylsulfonyl)-2-propenenitrile	120-130	CCAAT enhancer binding protein alpha	Homo sapiens	78-88
33995374-4	2021	Here, we showed that HP-PRRSV infection increased PGE2 production in microglia via COX-2 up-regulation depending on the activation of MEK1-ERK1/2-C/EBPbeta signaling pathways.	Dinoprostone	50-54	CCAAT enhancer binding protein alpha	Homo sapiens	146-155
33743412-9	2021	In contrast, ICA inhibited hBMSC adipogenic differentiation by reducing lipid droplet formation and cellular triglyceride levels as well as by downregulating the expression of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and CCAAT enhancer-binding protein-alpha (C/EBP-alpha).	icariin	13-16	CCAAT enhancer binding protein alpha	Homo sapiens	242-278
33743412-9	2021	In contrast, ICA inhibited hBMSC adipogenic differentiation by reducing lipid droplet formation and cellular triglyceride levels as well as by downregulating the expression of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and CCAAT enhancer-binding protein-alpha (C/EBP-alpha).	icariin	13-16	CCAAT enhancer binding protein alpha	Homo sapiens	280-291
33995374-5	2021	Then, we screened HP-PRRSV proteins and demonstrated that HP-PRRSV nonstructural protein 2 (NSP2) activated MEK1-ERK1/2-C/EBPbeta signaling pathways by interacting with 14-3-3zeta to promote COX-2 expression, leading to PGE2 production.	Dinoprostone	220-224	CCAAT enhancer binding protein alpha	Homo sapiens	120-129
33925539-5	2021	High salt intake and excess circulating aldosterone cause DNA demethylation around the CCAAT-enhancer-binding-protein (CEBP) sites of the CYP11B2 promoter region, thereby converting the phenotype of AGT expression from an inactive to an active state in visceral adipose tissue and heart.	Salts	5-9	CCAAT enhancer binding protein alpha	Homo sapiens	87-117
33925539-5	2021	High salt intake and excess circulating aldosterone cause DNA demethylation around the CCAAT-enhancer-binding-protein (CEBP) sites of the CYP11B2 promoter region, thereby converting the phenotype of AGT expression from an inactive to an active state in visceral adipose tissue and heart.	Salts	5-9	CCAAT enhancer binding protein alpha	Homo sapiens	119-123
33925539-5	2021	High salt intake and excess circulating aldosterone cause DNA demethylation around the CCAAT-enhancer-binding-protein (CEBP) sites of the CYP11B2 promoter region, thereby converting the phenotype of AGT expression from an inactive to an active state in visceral adipose tissue and heart.	Aldosterone	40-51	CCAAT enhancer binding protein alpha	Homo sapiens	87-117
33925539-5	2021	High salt intake and excess circulating aldosterone cause DNA demethylation around the CCAAT-enhancer-binding-protein (CEBP) sites of the CYP11B2 promoter region, thereby converting the phenotype of AGT expression from an inactive to an active state in visceral adipose tissue and heart.	Aldosterone	40-51	CCAAT enhancer binding protein alpha	Homo sapiens	119-123
33901013-7	2021	Moreover, silencing of C/EBPalpha attenuated ATRA-induced NEAT1 upregulation and APL cell differentiation.	Tretinoin	45-49	CCAAT enhancer binding protein alpha	Homo sapiens	23-33
33901013-8	2021	Finally, simultaneous knockdown of C/EBPalpha and C/EBPbeta reduces ATRA-induced upregulation of C/EBPepsilon and dramatically impaired NEAT1 activation and APL cell differentiation.	Tretinoin	68-72	CCAAT enhancer binding protein alpha	Homo sapiens	35-45
33901013-8	2021	Finally, simultaneous knockdown of C/EBPalpha and C/EBPbeta reduces ATRA-induced upregulation of C/EBPepsilon and dramatically impaired NEAT1 activation and APL cell differentiation.	Tretinoin	68-72	CCAAT enhancer binding protein alpha	Homo sapiens	50-59
33876818-11	2021	Moreover, butyric acid alleviated CIH-induced cell proliferation, lipid formation and inflammatory status and promoted cell apoptosis through regulating related genes including p21, PPARgamma, C/EBPa, IL-1beta, IL-6, TLR4, caspase-8 and caspase-3.	Butyric Acid	10-22	CCAAT enhancer binding protein alpha	Homo sapiens	193-199
33872936-7	2021	Four OPs treatment induced peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), and perilipin expression.	OPS	5-8	CCAAT enhancer binding protein alpha	Homo sapiens	89-125
33872936-7	2021	Four OPs treatment induced peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), and perilipin expression.	OPS	5-8	CCAAT enhancer binding protein alpha	Homo sapiens	127-137
33660927-8	2021	Taken together, our data indicate the oncogenic role of C/EBPbeta in human TNBC and reveal a novel mechanism by which C/EBPbeta promotes TNBC carcinogenesis.	tnbc	75-79	CCAAT enhancer binding protein alpha	Homo sapiens	56-65
33836827-8	2021	Treatment of hADMSCs with vitamin D plus BPA (0.1 nM) significantly inhibited the induction of PPARgamma, C/EBP beta, C/EBP alpha, and FASN related to adipocyte differentiation and development.	Vitamin D	26-35	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
33836827-8	2021	Treatment of hADMSCs with vitamin D plus BPA (0.1 nM) significantly inhibited the induction of PPARgamma, C/EBP beta, C/EBP alpha, and FASN related to adipocyte differentiation and development.	Vitamin D	26-35	CCAAT enhancer binding protein alpha	Homo sapiens	118-129
33836827-8	2021	Treatment of hADMSCs with vitamin D plus BPA (0.1 nM) significantly inhibited the induction of PPARgamma, C/EBP beta, C/EBP alpha, and FASN related to adipocyte differentiation and development.	bisphenol A	41-44	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
33836827-8	2021	Treatment of hADMSCs with vitamin D plus BPA (0.1 nM) significantly inhibited the induction of PPARgamma, C/EBP beta, C/EBP alpha, and FASN related to adipocyte differentiation and development.	bisphenol A	41-44	CCAAT enhancer binding protein alpha	Homo sapiens	118-129
33355181-4	2021	Here we show that upon cancer-induced activation of Toll-like receptor 4 (TLR4) in skeletal muscle, p38beta MAPK phosphorylates Ser-12 on p300 to stimulate C/EBPbeta acetylation, which is necessary and sufficient to cause muscle wasting.	Serine	128-131	CCAAT enhancer binding protein alpha	Homo sapiens	156-165
33582555-3	2021	C/EBPbeta is a leucine-zipper transcription factor that regulates expression of a variety of inflammatory cytokines or chemokines, such as IL-8, G-CSF (granulocyte colony stimulating factor), and GM-CSF (granulocyte macrophage colony stimulating factor) which induce neutrophil infiltration and differentiation.	Leucine	15-22	CCAAT enhancer binding protein alpha	Homo sapiens	0-9
33712053-7	2021	1,25-dihydroxyvitamin D3 at concentration of 10-8 M enhanced expression of sterol regulatory element-binding protein-1c (SREBP1c), CCAAT-enhancer-binding protein-beta (C/EBPbeta), a mitotic clonal expansion, peroxisome proliferator-activated receptor-gamma (PPARgamma), fatty acid synthase (FASN), a marker of de novo lipogenesis,and lipoprotein lipase (LPL).	Calcitriol	0-24	CCAAT enhancer binding protein alpha	Homo sapiens	168-177
33471067-0	2021	Inhibition of lipogenesis and induction of apoptosis by valproic acid in prostate cancer cells via the C/EBPalpha/SREBP-1 pathway.	Valproic Acid	56-69	CCAAT enhancer binding protein alpha	Homo sapiens	103-113
33471067-7	2021	Mechanistically, the overexpression of C/EBPalpha rescued the levels of SREBP-1, FASN, ACC1, and Bcl-2, enhanced lipid accumulation, and attenuated apoptosis of VPA-treated PC-3 cells.	Valproic Acid	161-164	CCAAT enhancer binding protein alpha	Homo sapiens	39-49
33471067-10	2021	Based on the results, we concluded that VPA significantly inhibits cell viability via decreasing lipogenesis and inducing apoptosis via the C/EBPalpha/SREBP-1 pathway in prostate cancer cells.	Valproic Acid	40-43	CCAAT enhancer binding protein alpha	Homo sapiens	140-150
33507306-6	2021	Tunicamycin increased the expression of A20 and C/EBPbeta, which are negative regulators of NF-kappaB, and this increase inhibited NF-kappaB activity in NESCs incubated with TNF-alpha- or IL-1beta.	Tunicamycin	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	48-57
33672932-8	2021	Piceatannol significantly attenuated the expression level of adipogenic markers (e.g., CCAAT/enhanced binding protein alpha (C/EBPalpha), peroxisome proliferator-activated receptor gamma (PPARgamma), and adipocyte fatty acid binding protein (aP2)) compared to resveratrol at the mRNA and protein levels.	3,3',4,5'-tetrahydroxystilbene	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	125-135
33507306-7	2021	Similarly, progesterone increased A20 and C/EBPbeta expression through upregulation of ER stress in NESCs, resulting in inhibition of NF-kappaB activity and IL-6 and COX2 production.	Progesterone	11-23	CCAAT enhancer binding protein alpha	Homo sapiens	42-51
31983283-5	2021	Mechanistically, m6A modification promoted translation of PPM1A (protein phosphatase 1A, magnesium dependent, alpha isoform), a negative AMP-activated protein kinase (AMPK) regulator, but decreased expression of CAMKK2 (calcium/calmodulin-dependent protein kinase kinase 2, beta), a positive AMPK regulator, by reducing its RNA stability.	Adenosine Monophosphate	137-140	CCAAT enhancer binding protein alpha	Homo sapiens	4-5
31983283-5	2021	Mechanistically, m6A modification promoted translation of PPM1A (protein phosphatase 1A, magnesium dependent, alpha isoform), a negative AMP-activated protein kinase (AMPK) regulator, but decreased expression of CAMKK2 (calcium/calmodulin-dependent protein kinase kinase 2, beta), a positive AMPK regulator, by reducing its RNA stability.	Adenosine Monophosphate	137-140	CCAAT enhancer binding protein alpha	Homo sapiens	11-12
31983283-1	2021	Macroautophagy/autophagy is indispensable for testosterone synthesis in Leydig cells (LCs), and here we report a negative association between m6A modification and autophagy in LCs during testosterone synthesis.	Testosterone	46-58	CCAAT enhancer binding protein alpha	Homo sapiens	1-2
31983283-9	2021	Collectively, this study highlights a vital role of m6A RNA methylation in the modulation of testosterone synthesis in LCs, providing insight into novel therapeutic strategies by exploiting m6A RNA methylation as targets for treating azoospermatism and oligospermatism patients with reduction in serum testosterone.	Testosterone	93-105	CCAAT enhancer binding protein alpha	Homo sapiens	36-37
31983283-9	2021	Collectively, this study highlights a vital role of m6A RNA methylation in the modulation of testosterone synthesis in LCs, providing insight into novel therapeutic strategies by exploiting m6A RNA methylation as targets for treating azoospermatism and oligospermatism patients with reduction in serum testosterone.	Testosterone	302-314	CCAAT enhancer binding protein alpha	Homo sapiens	36-37
33421904-11	2021	Z-LIG-promoted differentiation was found to be related to Nur77/NOR-1-mediated myeloid differentiation-associated transcription factors Jun B, c-Jun, and C/EBPbeta.	ligustilide	0-5	CCAAT enhancer binding protein alpha	Homo sapiens	154-163
32086435-6	2021	In contrast, depletion of C/EBPbeta from human alpha-Syn Tg mice abolishes rotenone-elicited PD pathologies and motor impairments via downregulating the expression of these key factors.	Rotenone	75-83	CCAAT enhancer binding protein alpha	Homo sapiens	26-35
33263949-0	2021	Neddylation inhibitor MLN4924 has anti-HBV activity via modulating the ERK-HNF1alpha-C/EBPalpha-HNF4alpha axis.	pevonedistat	22-29	CCAAT enhancer binding protein alpha	Homo sapiens	85-95
33061798-0	2020	Oleate acid-stimulated HMMR expression by CEBPalpha is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma.	oleate acid	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	42-51
33341231-10	2021	Conversely, CEBPa gene expression in PCOS cells negatively correlated with adipose-IR and serum free testosterone, whereas total lipid accumulation in these cells positively corelated with Si.	Testosterone	101-113	CCAAT enhancer binding protein alpha	Homo sapiens	12-17
33260349-6	2020	TGF-beta-induced C/EBPbeta phosphorylation was weakened by U0126, ADAM17 siRNA, and RSK1 siRNA.	U 0126	59-64	CCAAT enhancer binding protein alpha	Homo sapiens	17-26
33126698-7	2020	The presence of quercetin in adipo-induced hBM-MSC culture inhibited the adipogenic differentiation depicted as suppressed lipid accumulation and expression of adipogenesis markers such as PPARgamma, SREBP1c and C/EBPalpha.	Quercetin	16-25	CCAAT enhancer binding protein alpha	Homo sapiens	212-222
32623605-7	2020	Lentiviral knock-down of one of the candidate TFs, C/EBPalpha, partly rescued VPA-induced mitochondrial dysfunction.	Valproic Acid	78-81	CCAAT enhancer binding protein alpha	Homo sapiens	51-61
32623605-8	2020	Furthermore, RNA-Seq analysis of shC/EBPalpha and shGFP control PHHs identified 24 genuine C/EBPalpha target genes that are regulated in response to prolonged VPA exposure in PHHs.	Valproic Acid	159-162	CCAAT enhancer binding protein alpha	Homo sapiens	35-45
32623605-9	2020	Altogether this provides new insights on the involvement of C/EBPalpha in driving VPA-induced mitochondrial dysfunction in human liver cells.	Valproic Acid	82-85	CCAAT enhancer binding protein alpha	Homo sapiens	60-70
32366959-10	2020	In cultured adipocytes, sucralose exposure at early stages of differentiation caused increased lipid accumulation and expression of adipocyte differentiation genes (e.g., C/EBP-alpha, FABP4, and FASN).	trichlorosucrose	24-33	CCAAT enhancer binding protein alpha	Homo sapiens	171-182
32970728-6	2020	In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS).	L-valyl-L-proline	32-35	CCAAT enhancer binding protein alpha	Homo sapiens	246-282
32970728-6	2020	In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS).	L-valyl-L-proline	32-35	CCAAT enhancer binding protein alpha	Homo sapiens	284-294
33014457-0	2020	Lugol Increases Lipolysis through Upregulation of PPAR-Gamma and Downregulation of C/EBP-Alpha in Mature 3T3-L1 Adipocytes.	Lugol's solution	0-5	CCAAT enhancer binding protein alpha	Homo sapiens	83-94
33014457-6	2020	The levels of adipocyte-specific transcription factors C/EBP-alpha were downregulated and PPAR-gamma upregulated after 30 min with lugol.	Lugol's solution	131-136	CCAAT enhancer binding protein alpha	Homo sapiens	55-66
33014457-7	2020	These results indicate a lipolytic effect of lugol dependent on PPAR-gamma and C/EBP-alpha expression in mature 3T3-L1 adipocytes.	Lugol's solution	45-50	CCAAT enhancer binding protein alpha	Homo sapiens	79-90
32353732-7	2020	Additionally, significant increases in E2 production and the expression levels of associated genes (17betaHSD and C/EBP-alpha) further supported the involvement of the ERalpha signaling pathway in the lipid metabolic perturbation induced by 3-NFA.	3-nfa	241-246	CCAAT enhancer binding protein alpha	Homo sapiens	114-125
33437364-6	2020	Mechanistically, in all these cell lines, enzastaurin-ATRA (enz-ATRA) co-treatment enhanced the protein levels of PU.1, CCAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPepsilon.	enzastaurin-atra	42-58	CCAAT enhancer binding protein alpha	Homo sapiens	157-166
33437364-6	2020	Mechanistically, in all these cell lines, enzastaurin-ATRA (enz-ATRA) co-treatment enhanced the protein levels of PU.1, CCAAT/enhancer-binding protein beta (C/EBPbeta) and C/EBPepsilon.	enz-atra	60-68	CCAAT enhancer binding protein alpha	Homo sapiens	157-166
33437364-9	2020	Furthermore, in U937 cells, enz-ATRA activated MEK and ERK, and a MEK-specific inhibitor suppressed enz-ATRA-triggered differentiation and reduced the protein levels of PU.1, C/EBPbeta and C/EBPepsilon.	enz-atra	28-36	CCAAT enhancer binding protein alpha	Homo sapiens	175-184
33437364-12	2020	Therefore, PKCbeta inhibition, MEK/ERK and Akt activation were involved in enz-ATRA-induced differentiation in HL-60, U937 and HL-60Res cells, respectively, via modulation of the protein levels of C/EBPbeta, C/EBPepsilon and PU.1.	enz-atra	75-83	CCAAT enhancer binding protein alpha	Homo sapiens	197-206
33510942-0	2021	lncRNA-Xist/miR-101-3p/KLF6/C/EBPalpha axis promotes TAM polarization to regulate cancer cell proliferation and migration.	tam	53-56	CCAAT enhancer binding protein alpha	Homo sapiens	28-38
33510942-4	2021	Knockdown of Xist or overexpression of miR-101 in M1 could induce M1-to-M2 macrophage-type (M2) conversion to promote cell proliferation and migration of breast and ovarian cancer by inhibiting C/EBPalpha and KLF6 expression.	mir-101	39-46	CCAAT enhancer binding protein alpha	Homo sapiens	194-204
33510942-5	2021	Furthermore, miR-101 could combine with both Xist and C/EBPalpha and KLF6 through the same microRNA response element (MRE) predicted by bioinformatics and verified by luciferase reporter assays.	mir-101	13-20	CCAAT enhancer binding protein alpha	Homo sapiens	54-64
33510942-7	2021	Generally, the present study indicates that Xist could mediate macrophage polarization to affect cell proliferation and migration of breast and ovarian cancer by competing with miR-101 to regulate C/EBPalpha and KLF6 expression.	mir-101	177-184	CCAAT enhancer binding protein alpha	Homo sapiens	197-207
33241756-4	2021	Chromatin immunoprecipitation (ChIP) assays indicated that C/EBPbeta upregulated HOTAIR during ATRA induced differentiation in HL-60 cells.	Tretinoin	95-99	CCAAT enhancer binding protein alpha	Homo sapiens	59-68
32933750-2	2020	Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha).	Ribavirin	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	109-145
32933750-2	2020	Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha).	Ribavirin	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	147-157
32933750-2	2020	Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha).	Ribavirin	62-65	CCAAT enhancer binding protein alpha	Homo sapiens	109-145
32933750-2	2020	Recently, we demonstrated that the anti-viral drug ribavirin (RBV) reduces GPAM expression by downregulating CCAAT/enhancer-binding protein alpha (C/EBPalpha).	Ribavirin	62-65	CCAAT enhancer binding protein alpha	Homo sapiens	147-157
32673519-8	2020	Accordingly, gain-of-function for C/EBP-alpha increased claudin-5 expression and decreased endothelial permeability, as measured by the passage of FITC-dextran through endothelial monolayers.	fluorescein isothiocyanate dextran	147-159	CCAAT enhancer binding protein alpha	Homo sapiens	34-45
32622945-8	2020	Using Estradiol-inducible K562-C/EBPalpha-ER cells as yet another model of granulocytic differentiation, we further confirmed that SKP2 overexpression indeed inhibits granulocytic differentiation by mitigating C/EBPalpha stability.	Estradiol	6-15	CCAAT enhancer binding protein alpha	Homo sapiens	31-41
33061798-6	2020	Oleate acid (OA), one of fatty acids that induce cellular adipogenesis, stimulates HMMR expression via CCAAT/enhancer-binding protein alpha (CEBPalpha).	oleate acid	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	103-139
33061798-6	2020	Oleate acid (OA), one of fatty acids that induce cellular adipogenesis, stimulates HMMR expression via CCAAT/enhancer-binding protein alpha (CEBPalpha).	oleate acid	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	141-150
31477806-1	2020	Acute myeloid leukemia (AML) with double mutant CEBPA (CEBPAdm) is generally associated with favorable prognosis, but the heterogeneity still blatant and needs further exploration.	cebpadm	55-62	CCAAT enhancer binding protein alpha	Homo sapiens	48-53
32357963-2	2020	MTL-CEBPA is a first-in-class small activating RNA oligonucleotide drug which up-regulates C/EBP-alpha.	Oligonucleotides	51-66	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
32357963-2	2020	MTL-CEBPA is a first-in-class small activating RNA oligonucleotide drug which up-regulates C/EBP-alpha.	Oligonucleotides	51-66	CCAAT enhancer binding protein alpha	Homo sapiens	91-102
32652877-0	2020	LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPbeta.	Paclitaxel	19-29	CCAAT enhancer binding protein alpha	Homo sapiens	124-133
32652877-0	2020	LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPbeta.	Doxorubicin	34-45	CCAAT enhancer binding protein alpha	Homo sapiens	124-133
32416217-9	2020	Meanwhile, DT-13 induced the differentiation with morphological change related to myeloid differentiation, elevated NBT and alpha-NAE positive cell rates, differentiation markers CD11b and CD14 as well as level of transcription factors C/EBPalpha and C/EBPbeta.	DT-13	11-16	CCAAT enhancer binding protein alpha	Homo sapiens	236-246
32416217-9	2020	Meanwhile, DT-13 induced the differentiation with morphological change related to myeloid differentiation, elevated NBT and alpha-NAE positive cell rates, differentiation markers CD11b and CD14 as well as level of transcription factors C/EBPalpha and C/EBPbeta.	DT-13	11-16	CCAAT enhancer binding protein alpha	Homo sapiens	251-260
32720112-9	2020	However, BMP9-induced adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT enhancer-binding protein alpha (C/EBPalpha), were inhibited by beta-catenin.	bmp9	9-13	CCAAT enhancer binding protein alpha	Homo sapiens	121-157
32720112-9	2020	However, BMP9-induced adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT enhancer-binding protein alpha (C/EBPalpha), were inhibited by beta-catenin.	bmp9	9-13	CCAAT enhancer binding protein alpha	Homo sapiens	159-169
32474770-7	2020	Western blotting showed that the levels both activating and inhibitory C/EBPbeta isoforms were significantly increased in cells grown in arginine medium.	Arginine	137-145	CCAAT enhancer binding protein alpha	Homo sapiens	71-80
32474770-9	2020	When ornithine and arginine were depleted, albumin production was significantly reduced at the mRNA level, CEBPB mRNA levels were increased, and the level of activating form of C/EBPbeta was increased.	Ornithine	5-14	CCAAT enhancer binding protein alpha	Homo sapiens	177-186
32474770-9	2020	When ornithine and arginine were depleted, albumin production was significantly reduced at the mRNA level, CEBPB mRNA levels were increased, and the level of activating form of C/EBPbeta was increased.	Arginine	19-27	CCAAT enhancer binding protein alpha	Homo sapiens	177-186
32526700-3	2020	Here we show that C/EBPbeta, a ROS responsive transcription factor, regulates the transcription of NQO1 and GSTP1, two antioxidative reductases, which neutralize ROS in the GBM and mediates their proliferation.	ros	31-34	CCAAT enhancer binding protein alpha	Homo sapiens	18-27
32526700-3	2020	Here we show that C/EBPbeta, a ROS responsive transcription factor, regulates the transcription of NQO1 and GSTP1, two antioxidative reductases, which neutralize ROS in the GBM and mediates their proliferation.	ros	162-165	CCAAT enhancer binding protein alpha	Homo sapiens	18-27
32589556-9	2021	The treatment of astaxanthin could inhibit the expression of PPARgamma, C/EBPalpha and SREBP-1c in adipocytes, upregulate the expression of Wnt10b, LRP6, FZ in Wnt/ beta-catenin signaling pathway and increase the beta-catenin entry into nucleus, suggesting that activation of Wnt/ beta-catenin signaling was involved in axtaxanthin-regulated lipogenesis.	astaxanthine	17-28	CCAAT enhancer binding protein alpha	Homo sapiens	72-82
32526700-6	2020	Overexpression of C/EBPbeta selectively decreases the ROS in EGFR-overexpressed U87MG cells and promotes cell proliferation via upregulating NQO1 and GSTP1; whereas knocking down C/EBPbeta elevates the ROS and reduces proliferation by repressing the reductases.	ros	54-57	CCAAT enhancer binding protein alpha	Homo sapiens	18-27
32526700-6	2020	Overexpression of C/EBPbeta selectively decreases the ROS in EGFR-overexpressed U87MG cells and promotes cell proliferation via upregulating NQO1 and GSTP1; whereas knocking down C/EBPbeta elevates the ROS and reduces proliferation by repressing the reductases.	ros	202-205	CCAAT enhancer binding protein alpha	Homo sapiens	18-27
32526700-7	2020	Accordingly, C/EBPbeta mediates the brain tumor growth in vivo, coupling with NQO1 and GSTP1 expression and ROS levels.	ros	108-111	CCAAT enhancer binding protein alpha	Homo sapiens	13-22
32526700-8	2020	Hence, C/EBPbeta regulates the expression of antioxidative reductases and balances the ROS, promoting brain tumor proliferation.	ros	87-90	CCAAT enhancer binding protein alpha	Homo sapiens	7-16
32696739-5	2020	The real-time quantitative PCR and Western blot analysis were used to detect difference in the mRNA and protein expression of CD11b and CEBPbeta in the NR cells treated with 1, 25-dihydroxyvitamin D3 (1, 25D3) compared with NC cells treated with 1, 25D3.	Calcitriol	174-199	CCAAT enhancer binding protein alpha	Homo sapiens	136-144
32536766-7	2020	Despite increasing ASC proliferative potential, we showed that Nebivolol has an inhibitory effect on adipogenic and osteogenic differentiation potential as indicated by significantly reduced expression of CCAAT Enhancer Binding Protein alpha (P<0.01) and lipoprotein lipase (P<0.01) and inhibited activity of alkaline phosphatase (P<0.01), respectively.	Nebivolol	63-72	CCAAT enhancer binding protein alpha	Homo sapiens	205-241
32223896-6	2020	Therapeutically, functional studies demonstrated gene therapy-delivered cardiac-specific MAPK7 restoration or overexpression of CEBPbeta impeded cardiac injury after MI, at least partly due to normalization of mir128-3p.	Inositol	166-168	CCAAT enhancer binding protein alpha	Homo sapiens	128-136
32460775-10	2020	Transcription factors MYC and C/EBPbeta were both negatively associated with the expression profiling of failing heart tissues in GSEA assay.	gsea	130-134	CCAAT enhancer binding protein alpha	Homo sapiens	30-39
32566108-0	2020	Baicalin Represses C/EBPbeta via Its Antioxidative Effect in Parkinson"s Disease.	baicalin	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	19-28
32566108-7	2020	Interestingly, Baicalin could protect DA neurons against reactive oxygen species (ROS) and decreased C/EBPbeta and alpha-synuclein expression in pLVX-Tet3G-alpha-synuclein SH-SY5Y cells.	baicalin	15-23	CCAAT enhancer binding protein alpha	Homo sapiens	101-110
31941844-7	2020	Oil Red-O staining results revealed a decrease in lipid droplets; furthermore, PPARgamma, C/EBPalpha, and C/EBPbeta protein expression levels were inhibited upon treatment with caffeine during adipocyte differentiation.	Caffeine	177-185	CCAAT enhancer binding protein alpha	Homo sapiens	90-100
31996328-14	2020	In summary, our results suggest that miR-326 upregulate CREB and CREB may activate C/EBP-beta and later inhibited the transcription of CYP19A1 and decreased estradiol-17b production.	Estradiol	157-166	CCAAT enhancer binding protein alpha	Homo sapiens	83-93
32183002-0	2020	Sulforaphene Suppresses Adipocyte Differentiation via Induction of Post-Translational Degradation of CCAAT/Enhancer Binding Protein Beta (C/EBPbeta).	sulphoraphene	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	138-147
32196098-8	2020	Moreover, GS significantly decreased the formation of lipid droplets and expression of PPARgamma, C/EBP alpha/beta, and SREBP-1 in a dose-dependent manner.	pregna-4,17-diene-3,16-dione	10-12	CCAAT enhancer binding protein alpha	Homo sapiens	98-114
31769558-6	2020	Physiologically relevant high dosages MSG demonstrated a significant potential in reducing MCE and thereof adipogenic capacity of preadipocytes in a dose-dependent manner by restricting the availability of critical mitogenic proteins, CCAAT/enhancer-binding protein beta (CEBPbeta), and the mitotic cyclin B.	Sodium Glutamate	38-41	CCAAT enhancer binding protein alpha	Homo sapiens	272-280
32483753-2	2020	Compared with day 7, at 5% O2 on day 14 spontaneous upregulation of osteo- (RUNX2, SP7, BGLAP, and SPP1) and adipogenic differentiation (CEBPA, PPARG, and ADIPOQ) genes in MSCs was observed (p < 0.05).	Oxygen	27-29	CCAAT enhancer binding protein alpha	Homo sapiens	137-142
32231189-10	2020	Moreover, along with down-regulation of aberrant PLAP and up-regulation of TNAP, vitamin E increases C/EBPalpha mRNA expression.	Vitamin E	81-90	CCAAT enhancer binding protein alpha	Homo sapiens	101-111
31986076-9	2020	The false-negative rate was 6.5% (151 of 2341), and the largest single cause of these errors was difficulty in identifying variants in the sequence of CEBPA that is rich in cytosines and guanines.	Cytosine	173-182	CCAAT enhancer binding protein alpha	Homo sapiens	151-156
31958467-2	2020	Here, we establish C/EBPbeta (CCAAT/enhancer-binding protein beta) as an early marker of the metabolic derangement that triggers the imbalance in fatty acid (FA) oxidation and glucose uptake with increased lipid accumulation in cardiomyocytes during pathological hypertrophy, leading to contractile dysfunction and endoplasmic reticulum (ER) stress.	Fatty Acids	146-156	CCAAT enhancer binding protein alpha	Homo sapiens	19-28
31958467-2	2020	Here, we establish C/EBPbeta (CCAAT/enhancer-binding protein beta) as an early marker of the metabolic derangement that triggers the imbalance in fatty acid (FA) oxidation and glucose uptake with increased lipid accumulation in cardiomyocytes during pathological hypertrophy, leading to contractile dysfunction and endoplasmic reticulum (ER) stress.	Glucose	176-183	CCAAT enhancer binding protein alpha	Homo sapiens	19-28
31958467-5	2020	Before the functional and structural remodeling sets in the diseased myocardium, C/EBPbeta aggravates lipid accumulation with the aid of the increased FA uptake involving induced PPARgamma expression and decreased fatty acid oxidation (FAO) by suppressing PPARalpha expression.	Fatty Acids	214-224	CCAAT enhancer binding protein alpha	Homo sapiens	81-90
31958467-6	2020	Glucose uptake into cardiomyocytes was greatly increased by C/EBPbeta via PPARalpha suppression.	Glucose	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	60-69
31958467-7	2020	The activation of mammalian target of rapamycin complex-1 (mTORC1) during increased workload in presence of glucose as the only substrate was prevented by C/EBPbeta knockdown, thereby abating contractile dysfunction in cardiomyocytes.	Sirolimus	38-47	CCAAT enhancer binding protein alpha	Homo sapiens	155-164
31958467-7	2020	The activation of mammalian target of rapamycin complex-1 (mTORC1) during increased workload in presence of glucose as the only substrate was prevented by C/EBPbeta knockdown, thereby abating contractile dysfunction in cardiomyocytes.	Glucose	108-115	CCAAT enhancer binding protein alpha	Homo sapiens	155-164
31851340-0	2020	Methylmercury Induces Metabolic Alterations in Caenorhabditis elegans: Role for C/EBP Transcription Factor.	methylmercury II	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	80-85
31851340-6	2020	Of particular interest was cebp-1, the worm ortholog to human C/EBP, a pro-adipogenic transcription factor implicated in MS. MeHg increased the expression of cebp-1 as well as pro-adipogenic transcription factors sbp-1 and nhr-49, triglyceride synthesis enzyme acl-6, and lipid transport proteins vit-2 and vit-6.	Mercury	125-129	CCAAT enhancer binding protein alpha	Homo sapiens	62-67
31986076-9	2020	The false-negative rate was 6.5% (151 of 2341), and the largest single cause of these errors was difficulty in identifying variants in the sequence of CEBPA that is rich in cytosines and guanines.	Guanine	187-195	CCAAT enhancer binding protein alpha	Homo sapiens	151-156
32038705-15	2019	Conclusions: In the OSCC cisplatin-resistant cell lines, NOTCH1, JUN, CTNNB1, CEBPA, and ETS1 were found as the hub genes involved in regulating the cisplatin resistance of OSCC.	Cisplatin	25-34	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
32038705-15	2019	Conclusions: In the OSCC cisplatin-resistant cell lines, NOTCH1, JUN, CTNNB1, CEBPA, and ETS1 were found as the hub genes involved in regulating the cisplatin resistance of OSCC.	Cisplatin	149-158	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
32010124-7	2019	Accordingly, we found that transcription factors NF-kappaB, CREB, and C/EBP are belatedly activated by MSU crystals, and at least the former is involved in chemokine generation.	Uric Acid	103-106	CCAAT enhancer binding protein alpha	Homo sapiens	70-75
32698734-0	2020	ATF4, DLX3, FRA1, MSX2, C/EBP-zeta, and C/EBP-alpha Shape the Molecular Basis of Therapeutic Effects of Zoledronic Acid in Bone Disorders.	Zoledronic Acid	104-119	CCAAT enhancer binding protein alpha	Homo sapiens	40-51
32698734-8	2020	RESULTS: Gene expression and promoter methylation level for DLX3, FRA1, ATF4, MSX2, C/EBPzeta, and C/EBPa was up or down-regulated in both ZA-treated and untreated cells during the osteodifferentiation process on days 0 to 21.	Zoledronic Acid	139-141	CCAAT enhancer binding protein alpha	Homo sapiens	99-105
32698734-10	2020	On the other hand, ATF4 and DLX3 methylation levels were falling in both ZA-treated and untreated cells during the osteodifferentiation process on days 0 to 21, while the pattern was increasing for MSX2 and C/EBPa.	Zoledronic Acid	73-75	CCAAT enhancer binding protein alpha	Homo sapiens	207-213
32277682-8	2020	The changing of C/EBPalpha expression was found at 8 h. Interestingly, the reducing mRNA of c-Myb by EGCG was observed at 4 h, earlier than FLT3 was downregulated.	epigallocatechin gallate	101-105	CCAAT enhancer binding protein alpha	Homo sapiens	16-26
31615122-0	2019	Genome-Wide Mapping Defines a Role for C/EBPbeta and c-Jun in Non-Canonical Cyclic AMP Signalling.	Cyclic AMP	76-86	CCAAT enhancer binding protein alpha	Homo sapiens	39-48
31829168-11	2019	CEBPA over-expression by transient transfection in IPF-derived fibroblasts significantly reduced pro-fibrotic gene expression, ECM deposition and alphaSMA expression and promoted the formation of lipid droplets measured by Oil Red O staining and increased lipofibroblast gene expression.	oil red O	223-232	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
31479709-0	2019	Modulation of FLT3 through decitabine-activated C/EBPa-PU.1 signal pathway in FLT3-ITD positive cells.	Decitabine	27-37	CCAAT enhancer binding protein alpha	Homo sapiens	48-54
31479709-4	2019	DAC treatment could increase the percentage of apoptotic cells and CD11b positive cells tested by flow cytometry and upregulate the expression of cleaved caspase3, cleaved PARP, C/EBPa and PU.1 detected by western blot.	Decitabine	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	178-184
31100494-3	2019	We hypothesized estradiol (E2) facilitates adipocyte differentiation/glucose disposal by an estrogen receptor 1 (ESR1)-dependent and CEBPA-mediated mechanism.	Estradiol	16-25	CCAAT enhancer binding protein alpha	Homo sapiens	133-138
31100494-3	2019	We hypothesized estradiol (E2) facilitates adipocyte differentiation/glucose disposal by an estrogen receptor 1 (ESR1)-dependent and CEBPA-mediated mechanism.	Glucose	69-76	CCAAT enhancer binding protein alpha	Homo sapiens	133-138
31769250-6	2019	Quantitative real-time polymerase chain reaction and Western blot assay were applied to measure the expressions of miR-138, LPL, and the two adipogenic transcription factors cytidine-cytidine-adenosine-adenosine-thymidine enhancer binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma).	Adenosine	202-211	CCAAT enhancer binding protein alpha	Homo sapiens	254-264
31062357-6	2019	Mechanistically, miR-92a-3p inhibited adipogenesis of ADSCs via posttranscriptionally decreasing C/EBPalpha expression when transferred into the ADSCs with the exosomes, and encapsulating miR-92a-3p inhibitor into CML exosomes blocked the antiadipogenic effects of CML exosomes.	mir-92a-3p	17-27	CCAAT enhancer binding protein alpha	Homo sapiens	97-107
31062357-6	2019	Mechanistically, miR-92a-3p inhibited adipogenesis of ADSCs via posttranscriptionally decreasing C/EBPalpha expression when transferred into the ADSCs with the exosomes, and encapsulating miR-92a-3p inhibitor into CML exosomes blocked the antiadipogenic effects of CML exosomes.	mir-92a-	17-25	CCAAT enhancer binding protein alpha	Homo sapiens	97-107
31874211-7	2020	Saturated fatty acids increase the expression of lipogenic factors cooperated with C/EBPalpha and LXRalpha.	Fatty Acids	0-21	CCAAT enhancer binding protein alpha	Homo sapiens	83-93
31546122-5	2019	The RT-qPCR results showed that DINP could upregulate the expression of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha) and C/EBPbeta, while the expression of sterol regulatory element binding transcription factor 1 (SREBF1) and C/EBPdelta was not affected.	diisononyl phthalate	32-36	CCAAT enhancer binding protein alpha	Homo sapiens	134-170
31546122-5	2019	The RT-qPCR results showed that DINP could upregulate the expression of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha) and C/EBPbeta, while the expression of sterol regulatory element binding transcription factor 1 (SREBF1) and C/EBPdelta was not affected.	diisononyl phthalate	32-36	CCAAT enhancer binding protein alpha	Homo sapiens	172-182
31100494-0	2019	Estradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via ESR1-mediated activation of CEBPA.	Estradiol	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	94-99
31100494-2	2019	The CCAAT/enhancer-binding protein alpha (CEBPA) enhances the expression of the Slc2a4 gene and GLUT4 protein, which are markers of adipocyte differentiation/glucose disposal.	Glucose	158-165	CCAAT enhancer binding protein alpha	Homo sapiens	4-40
31100494-2	2019	The CCAAT/enhancer-binding protein alpha (CEBPA) enhances the expression of the Slc2a4 gene and GLUT4 protein, which are markers of adipocyte differentiation/glucose disposal.	Glucose	158-165	CCAAT enhancer binding protein alpha	Homo sapiens	42-47
31593984-6	2019	Decrease in lipid droplets and expression of PPARgamma and c/EBPalpha/beta were noted in fibroblasts treated with curcumin during adipose differentiation.	Curcumin	114-122	CCAAT enhancer binding protein alpha	Homo sapiens	59-74
31412584-3	2019	Docetaxel or vinorelbine inhibits proliferation and stimulates the differentiation of breast preadipocytes, by increasing C/EBPalpha and PPARgamma expression and by downregulating tumor necrosis factor alpha (TNFalpha), interleukin 6 (IL-6), and IL-11 expression.	Docetaxel	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	122-132
31570689-0	2019	The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients.	Tretinoin	4-8	CCAAT enhancer binding protein alpha	Homo sapiens	67-72
31569380-10	2019	A non-cytotoxic dose of curcumin (15 microM) inhibited MCE, downregulated the expression of PPARgamma and C/EBPalpha, prevented differentiation medium-induced beta-catenin downregulation, and decreased the lipid accumulation in 3T3-L1 adipocytes.	Curcumin	24-32	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
31572402-4	2019	These investigations provided genome-wide maps illustrating significant effects of 1,25(OH)2D3 on the binding of VDR, the pioneer transcription factors purine-rich box 1 (PU.1) and CCAAT/enhancer binding protein alpha (CEBPA) and the chromatin modifier CCCTC-binding factor (CTCF) as well as on chromatin accessibility and histone markers of promoter and enhancer regions, H3K4me3 and H3K27ac.	25-hydroxyvitamin D3-bromoacetate	83-94	CCAAT enhancer binding protein alpha	Homo sapiens	181-217
31572402-4	2019	These investigations provided genome-wide maps illustrating significant effects of 1,25(OH)2D3 on the binding of VDR, the pioneer transcription factors purine-rich box 1 (PU.1) and CCAAT/enhancer binding protein alpha (CEBPA) and the chromatin modifier CCCTC-binding factor (CTCF) as well as on chromatin accessibility and histone markers of promoter and enhancer regions, H3K4me3 and H3K27ac.	25-hydroxyvitamin D3-bromoacetate	83-94	CCAAT enhancer binding protein alpha	Homo sapiens	219-224
31572402-4	2019	These investigations provided genome-wide maps illustrating significant effects of 1,25(OH)2D3 on the binding of VDR, the pioneer transcription factors purine-rich box 1 (PU.1) and CCAAT/enhancer binding protein alpha (CEBPA) and the chromatin modifier CCCTC-binding factor (CTCF) as well as on chromatin accessibility and histone markers of promoter and enhancer regions, H3K4me3 and H3K27ac.	H-2K(K) antigen	373-380	CCAAT enhancer binding protein alpha	Homo sapiens	219-224
31278031-2	2019	Previously we reported that Styryl quinazolinones induce myeloid differentiation in HL-60 cells by upregulating C/EBPalpha expression.	styryl quinazolinones	28-49	CCAAT enhancer binding protein alpha	Homo sapiens	112-122
31075711-0	2019	Shikonin induces apoptosis and suppresses growth in keratinocytes via CEBP-delta upregulation.	shikonin	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	70-74
31412584-3	2019	Docetaxel or vinorelbine inhibits proliferation and stimulates the differentiation of breast preadipocytes, by increasing C/EBPalpha and PPARgamma expression and by downregulating tumor necrosis factor alpha (TNFalpha), interleukin 6 (IL-6), and IL-11 expression.	Vinorelbine	13-24	CCAAT enhancer binding protein alpha	Homo sapiens	122-132
31412584-6	2019	Melatonin potentiates the stimulatory effect of docetaxel and vinorelbine on differentiation and their inhibitory effects on aromatase activity and expression, by increasing the stimulatory effect on C/EBPalpha and PPARgamma expression and the downregulation of antiadipogenic cytokines and COX expression.	Melatonin	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	200-210
31412584-6	2019	Melatonin potentiates the stimulatory effect of docetaxel and vinorelbine on differentiation and their inhibitory effects on aromatase activity and expression, by increasing the stimulatory effect on C/EBPalpha and PPARgamma expression and the downregulation of antiadipogenic cytokines and COX expression.	Docetaxel	48-57	CCAAT enhancer binding protein alpha	Homo sapiens	200-210
31412584-6	2019	Melatonin potentiates the stimulatory effect of docetaxel and vinorelbine on differentiation and their inhibitory effects on aromatase activity and expression, by increasing the stimulatory effect on C/EBPalpha and PPARgamma expression and the downregulation of antiadipogenic cytokines and COX expression.	Vinorelbine	62-73	CCAAT enhancer binding protein alpha	Homo sapiens	200-210
31412584-7	2019	Melatonin also counteracts the inhibitory effect of radiation on differentiation of preadipocytes, by increasing C/EBPalpha and PPARgamma expression and by decreasing TNFalpha expression.	Melatonin	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	113-123
31226809-6	2019	Furthermore, the hepatogenic medium + NaBu pre-treatment up-regulated hepatoblast (AFP and HNF3beta) and hepatic (CK18 and ALB) markers, and increased the proportion of mature hepatocyte functions, including G6P, C/EBPalpha, and CYP2B6 mRNAs, glycogen storage and urea secretion.	sethoxydim	38-42	CCAAT enhancer binding protein alpha	Homo sapiens	213-223
30355436-0	2019	CCAAT/enhancer-binding protein beta (C/EBPbeta) is an important mediator of 1,25 dihydroxyvitamin D3 (1,25D3)-induced receptor activator of nuclear factor kappa-B ligand (RANKL) expression in osteoblasts.	Calcitriol	76-100	CCAAT enhancer binding protein alpha	Homo sapiens	37-46
30611528-7	2019	The results showed that curcumin can suppresses adipocyte differentiation in a dose-dependent manner and inhibited the expression of PPARgamma, C/EBPalpha, and FABP4.	Curcumin	24-32	CCAAT enhancer binding protein alpha	Homo sapiens	144-154
31015230-6	2019	C/EBPalpha associated with and was methylated by PRMT1 at three arginine residues (R35, R156, and R165).	Arginine	64-72	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
30939750-7	2019	Our data indicate that 2 microM rosiglitazone enhanced adipogenesis by over-expression of PPAR-gamma and C/EBP-alpha.	Rosiglitazone	32-45	CCAAT enhancer binding protein alpha	Homo sapiens	105-116
30776459-0	2019	Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBPalpha-SIRT1 pathway.	Caffeine	9-17	CCAAT enhancer binding protein alpha	Homo sapiens	139-149
30776459-8	2019	Taken together, PCE-induced high glucocorticoids levels enhanced histone modifications and expression of SREBP1c and FASN via activation of the GR-C/EBPalpha-SIRT1 pathway in utero.	pce	16-19	CCAAT enhancer binding protein alpha	Homo sapiens	147-157
30738844-9	2019	In contrast, PFOS enhanced adipogenesis in regard to lipid droplet formation and marker gene expression of PPARgamma, CCAAT/enhancer-binding protein-alpha (C/EBPalpha), lipoprotein lipase and leptin.	perfluorooctane sulfonic acid	13-17	CCAAT enhancer binding protein alpha	Homo sapiens	118-154
30867686-12	2019	The expression of phosphorylated AKT (p-AKT), C/EBPalpha, C/EBPbeta, PPARgamma and adiponectin was increased in IGF-2-treated HemSCs culture, whereas these changes were repressed by the inhibition of either the IGF-1 receptor (IGF-1R) or phosphoinositide 3-kinase (PI3K).	hemscs	126-132	CCAAT enhancer binding protein alpha	Homo sapiens	46-56
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	celastrol	34-43	CCAAT enhancer binding protein alpha	Homo sapiens	138-143
30867764-9	2019	In addition, it was observed that celastrol/cisplatin upregulated the expression of Bcl-associated X protein, cytochrome c, caspase-3 and C/EBP homologous protein, and downregulated the expression of Bcl-2, poly(ADP-ribose) polymerase, 78 kDa glucose-regulated protein and caspase-9, whereas the expression of caspase-8 remained unchanged.	Cisplatin	44-53	CCAAT enhancer binding protein alpha	Homo sapiens	138-143
30759398-4	2019	Upon exposure to ionizing radiation (IR), GSCs, initially enriched for a CD133+ PN signature, transition to a CD109+ MES subtype in a C/EBP-beta-dependent manner.	2-(N-morpholino)ethanesulfonic acid	117-120	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
31042624-6	2019	Further experiments demonstrated that CCAAT/enhancer-binding protein beta (CEBPbeta) was upregulated by metformin and that two isoforms of CEBPbeta reciprocally regulated the expression of CD133.	Metformin	104-113	CCAAT enhancer binding protein alpha	Homo sapiens	75-83
31042624-9	2019	Our results indicated that metformin-AMPK-CEBPbeta signaling plays a crucial role in regulating the gene expression of CD133.	Metformin	27-36	CCAAT enhancer binding protein alpha	Homo sapiens	42-50
31114166-12	2019	EGCG at all three concentrations was associated with significantly lower levels of phosphorylated STAT3, C/EBP-alpha, and PPAR-gamma.	epigallocatechin gallate	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	105-116
30975281-0	2019	[The 161th lysine of C/EBPalpha in alveolar type II epithelial cells is modified by small ubiquitin-related modification].	Lysine	11-17	CCAAT enhancer binding protein alpha	Homo sapiens	21-31
30975281-4	2019	The SUMO site of C/EBPalpha was predicted to be the 161st lysine (K161) by the SUMOsp software.	Lysine	58-64	CCAAT enhancer binding protein alpha	Homo sapiens	17-27
30975281-4	2019	The SUMO site of C/EBPalpha was predicted to be the 161st lysine (K161) by the SUMOsp software.	Ampicillin sodium	66-70	CCAAT enhancer binding protein alpha	Homo sapiens	17-27
30975281-10	2019	These suggested that the SUMO site of C/EBPalpha was the 161st lysine.	Lysine	63-69	CCAAT enhancer binding protein alpha	Homo sapiens	38-48
30975281-11	2019	Conclusion C/EBPalpha can be modified by SUMO1 and the site of its modification is the 161st lysine in human AECII.	Lysine	93-99	CCAAT enhancer binding protein alpha	Homo sapiens	11-21
30552141-0	2019	Ribavirin-induced down-regulation of CCAAT/enhancer-binding protein alpha leads to suppression of lipogenesis.	Ribavirin	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	37-73
30552141-4	2019	Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway.	Ribavirin	47-50	CCAAT enhancer binding protein alpha	Homo sapiens	78-88
30552141-4	2019	Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway.	Ribavirin	47-50	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
30552141-4	2019	Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway.	Ribavirin	106-109	CCAAT enhancer binding protein alpha	Homo sapiens	78-88
30552141-4	2019	Treatment with proteasome inhibitor attenuated RBV-induced down-regulation of C/EBPalpha, suggesting that RBV promoted degradation of C/EBPalpha protein via the ubiquitin-proteasome pathway.	Ribavirin	106-109	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
30552141-5	2019	Depletion of intracellular GTP through inosine monophosphate dehydrogenase inhibition by RBV led to down-regulation of C/EBPalpha.	Guanosine Triphosphate	27-30	CCAAT enhancer binding protein alpha	Homo sapiens	119-129
30552141-5	2019	Depletion of intracellular GTP through inosine monophosphate dehydrogenase inhibition by RBV led to down-regulation of C/EBPalpha.	Ribavirin	89-92	CCAAT enhancer binding protein alpha	Homo sapiens	119-129
30552141-6	2019	In contrast, down-regulation of C/EBPalpha by RBV was independent of RXRalpha and MARK4.	Ribavirin	46-49	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
30552141-7	2019	Knockdown of C/EBPalpha reduced the intracellular neutral lipid levels and the expression of genes related to the triglyceride (TG) synthesis pathway, especially glycerol-3-phosphate acyltransferase, mitochondrial (GPAM), which encodes the first rate-limiting TG enzyme.	Triglycerides	114-126	CCAAT enhancer binding protein alpha	Homo sapiens	13-23
30552141-7	2019	Knockdown of C/EBPalpha reduced the intracellular neutral lipid levels and the expression of genes related to the triglyceride (TG) synthesis pathway, especially glycerol-3-phosphate acyltransferase, mitochondrial (GPAM), which encodes the first rate-limiting TG enzyme.	Triglycerides	128-130	CCAAT enhancer binding protein alpha	Homo sapiens	13-23
30552141-11	2019	These data suggest that down-regulation of C/EBPalpha by RBV leads to the reduction in GPAM expression, which contributes to the suppression of lipogenesis.	Ribavirin	57-60	CCAAT enhancer binding protein alpha	Homo sapiens	43-53
30031040-7	2018	PFBS treatments significantly increased the protein and mRNA levels of the master transcription factors in adipocyte differentiation; CCAAT/enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma), along with acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), the key proteins in lipogenesis.	perfluorobutanesulfonic acid	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	134-170
30621146-4	2019	High salt dose-dependently increased the expression of adipogenic/lipogenic genes, such as PPAR-gamma, C/EBPalpha, SREBP1c, ACC, FAS, and aP2, but decreased the gene of lipolysis like AMPK, ultimately resulting in fat accumulation.	Salts	5-9	CCAAT enhancer binding protein alpha	Homo sapiens	103-113
30550771-0	2019	Modulation of vitamin D signaling by the pioneer factor CEBPA.	Vitamin D	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	56-61
30550771-2	2019	In this study, we report the CEBPA cistrome of THP-1 human monocytes after stimulation with the vitamin D receptor (VDR) ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) for 2, 8 and 24 h. About a third of the genomic VDR binding sites co-located with those of CEBPA.	dihydroxy-vitamin D3	138-157	CCAAT enhancer binding protein alpha	Homo sapiens	29-34
30550771-2	2019	In this study, we report the CEBPA cistrome of THP-1 human monocytes after stimulation with the vitamin D receptor (VDR) ligand 1alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) for 2, 8 and 24 h. About a third of the genomic VDR binding sites co-located with those of CEBPA.	dihydroxy-vitamin D3	138-157	CCAAT enhancer binding protein alpha	Homo sapiens	263-268
30550771-4	2019	Transcriptome-wide analysis after CEBPA silencing indicated that the pioneer factor enhances both the basal expression and ligand inducibility of 70 vitamin D target genes largely involved in lipid signaling and metabolism.	Vitamin D	149-158	CCAAT enhancer binding protein alpha	Homo sapiens	34-39
30550771-5	2019	In contrast, CEBPA suppresses 82 vitamin D target genes many of which are related to the modulation of T cell activity by monocytes.	Vitamin D	33-42	CCAAT enhancer binding protein alpha	Homo sapiens	13-18
30550771-7	2019	Moreover, prominent occupancy of the myeloid pioneer factor PU.1 on 1,25(OH)2D3-sensitive CEBPA enhancers mechanistically explains the dichotomy of vitamin D target genes.	Vitamin D	148-157	CCAAT enhancer binding protein alpha	Homo sapiens	90-95
30550771-8	2019	In conclusion, CEBPA supports vitamin D signaling concerning actions of the innate immune system, but uses the antagonism with PU.1 for suppressing possible overreactions of adaptive immunity.	Vitamin D	30-39	CCAAT enhancer binding protein alpha	Homo sapiens	15-20
30394654-0	2019	Diallyl disulfide down-regulates calreticulin and promotes C/EBPalpha expression in differentiation of human leukaemia cells.	diallyl disulfide	0-17	CCAAT enhancer binding protein alpha	Homo sapiens	59-69
30394654-5	2019	DADS induction of differentiation of HL-60 cells resulted in down-regulated CRT expression and elevated C/EBPalpha expression.	diallyl disulfide	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	104-114
30394654-6	2019	In severe combined immunodeficiency mice injected with HL-60 cells, DADS inhibited the growth of tumour tissue and decreased CRT levels and increased C/EBPalpha in vivo.	diallyl disulfide	68-72	CCAAT enhancer binding protein alpha	Homo sapiens	150-160
30394654-9	2019	In conclusion, the present study demonstrates the C/EBPalpha expression was correlated with CRT expression in vitro and in vivo and the molecular mechanism of DADS-induced leukaemic cell differentiation.	diallyl disulfide	159-163	CCAAT enhancer binding protein alpha	Homo sapiens	50-60
30805392-12	2019	Ectopic expression of CEBPA-AS was detected in seven of the AML patients.	Arsenic	28-30	CCAAT enhancer binding protein alpha	Homo sapiens	22-27
29644527-8	2018	Site-directed mutagenesis of human CRP promoter revealed that the overlapping downstream C/EBP and NF-kappaB binding sites are important for gemcabene-mediated CRP transcription.	gemcabene	141-150	CCAAT enhancer binding protein alpha	Homo sapiens	89-94
30424524-5	2018	Flubendiamide treatment not only enhanced triglyceride content in 3T3-L1 adipocytes, but also increased the expression of cytosine-cytosine-adenosine-adenosine-thymidine (CCAAT)/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma-gamma, two important regulators of adipocyte differentiation.	flubendiamide	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	122-208
30593760-6	2018	The aim of the study was to assess the potential of vitamin E as the possible inducer of C/EBP alpha expression in BCR-ABL-positive CML K562 cells.	Vitamin E	52-61	CCAAT enhancer binding protein alpha	Homo sapiens	89-100
30593760-9	2018	Upon 48-h culture with vitamin E at a dose of 100 microM, K562 cells expressed both C/EBP alpha and G-CSFR.	Vitamin E	23-32	CCAAT enhancer binding protein alpha	Homo sapiens	84-95
30593760-10	2018	CONCLUSION: Vitamin E restored the expression of C/EBP alpha mRNA in chronic myelogenous leukemia K562 cells.	Vitamin E	12-21	CCAAT enhancer binding protein alpha	Homo sapiens	49-60
30593760-12	2018	It should be further elucidated whether such effects of vitamin E on C/EBP alpha transcription factor are direct or mediated indirectly due to antioxidant properties of vitamin E.	Vitamin E	56-65	CCAAT enhancer binding protein alpha	Homo sapiens	69-80
30400605-8	2018	The expression of the adipogenic genes peroxisome proliferator-activated receptor gamma, CCAAT-enhancer binding protein alpha, and leptin was suppressed by selenate.	Selenic Acid	156-164	CCAAT enhancer binding protein alpha	Homo sapiens	89-125
30031040-7	2018	PFBS treatments significantly increased the protein and mRNA levels of the master transcription factors in adipocyte differentiation; CCAAT/enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma), along with acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), the key proteins in lipogenesis.	perfluorobutanesulfonic acid	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	172-182
30015632-7	2018	Direct depletion of the corepressor DNA methyltransferase 1 (DNMT1) from the CEBPA/RUNX1 protein interactome using the clinical drug decitabine activated terminal granulocytic fates.	Decitabine	133-143	CCAAT enhancer binding protein alpha	Homo sapiens	77-82
30002127-10	2018	SK053 increased the levels of CCAAT enhancer-binding protein alpha and upregulated mRNA levels for differentiation-associated genes.	2,6-bis-trifluoromethylbenzoic acid 2-(1-(ethoxycarbonylmethylcarbamoyl)-3-methylbutylcarbamoyl)allyl ester	0-5	CCAAT enhancer binding protein alpha	Homo sapiens	30-66
29899261-1	2018	Previous studies suggest that signal transducer and activator of transcription 3 (STAT3) and CCAAT/enhancer binding protein beta (C/EBP&amp;beta;) play an essential role in ovarian granulosa cells (GCs) for mammalian follicular development.	Adenosine Monophosphate	136-139	CCAAT enhancer binding protein alpha	Homo sapiens	130-135
29735004-0	2018	Exchange protein directly activated by cAMP (EPAC) promotes transcriptional activation of the decidual prolactin gene via CCAAT/enhancer-binding protein in human endometrial stromal cells.	Cyclic AMP	39-43	CCAAT enhancer binding protein alpha	Homo sapiens	122-152
30254053-2	2018	CCAAT/enhancer-binding protein (C/EBP) family transcription factors are crucial Tribbles substrates in adipocyte and myeloid cell development.	tribbles	80-88	CCAAT enhancer binding protein alpha	Homo sapiens	0-30
30254053-2	2018	CCAAT/enhancer-binding protein (C/EBP) family transcription factors are crucial Tribbles substrates in adipocyte and myeloid cell development.	tribbles	80-88	CCAAT enhancer binding protein alpha	Homo sapiens	32-37
30193323-11	2018	Oil Red-O staining results revealed a decrease in lipid droplets and suppressed expression of PPARgamma and c/EBPalpha/beta upon treatment with idelalisib during adipose differentiation.	oil red O	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	108-118
30081475-0	2018	Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPalpha.	styryl quinazolinones	0-21	CCAAT enhancer binding protein alpha	Homo sapiens	91-101
30081475-2	2018	We found that styryl quinazolinones induce upregulation of C/EBPalpha expression, and thereby induce myeloid differentiation in human myeloid leukemia cell lines.	styryl quinazolinones	14-35	CCAAT enhancer binding protein alpha	Homo sapiens	59-69
30081475-3	2018	We screened a series of active styryl quinazolinones and evaluated the structure-activity relationship (SAR) of these small molecules in inducing C/EBPalpha expression-thereby prompting the leukemic cells to differentiate.	styryl quinazolinones	31-52	CCAAT enhancer binding protein alpha	Homo sapiens	146-156
29663555-4	2018	Thus, not only did dehydroleucodine downregulate the expression of C/EBPalpha and PPARgamma, it also strongly blocked the expression of C/EBPbeta, an early stage biomarker of early adipogenesis, in a concentration-dependent manner.	dehydroleucodine	19-35	CCAAT enhancer binding protein alpha	Homo sapiens	67-77
29772230-5	2018	Zta(C189S) and Zta(C189T) bound the TRE (AP-1) motif (TGAG/CTCA) more strongly than wild-type Zta, while binding to other sequences, including the C/EBP half site GCAA was reduced.	zta	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	147-152
29772230-5	2018	Zta(C189S) and Zta(C189T) bound the TRE (AP-1) motif (TGAG/CTCA) more strongly than wild-type Zta, while binding to other sequences, including the C/EBP half site GCAA was reduced.	zta	15-18	CCAAT enhancer binding protein alpha	Homo sapiens	147-152
29899261-2	2018	Several C/EBP&amp;beta; putative binding sites were previously predicted on the STAT3 promoter in mammals.	Adenosine Monophosphate	14-17	CCAAT enhancer binding protein alpha	Homo sapiens	8-13
29899261-3	2018	However, the molecular regulation of C/EBP&amp;beta; on STAT3 and their effects on cell proliferation and apoptosis remain virtually unexplored in GCs.	Adenosine Monophosphate	43-46	CCAAT enhancer binding protein alpha	Homo sapiens	37-42
29899261-5	2018	We found that over and interfering with the expression of C/EBP&amp;beta; significantly increased and decreased the messenger RNA (mRNA) and protein levels of STAT3, respectively.	Adenosine Monophosphate	64-67	CCAAT enhancer binding protein alpha	Homo sapiens	58-63
29899261-6	2018	The dual luciferase reporter assay showed that C/EBP&amp;beta; directly bound at &amp;minus;1397/&amp;minus;1387 of STAT3 to positively regulate the mRNA and protein expressions of STAT3.	Adenosine Monophosphate	53-56	CCAAT enhancer binding protein alpha	Homo sapiens	47-52
29899261-6	2018	The dual luciferase reporter assay showed that C/EBP&amp;beta; directly bound at &amp;minus;1397/&amp;minus;1387 of STAT3 to positively regulate the mRNA and protein expressions of STAT3.	Adenosine Monophosphate	82-85	CCAAT enhancer binding protein alpha	Homo sapiens	47-52
29899261-6	2018	The dual luciferase reporter assay showed that C/EBP&amp;beta; directly bound at &amp;minus;1397/&amp;minus;1387 of STAT3 to positively regulate the mRNA and protein expressions of STAT3.	Adenosine Monophosphate	82-85	CCAAT enhancer binding protein alpha	Homo sapiens	47-52
29899261-7	2018	Both C/EBP&amp;beta; and STAT3 were observed to inhibit cell apoptosis and promote cell proliferation.	Adenosine Monophosphate	11-14	CCAAT enhancer binding protein alpha	Homo sapiens	5-10
29899261-8	2018	Furthermore, C/EBP&amp;beta; might enhance the antiapoptotic and pro-proliferative effects of STAT3.	Adenosine Monophosphate	19-22	CCAAT enhancer binding protein alpha	Homo sapiens	13-18
29899261-9	2018	These results would be of great insight in further exploring the molecular mechanism of C/EBP&amp;beta; and STAT3 on the function of GCs and the development of ovarian follicles in mammals.	Adenosine Monophosphate	94-97	CCAAT enhancer binding protein alpha	Homo sapiens	88-93
29892907-2	2018	In order to understand how a single 5mC regulates protein-DNA interactions, we have compared the structures and dynamics of CEBP/betaprotein-DNA complexes before and after methylation, and the results indicate that even a single 5mC can regulate protein-DNA recognition by steric-hindrance effect of methyl group and changing the hydrogen bond interactions.	5-Methylcytidine 5'-monophosphate	36-39	CCAAT enhancer binding protein alpha	Homo sapiens	124-128
29892907-2	2018	In order to understand how a single 5mC regulates protein-DNA interactions, we have compared the structures and dynamics of CEBP/betaprotein-DNA complexes before and after methylation, and the results indicate that even a single 5mC can regulate protein-DNA recognition by steric-hindrance effect of methyl group and changing the hydrogen bond interactions.	5-Methylcytidine 5'-monophosphate	229-232	CCAAT enhancer binding protein alpha	Homo sapiens	124-128
29892907-2	2018	In order to understand how a single 5mC regulates protein-DNA interactions, we have compared the structures and dynamics of CEBP/betaprotein-DNA complexes before and after methylation, and the results indicate that even a single 5mC can regulate protein-DNA recognition by steric-hindrance effect of methyl group and changing the hydrogen bond interactions.	Hydrogen	330-338	CCAAT enhancer binding protein alpha	Homo sapiens	124-128
29638041-4	2018	L-rhamnose treatment in 3T3-L1 adipocytes also significantly elevated protein levels of p-HSL, p-AMPK, ACOX, and CPT1 as well as reduced levels of ACC, FAS, C/EBPalpha, and PPARgamma, suggesting its possible role in enhancement of lipolysis and lipid catabolism as well as reduced adipogenesis and lipogenesis, respectively.	Rhamnose	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	157-167
29180507-4	2018	Here, the performance of an amplicon-based NGS method using a laboratory-developed CEBPA-specific Nextera XT (CEBNX) was evaluated.	cebnx	110-115	CCAAT enhancer binding protein alpha	Homo sapiens	83-88
29180507-13	2018	CONCLUSIONS: Our laboratory-developed CEBNX workflow shows high coverage and thus overcomes the challenges associated with amplification efficiency and low coverage of CEBPA.	cebnx	38-43	CCAAT enhancer binding protein alpha	Homo sapiens	168-173
29594316-5	2018	A functional analysis of transcription factors using transcription factor-DNA interaction array and IPA analysis demonstrated that dioscin induced a profound increase of protein expression of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for myeloid differentiation.	dioscin	131-138	CCAAT enhancer binding protein alpha	Homo sapiens	192-228
29594316-5	2018	A functional analysis of transcription factors using transcription factor-DNA interaction array and IPA analysis demonstrated that dioscin induced a profound increase of protein expression of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a critical factor for myeloid differentiation.	dioscin	131-138	CCAAT enhancer binding protein alpha	Homo sapiens	230-240
29511346-5	2018	Injection of MTL-CEBPA, a small activating RNA oligonucleotide therapy (CEBPA-51) formulated in liposomal nanoparticles (NOV340- SMARTICLES) upregulates hepatic CEBPA expression.	Oligonucleotides	47-62	CCAAT enhancer binding protein alpha	Homo sapiens	17-22
29511346-5	2018	Injection of MTL-CEBPA, a small activating RNA oligonucleotide therapy (CEBPA-51) formulated in liposomal nanoparticles (NOV340- SMARTICLES) upregulates hepatic CEBPA expression.	Oligonucleotides	47-62	CCAAT enhancer binding protein alpha	Homo sapiens	72-77
29511346-5	2018	Injection of MTL-CEBPA, a small activating RNA oligonucleotide therapy (CEBPA-51) formulated in liposomal nanoparticles (NOV340- SMARTICLES) upregulates hepatic CEBPA expression.	Oligonucleotides	47-62	CCAAT enhancer binding protein alpha	Homo sapiens	72-77
29511346-9	2018	MTL-CEBPA reversed changes associated with hepatosteatosis in non-alcoholic methionine and cholic-deficient diet-induced steaotic liver disease.	Methionine	76-86	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
29511346-9	2018	MTL-CEBPA reversed changes associated with hepatosteatosis in non-alcoholic methionine and cholic-deficient diet-induced steaotic liver disease.	Cholic	91-97	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
29511346-11	2018	The data included here and the rapid adoption of MTL-CEBPA into a Phase 1 study may lead to new therapeutic oligonucleotides for undruggable diseases.	Oligonucleotides	108-124	CCAAT enhancer binding protein alpha	Homo sapiens	53-58
29467326-4	2018	Loss of TET2 impairs the maturation of myeloid lineage-derived mast cells by dysregulating the expression of Mitf and Cebpa, which is restored by low-dose ascorbic acid and 5-azacytidine.	Ascorbic Acid	155-168	CCAAT enhancer binding protein alpha	Homo sapiens	118-123
29594316-10	2018	In addition, proteomics approach reveals an altered metabolic signature of dioscin-treated cells and the induction of differentiation of promyelocytes to granulocytes and monocytes in which the C/EBPalpha plays a key role.	dioscin	75-82	CCAAT enhancer binding protein alpha	Homo sapiens	194-204
30060630-12	2018	CTP treatment also downregulated the expression of PPAR-gamma and C/EBP-alpha, adipogenic differentiation markers in hASCs, compared to the adipogenic differentiation group.	Cytidine Triphosphate	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	66-77
29780383-6	2018	Instead, we identified C/EBPalpha as the key modulator of hMPV-mediated suppression of CAMP.	Cyclic AMP	87-91	CCAAT enhancer binding protein alpha	Homo sapiens	23-33
29780383-7	2018	hMPV infection strongly repressed the expression of C/EBPalpha, and a knockdown study confirmed that C/EBPalpha is critical for CAMP expression in human macrophages.	Cyclic AMP	128-132	CCAAT enhancer binding protein alpha	Homo sapiens	101-111
29780383-8	2018	Such modulation of CAMP (and C/EBPalpha) could be reproduced by TLR1/2 ligand treatment in human macrophages, suggesting a common mechanism underlying pathogen-mediated downregulation of CAMP through C/EBPalpha.	Cyclic AMP	19-23	CCAAT enhancer binding protein alpha	Homo sapiens	200-210
29780383-8	2018	Such modulation of CAMP (and C/EBPalpha) could be reproduced by TLR1/2 ligand treatment in human macrophages, suggesting a common mechanism underlying pathogen-mediated downregulation of CAMP through C/EBPalpha.	Cyclic AMP	187-191	CCAAT enhancer binding protein alpha	Homo sapiens	29-39
29780383-8	2018	Such modulation of CAMP (and C/EBPalpha) could be reproduced by TLR1/2 ligand treatment in human macrophages, suggesting a common mechanism underlying pathogen-mediated downregulation of CAMP through C/EBPalpha.	Cyclic AMP	187-191	CCAAT enhancer binding protein alpha	Homo sapiens	200-210
29058777-7	2018	The relationship of miR-103 and COP1, Trib1, and C/EBPalpha were analyzed by qRT-PCR and Western blot.	mir-103	20-27	CCAAT enhancer binding protein alpha	Homo sapiens	49-59
29058777-13	2018	COP1 was positively regulated by miR-103, suppression of miR-103 recovered K562/ADR cells drug resistance by regulation of COP1, Trib1, and C/EBPalpha.	mir-103	33-40	CCAAT enhancer binding protein alpha	Homo sapiens	140-150
29058777-13	2018	COP1 was positively regulated by miR-103, suppression of miR-103 recovered K562/ADR cells drug resistance by regulation of COP1, Trib1, and C/EBPalpha.	mir-103	57-64	CCAAT enhancer binding protein alpha	Homo sapiens	140-150
29483301-4	2018	When mature adipocytes are depleted of both PPARgamma and CCAAT-enhancer-binding protein alpha (C/EBPalpha), they are rapidly depleted of lipids and undergo adipocyte death, both in vitro and in vivo Surprisingly, although thiazolidinediones (TZDs; PPARgamma agonists) are thought to act mainly on PPARgamma, PPARgamma in adipocytes is not required for the whole-body insulin-sensitizing effect of TZDs.	Thiazolidinediones	223-241	CCAAT enhancer binding protein alpha	Homo sapiens	58-94
29483301-4	2018	When mature adipocytes are depleted of both PPARgamma and CCAAT-enhancer-binding protein alpha (C/EBPalpha), they are rapidly depleted of lipids and undergo adipocyte death, both in vitro and in vivo Surprisingly, although thiazolidinediones (TZDs; PPARgamma agonists) are thought to act mainly on PPARgamma, PPARgamma in adipocytes is not required for the whole-body insulin-sensitizing effect of TZDs.	Thiazolidinediones	223-241	CCAAT enhancer binding protein alpha	Homo sapiens	96-106
29483301-4	2018	When mature adipocytes are depleted of both PPARgamma and CCAAT-enhancer-binding protein alpha (C/EBPalpha), they are rapidly depleted of lipids and undergo adipocyte death, both in vitro and in vivo Surprisingly, although thiazolidinediones (TZDs; PPARgamma agonists) are thought to act mainly on PPARgamma, PPARgamma in adipocytes is not required for the whole-body insulin-sensitizing effect of TZDs.	Thiazolidinediones	243-247	CCAAT enhancer binding protein alpha	Homo sapiens	96-106
29483301-4	2018	When mature adipocytes are depleted of both PPARgamma and CCAAT-enhancer-binding protein alpha (C/EBPalpha), they are rapidly depleted of lipids and undergo adipocyte death, both in vitro and in vivo Surprisingly, although thiazolidinediones (TZDs; PPARgamma agonists) are thought to act mainly on PPARgamma, PPARgamma in adipocytes is not required for the whole-body insulin-sensitizing effect of TZDs.	Thiazolidinediones	398-402	CCAAT enhancer binding protein alpha	Homo sapiens	96-106
29543748-9	2018	The remaining genes were regulated by the combined treatments of 3alpha-THP + F or P4 + F. An in-silico analysis revealed that promoters of the six up-regulated genes by 3alpha-THP possess cyclic adenosine monophosphate (cAMP) responsive elements along with CCAAT/Enhancer binding protein alpha (CEBPalpha) binding sites.	Cyclic AMP	189-219	CCAAT enhancer binding protein alpha	Homo sapiens	258-294
29543748-9	2018	The remaining genes were regulated by the combined treatments of 3alpha-THP + F or P4 + F. An in-silico analysis revealed that promoters of the six up-regulated genes by 3alpha-THP possess cyclic adenosine monophosphate (cAMP) responsive elements along with CCAAT/Enhancer binding protein alpha (CEBPalpha) binding sites.	Cyclic AMP	189-219	CCAAT enhancer binding protein alpha	Homo sapiens	296-305
29543748-9	2018	The remaining genes were regulated by the combined treatments of 3alpha-THP + F or P4 + F. An in-silico analysis revealed that promoters of the six up-regulated genes by 3alpha-THP possess cyclic adenosine monophosphate (cAMP) responsive elements along with CCAAT/Enhancer binding protein alpha (CEBPalpha) binding sites.	Cyclic AMP	221-225	CCAAT enhancer binding protein alpha	Homo sapiens	258-294
29543748-9	2018	The remaining genes were regulated by the combined treatments of 3alpha-THP + F or P4 + F. An in-silico analysis revealed that promoters of the six up-regulated genes by 3alpha-THP possess cyclic adenosine monophosphate (cAMP) responsive elements along with CCAAT/Enhancer binding protein alpha (CEBPalpha) binding sites.	Cyclic AMP	221-225	CCAAT enhancer binding protein alpha	Homo sapiens	296-305
29467326-4	2018	Loss of TET2 impairs the maturation of myeloid lineage-derived mast cells by dysregulating the expression of Mitf and Cebpa, which is restored by low-dose ascorbic acid and 5-azacytidine.	Azacitidine	173-186	CCAAT enhancer binding protein alpha	Homo sapiens	118-123
28557353-9	2017	Sodium phenylbutyrate and resveratrol were identified to enhance metabolism-related gene expression and liver-enriched transcription factors C/EBPalpha, HNF4alpha.	4-phenylbutyric acid	0-21	CCAAT enhancer binding protein alpha	Homo sapiens	141-151
30016791-11	2018	Exposure to 100 nM 1,25(OH)2D3 induced VDR, CEBPA, and CEBPB expression, even in the preadipocyte stage.	Calcitriol	19-30	CCAAT enhancer binding protein alpha	Homo sapiens	44-49
30016791-12	2018	During adipogenesis, 1,25(OH)2D3 had limited effects on processes such as VDR and PPARG gene expression, but it upregulated CEBPA expression.	Calcitriol	21-32	CCAAT enhancer binding protein alpha	Homo sapiens	124-129
29333383-3	2017	Butein treatment reduced protein expression of key adipogenic transcription factors such as CCAAT-enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma).	butein	0-6	CCAAT enhancer binding protein alpha	Homo sapiens	92-128
29333383-3	2017	Butein treatment reduced protein expression of key adipogenic transcription factors such as CCAAT-enhancer-binding protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma).	butein	0-6	CCAAT enhancer binding protein alpha	Homo sapiens	130-140
29258500-8	2017	Furthermore, our results found that DHSMT significantly suppressed the adipocyte differentiation by downregulating adipogenic-specific transcriptional factors such as peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding proteins alpha (C/EBPalpha) and fatty acid binding protein 4 (FABP4) in adipocytes.	dhsmt	36-41	CCAAT enhancer binding protein alpha	Homo sapiens	268-278
28557353-9	2017	Sodium phenylbutyrate and resveratrol were identified to enhance metabolism-related gene expression and liver-enriched transcription factors C/EBPalpha, HNF4alpha.	Resveratrol	26-37	CCAAT enhancer binding protein alpha	Homo sapiens	141-151
29312632-6	2017	The mRNA and protein levels of CCAAT/enhancer binding protein alpha (CEBPA), known to be a transcription factor regulating cell differentiation and a target for degradation by TRIB2, as well as selected cancer stem cell makers in the Cisplatin-resistant cells, were measured.	Cisplatin	234-243	CCAAT enhancer binding protein alpha	Homo sapiens	69-74
28901467-10	2017	Following imatinib treatment, the expression of SOX4 was downregulated in the progression-free patients, but upregulated in the blastic phase patients, whereas the expression of C/EBPalpha showed the opposite trend.	Imatinib Mesylate	10-18	CCAAT enhancer binding protein alpha	Homo sapiens	178-188
29312632-7	2017	We found that CEBPA protein levels could be upregulated by knocking down the overexpressed TRIB2, which also reversed the Cisplatin-resistance of these cells; further, the Cisplatin-resistant SCLC cells demonstrated certain cancer stem cell-like properties.	Cisplatin	122-131	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
29312632-7	2017	We found that CEBPA protein levels could be upregulated by knocking down the overexpressed TRIB2, which also reversed the Cisplatin-resistance of these cells; further, the Cisplatin-resistant SCLC cells demonstrated certain cancer stem cell-like properties.	Cisplatin	172-181	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
29312632-9	2017	Our study revealed a possible molecular mechanism for Cisplatin-resistant SCLC involving induced TRIB2 overexpression and downregulation of CEBPA protein.	Cisplatin	54-63	CCAAT enhancer binding protein alpha	Homo sapiens	140-145
28934090-9	2017	RESULTS: FM550 triphenyl phosphate (TPP) and isopropylated triphenyl phosphates (IPTP), increased adipogenesis in human primary preadipocytes as assessed by lipid accumulation and mRNA expression of regulators of adipogenesis such as PPARgamma, CCAAT enhancer binding protein (C/EBP) alpha and sterol regulatory element binding protein (SREBP) 1 as well as the adipogenic markers FABP4 LPL and perilipin.	triphenyl phosphate	15-34	CCAAT enhancer binding protein alpha	Homo sapiens	277-289
28713903-6	2017	We also found that SNX-2112 increased the expression of the differentiation transcription factors PU.1 and CCAAT-enhancer-binding protein-alpha.	SNX 2112	19-27	CCAAT enhancer binding protein alpha	Homo sapiens	107-143
28659738-8	2017	Results: During the preadipocyte differentiation process, RA suppressed peroxisome proliferator-activated receptor-gamma and CCAAT/enhancer binding protein-alpha, and activated p-ERK1/2 and p-Smad3; inhibition of adipogenesis by RA was partially restored following treatment with p-ERK1/2 and p-Smad3 inhibitors.	rosmarinic acid	58-60	CCAAT enhancer binding protein alpha	Homo sapiens	125-161
28652211-7	2017	Notably, we identified two C/EBPalpha responsive elements at positions -2002 and -948, to which C/EBPalpha or CHOP binding was enhanced by BFA under in vitro and in vivo conditions.	Brefeldin A	139-142	CCAAT enhancer binding protein alpha	Homo sapiens	27-37
28652211-7	2017	Notably, we identified two C/EBPalpha responsive elements at positions -2002 and -948, to which C/EBPalpha or CHOP binding was enhanced by BFA under in vitro and in vivo conditions.	Brefeldin A	139-142	CCAAT enhancer binding protein alpha	Homo sapiens	96-106
28652211-10	2017	CHOP may up-regulate DNA-binding affinities after BFA treatment, via recruiting C/EBPalpha to the upstream-promoter of Plk2.	Brefeldin A	50-53	CCAAT enhancer binding protein alpha	Homo sapiens	80-90
28341486-10	2017	Elevated levels of C/EBPalpha by butyrate treatment of CRC cells competed out the activator protein Oct-1 from binding to the PLK1 promoter and sequestered it.	Butyrates	33-41	CCAAT enhancer binding protein alpha	Homo sapiens	19-29
28772148-3	2017	In 3T3-L1 preadipocytes, A-type ECG and EGCG dimers possibly bonded to lipid rafts cholesterol and disrupted the integrity of lipid rafts, thus exerting their notable inhibitory effects on 3T3-L1 preadipocytes differentiation by suppressing mitotic clonal expansion process and mRNA levels of PPARgamma, C/EBPalpha and SREBP1C.	epigallocatechin gallate	40-44	CCAAT enhancer binding protein alpha	Homo sapiens	304-314
28827782-4	2017	We observed that increasing extracellular calcium concentration during brown adipocyte differentiation blocks lipid accumulation and suppresses induction of major adipogenic transcription factors such as PPARgamma and C/EBPalpha.	Calcium	42-49	CCAAT enhancer binding protein alpha	Homo sapiens	218-228
28413486-4	2017	Furthermore, the expression levels of calreticulin and CCAAT/enhancer-binding protein alpha (C/EBP-alpha) in CSE-stimulated ASMCs were determined by polymerase chain reaction and western blot analyses.	asmcs	124-129	CCAAT enhancer binding protein alpha	Homo sapiens	55-91
28413486-4	2017	Furthermore, the expression levels of calreticulin and CCAAT/enhancer-binding protein alpha (C/EBP-alpha) in CSE-stimulated ASMCs were determined by polymerase chain reaction and western blot analyses.	asmcs	124-129	CCAAT enhancer binding protein alpha	Homo sapiens	93-104
28413486-6	2017	CSE was found to promote the proliferation of ASMCs, which was associated with increased expression of calreticulin and decreased expression of C/EBP-alpha.	asmcs	46-51	CCAAT enhancer binding protein alpha	Homo sapiens	144-155
28413486-8	2017	The present study revealed that CSE promoted the proliferation of ASMCs, which was mediated by inhibition of C/EBP-alpha.	asmcs	66-71	CCAAT enhancer binding protein alpha	Homo sapiens	109-120
28278164-0	2017	Rosiglitazone drives cavin-2/SDPR expression in adipocytes in a CEBPalpha-dependent manner.	Rosiglitazone	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	64-73
28285642-4	2017	Boron treatment repressed the expression of adipogenesis-related genes and proteins, including CCAAT-enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma, by regulating critical growth factors and the beta-catenin, AKT, and extracellular signal-regulated kinase signaling pathways.	Boron	0-5	CCAAT enhancer binding protein alpha	Homo sapiens	95-131
28278164-6	2017	Treatment of 3T3-L1-derived adipocytes with the PPARgamma-activator Rosiglitazone increased SDPR and CEBPalpha expression at both the mRNA and protein levels.	Rosiglitazone	68-81	CCAAT enhancer binding protein alpha	Homo sapiens	101-110
28253368-8	2017	We found that when treated with LMHFV, the cells showed a higher expression of PPARgamma, C/EBPalpha, adiponectin and showed more oil droplets.	lmhfv	32-37	CCAAT enhancer binding protein alpha	Homo sapiens	90-100
27815535-0	2017	Pattern analysis uncovers a chronic ethanol-induced disruption of the switch-like dynamics of C/EBP-beta and C/EBP-alpha genome-wide binding during liver regeneration.	Ethanol	36-43	CCAAT enhancer binding protein alpha	Homo sapiens	109-120
27829312-6	2017	Chromatin immune precipitation combined with quantitative polymerase chain reaction showed significant increase in H3K9ac epigenetic marker in the promoter regions of AdipoQ, FABP4, PPARgamma, KLF15, and CEBPA in CUDC-907-treated hBMSCs.	CUDC-907	213-221	CCAAT enhancer binding protein alpha	Homo sapiens	204-209
28639200-10	2017	In preclinical models of liver disease, treatment with C/EBPalpha saRNA has shown reduction in tumor volume and improvement in serum markers of essential liver function such as albumin, bilirubin, aspartate aminotransferase (AST), and alanine transaminase (ALT).	Bilirubin	186-195	CCAAT enhancer binding protein alpha	Homo sapiens	55-65
28955733-7	2017	RESULTS: PP IX significantly decreased mRNA levels of DMT1 (IRE) and (non-IRE) from 4 h. PP IX markedly decreased protein levels of C/EBPalpha, PAP7 and DMT1.	protoporphyrin IX	89-94	CCAAT enhancer binding protein alpha	Homo sapiens	132-142
28955733-10	2017	GENERAL SIGNIFICANCE: These results suggest that exogenous PP IX disrupts iron metabolism by decreasing the protein expression levels of PAP7, DMT1 and C/EBPalpha.	protoporphyrin IX	59-64	CCAAT enhancer binding protein alpha	Homo sapiens	152-162
28955733-10	2017	GENERAL SIGNIFICANCE: These results suggest that exogenous PP IX disrupts iron metabolism by decreasing the protein expression levels of PAP7, DMT1 and C/EBPalpha.	Iron	74-78	CCAAT enhancer binding protein alpha	Homo sapiens	152-162
28128224-3	2017	In vitro, Ptn stimulated human adipose tissue derived ASCs to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARgamma) and CCAAT/enhancer-binding protein-alpha (C/EBPalpha), with differentiated cells increasingly secreting adiponectin, leptin, glycerol and total triglycerides.	pyrintegrin	10-13	CCAAT enhancer binding protein alpha	Homo sapiens	179-215
28128224-3	2017	In vitro, Ptn stimulated human adipose tissue derived ASCs to differentiate into lipid-laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARgamma) and CCAAT/enhancer-binding protein-alpha (C/EBPalpha), with differentiated cells increasingly secreting adiponectin, leptin, glycerol and total triglycerides.	pyrintegrin	10-13	CCAAT enhancer binding protein alpha	Homo sapiens	217-227
28128224-6	2017	Ptn promoted adipogenesis by upregulating PPARgamma and C/EBPalpha not only in adipogenesis induction medium, but also in chemically defined medium specifically for osteogenesis, and concurrently attenuated Runx2 and Osx via BMP-mediated SMAD1/5 phosphorylation.	pyrintegrin	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	56-66
28060835-1	2017	Previous studies have shown that tri- or di-methylation of histone H3 at lysine 9 (H3K9me3/me2) on the promoter of the peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding protein alpha (C/EBPalpha) contribute to the repression of PPARgamma and C/EBPalpha and inhibition of adipogenesis in 3T3-L1 preadipocytes.	Lysine	73-79	CCAAT enhancer binding protein alpha	Homo sapiens	184-220
28060835-1	2017	Previous studies have shown that tri- or di-methylation of histone H3 at lysine 9 (H3K9me3/me2) on the promoter of the peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding protein alpha (C/EBPalpha) contribute to the repression of PPARgamma and C/EBPalpha and inhibition of adipogenesis in 3T3-L1 preadipocytes.	Lysine	73-79	CCAAT enhancer binding protein alpha	Homo sapiens	222-232
28060835-1	2017	Previous studies have shown that tri- or di-methylation of histone H3 at lysine 9 (H3K9me3/me2) on the promoter of the peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding protein alpha (C/EBPalpha) contribute to the repression of PPARgamma and C/EBPalpha and inhibition of adipogenesis in 3T3-L1 preadipocytes.	Lysine	73-79	CCAAT enhancer binding protein alpha	Homo sapiens	280-290
27979310-5	2017	ADI-PEG 20 induced general control nonderepressible 2-dependent eukaryotic initiation factor 2alpha phosphorylation and activating transcription factor 4 and C/EBP homologous protein up-regulation, associated with caspase-independent apoptosis and autophagy.	ADI PEG20	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	158-163
27404795-13	2017	SAHA suppressed the expression of miR-9 but enhanced the activity of the MCPIP1 promoter localized to a 156bp region which also harbors the binding site for CEBPalpha.	Vorinostat	0-4	CCAAT enhancer binding protein alpha	Homo sapiens	157-166
27404795-14	2017	Treatment with SAHA enhanced the recruitment of CEBPalpha to the MCPIP1 promoter.	Vorinostat	15-19	CCAAT enhancer binding protein alpha	Homo sapiens	48-57
27404795-16	2017	CONCLUSIONS: Taken together our data indicate that SAHA-mediated suppression of the IL-6 expression is achieved through increased recruitment of CEBPalpha to the MCPIP1 promoter and by relieving the miR-9-mediated inhibition of MCPIP1 expression in OA chondrocytes.	Vorinostat	51-55	CCAAT enhancer binding protein alpha	Homo sapiens	145-154
27815535-2	2017	Our study focused on the initial phase of response to 2/3rd partial hepatectomy (PHx) to investigate how adaptation to chronic ethanol intake affects the genome-wide binding profiles of the transcription factors C/EBP-beta and C/EBP-alpha.	Ethanol	127-134	CCAAT enhancer binding protein alpha	Homo sapiens	227-238
27815535-5	2017	We found that adaptation to chronic ethanol intake significantly alters the genome-wide binding profile of C/EBP-beta and C/EBP-alpha before and following PHx.	Ethanol	36-43	CCAAT enhancer binding protein alpha	Homo sapiens	122-133
27815535-6	2017	A subset of these ethanol-induced changes include C/EBP-beta binding to promoters of genes involved in the profibrogenic transforming growth factor-beta pathway, and both C/EBP-beta and C/EBP-alpha binding to promoters of genes involved in the cell cycle, apoptosis, homeostasis, and metabolic processes.	Ethanol	18-25	CCAAT enhancer binding protein alpha	Homo sapiens	186-197
27815535-7	2017	The shift in C/EBP binding loci, coupled with an ethanol-induced increase in C/EBP-beta binding at 6 h post-resection, indicates that ethanol adaptation may change both the amount and nature of C/EBP binding postresection.	Ethanol	49-56	CCAAT enhancer binding protein alpha	Homo sapiens	77-82
27815535-7	2017	The shift in C/EBP binding loci, coupled with an ethanol-induced increase in C/EBP-beta binding at 6 h post-resection, indicates that ethanol adaptation may change both the amount and nature of C/EBP binding postresection.	Ethanol	134-141	CCAAT enhancer binding protein alpha	Homo sapiens	13-18
27815535-7	2017	The shift in C/EBP binding loci, coupled with an ethanol-induced increase in C/EBP-beta binding at 6 h post-resection, indicates that ethanol adaptation may change both the amount and nature of C/EBP binding postresection.	Ethanol	134-141	CCAAT enhancer binding protein alpha	Homo sapiens	77-82
28025449-11	2017	By contrast, when CV-MSCs were cultured for 14 days in the adipogenic medium, 0.05 mM metformin inhibited the expression of adipogenic protein mRNAs, including proliferators-activated receptor-gamma and CCAAT/enhancer binding protein-alpha.	Metformin	86-95	CCAAT enhancer binding protein alpha	Homo sapiens	160-239
27600587-12	2016	The WST-8 assay revealed no effect on proliferation or growth inhibition following metformin treatment, although metformin suppressed the expression of PPARgamma and C/EBPalpha.	Metformin	113-122	CCAAT enhancer binding protein alpha	Homo sapiens	166-176
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	Platinum	72-80	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	Cyclophosphamide	81-97	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	pc	99-101	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	taxane	118-124	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	Platinum	125-133	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27602952-3	2016	The CEBPA gene sequence was analyzed in 118 ovarian cancer patients (44 platinum/cyclophosphamide (PC)-treated and 74 taxane/platinum (TP)-treated), both in tumors and blood samples, and in blood from 236 healthy women, using PCR-Sanger sequencing and Real-Time quantitative PCR (qPCR)-based genotyping methods, respectively.	tp	135-137	CCAAT enhancer binding protein alpha	Homo sapiens	4-9
27602952-10	2016	This is the first study providing evidence that the c.690G&gt;T, p.(Thr230Thr) (rs34529039) polymorphism of the CEBPA gene, together with up-regulation of its mRNA expression, are negative factors worsening ovarian cancer outcome.	thr230thr	68-77	CCAAT enhancer binding protein alpha	Homo sapiens	112-117
27489231-0	2016	Obovatol Induces Apoptosis in Non-small Cell Lung Cancer Cells via C/EBP Homologous Protein Activation.	obovatol	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	67-72
27273788-7	2016	Our study also showed a significantly increased cell proliferation in BA treated normal human hepatic cell lines and a down-regulated expression of tumor suppressor gene CEBPalpha in TCDCA treated HepG2 cell line, suggesting that several hydrophobic BAs may collaboratively promote liver carcinogenesis.	Taurochenodeoxycholic Acid	183-188	CCAAT enhancer binding protein alpha	Homo sapiens	170-179
27644413-0	2016	Role of C/EBP-alpha in Adriamycin-induced podocyte injury.	Doxorubicin	23-33	CCAAT enhancer binding protein alpha	Homo sapiens	8-19
27644413-4	2016	Genetic ablation of C/EBP-alpha in podocytes resulted in increased proteinuria, increased podocyte foot process effacement, and to decreased podocyte number in the setting of Adriamycin (ADR)-induced nephropathy.	Doxorubicin	175-185	CCAAT enhancer binding protein alpha	Homo sapiens	20-31
27297623-9	2016	Imatinib, the drug of choice for CML, abrogates MEF2C expression and reverses CEBPA repression both in the cell line and the primary cells.	Imatinib Mesylate	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
27320865-5	2016	Furthermore, we confirmed that agrimol B dramatically inhibited 3T3-L1 adipocyte differentiation by reducing PPARgamma, C/EBPalpha, FAS, UCP-1, and apoE expression.	agrimol B	31-40	CCAAT enhancer binding protein alpha	Homo sapiens	120-130
27015538-7	2016	Doxorubicin also reduced the serum level of adiponectin and, to a greater extent, the expression of genes encoding lipogenic (Fas and Acc) and adipogenic factors (Pparg, C/ebpa, and Srebp1c) in retroperitoneal adipose tissue.	Doxorubicin	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	170-176
27494347-8	2016	Oil Red-O staining results revealed a decrease in lipid droplets and suppressed expression of the adipogenesis-related proteins peroxisome proliferator-activated receptor (PPAR)-gamma, CCAAT/enhancer binding protein (c/EBP)-alpha, and c/EBP-beta upon treatment with PCA during adipose differentiation.	oil red O	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	217-229
27105533-5	2016	EC-8042 inhibited the growth of TIC cultures, induced cell cycle arrest and apoptosis and upregulated the adipogenic factor CEBPalpha.	demycarosyl-3D-digitoxosylmithramycin SK	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	124-133
27115471-10	2016	Reduced expression of heat shock proteins (HSPs) was observed in AA cells, whereas DCA induced expression of CHOP, C/EBP, HSP60, and HSP90 in CA cells.	Dichloroacetic Acid	83-86	CCAAT enhancer binding protein alpha	Homo sapiens	115-120
27103584-4	2016	Fipronil treatment, at 10 muM, increased fat accumulation in 3T3-L1 adipocytes as well as promoted key regulators of adipocyte differentiation (CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma-gamma), and key regulators of lipogenesis (acetyl-CoA carboxylase and fatty acid synthase).	fipronil	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	144-180
27005833-2	2016	Here we demonstrate that acetylation of C/EBPalpha at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPalpha DNA-binding ability and modulates C/EBPalpha transcriptional activity.	Lysine	54-60	CCAAT enhancer binding protein alpha	Homo sapiens	40-50
27005833-2	2016	Here we demonstrate that acetylation of C/EBPalpha at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPalpha DNA-binding ability and modulates C/EBPalpha transcriptional activity.	Lysine	54-60	CCAAT enhancer binding protein alpha	Homo sapiens	166-176
27005833-2	2016	Here we demonstrate that acetylation of C/EBPalpha at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPalpha DNA-binding ability and modulates C/EBPalpha transcriptional activity.	Lysine	54-60	CCAAT enhancer binding protein alpha	Homo sapiens	166-176
27005833-2	2016	Here we demonstrate that acetylation of C/EBPalpha at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPalpha DNA-binding ability and modulates C/EBPalpha transcriptional activity.	6-nitroindazole	79-83	CCAAT enhancer binding protein alpha	Homo sapiens	40-50
27005833-2	2016	Here we demonstrate that acetylation of C/EBPalpha at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPalpha DNA-binding ability and modulates C/EBPalpha transcriptional activity.	6-nitroindazole	79-83	CCAAT enhancer binding protein alpha	Homo sapiens	166-176
27005833-2	2016	Here we demonstrate that acetylation of C/EBPalpha at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPalpha DNA-binding ability and modulates C/EBPalpha transcriptional activity.	6-nitroindazole	79-83	CCAAT enhancer binding protein alpha	Homo sapiens	166-176
26903652-2	2016	ER stress increases cellular ceramide and one of its distal metabolites, S1P, which activates NF-kappaB followed by C/EBPalpha activation, leading to CAMP production, but in a S1P receptor-independent fashion.	Ceramides	29-37	CCAAT enhancer binding protein alpha	Homo sapiens	116-126
26964098-7	2016	Furthermore, overexpression of pFTO in differentiating porcine intramuscular preadipocytes also significantly increased the mRNA levels of adipocyte differentiation transcription factors peroxisome proliferators-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), lipoprotein lipase (LPL) and fatty acid synthase (FAS).	pfto	31-35	CCAAT enhancer binding protein alpha	Homo sapiens	250-286
26964098-7	2016	Furthermore, overexpression of pFTO in differentiating porcine intramuscular preadipocytes also significantly increased the mRNA levels of adipocyte differentiation transcription factors peroxisome proliferators-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), lipoprotein lipase (LPL) and fatty acid synthase (FAS).	pfto	31-35	CCAAT enhancer binding protein alpha	Homo sapiens	288-298
26681956-4	2016	Uric acid increased adipogenesis by increasing NADPH oxidase expression and elevation in the adipogenesis markers C/EBPalpha, PPARgamma, and Mest, while decreasing small lipid droplets and Wnt10b levels.	Uric Acid	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	114-124
26660162-7	2016	Furthermore, using a dual-luciferase reporter assay, it was found that nicotinamide exhibited a marked inhibitory effect on the HBV core, SpI, SpII and X promoters, accompanied by decreased expression of the transcription factors AP-1, C/EBPalpha and PPARalpha.	Niacinamide	71-83	CCAAT enhancer binding protein alpha	Homo sapiens	236-246
26264132-0	2016	The Glutamine-Alanine Repeat Domain of TCERG1 is Required for the Inhibition of the Growth Arrest Activity of C/EBPalpha.	Glutamine	4-13	CCAAT enhancer binding protein alpha	Homo sapiens	110-120
26264132-0	2016	The Glutamine-Alanine Repeat Domain of TCERG1 is Required for the Inhibition of the Growth Arrest Activity of C/EBPalpha.	Alanine	14-21	CCAAT enhancer binding protein alpha	Homo sapiens	110-120
26381255-9	2016	The data showed that docosahexaenoic acid administration substantially reduced tau hyperphosphorylation (t = 4.111, p &lt; 0.05), improved cognition (t = 6.532, p &lt; 0.001), and inhibited C/EBP homology protein activation (t = 5.631, p &lt; 0.01).	Docosahexaenoic Acids	21-41	CCAAT enhancer binding protein alpha	Homo sapiens	190-195
32263113-3	2016	Furthermore, the silver coated surface promoted adipogenic differentiation of hMSCs as demonstrated by more accumulation of lipid droplets and upregulation of adipogenesis-related genes such as peroxisome proliferator activated receptor gamma (PPARgamma), adipocyte determination and differentiation factor (ADD1) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Silver	17-23	CCAAT enhancer binding protein alpha	Homo sapiens	318-354
32263113-3	2016	Furthermore, the silver coated surface promoted adipogenic differentiation of hMSCs as demonstrated by more accumulation of lipid droplets and upregulation of adipogenesis-related genes such as peroxisome proliferator activated receptor gamma (PPARgamma), adipocyte determination and differentiation factor (ADD1) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Silver	17-23	CCAAT enhancer binding protein alpha	Homo sapiens	356-366
26805878-6	2016	There was a significant increase in serine phosphorylation of insulin receptor substrate (IRS)-1 and the expression of C/EBPalpha and gluconeogenic genes in the thapsigargin-stimulated control group compared to the normal control.	Thapsigargin	161-173	CCAAT enhancer binding protein alpha	Homo sapiens	119-129
26598521-3	2016	Mutation of the four Runx1 C-terminal tyrosines to aspartate or glutamate to mimic phosphorylation increases trans-activation of the reporter in 293T cells and allows induction of Cebpa or Pu.1 mRNAs in 32Dcl3 myeloid cells, whereas mutation of these residues to phenylalanine to prevent phosphorylation obviates these effects.	Tyrosine	38-47	CCAAT enhancer binding protein alpha	Homo sapiens	180-185
26598521-3	2016	Mutation of the four Runx1 C-terminal tyrosines to aspartate or glutamate to mimic phosphorylation increases trans-activation of the reporter in 293T cells and allows induction of Cebpa or Pu.1 mRNAs in 32Dcl3 myeloid cells, whereas mutation of these residues to phenylalanine to prevent phosphorylation obviates these effects.	Glutamic Acid	64-73	CCAAT enhancer binding protein alpha	Homo sapiens	180-185
27161125-8	2016	Additionally, imatinib enhanced the expression of C/EBPalpha in K562 cells compared with untreated cells (p &lt; 0.05).	Imatinib Mesylate	14-22	CCAAT enhancer binding protein alpha	Homo sapiens	50-60
27161125-11	2016	Imatinib enhances the expression of C/EBPalpha in K562 cells, and the overexpression of C/EBPalpha inhibits cell proliferation and increases apoptosis via the Foxo3a-Bim pathway.	Imatinib Mesylate	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	36-46
26537612-7	2016	On multivariate analysis, CEBPA (dm) (p = 0.007, OR 39.593) was an independent risk factor for achievement of complete remission (CR).	dm	33-35	CCAAT enhancer binding protein alpha	Homo sapiens	26-31
26537612-8	2016	With a median follow-up of 40.1 months, CEBPA (dm) showed a favorable overall survival (OS), event-free survival (EFS), and lower relapse incidence (RI) in comparison with CEBPA (wild) (all p values &lt;0.005).	dm	47-49	CCAAT enhancer binding protein alpha	Homo sapiens	40-45
26537612-9	2016	Comparison of clinical outcome analyses (consolidation chemotherapy vs. allogeneic hematopoietic cell transplantation (HCT)) demonstrated the role of consolidation treatment in patients with CEBPA (dm).	dm	198-200	CCAAT enhancer binding protein alpha	Homo sapiens	191-196
26537612-12	2016	In conclusion, CEBPA (dm) was associated with other molecular mutations.	dm	22-24	CCAAT enhancer binding protein alpha	Homo sapiens	15-20
26537612-13	2016	Consolidation chemotherapy alone may overcome higher relapse rates by reducing the treatment mortality and increasing survival after relapse events in patients with CEBPA (dm) in NK-AML.	dm	172-174	CCAAT enhancer binding protein alpha	Homo sapiens	165-170
26765462-9	2016	The expression of adipogenic transcription factors, including PPARgamma, C/EBPalpha, and beta, was also inhibited.ALA is a potential therapeutic agent for GO because of the inhibitory effects on ROS production and gene expression of proinflammatory cytokines and chemokines, resulting in prevention of adipose-tissue expansion.	Thioctic Acid	114-117	CCAAT enhancer binding protein alpha	Homo sapiens	73-93
26797706-9	2016	The cAMP triggered the activity of C/EBPbeta which is a critical inducer of PPARgamma and C/EBPalpha activation in the early stage of adipogenic differentiation, and this is further affected by ROS production.	Cyclic AMP	4-8	CCAAT enhancer binding protein alpha	Homo sapiens	90-100
26797706-9	2016	The cAMP triggered the activity of C/EBPbeta which is a critical inducer of PPARgamma and C/EBPalpha activation in the early stage of adipogenic differentiation, and this is further affected by ROS production.	Reactive Oxygen Species	194-197	CCAAT enhancer binding protein alpha	Homo sapiens	90-100
26797706-10	2016	The adipogenic marker proteins such as PPARgamma, C/EBPalpha, C/EBPbeta, and pERK were also decreased by melatonin.	Melatonin	105-114	CCAAT enhancer binding protein alpha	Homo sapiens	50-60
26782830-7	2016	In addition, myricetin upregulated ER stress-associated proteins, glucose-regulated protein-78 and C/EBP homologous protein in SKOV3 cells.	myricetin	13-22	CCAAT enhancer binding protein alpha	Homo sapiens	99-104
26304030-5	2016	Historically, the Celts may have overcome this geographical disadvantage of deficient CAMP production during the winter through an as-yet undefined acquired mutation that activates the alternative vitamin D-independent CAMP promoter C/EBPalpha.	Vitamin D	197-206	CCAAT enhancer binding protein alpha	Homo sapiens	233-243
26812497-4	2016	Here, we show that treatment of quiescent HSCs with vitamin A partially maintained the accumulation of lipid droplets and expression of quiescent HSC markers (glial fibrillary acidic protein, peroxisome proliferator-activator receptor-gamma and CCAAT/enhancer-binding protein-alpha) and also the expression of myofibroblastic markers (alpha-smooth muscle actin, heat shock protein 47 and collagen type I).	Vitamin A	52-61	CCAAT enhancer binding protein alpha	Homo sapiens	245-281
26119076-1	2015	It has been reported that alkaloids derived from Coptis chinensis exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating peroxisome proliferation-activity receptor-gamma (PPAR-gamma) and CCAAT/enhancer binding protein-alpha (C/EBP-alpha).	Alkaloids	26-35	CCAAT enhancer binding protein alpha	Homo sapiens	202-238
26119076-1	2015	It has been reported that alkaloids derived from Coptis chinensis exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating peroxisome proliferation-activity receptor-gamma (PPAR-gamma) and CCAAT/enhancer binding protein-alpha (C/EBP-alpha).	Alkaloids	26-35	CCAAT enhancer binding protein alpha	Homo sapiens	240-251
26119076-6	2015	These results indicate that the anti-adipogenic mechanism of epiberberine is associated with inhibition of phosphorylation of Raf/MEK1/ERK1/2 and AMPKalpha/Akt, followed by downregulation of the major transcription factors of adipogenesis, such as PPAR-gamma, C/EBP-alpha, and SREBP-1, and FAS.	epiberberine	61-73	CCAAT enhancer binding protein alpha	Homo sapiens	260-271
26324181-5	2015	Crucially, diabetes represses transcription of the key myeloid transcription factor CEBPA via diminished H3 Lys 27 promoter acetylation, leading to a failure in monocyte and granulocyte maturation.	Lysine	108-111	CCAAT enhancer binding protein alpha	Homo sapiens	84-89
26396188-6	2015	Polyamine depletion inhibited the second division of the mitotic clonal expansion (MCE), and inhibited the expression of PPARgamma and C/EBPalpha, the master regulators of adipogenesis.	Polyamines	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	135-145
25510894-10	2015	Persimmon tannin suppressed the expression of C/EBPalpha and peroxisome proliferator-activated receptor-gamma (PPARgamma), significantly.	persimmon tannin	0-16	CCAAT enhancer binding protein alpha	Homo sapiens	46-56
26383538-6	2015	Desferoxamine and n-acetylcysteine ameliorated these deteriorations by inhibiting p38 MAPK and C/EBPalpha activity through iron chelation and ROS scavenging activity.	desferoxamine	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	95-105
26383538-6	2015	Desferoxamine and n-acetylcysteine ameliorated these deteriorations by inhibiting p38 MAPK and C/EBPalpha activity through iron chelation and ROS scavenging activity.	Acetylcysteine	18-34	CCAAT enhancer binding protein alpha	Homo sapiens	95-105
26383538-6	2015	Desferoxamine and n-acetylcysteine ameliorated these deteriorations by inhibiting p38 MAPK and C/EBPalpha activity through iron chelation and ROS scavenging activity.	Iron	123-127	CCAAT enhancer binding protein alpha	Homo sapiens	95-105
26383538-6	2015	Desferoxamine and n-acetylcysteine ameliorated these deteriorations by inhibiting p38 MAPK and C/EBPalpha activity through iron chelation and ROS scavenging activity.	Reactive Oxygen Species	142-145	CCAAT enhancer binding protein alpha	Homo sapiens	95-105
25982911-0	2015	The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha.	mir-125b	30-38	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
25640641-6	2015	Phenylacetylamide triggered the expression of C/EBP homologous protein at the early treatment stage, followed by death receptor-5 upregulation, caspase activation, and beta-actin/tubulin degradation.	phenylacetylamide	0-17	CCAAT enhancer binding protein alpha	Homo sapiens	46-51
26362599-3	2015	Activation of adenylyl cyclase by forskolin resulted in 2.5-fold increase in the intensity of luminescence and over 3-fold increase in luminescence was observed when the cells were cotransfected with the vector overexpressing C/EBP.	Colforsin	34-43	CCAAT enhancer binding protein alpha	Homo sapiens	226-231
26362599-4	2015	The incubation of C/EBP-cotransfected cells with forskolin caused over 6-fold increase in the intensity of luminescence, suggesting that the effects of C/EBPalpha and forskolin are additive.	Colforsin	49-58	CCAAT enhancer binding protein alpha	Homo sapiens	18-23
26362599-4	2015	The incubation of C/EBP-cotransfected cells with forskolin caused over 6-fold increase in the intensity of luminescence, suggesting that the effects of C/EBPalpha and forskolin are additive.	Colforsin	49-58	CCAAT enhancer binding protein alpha	Homo sapiens	152-162
26362599-4	2015	The incubation of C/EBP-cotransfected cells with forskolin caused over 6-fold increase in the intensity of luminescence, suggesting that the effects of C/EBPalpha and forskolin are additive.	Colforsin	167-176	CCAAT enhancer binding protein alpha	Homo sapiens	18-23
26362599-8	2015	This suggests that C/EBPalpha might be involved in the regulation of LIPE expression and thus cholesterol supply for steroid hormone synthesis.	Cholesterol	94-105	CCAAT enhancer binding protein alpha	Homo sapiens	19-29
26362599-8	2015	This suggests that C/EBPalpha might be involved in the regulation of LIPE expression and thus cholesterol supply for steroid hormone synthesis.	Steroids	117-132	CCAAT enhancer binding protein alpha	Homo sapiens	19-29
26187065-2	2015	Here we show that IGF-I gene promoter activity in prostaglandin E2 (PGE2) induced osteoblasts is suppressed by dihydrotestosterone (DHT) through an essential C/EBP response element (RE) in exon 1 of the igf1 gene.	Dinoprostone	50-66	CCAAT enhancer binding protein alpha	Homo sapiens	158-163
26187065-2	2015	Here we show that IGF-I gene promoter activity in prostaglandin E2 (PGE2) induced osteoblasts is suppressed by dihydrotestosterone (DHT) through an essential C/EBP response element (RE) in exon 1 of the igf1 gene.	Dinoprostone	68-72	CCAAT enhancer binding protein alpha	Homo sapiens	158-163
26187065-2	2015	Here we show that IGF-I gene promoter activity in prostaglandin E2 (PGE2) induced osteoblasts is suppressed by dihydrotestosterone (DHT) through an essential C/EBP response element (RE) in exon 1 of the igf1 gene.	Dihydrotestosterone	111-130	CCAAT enhancer binding protein alpha	Homo sapiens	158-163
26187065-2	2015	Here we show that IGF-I gene promoter activity in prostaglandin E2 (PGE2) induced osteoblasts is suppressed by dihydrotestosterone (DHT) through an essential C/EBP response element (RE) in exon 1 of the igf1 gene.	Dihydrotestosterone	132-135	CCAAT enhancer binding protein alpha	Homo sapiens	158-163
26598603-6	2016	PLIN2 siRNA reduces inhibitory GSK3 levels and lithium chloride (LiCl)-upregulated beta-catenin or CCAAT/enhancer binding protein alpha (c/EBPalpha) expression.	Lithium Chloride	47-63	CCAAT enhancer binding protein alpha	Homo sapiens	99-135
26598603-6	2016	PLIN2 siRNA reduces inhibitory GSK3 levels and lithium chloride (LiCl)-upregulated beta-catenin or CCAAT/enhancer binding protein alpha (c/EBPalpha) expression.	Lithium Chloride	47-63	CCAAT enhancer binding protein alpha	Homo sapiens	137-147
26598603-6	2016	PLIN2 siRNA reduces inhibitory GSK3 levels and lithium chloride (LiCl)-upregulated beta-catenin or CCAAT/enhancer binding protein alpha (c/EBPalpha) expression.	Lithium Chloride	65-69	CCAAT enhancer binding protein alpha	Homo sapiens	99-135
26598603-6	2016	PLIN2 siRNA reduces inhibitory GSK3 levels and lithium chloride (LiCl)-upregulated beta-catenin or CCAAT/enhancer binding protein alpha (c/EBPalpha) expression.	Lithium Chloride	65-69	CCAAT enhancer binding protein alpha	Homo sapiens	137-147
26598603-7	2016	OA treatment decreases LiCl-increased c/EBPalpha via PLIN2-c/EBPalpha dissociation.	Lithium Chloride	23-27	CCAAT enhancer binding protein alpha	Homo sapiens	38-48
26598603-7	2016	OA treatment decreases LiCl-increased c/EBPalpha via PLIN2-c/EBPalpha dissociation.	Lithium Chloride	23-27	CCAAT enhancer binding protein alpha	Homo sapiens	59-69
26187065-9	2015	Finally, although the PGE2 sensitive C/EBP RE in the igf1 gene is not essential for basal TGF-beta induction, C/EBPdelta activity through this site is potently enhanced by TGF-beta.	Dinoprostone	22-26	CCAAT enhancer binding protein alpha	Homo sapiens	37-42
26396188-9	2015	Conditional knockdown of CHOP in polyamine-depleted preadipocytes restored PPARgamma and C/EBPalpha expression, but failed to recover MCE and differentiation.	Polyamines	33-42	CCAAT enhancer binding protein alpha	Homo sapiens	89-99
26484536-0	2015	Axon Regeneration Is Regulated by Ets-C/EBP Transcription Complexes Generated by Activation of the cAMP/Ca2+ Signaling Pathways.	Cyclic AMP	99-103	CCAAT enhancer binding protein alpha	Homo sapiens	38-43
26397153-4	2015	In the present study, we found that expression of C/EBPalpha, an important transcription factor for myeloid differentiation, was significantly suppressed in ATRA resistant APL cell line NB4-R1 compared with ATRA sensitive NB4 cells.	Tretinoin	157-161	CCAAT enhancer binding protein alpha	Homo sapiens	50-60
26397153-8	2015	Moreover, C/EBPalpha expression was reduced by PI3K inhibitor LY294002 and mTOR inhibitor RAD001 in NB4 cells, suggesting that inactivation of the PI3K/Akt/mTOR pathway was responsible for C/EBPalpha suppression in APL cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	62-70	CCAAT enhancer binding protein alpha	Homo sapiens	10-20
26397153-10	2015	Further upregulating of CD11b expression and differential morphological changes were found in NB4-R1 cells with restored C/EBPalpha P42 after ATRA treatment.	Tretinoin	142-146	CCAAT enhancer binding protein alpha	Homo sapiens	121-131
26397153-13	2015	In addition, we used histone deacetylase inhibitor trichostatin (TSA) to restore C/EBPalpha expression in NB4-R1 cells.	trichostatin A	51-63	CCAAT enhancer binding protein alpha	Homo sapiens	81-91
26397153-13	2015	In addition, we used histone deacetylase inhibitor trichostatin (TSA) to restore C/EBPalpha expression in NB4-R1 cells.	trichostatin A	65-68	CCAAT enhancer binding protein alpha	Homo sapiens	81-91
26008221-6	2015	This CpG is associated with C/EBP and CREB binding sites in the IL-8 promoter and its demethylation by arsenic coupled with increased H3 histone acetylation and CBP/P300 recruitment could lead to induction of IL-8.	Arsenic	103-110	CCAAT enhancer binding protein alpha	Homo sapiens	28-33
26383638-3	2015	Transcription is additionally regulated via a cAMP response unit, which includes a cAMP response element and four binding sites for CCAAT/enhancer-binding protein (C/EBP).	Cyclic AMP	46-50	CCAAT enhancer binding protein alpha	Homo sapiens	132-162
26383638-3	2015	Transcription is additionally regulated via a cAMP response unit, which includes a cAMP response element and four binding sites for CCAAT/enhancer-binding protein (C/EBP).	Cyclic AMP	46-50	CCAAT enhancer binding protein alpha	Homo sapiens	164-169
26278180-12	2015	In vivo analysis of the computationally suggested mutations reveals that double mutations of the leucine residues (L317D+L335D) may disrupt the interaction between GR and C/EBPalpha.	Leucine	97-104	CCAAT enhancer binding protein alpha	Homo sapiens	171-181
25595190-6	2015	It was also ascertained that hMSC exposed just to dexamethasone and rosiglitazone (D&amp;R) differentiated into cells which accumulated neutral lipid droplets, expressed C/EBP-alpha, PPAR-gamma, aP2, lipoprotein lipase, acyl-CoA synthetase, phosphoenolpyruvate carboxykinase, adiponectin, and leptin genes but did not proliferate.	Dexamethasone	50-63	CCAAT enhancer binding protein alpha	Homo sapiens	170-181
25595190-6	2015	It was also ascertained that hMSC exposed just to dexamethasone and rosiglitazone (D&amp;R) differentiated into cells which accumulated neutral lipid droplets, expressed C/EBP-alpha, PPAR-gamma, aP2, lipoprotein lipase, acyl-CoA synthetase, phosphoenolpyruvate carboxykinase, adiponectin, and leptin genes but did not proliferate.	Rosiglitazone	68-81	CCAAT enhancer binding protein alpha	Homo sapiens	170-181
25595190-6	2015	It was also ascertained that hMSC exposed just to dexamethasone and rosiglitazone (D&amp;R) differentiated into cells which accumulated neutral lipid droplets, expressed C/EBP-alpha, PPAR-gamma, aP2, lipoprotein lipase, acyl-CoA synthetase, phosphoenolpyruvate carboxykinase, adiponectin, and leptin genes but did not proliferate.	Benzoic acid, 2-[[4-[bis(2-hydroxyethyl)amino]phenyl]azo]-	83-88	CCAAT enhancer binding protein alpha	Homo sapiens	170-181
26109609-5	2015	Using a cell-based high-throughput screening, we identified 2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3-(2-methoxyphenyl)-4(3H)-quinazolinone as a potent inducer of C/EBPalpha and myeloid differentiation.	2-[(e)-2-(3,4-dihydroxyphenyl)vinyl]-3-(2-methoxyphenyl)-4(3h)-quinazolinone	60-136	CCAAT enhancer binding protein alpha	Homo sapiens	160-170
26193632-6	2015	In contrast, sivelestat, an NE-specific small-molecule inhibitor, corrected dysgranulopoiesis by restoring normal intracellular NE localization in primary granules; ameliorating UPR/ER stress; increasing expression of CEBPA, but not CEBPB; and promoting promyelocyte survival and differentiation.	sivelestat	13-23	CCAAT enhancer binding protein alpha	Homo sapiens	218-223
26193637-8	2015	Pharmacologic inhibition of H3K9me3 with chaetocin decreased DDLPS proliferation and increased expression of the adipogenesis-associated factors PPARgamma, CEBPalpha, and CEBPbeta, suggesting that increased H3K9me3 may mediate DDLPS-associated aggressiveness and dedifferentiation properties.	chaetocin	41-50	CCAAT enhancer binding protein alpha	Homo sapiens	156-165
25920395-0	2015	Correlation of C/EBPalpha expression with response and resistance to imatinib in chronic myeloid leukaemia.	Imatinib Mesylate	69-77	CCAAT enhancer binding protein alpha	Homo sapiens	15-25
25920395-4	2015	METHODS: We quantified the expression of C/EBPalpha gene in 126 chronic myeloid leukaemia samples (82 from newly diagnosed and 44 from imatinib-resistant patients) and 20 control samples.	Imatinib Mesylate	135-143	CCAAT enhancer binding protein alpha	Homo sapiens	41-51
25920395-6	2015	RESULTS: C/EBPalpha expression level was significantly lower in the imatinib-resistant group than in the pretreatment and control group (P = 0.0398).	Imatinib Mesylate	68-76	CCAAT enhancer binding protein alpha	Homo sapiens	9-19
26121644-0	2015	Doxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1/Cip1) and C/EBPalpha Expression.	Doxorubicin	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	88-98
25824695-12	2015	In addition, groups of cells treated with 3-(5"-hydroxymethyl-2"-furyl)-1-benzylindazole, which inhibits the expression of HIF-1alpha in hypoxia, contributed to the inhibited expression of HIF-1alpha and enhanced expression of C/EBPalpha in hypoxic bladder cancer cells.	3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole	42-88	CCAAT enhancer binding protein alpha	Homo sapiens	227-237
25779641-3	2015	Here, we used the electrophoretic mobility shift assay (EMSA) to examine C/EBPalpha and C/EBPbeta homodimers binding to all 25 chemical forms of a CG dinucleotide for two DNA sequences: the canonical C/EBP 8-mer TTGC GCAA and the chimeric C/EBP CRE 8-mer TTGC GTCA.	Dinucleoside Phosphates	150-162	CCAAT enhancer binding protein alpha	Homo sapiens	73-83
25560764-4	2015	Lentivirus-mediated overexpression of miR-540 resulted in blockade of the expression of C/EBP-alpha and PPARgamma, the two master transcription factors of adipogenesis, and deficient lipid accumulation, whereas inhibition of miR-540 promoted these processes.	mir-540	38-45	CCAAT enhancer binding protein alpha	Homo sapiens	88-99
25429790-7	2015	RK suppressed the expression of major genes involved in the adipogenesis pathway including peroxisome proliferator-activated receptor-gamma (PPARgamma) and CCAAT enhancer binding protein-alpha (C/EBPalpha), which led to further down-regulation of adipocyte fatty acid-binding protein-2 (aP2).	Fatty Acids	257-267	CCAAT enhancer binding protein alpha	Homo sapiens	194-204
25945786-6	2015	Furthermore, fisetin inhibited the phosphorylation of the mammalian target of rapamycin (mTOR) and that of p70 ribosomal S6 kinase, a target of the mTOR complex, the inhibition of which was followed by a decreased mRNA level of the C/EBPalpha gene.	fisetin	13-20	CCAAT enhancer binding protein alpha	Homo sapiens	232-242
25928058-4	2015	In the present study, we found that berberine significantly suppressed the expressions of CCAAT/enhancer-binding protein (C/EBP)alpha, peroxisome proliferators-activated receptor gamma2 (PPARgamma2), and other adipogenic genes in the process of adipogenesis.	Berberine	36-45	CCAAT enhancer binding protein alpha	Homo sapiens	122-133
25428599-5	2015	Consistently, a dramatic reduction in mRNA expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding protein alpha (C/EBPalpha), glucose transporters, 1 and 4 (Glut1, Glut4), and adipocyte markers, aP2 and adipsin, was observed in the presence of creatine.	Creatine	325-333	CCAAT enhancer binding protein alpha	Homo sapiens	194-204
26204837-9	2015	Fluoxetine also significantly inhibited lipid accumulation and down-regulated the levels of PPAR-gamma and C/EBP-alpha in ASCs.	Fluoxetine	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	107-118
25994559-8	2015	Capsaicin significantly inhibited the early adipogenic differentiation, lipogenesis and maturation of adipocytes with concomitant repression of PPARgamma, C/EBPalpha, FABP4 and SCD-1.	Capsaicin	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	155-165
25779641-7	2015	The structural differences between C/EBPalpha and C/EBPbeta that may account for the difference in binding 5hmC in the 8-mer TGAC GCAA are explored.	5-hydroxymethylcytosine	107-111	CCAAT enhancer binding protein alpha	Homo sapiens	35-45
25995742-6	2015	RESULTS: It was noted that combined treatment of 5-FU + PUFAs on gastric carcinoma (MGC and SGC) cells produced a significant growth inhibitory action compared with either agent alone by inhibiting the production of TNF-alpha and VEGF and a simultaneous increase in the expression of LPL, PPAR-gamma, and C/EBP.	Fluorouracil	49-53	CCAAT enhancer binding protein alpha	Homo sapiens	305-310
25523390-7	2015	Subsequently, the activation of PPARgamma1 by indomethacin, its exogenous ligand, activated C/EBPalpha, which, together with IBMX, up-regulated PPARgamma2 expression and therefore the fullest adipogenesis.	Indomethacin	46-58	CCAAT enhancer binding protein alpha	Homo sapiens	92-102
25644705-9	2015	The same oligonucleotide mixed with HEK293 cell nuclear extract allowed the unambiguous identification of native human C/EBP alpha with 24.3% sequence coverage.	Oligonucleotides	9-24	CCAAT enhancer binding protein alpha	Homo sapiens	119-130
25753223-5	2015	Absence of C/EBPalpha prevents GMP formation, and higher levels are required for granulopoiesis compared to monopoiesis.	guanosine 5'-monophosphorothioate	31-34	CCAAT enhancer binding protein alpha	Homo sapiens	11-21
25753223-8	2015	RUNX1 mutation, CEBPA promoter methylation, Trib1 or Trib2-mediated C/EBPalphap42 degradation, and signaling pathways leading to C/EBPalpha serine 21 phosphorylation reduce C/EBPalpha expression or activity in additional AML cases.	Serine	140-146	CCAAT enhancer binding protein alpha	Homo sapiens	129-139
25724338-5	2015	Myricetin downregulated the mRNA and protein levels of CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma, both of which are major adipogenic transcription factors.	myricetin	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	55-91
25948182-7	2015	RESULTS: The metformin lowered the OD value, and the expression levels of both adipogenic genes C/EBPalpha and FABP4 were lower than those of controls, while the expression level of PPARgamma mRNA was not significantly changed, the apoptosis rate of leukemia cells co-caltured with metformin-treated adipocytes was higher than that of co-cultured cells without metformin treatment.	Metformin	13-22	CCAAT enhancer binding protein alpha	Homo sapiens	96-106
25813451-4	2015	In addition, PG significantly reduced the expression of adipocyte-specific markers including peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT enhancer binding protein-alpha (C/EBP-alpha), lipoprotein lipase (LPL), and adipocyte fatty acid-binding protein 2 (aP2).	Propyl Gallate	13-15	CCAAT enhancer binding protein alpha	Homo sapiens	156-192
25813451-4	2015	In addition, PG significantly reduced the expression of adipocyte-specific markers including peroxisome proliferator-activated receptor-gamma (PPAR-gamma), CCAAT enhancer binding protein-alpha (C/EBP-alpha), lipoprotein lipase (LPL), and adipocyte fatty acid-binding protein 2 (aP2).	Propyl Gallate	13-15	CCAAT enhancer binding protein alpha	Homo sapiens	194-205
25714610-8	2015	In contrast, the expression of adipogenic proteins (PPARgamma, C/EBPalpha, and acetyl CoA carboxylase) were decreased significantly with LiCl (by 1.6, 2.6, and 1.9-fold respectively) and BIO (by 7, 17, and 5.6-fold respectively) treatments.	Lithium Chloride	137-141	CCAAT enhancer binding protein alpha	Homo sapiens	63-73
25363290-6	2015	Expression of C/EBPalpha protected HCC cells in vitro from glucose and glutamine starvation-induced cell death through autophagy-involved lipid catabolism.	Glucose	59-66	CCAAT enhancer binding protein alpha	Homo sapiens	14-24
25363290-6	2015	Expression of C/EBPalpha protected HCC cells in vitro from glucose and glutamine starvation-induced cell death through autophagy-involved lipid catabolism.	Glutamine	71-80	CCAAT enhancer binding protein alpha	Homo sapiens	14-24
25242579-8	2015	Deguelin induced differentiation of OCI-AML3 cells at a nontoxic concentration which was associated with a decrease in expression of activated caspase-8, p53, p21, and the 30-kD form of CCAAT/enhancer binding protein alpha (C/EBPalpha), whereas no effects were found in OCIM2 cells expressing NPM-wt.	deguelin	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	186-222
25462562-5	2015	Expression of the adipogenic master regulators PPARgamma and C/EBPalpha, and their target gene aP2, was suppressed by atorvastatin.	Atorvastatin	118-130	CCAAT enhancer binding protein alpha	Homo sapiens	61-71
25242579-8	2015	Deguelin induced differentiation of OCI-AML3 cells at a nontoxic concentration which was associated with a decrease in expression of activated caspase-8, p53, p21, and the 30-kD form of CCAAT/enhancer binding protein alpha (C/EBPalpha), whereas no effects were found in OCIM2 cells expressing NPM-wt.	deguelin	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	224-234
24699304-3	2014	Here, treatment with the novel LSD1 antagonist SP2509 attenuated the binding of LSD1 with the corepressor CoREST, increased the permissive H3K4Me3 mark on the target gene promoters, and increased the levels of p21, p27 and CCAAT/enhancer binding protein alpha in cultured AML cells.	SP2509	47-53	CCAAT enhancer binding protein alpha	Homo sapiens	223-259
25258381-0	2014	miR-199a-5p inhibits monocyte/macrophage differentiation by targeting the activin A type 1B receptor gene and finally reducing C/EBPalpha expression.	199a-	4-9	CCAAT enhancer binding protein alpha	Homo sapiens	127-137
25320182-7	2014	Compared with control, short-term treatment of propionate and butyrate enhanced PPARG and CEBPA mRNA expression in porcine SVF by 50-100%.	Propionates	47-57	CCAAT enhancer binding protein alpha	Homo sapiens	90-95
25320182-7	2014	Compared with control, short-term treatment of propionate and butyrate enhanced PPARG and CEBPA mRNA expression in porcine SVF by 50-100%.	Butyrates	62-70	CCAAT enhancer binding protein alpha	Homo sapiens	90-95
25320182-10	2014	Trichostatin A, a specific inhibitor of histone deacetylases (HDACs), enhanced the formation of adipocytes in porcine SVF by nearly 100% and the expression of PPARG and CEBPA mRNAs by 150% and 50%, respectively.	trichostatin A	0-14	CCAAT enhancer binding protein alpha	Homo sapiens	169-174
24947179-12	2014	Together, our results propose a significant role for the KDM6B-C/EBPalpha axis in the PDAC phenotype.	pdac	86-90	CCAAT enhancer binding protein alpha	Homo sapiens	63-73
26446202-11	2015	Transcriptional factors of C/EBPalpha, SREBP-1c and PPARgamma were markedly decreased in both GTP and EGCG-treated cells and GTP exhibited stronger inhibitory effects on C/EBPalpha and PPARgamma protein expression than EGCG (p &lt; 0.05).	epigallocatechin gallate	94-97	CCAAT enhancer binding protein alpha	Homo sapiens	27-37
26446202-11	2015	Transcriptional factors of C/EBPalpha, SREBP-1c and PPARgamma were markedly decreased in both GTP and EGCG-treated cells and GTP exhibited stronger inhibitory effects on C/EBPalpha and PPARgamma protein expression than EGCG (p &lt; 0.05).	epigallocatechin gallate	102-106	CCAAT enhancer binding protein alpha	Homo sapiens	27-37
26446202-11	2015	Transcriptional factors of C/EBPalpha, SREBP-1c and PPARgamma were markedly decreased in both GTP and EGCG-treated cells and GTP exhibited stronger inhibitory effects on C/EBPalpha and PPARgamma protein expression than EGCG (p &lt; 0.05).	epigallocatechin gallate	102-106	CCAAT enhancer binding protein alpha	Homo sapiens	170-180
26446202-11	2015	Transcriptional factors of C/EBPalpha, SREBP-1c and PPARgamma were markedly decreased in both GTP and EGCG-treated cells and GTP exhibited stronger inhibitory effects on C/EBPalpha and PPARgamma protein expression than EGCG (p &lt; 0.05).	epigallocatechin gallate	125-128	CCAAT enhancer binding protein alpha	Homo sapiens	170-180
26446202-11	2015	Transcriptional factors of C/EBPalpha, SREBP-1c and PPARgamma were markedly decreased in both GTP and EGCG-treated cells and GTP exhibited stronger inhibitory effects on C/EBPalpha and PPARgamma protein expression than EGCG (p &lt; 0.05).	epigallocatechin gallate	219-223	CCAAT enhancer binding protein alpha	Homo sapiens	27-37
26446202-12	2015	In conclusion, total GTP exerted greater inhibitory effects than purified EGCG on adipogenesis through down-regulating the adipogenic factor C/EBPalpha, SREBP-1c and PPARgamma expression.	epigallocatechin gallate	21-24	CCAAT enhancer binding protein alpha	Homo sapiens	141-151
26446202-12	2015	In conclusion, total GTP exerted greater inhibitory effects than purified EGCG on adipogenesis through down-regulating the adipogenic factor C/EBPalpha, SREBP-1c and PPARgamma expression.	epigallocatechin gallate	74-78	CCAAT enhancer binding protein alpha	Homo sapiens	141-151
25222709-6	2014	The overall expression of C/EBPalpha, beta, and delta, PPARgamma2, ACC, FAS, and perilipin A in preadipocytes was downregulated by the treatment of 2,4,5-TMBA.	2,4,5-trimethoxybenzaldehyde	148-158	CCAAT enhancer binding protein alpha	Homo sapiens	26-53
24951473-8	2014	However, MDI-I treated cells had significantly more C/EBPalpha protein compared to MDI or MDI-R, suggesting that indomethacin-dependent increased C/EBPalpha may contribute to the adipogenesis-inducing potency of MDI-I.	Indomethacin	113-125	CCAAT enhancer binding protein alpha	Homo sapiens	52-62
24951473-8	2014	However, MDI-I treated cells had significantly more C/EBPalpha protein compared to MDI or MDI-R, suggesting that indomethacin-dependent increased C/EBPalpha may contribute to the adipogenesis-inducing potency of MDI-I.	Indomethacin	113-125	CCAAT enhancer binding protein alpha	Homo sapiens	146-156
24961835-5	2014	The present study investigated whether aspartame suppresses 3T3-L1 differentiation, by downregulating phosphorylated peroxisome proliferator-activated receptor gamma (p-PPARgamma), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid-binding protein 4 (FABP4), CCAAT/enhancer-binding protein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP1), which are critical for adipogenesis.	Aspartame	39-48	CCAAT enhancer binding protein alpha	Homo sapiens	281-317
24961835-5	2014	The present study investigated whether aspartame suppresses 3T3-L1 differentiation, by downregulating phosphorylated peroxisome proliferator-activated receptor gamma (p-PPARgamma), peroxisome proliferator-activated receptor gamma (PPARgamma), fatty acid-binding protein 4 (FABP4), CCAAT/enhancer-binding protein alpha (C/EBPalpha), and sterol regulatory element-binding protein 1 (SREBP1), which are critical for adipogenesis.	Aspartame	39-48	CCAAT enhancer binding protein alpha	Homo sapiens	319-329
25115372-12	2014	In contrast, RXRalpha and RXRgamma levels were significantly decreased (P&lt;0.05), and C/EBPalpha, a gene required for terminal adipocyte differentiation, was strongly suppressed by propranolol when compared to vehicle-treated cells (P&lt;0.01).	Propranolol	183-194	CCAAT enhancer binding protein alpha	Homo sapiens	88-98
25115372-15	2014	However, propranolol treatment also led to improper induction of PPARdelta and suppression of C/EBPalpha, RXRalpha, and RXRgamma.	Propranolol	9-20	CCAAT enhancer binding protein alpha	Homo sapiens	94-104
24800886-9	2014	Combined treatment with belinostat and RA dose dependently accelerated and reinforced granulocytic differentiation, accompanied by changes in the expression of CD11b, C/EBPalpha (CCAAT/enhancer binding protein-alpha), and C/EBPepsilon.	belinostat	24-34	CCAAT enhancer binding protein alpha	Homo sapiens	167-177
24800886-9	2014	Combined treatment with belinostat and RA dose dependently accelerated and reinforced granulocytic differentiation, accompanied by changes in the expression of CD11b, C/EBPalpha (CCAAT/enhancer binding protein-alpha), and C/EBPepsilon.	belinostat	24-34	CCAAT enhancer binding protein alpha	Homo sapiens	179-215
24800886-9	2014	Combined treatment with belinostat and RA dose dependently accelerated and reinforced granulocytic differentiation, accompanied by changes in the expression of CD11b, C/EBPalpha (CCAAT/enhancer binding protein-alpha), and C/EBPepsilon.	Tretinoin	39-41	CCAAT enhancer binding protein alpha	Homo sapiens	167-177
24800886-9	2014	Combined treatment with belinostat and RA dose dependently accelerated and reinforced granulocytic differentiation, accompanied by changes in the expression of CD11b, C/EBPalpha (CCAAT/enhancer binding protein-alpha), and C/EBPepsilon.	Tretinoin	39-41	CCAAT enhancer binding protein alpha	Homo sapiens	179-215
25054323-5	2014	Furthermore, arginine demonstrated its antiadipogenicity by decreasing adipocyte formation and triglyceride (TG) content in MSCs and inhibiting the mRNA expression of the adipogenic transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), and fatty acid binding protein 4 (Fabp4).	Arginine	13-21	CCAAT enhancer binding protein alpha	Homo sapiens	266-302
25054323-5	2014	Furthermore, arginine demonstrated its antiadipogenicity by decreasing adipocyte formation and triglyceride (TG) content in MSCs and inhibiting the mRNA expression of the adipogenic transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), and fatty acid binding protein 4 (Fabp4).	Arginine	13-21	CCAAT enhancer binding protein alpha	Homo sapiens	304-314
25112011-8	2014	In addition, the expression of adipogenic differentiation marker C/EBPalpha was increased while the osteogenic differentiation marker OPN was decreased in EBs after RA treatment for 5 days.	Tretinoin	165-167	CCAAT enhancer binding protein alpha	Homo sapiens	65-75
24797079-12	2014	Activation of C/EBP may induce excessive Nox-derived reactive oxygen species formation, further contributing to SMCs dysfunction and atherosclerotic plaque development.	Reactive Oxygen Species	53-76	CCAAT enhancer binding protein alpha	Homo sapiens	14-19
25341288-3	2014	The molecular mechanisms mediating the adipogenic action of thiazolidinediones and fatty acids in myoblasts could involve peroxisome proliferators-activated receptor-gamma (PPARgamma and CCAAT-enhancer-binding protein C/EBP.	Thiazolidinediones	60-78	CCAAT enhancer binding protein alpha	Homo sapiens	218-223
25341288-3	2014	The molecular mechanisms mediating the adipogenic action of thiazolidinediones and fatty acids in myoblasts could involve peroxisome proliferators-activated receptor-gamma (PPARgamma and CCAAT-enhancer-binding protein C/EBP.	Fatty Acids	83-94	CCAAT enhancer binding protein alpha	Homo sapiens	218-223
24824185-8	2014	RESULTS: The results demonstrated that high phosphorus induced the calcification of differentiated adipocytes with increased expression of osteopontin, the osteoblast transcription factor Runx2 and decreased expression of adipocyte transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT-enhancer-binding protein alpha (CEBPalpha), indicating that high phosphorus led to a phenotypic switch of adipocytes to an osteoblast like phenotype.	Phosphorus	44-54	CCAAT enhancer binding protein alpha	Homo sapiens	319-355
24824185-8	2014	RESULTS: The results demonstrated that high phosphorus induced the calcification of differentiated adipocytes with increased expression of osteopontin, the osteoblast transcription factor Runx2 and decreased expression of adipocyte transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT-enhancer-binding protein alpha (CEBPalpha), indicating that high phosphorus led to a phenotypic switch of adipocytes to an osteoblast like phenotype.	Phosphorus	44-54	CCAAT enhancer binding protein alpha	Homo sapiens	357-366
24671039-5	2014	The EP18 oligonucleotide which binds to the CAAT enhancer binding protein (C/EBP) was synthesized with a 3" ribose (rEP18) and coupled to hydrazide-agarose.	Oligonucleotides	9-24	CCAAT enhancer binding protein alpha	Homo sapiens	44-73
24671039-5	2014	The EP18 oligonucleotide which binds to the CAAT enhancer binding protein (C/EBP) was synthesized with a 3" ribose (rEP18) and coupled to hydrazide-agarose.	Oligonucleotides	9-24	CCAAT enhancer binding protein alpha	Homo sapiens	75-80
24671039-5	2014	The EP18 oligonucleotide which binds to the CAAT enhancer binding protein (C/EBP) was synthesized with a 3" ribose (rEP18) and coupled to hydrazide-agarose.	Isoniazid	138-147	CCAAT enhancer binding protein alpha	Homo sapiens	44-73
24671039-5	2014	The EP18 oligonucleotide which binds to the CAAT enhancer binding protein (C/EBP) was synthesized with a 3" ribose (rEP18) and coupled to hydrazide-agarose.	Isoniazid	138-147	CCAAT enhancer binding protein alpha	Homo sapiens	75-80
24671039-5	2014	The EP18 oligonucleotide which binds to the CAAT enhancer binding protein (C/EBP) was synthesized with a 3" ribose (rEP18) and coupled to hydrazide-agarose.	Sepharose	148-155	CCAAT enhancer binding protein alpha	Homo sapiens	44-73
24671039-5	2014	The EP18 oligonucleotide which binds to the CAAT enhancer binding protein (C/EBP) was synthesized with a 3" ribose (rEP18) and coupled to hydrazide-agarose.	Sepharose	148-155	CCAAT enhancer binding protein alpha	Homo sapiens	75-80
24769646-3	2014	Treatment with ATRA induced significant myeloid differentiation accompanied by upregulation of RARalpha, C/EBPalpha, C/EBPe and PU.1 in MLL-AF9-positive but not in MLL-AF4/5q31-positive cells.	Tretinoin	15-19	CCAAT enhancer binding protein alpha	Homo sapiens	105-115
23995352-11	2014	Over the same range of concentrations, hydroxytyrosol downregulated the expression of adipose triglyceride lipase, hormone sensitive lipase (HSL), and adipogenesis-related transcription factors PPARgamma and C/EBPalpha.	3,4-dihydroxyphenylethanol	39-53	CCAAT enhancer binding protein alpha	Homo sapiens	208-218
25039167-4	2014	The mechanisms of berberine in diabetes include: improving the function of beta-cell; prompting insulin secretion and islets regeneration, lowing lipid level, regulating glucose and lipid metabolic by influence transcriptional factors expression such as PPARgamma, C/EBPalpha, SREBP-1c, LXR, having the activities of anti-oxidation and inhibiting reductase to repress oxidative stress state and regulate metabolic signal pathway.	Berberine	18-27	CCAAT enhancer binding protein alpha	Homo sapiens	265-275
24333181-12	2014	Intriguingly, miR-223 expression was suppressed by sulfatide in HCC in association with reduced recruitment of acetylated histone H3 and C/EBPalpha to the pre-miR-223 gene promoter, where monocytic leukemia zinc finger (MOZ) protein, a MYST-type histone acetyltransferase, lost its attachment.	Sulfoglycosphingolipids	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	137-147
24530909-5	2014	Kirenol down-regulated the expression levels of PPARgamma and C/EBPalpha, which were up-regulated by siRNA knockdown of beta-catenin.	kirenol	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	62-72
24584857-4	2014	In addition, we found CEBPA-dependent activation of HK3 and KLF5 transcription during all-trans retinoic acid (ATRA) mediated neutrophil differentiation of acute promyelocytic leukemia (APL) cells.	Tretinoin	96-109	CCAAT enhancer binding protein alpha	Homo sapiens	22-27
24614182-0	2014	Differential effects of nitrostyrene derivatives on myelopoiesis involve regulation of C/EBPalpha and p38MAPK activity.	nitrostyrene	24-36	CCAAT enhancer binding protein alpha	Homo sapiens	87-97
24584857-4	2014	In addition, we found CEBPA-dependent activation of HK3 and KLF5 transcription during all-trans retinoic acid (ATRA) mediated neutrophil differentiation of acute promyelocytic leukemia (APL) cells.	Tretinoin	111-115	CCAAT enhancer binding protein alpha	Homo sapiens	22-27
24551078-8	2014	Moreover, cyclosporine A treatment, which has been shown to prevent dephosphorylation and nuclear translocation of NFAT isoforms, resulted in enhanced C/EBPalpha binding.	Cyclosporine	10-24	CCAAT enhancer binding protein alpha	Homo sapiens	151-161
24374344-5	2014	Adipocytes differentiated in the presence of fructose showed increased FABP4 expression, C/EBPalpha to C/EBPbeta ratio and lipolysis.	Fructose	45-53	CCAAT enhancer binding protein alpha	Homo sapiens	89-99
24191285-9	2014	High salt intake led to upregulation of Agt expression, DNA hypomethylation around 2 CEBP binding sites and a transcription start site, and decreased DNA methylation activity in rat visceral adipose tissue.	Salts	5-9	CCAAT enhancer binding protein alpha	Homo sapiens	85-89
25119735-8	2014	Mutation of the CCAAT/enhancer-binding protein (CEBP) beta binding site of the IL-8 promoter affected only DON-, but not VA- and TNFalpha-induced luciferase expression.	deoxynivalenol	107-110	CCAAT enhancer binding protein alpha	Homo sapiens	16-46
25301360-9	2014	The addition of BMP2 in the control culture media containing dexamethasone alone lead to formation of lipid droplets and increased C/EBP-alpha expression in hADSCs.	Dexamethasone	61-74	CCAAT enhancer binding protein alpha	Homo sapiens	131-142
25295069-4	2014	During adipogenesis, Oligonol downregulated the mRNA levels of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding proteins alpha (C/EBPalpha), and delta (C/EBPdelta) in a dose-dependent manner and the expression of genes involved in lipid biosynthesis.	oligonol	21-29	CCAAT enhancer binding protein alpha	Homo sapiens	164-174
23929703-10	2014	CONCLUSION: A novel injectable saRNA-oligonucleotide that enhances C/EBPalpha expression successfully reduces tumor burden and simultaneously improves liver function in a clinically relevant liver cirrhosis/HCC model.	sarna-oligonucleotide	31-52	CCAAT enhancer binding protein alpha	Homo sapiens	67-77
25119735-8	2014	Mutation of the CCAAT/enhancer-binding protein (CEBP) beta binding site of the IL-8 promoter affected only DON-, but not VA- and TNFalpha-induced luciferase expression.	deoxynivalenol	107-110	CCAAT enhancer binding protein alpha	Homo sapiens	48-52
24376792-9	2013	Chemical inhibition of JNK, p38MAPK and ERK1/2 diminished significantly the high glucose-induced nuclear translocation of C/EBP and ET-1 expression.	Glucose	81-88	CCAAT enhancer binding protein alpha	Homo sapiens	122-127
24376792-4	2013	In this study, we aimed at elucidating the role of C/EBP in mediating the high glucose effect on ET-1 expression in human endothelial cells (EC).	Glucose	79-86	CCAAT enhancer binding protein alpha	Homo sapiens	51-56
24376792-7	2013	High glucose activated C/EBPalpha, C/EBPbeta, and C/EBPdelta in a dose-dependent manner.	Glucose	5-12	CCAAT enhancer binding protein alpha	Homo sapiens	23-33
24376792-10	2013	Silencing of C/EBPalpha, C/EBPbeta or C/EBPdelta greatly reduced the high glucose-induced upregulation of ET-1 mRNA, pre-pro-ET-1, and ET-1 secretion.	Glucose	74-81	CCAAT enhancer binding protein alpha	Homo sapiens	13-23
24376792-14	2013	The direct interaction of C/EBPalpha, C/EBPbeta or C/EBPdelta proteins with the ET-1 promoter in high glucose-exposed EC was confirmed by chromatin immunoprecipitation assay.	Glucose	102-109	CCAAT enhancer binding protein alpha	Homo sapiens	26-36
23881867-10	2013	This suggests that IL-13-enhanced PLA2 activity regulates COX-2/PGE2 expression through C/EBP-alpha activation.	Dinoprostone	64-68	CCAAT enhancer binding protein alpha	Homo sapiens	88-99
24580717-3	2013	Using HepG2 and K562 cells in culture, we show here that whereas both C/EBPalpha and C/EBPbeta induced transcription from the Galphai2 gene promoter, C/EBPalpha, but not C/EBPbeta, inhibited butyrate-induced Galphai2 expression.	Butyrates	191-199	CCAAT enhancer binding protein alpha	Homo sapiens	70-80
24580717-6	2013	ChIP analysis showed decreased butyrate-induced recruitment of Sp1 to the Galphai2 gene promoter in response to C/EBPalpha treatment.	Butyrates	31-39	CCAAT enhancer binding protein alpha	Homo sapiens	112-122
24580717-7	2013	Incubating cells with acetate or transfecting them with expression plasmid for either the acetyltransferase p300 or CREB-binding protein (CBP) reversed the antagonistic effect of C/EBPalpha on Sp1-dependent gene transcription, suggesting that the mechanistic basis for the antagonism is related to the squelching of co-activator acetyltransferase(s) by C/EBPalpha or the acetylation of Sp1 and/or C/EBPalpha.	Acetates	22-29	CCAAT enhancer binding protein alpha	Homo sapiens	179-189
24580717-7	2013	Incubating cells with acetate or transfecting them with expression plasmid for either the acetyltransferase p300 or CREB-binding protein (CBP) reversed the antagonistic effect of C/EBPalpha on Sp1-dependent gene transcription, suggesting that the mechanistic basis for the antagonism is related to the squelching of co-activator acetyltransferase(s) by C/EBPalpha or the acetylation of Sp1 and/or C/EBPalpha.	Acetates	22-29	CCAAT enhancer binding protein alpha	Homo sapiens	353-363
24580717-7	2013	Incubating cells with acetate or transfecting them with expression plasmid for either the acetyltransferase p300 or CREB-binding protein (CBP) reversed the antagonistic effect of C/EBPalpha on Sp1-dependent gene transcription, suggesting that the mechanistic basis for the antagonism is related to the squelching of co-activator acetyltransferase(s) by C/EBPalpha or the acetylation of Sp1 and/or C/EBPalpha.	Acetates	22-29	CCAAT enhancer binding protein alpha	Homo sapiens	353-363
24076158-0	2013	Identification of the C/EBPalpha C-terminal tail residues involved in the protein interaction with GABP and their potency in myeloid differentiation of K562 cells.	gabp	99-103	CCAAT enhancer binding protein alpha	Homo sapiens	22-32
23814099-4	2013	We observed that the phosphorylation of C/EBPalpha Ser-21 was inhibited by a PKCdelta-specific inhibitor, rottlerin, or IL-32beta knockdown by siRNA and that IL-32beta shifted to the membrane from the cytosol upon phorbol 12-myristate 13-acetate treatment.	Serine	51-54	CCAAT enhancer binding protein alpha	Homo sapiens	40-50
23833041-7	2013	VPA treatment resulted in an accumulation of acetylated histones H3 and H4 in the promoter region of the C/EBPalpha gene in ECSCs.	Valproic Acid	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	105-115
23707571-7	2013	We found that a 3-day exposure of hASCs to T (50nM) or DHT (5nM) in adipogenesis-inducing medium impaired lipid acquisition and decreased PPARgamma, C/EBPalpha and C/EBPbeta gene expression.	Dihydrotestosterone	55-58	CCAAT enhancer binding protein alpha	Homo sapiens	149-159
23707571-10	2013	T (50nM) and DHT (5nM) significantly inhibited the stimulatory effect of BMP4-induced ASC commitment to the preadipocyte phenotype, as regards PPARgamma and C/EBPalpha gene expression.	Dihydrotestosterone	13-16	CCAAT enhancer binding protein alpha	Homo sapiens	157-167
23991164-12	2013	Finally, the methylation patterns of several CpG dinucleotides proximal to two C/EBPalpha-binding sites in the miR-328 5"-flanking region were correlated negatively with miR-328 levels, and positively with BCRP levels in human placental samples.	cytidylyl-3'-5'-guanosine	45-62	CCAAT enhancer binding protein alpha	Homo sapiens	79-89
23814099-4	2013	We observed that the phosphorylation of C/EBPalpha Ser-21 was inhibited by a PKCdelta-specific inhibitor, rottlerin, or IL-32beta knockdown by siRNA and that IL-32beta shifted to the membrane from the cytosol upon phorbol 12-myristate 13-acetate treatment.	rottlerin	106-115	CCAAT enhancer binding protein alpha	Homo sapiens	40-50
23814099-4	2013	We observed that the phosphorylation of C/EBPalpha Ser-21 was inhibited by a PKCdelta-specific inhibitor, rottlerin, or IL-32beta knockdown by siRNA and that IL-32beta shifted to the membrane from the cytosol upon phorbol 12-myristate 13-acetate treatment.	Tetradecanoylphorbol Acetate	214-245	CCAAT enhancer binding protein alpha	Homo sapiens	40-50
23814099-7	2013	We next demonstrated by immunoprecipitation that IL-32beta interacted with PKCdelta and C/EBPalpha, thereby mediating C/EBPalpha Ser-21 phosphorylation by PKCdelta.	Serine	129-132	CCAAT enhancer binding protein alpha	Homo sapiens	88-98
23814099-7	2013	We next demonstrated by immunoprecipitation that IL-32beta interacted with PKCdelta and C/EBPalpha, thereby mediating C/EBPalpha Ser-21 phosphorylation by PKCdelta.	Serine	129-132	CCAAT enhancer binding protein alpha	Homo sapiens	118-128
23814099-11	2013	Taken together, our results show that IL-32beta-mediated C/EBPalpha Ser-21 phosphorylation by PKCdelta suppressed C/EBPalpha binding to IL-10 promoter, which promoted IL-10 production in U937 cells.	Serine	68-71	CCAAT enhancer binding protein alpha	Homo sapiens	57-67
23814099-11	2013	Taken together, our results show that IL-32beta-mediated C/EBPalpha Ser-21 phosphorylation by PKCdelta suppressed C/EBPalpha binding to IL-10 promoter, which promoted IL-10 production in U937 cells.	Serine	68-71	CCAAT enhancer binding protein alpha	Homo sapiens	114-124
23665916-0	2013	C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements.	Steroids	104-111	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
23922935-6	2013	The results demonstrated that ursolic acid at concentrations ranging from 2.5 microM to 10 microM dose-dependently attenuated adipogenesis, accompanied by reduced protein expression of CCAAT element binding protein beta (C/EBPbeta), peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT element binding protein alpha (C/EBPalpha) and sterol regulatory element binding protein 1c (SREBP-1c), respectively.	ursolic acid	30-42	CCAAT enhancer binding protein alpha	Homo sapiens	332-342
23727383-5	2013	It was found that radicicol dose-dependently decreased intracellular fat accumulation through down-regulating the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT element binding protein alpha (C/EBPalpha), fatty acid synthase (FAS) and fatty acid-binding protein 4 (FABP4).	monorden	18-27	CCAAT enhancer binding protein alpha	Homo sapiens	230-240
23575353-6	2013	We further observed that decreasing binding effects between the risk alleles A of IL12B and CCAAT/enhancer binding protein alpha (C/EBPalpha) through A allele sequence mediated streptavidin-conjugated agarose pulldown and biotin-labelled A allele mediated electrophoretic mobility shift assay.	Sepharose	201-208	CCAAT enhancer binding protein alpha	Homo sapiens	92-128
23575353-6	2013	We further observed that decreasing binding effects between the risk alleles A of IL12B and CCAAT/enhancer binding protein alpha (C/EBPalpha) through A allele sequence mediated streptavidin-conjugated agarose pulldown and biotin-labelled A allele mediated electrophoretic mobility shift assay.	Sepharose	201-208	CCAAT enhancer binding protein alpha	Homo sapiens	130-140
23575353-6	2013	We further observed that decreasing binding effects between the risk alleles A of IL12B and CCAAT/enhancer binding protein alpha (C/EBPalpha) through A allele sequence mediated streptavidin-conjugated agarose pulldown and biotin-labelled A allele mediated electrophoretic mobility shift assay.	Biotin	222-228	CCAAT enhancer binding protein alpha	Homo sapiens	92-128
23575353-6	2013	We further observed that decreasing binding effects between the risk alleles A of IL12B and CCAAT/enhancer binding protein alpha (C/EBPalpha) through A allele sequence mediated streptavidin-conjugated agarose pulldown and biotin-labelled A allele mediated electrophoretic mobility shift assay.	Biotin	222-228	CCAAT enhancer binding protein alpha	Homo sapiens	130-140
23587162-5	2013	RESULTS: Peretinoin treatment elevated the expression levels of IGFBP6, RBP1, PRB4, CEBPA, G0S2, TGM2, GPRC5A, CYP26B1, and many other retinoid target genes.	(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid	9-19	CCAAT enhancer binding protein alpha	Homo sapiens	84-89
22269963-3	2013	A previous report linked rs12691 SNP in CEBPA to altered concentration of fasting triglycerides.	Triglycerides	82-95	CCAAT enhancer binding protein alpha	Homo sapiens	40-45
23598402-7	2013	We show that overexpression of catalytically inactive E6AP-C843A in C/EBPalpha inducible K562- p42C/EBPalpha-estrogen receptor (ER) cells inhibits beta-estradiol (E2)-induced C/EBPalpha degradation leading to enhanced granulocytic differentiation.	Estradiol	147-161	CCAAT enhancer binding protein alpha	Homo sapiens	68-78
23598402-7	2013	We show that overexpression of catalytically inactive E6AP-C843A in C/EBPalpha inducible K562- p42C/EBPalpha-estrogen receptor (ER) cells inhibits beta-estradiol (E2)-induced C/EBPalpha degradation leading to enhanced granulocytic differentiation.	Estradiol	147-161	CCAAT enhancer binding protein alpha	Homo sapiens	98-108
23637829-6	2013	The mRNA and protein levels of adipogenic genes, including C/EBPbeta, C/EBPalpha, PPARgamma, SREBP-1c, FAS, and aP2, were significantly lower in DMF-treated 3T3-L1 preadipocytes.	Dimethyl Fumarate	145-148	CCAAT enhancer binding protein alpha	Homo sapiens	70-80
23143154-12	2013	Additionally, the expressions of PPARgamma, C/EBPalpha, and C/EBPbeta proteins were reduced in the quercetin-treated OFs.	Quercetin	99-108	CCAAT enhancer binding protein alpha	Homo sapiens	44-54
23473759-3	2013	In this study, we reported that C/EBPalpha was phosphorylated by activated PKCdelta on three serines, two of which were reported for the first time.	Serine	93-100	CCAAT enhancer binding protein alpha	Homo sapiens	32-42
23318274-0	2013	The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARalpha; and repressed by C/EBPalpha: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease.	Fatty Acids	16-26	CCAAT enhancer binding protein alpha	Homo sapiens	110-120
23381107-0	2013	CEBPA-CEBPG axis as a novel promising therapeutic target in acute myeloid leukemia.	cebpg	6-11	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
23547051-3	2013	C/EBPalpha was needed for differentiation from stem/progenitor cells to common DC progenitors (CDPs), but not for transition of CDP to mature DCs.	cdps	95-99	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
23547051-3	2013	C/EBPalpha was needed for differentiation from stem/progenitor cells to common DC progenitors (CDPs), but not for transition of CDP to mature DCs.	Cytidine Diphosphate	95-98	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
23339468-9	2013	The effect of GADD153 on the binding of C/EBP to the Bak promoters were analyzed ChIP assay.	bakuchiol	53-56	CCAAT enhancer binding protein alpha	Homo sapiens	40-45
23100311-0	2013	Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.	Lenalidomide	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	46-56
23100311-6	2013	Furthermore, we show that lenalidomide, a drug approved for myelodysplastic syndromes and multiple myeloma, enhances translation of the C/EBPalpha-p30 isoform, resulting in higher miR-181a levels.	Lenalidomide	26-38	CCAAT enhancer binding protein alpha	Homo sapiens	136-146
23100311-10	2013	Altogether, our data provide a potential explanation for the improved clinical outcomes observed in CEBPA-mutated CN-AML patients, and suggest that lenalidomide treatment enhancing the C/EBPalpha-p30 protein levels and in turn miR-181a may sensitize AML blasts to chemotherapy.	Lenalidomide	148-160	CCAAT enhancer binding protein alpha	Homo sapiens	100-105
23100311-10	2013	Altogether, our data provide a potential explanation for the improved clinical outcomes observed in CEBPA-mutated CN-AML patients, and suggest that lenalidomide treatment enhancing the C/EBPalpha-p30 protein levels and in turn miR-181a may sensitize AML blasts to chemotherapy.	Lenalidomide	148-160	CCAAT enhancer binding protein alpha	Homo sapiens	185-195
23081744-7	2013	Importantly, the combination of rosiglitazone plus Tyrphostin AG490 further increased this effect and was specifically associated with significant upregulation of C-enhanced binding protein (C/EBP) (p &lt; 0.0001).	Rosiglitazone	32-45	CCAAT enhancer binding protein alpha	Homo sapiens	163-189
23063590-0	2013	Artemisinic acid inhibits melanogenesis through downregulation of C/EBP alpha-dependent expression of HMG-CoA reductase gene.	artemisic acid	0-16	CCAAT enhancer binding protein alpha	Homo sapiens	66-77
23063590-7	2013	Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) alpha gene.	artemisic acid	68-84	CCAAT enhancer binding protein alpha	Homo sapiens	360-372
23063590-7	2013	Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) alpha gene.	artemisic acid	116-132	CCAAT enhancer binding protein alpha	Homo sapiens	360-372
23063590-8	2013	Taken together, these findings indicate that the inhibition of melanogenesis by artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C/EBP alpha inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.	artemisic acid	80-96	CCAAT enhancer binding protein alpha	Homo sapiens	183-194
23081744-7	2013	Importantly, the combination of rosiglitazone plus Tyrphostin AG490 further increased this effect and was specifically associated with significant upregulation of C-enhanced binding protein (C/EBP) (p &lt; 0.0001).	Rosiglitazone	32-45	CCAAT enhancer binding protein alpha	Homo sapiens	191-196
23081744-7	2013	Importantly, the combination of rosiglitazone plus Tyrphostin AG490 further increased this effect and was specifically associated with significant upregulation of C-enhanced binding protein (C/EBP) (p &lt; 0.0001).	Tyrphostins	51-61	CCAAT enhancer binding protein alpha	Homo sapiens	163-189
23081744-7	2013	Importantly, the combination of rosiglitazone plus Tyrphostin AG490 further increased this effect and was specifically associated with significant upregulation of C-enhanced binding protein (C/EBP) (p &lt; 0.0001).	Tyrphostins	51-61	CCAAT enhancer binding protein alpha	Homo sapiens	191-196
23383279-6	2013	Microarray profiling of lithium-stimulated hMSC revealed decreased expression of adipogenic genes (CEBPA, CMKLR1, HSD11B1) and genes involved in lipid biosynthesis.	Lithium	24-31	CCAAT enhancer binding protein alpha	Homo sapiens	99-104
23999235-5	2013	Dexamethasone increased and accelerated the expression of main adipogenic genes such as pparg2, cebpa and srebf1c.	Dexamethasone	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	96-101
22678810-4	2012	Wedelolactone reduced the formation of lipid droplets and the expression of adipogenesis-related proteins, such as CCAAT enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), lipoprotein lipase (LPL), and adipocyte fatty acid-binding protein aP2 (aP2).	wedelolactone	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	115-151
23086932-6	2012	NQO1 in presence of its cofactor NADH protected C/EBPalpha against 20S degradation.	NAD	33-37	CCAAT enhancer binding protein alpha	Homo sapiens	48-58
23086932-8	2012	Mutagenesis studies also revealed that NQO1Y127/Y129 required for NADH binding is essential for NQO1 stabilization of C/EBPalpha.	NAD	66-70	CCAAT enhancer binding protein alpha	Homo sapiens	118-128
22678810-4	2012	Wedelolactone reduced the formation of lipid droplets and the expression of adipogenesis-related proteins, such as CCAAT enhancer-binding protein-alpha (C/EBP-alpha), peroxisome proliferator-activated receptor-gamma (PPAR-gamma), lipoprotein lipase (LPL), and adipocyte fatty acid-binding protein aP2 (aP2).	wedelolactone	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	153-164
22766217-0	2012	Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPalpha.	bisbenzylisoquinoline alkaloids	33-64	CCAAT enhancer binding protein alpha	Homo sapiens	80-90
23063977-0	2012	All-trans retinoic acid combined with 5-Aza-2"-deoxycitidine induces C/EBPalpha expression and growth inhibition in MLL-AF9-positive leukemic cells.	Tretinoin	0-23	CCAAT enhancer binding protein alpha	Homo sapiens	69-79
23063977-0	2012	All-trans retinoic acid combined with 5-Aza-2"-deoxycitidine induces C/EBPalpha expression and growth inhibition in MLL-AF9-positive leukemic cells.	5-aza-2"-deoxycitidine	38-60	CCAAT enhancer binding protein alpha	Homo sapiens	69-79
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	2-octenal	37-42	CCAAT enhancer binding protein alpha	Homo sapiens	168-204
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	Tretinoin	43-56	CCAAT enhancer binding protein alpha	Homo sapiens	168-204
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	Tretinoin	43-56	CCAAT enhancer binding protein alpha	Homo sapiens	206-216
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	Tretinoin	58-62	CCAAT enhancer binding protein alpha	Homo sapiens	168-204
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	Tretinoin	58-62	CCAAT enhancer binding protein alpha	Homo sapiens	206-216
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	5-aza-2"-deoxycitidine	68-90	CCAAT enhancer binding protein alpha	Homo sapiens	168-204
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	5-aza-2"-deoxycitidine	68-90	CCAAT enhancer binding protein alpha	Homo sapiens	206-216
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	Azacitidine	68-73	CCAAT enhancer binding protein alpha	Homo sapiens	168-204
23063977-1	2012	The present study tested whether all-trans retinoic acid (ATRA) and 5-Aza-2"-deoxycitidine (5-Aza) affect AML cell differentiation and growth in vitro by acting on the CCAAT/enhancer binding protein alpha (C/EBPalpha) and c-Myc axis.	Azacitidine	68-73	CCAAT enhancer binding protein alpha	Homo sapiens	206-216
22851716-3	2012	In this study, we used electrophoretic mobility shift assay to analyze 46 arylstibonic acids for their activity to disrupt the DNA binding of three B-ZIP [CCAAT/enhancer-binding protein alpha, cyclic AMP-response element-binding protein (CREB), and vitellogenin gene-binding protein (VBP)] and two basic helix-loop-helix leucine zipper (B-HLH-ZIP) [USF (upstream stimulating factor) and Mitf] proteins.	arylstibonic acids	74-92	CCAAT enhancer binding protein alpha	Homo sapiens	155-191
23063366-4	2012	Conversion begins by glucocorticoid and cAMP signals raising C/EBPbeta levels above a critical threshold, triggering three consecutive positive feedback loops: from PPARgamma to C/EBPalpha, then to C/EBPbeta, and last to the insulin receptor.	Cyclic AMP	40-44	CCAAT enhancer binding protein alpha	Homo sapiens	178-188
22945685-7	2012	Trans-resveratrol-3-O-sulfate also reduced C/EBP-alpha, peroxisome proliferator-activated receptor gamma (PPAR-gamma), and lipoprotein lipase (LPL) expression.	Resveratrol	0-29	CCAAT enhancer binding protein alpha	Homo sapiens	43-54
22902635-8	2012	Hydrogen treatment also induced the transcription factors C/EBPalpha and C/EBPbeta, which are known regulators of surfactant-related genes.	Hydrogen	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	58-68
22766217-2	2012	An extract of the fruit of Gyrocarpus jacquinii showed induction of C/EBPalpha activity that was attributed to the bisbenzylisoquinoline (BBIQ) alkaloid pheanthine (13) by dereplication analysis.	bisbenzylisoquinoline (bbiq) alkaloid	115-152	CCAAT enhancer binding protein alpha	Homo sapiens	68-78
22766217-2	2012	An extract of the fruit of Gyrocarpus jacquinii showed induction of C/EBPalpha activity that was attributed to the bisbenzylisoquinoline (BBIQ) alkaloid pheanthine (13) by dereplication analysis.	tetrandrine	153-163	CCAAT enhancer binding protein alpha	Homo sapiens	68-78
22555844-5	2012	Consistent with its cytoprotective effects, NaHS markedly reduced 6-OHDA induced-ER stress responses, including the upregulated levels of eukaryotic initiation factor-2alpha phosphorylation, glucose-regulated protein 78, and C/EBP homologous protein expression.	sodium bisulfide	44-48	CCAAT enhancer binding protein alpha	Homo sapiens	225-230
22260161-5	2012	Interestingly, treatment of human DLBCL cell lines with the histone deacetylase-inhibitor suberoylanilide hydroxamic acid (SAHA) significantly increased the expression of C/EBPalpha and Per2, accompanied by cell growth inhibition; in contrast, siRNA knockdown of CEBPA reduced the anti-proliferative effect of SAHA treatment.	Vorinostat	90-121	CCAAT enhancer binding protein alpha	Homo sapiens	171-181
22260161-5	2012	Interestingly, treatment of human DLBCL cell lines with the histone deacetylase-inhibitor suberoylanilide hydroxamic acid (SAHA) significantly increased the expression of C/EBPalpha and Per2, accompanied by cell growth inhibition; in contrast, siRNA knockdown of CEBPA reduced the anti-proliferative effect of SAHA treatment.	Vorinostat	90-121	CCAAT enhancer binding protein alpha	Homo sapiens	263-268
22260161-5	2012	Interestingly, treatment of human DLBCL cell lines with the histone deacetylase-inhibitor suberoylanilide hydroxamic acid (SAHA) significantly increased the expression of C/EBPalpha and Per2, accompanied by cell growth inhibition; in contrast, siRNA knockdown of CEBPA reduced the anti-proliferative effect of SAHA treatment.	Vorinostat	123-127	CCAAT enhancer binding protein alpha	Homo sapiens	171-181
22260161-5	2012	Interestingly, treatment of human DLBCL cell lines with the histone deacetylase-inhibitor suberoylanilide hydroxamic acid (SAHA) significantly increased the expression of C/EBPalpha and Per2, accompanied by cell growth inhibition; in contrast, siRNA knockdown of CEBPA reduced the anti-proliferative effect of SAHA treatment.	Vorinostat	123-127	CCAAT enhancer binding protein alpha	Homo sapiens	263-268
22260161-5	2012	Interestingly, treatment of human DLBCL cell lines with the histone deacetylase-inhibitor suberoylanilide hydroxamic acid (SAHA) significantly increased the expression of C/EBPalpha and Per2, accompanied by cell growth inhibition; in contrast, siRNA knockdown of CEBPA reduced the anti-proliferative effect of SAHA treatment.	Vorinostat	310-314	CCAAT enhancer binding protein alpha	Homo sapiens	171-181
22797303-5	2012	We further demonstrated that CDK1 phosphorylates C/EBPalpha on serine 21, which inhibits its differentiation-inducing function.	Serine	63-69	CCAAT enhancer binding protein alpha	Homo sapiens	49-59
22396222-3	2012	The mRNA levels of peroxidase proliferation-activated receptor (PPAR) gamma and CCAAT/enhancer binding protein (C/EBP) alpha, late adipogenic factors, were reduced by artemisinic acid.	artemisic acid	167-183	CCAAT enhancer binding protein alpha	Homo sapiens	112-124
22362118-1	2012	We and others have shown that cytogenetically normal (CN)-AML patients with biallelic CEBPA gene mutations (biCEBPA) represent a molecularly distinct group with a favorable prognosis.	bicebpa	108-115	CCAAT enhancer binding protein alpha	Homo sapiens	86-91
22362118-2	2012	Patients carrying a monoallelic CEBPA mutation (moCEBPA), however, show no different outcome compared to patients with wildtype CEBPA, and these mutations are frequently associated with mutated NPM1 or FLT3-ITD.	mocebpa	48-55	CCAAT enhancer binding protein alpha	Homo sapiens	32-37
22430974-5	2012	Rilpivirine caused a repression of adipocyte differentiation that was associated with impaired expression of the master adipogenesis regulators peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT enhancer binding protein alpha (C/EBPalpha), and sterol regulatory element binding transcription factor 1 (SREBP-1) and their target genes encoding lipoprotein lipase and the adipokines leptin and adiponectin.	Rilpivirine	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	206-242
22430974-5	2012	Rilpivirine caused a repression of adipocyte differentiation that was associated with impaired expression of the master adipogenesis regulators peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT enhancer binding protein alpha (C/EBPalpha), and sterol regulatory element binding transcription factor 1 (SREBP-1) and their target genes encoding lipoprotein lipase and the adipokines leptin and adiponectin.	Rilpivirine	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	244-254
22349414-2	2012	In this study, the induction/activation of C/EBPalpha in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor.	all-trans	116-125	CCAAT enhancer binding protein alpha	Homo sapiens	43-53
22349414-2	2012	In this study, the induction/activation of C/EBPalpha in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor.	Tretinoin	126-139	CCAAT enhancer binding protein alpha	Homo sapiens	43-53
22349414-2	2012	In this study, the induction/activation of C/EBPalpha in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor.	Tretinoin	141-145	CCAAT enhancer binding protein alpha	Homo sapiens	43-53
22349414-2	2012	In this study, the induction/activation of C/EBPalpha in myelomonocytic AML was investigated using a combination of all-trans retinoic acid (ATRA) and RAD001 (Everolimus), a mammalian target of rapamycin complex 1 (mTORC1) inhibitor.	Everolimus	159-169	CCAAT enhancer binding protein alpha	Homo sapiens	43-53
22212957-8	2012	By contrast, phosphorylation of serine 21 appears to have a modest role in modulating the differentiation-inducing effects of C/EBPalpha in K562 cells.	Serine	32-38	CCAAT enhancer binding protein alpha	Homo sapiens	126-136
22474248-2	2012	Recent studies have suggested that oncogenic FLT3 activity disrupts wild-type C/EBPalpha function via phosphorylation on serine 21 (S21).	Serine	121-127	CCAAT enhancer binding protein alpha	Homo sapiens	78-88
22212957-2	2012	In acute myeloid leukemia (AML) cells expressing the constitutively active FLT3-ITD receptor tyrosine kinase, MAP kinase-dependent phosphorylation of serine 21 (S21) inhibits the ability of C/EBPalpha to induce granulocytic differentiation.	Serine	150-156	CCAAT enhancer binding protein alpha	Homo sapiens	190-200
22107041-5	2012	RESULTS: Our results showed that PGF2alpha and topical prostaglandin analogs down-regulated the expression of PPARgamma and C/EBPalpha, and inhibited accumulation of intra-cytoplasmic lipid droplets and expression of LPL compared with the untreated control.	Dinoprost	33-42	CCAAT enhancer binding protein alpha	Homo sapiens	124-134
22107041-5	2012	RESULTS: Our results showed that PGF2alpha and topical prostaglandin analogs down-regulated the expression of PPARgamma and C/EBPalpha, and inhibited accumulation of intra-cytoplasmic lipid droplets and expression of LPL compared with the untreated control.	Prostaglandins	55-68	CCAAT enhancer binding protein alpha	Homo sapiens	124-134
22293124-0	2012	Methanol extract of Antrodia cinnamomea mycelia induces phenotypic and functional differentiation of HL60 into monocyte-like cells via an ERK/CEBP-beta signaling pathway.	Methanol	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	142-146
21902673-5	2012	RT-PCR (real-time PCR) demonstrated that EGCG noticeably reduced mRNA expression of PPARgamma (peroxisome proliferator-activated receptor gamma), C/EBPalpha (CCAAT/enhancer-binding protein alpha) and FoxO1 (forkhead box class O1).	epigallocatechin gallate	41-45	CCAAT enhancer binding protein alpha	Homo sapiens	146-156
21856370-0	2012	Human liver fatty acid binding protein (hFABP1) gene is regulated by liver-enriched transcription factors HNF3beta and C/EBPalpha.	Fatty Acids	12-22	CCAAT enhancer binding protein alpha	Homo sapiens	119-129
21902673-5	2012	RT-PCR (real-time PCR) demonstrated that EGCG noticeably reduced mRNA expression of PPARgamma (peroxisome proliferator-activated receptor gamma), C/EBPalpha (CCAAT/enhancer-binding protein alpha) and FoxO1 (forkhead box class O1).	epigallocatechin gallate	41-45	CCAAT enhancer binding protein alpha	Homo sapiens	158-194
22474499-3	2012	We have shown that treatment with 10 muM berberine resulted in a major inhibition of human preadipocyte differentiation and leptin and adiponectin secretion accompanied by downregulation of PPARgamma2, C/EBPalpha, adiponectin, and leptin mRNA expression.	Berberine	41-50	CCAAT enhancer binding protein alpha	Homo sapiens	202-212
22113278-5	2012	Here, we describe in detail how to identify and measure cAMP-mediated recruitment of a specific C/EBP isoform to a candidate regulator region of the SOCS-3 promoter in vascular endothelial cells in vitro.	Cyclic AMP	56-60	CCAAT enhancer binding protein alpha	Homo sapiens	96-101
21557367-8	2012	The effect of berberine involves an inhibition of the mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Berberine	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	150-186
21557367-8	2012	The effect of berberine involves an inhibition of the mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer binding protein alpha (C/EBPalpha).	Berberine	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	188-198
21557367-10	2012	These findings suggest that an antiobesity effect could be a new indication for Orengedokuto and that its active ingredient is berberine, with a mechanism involving the inhibition of PPARgamma and C/EBPalpha expression.	Berberine	127-136	CCAAT enhancer binding protein alpha	Homo sapiens	197-207
23240010-0	2012	Signal transduction pathways (MAPKs, NF-kappaB, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.	Aspirin	134-141	CCAAT enhancer binding protein alpha	Homo sapiens	52-57
23029193-6	2012	Computational prediction of enriched transcription factor binding sites identified sequence motifs corresponding to several stress-responsive transcription factors, such as activator protein 1 (AP1), cAMP response element-binding (CREB), or CCAAT-enhancer binding protein (CEBP).	Cyclic AMP	200-204	CCAAT enhancer binding protein alpha	Homo sapiens	273-277
21641731-4	2011	Expressions of C/EBPalpha and myostatin in semitendinosus and longissimus lumborum (LL) muscles were higher in the CT group than in the GH group at the end of fattening.	ct	115-117	CCAAT enhancer binding protein alpha	Homo sapiens	15-25
21963454-4	2011	The addition of DhL significantly inhibited the differentiation of 3T3-L1 preadipocytes along with a significant decrease in the accumulation of lipid content by a dramatic downregulation of the expression of adipogenic-specific transcriptional factors PPARgamma and C-EBPalpha.	dehydroleucodine	16-19	CCAAT enhancer binding protein alpha	Homo sapiens	267-277
21912254-4	2011	Recent investigations have shown that the regulation of I antigen formation during erythropoiesis is determined by transcription factor CCAAT/enhancer binding protein-alpha (C/EBPalpha) and the phosphorylation status of C/EBPalpha Ser-21 residue.	Serine	231-234	CCAAT enhancer binding protein alpha	Homo sapiens	220-230
21912254-7	2011	Analysis of the regulation for I antigen expression shows that the regulation during erythropoiesis and granulopoiesis share a common mechanism, with dephosphorylation of the Ser-21 residue on C/EBPalpha playing the critical role.	Serine	175-178	CCAAT enhancer binding protein alpha	Homo sapiens	193-203
21893041-0	2011	Berberine exerts anti-adipogenic activity through up-regulation of C/EBP inhibitors, CHOP and DEC2.	Berberine	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	67-72
21893041-1	2011	Berberine exerts an anti-adipogenic activity that is associated with the down-regulation of C/EBPalpha and PPARgamma.	Berberine	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	92-102
21893041-3	2011	In the present study, we show that berberine up-regulated the expression of two different sets of C/EBP inhibitors, CHOP and DEC2, while down-modulating C/EBPalpha, PPARgamma and other adipogenic markers and effectors in differentiating 3T3-L1 preadipocytes and mature adipocytes.	Berberine	35-44	CCAAT enhancer binding protein alpha	Homo sapiens	98-103
21893041-3	2011	In the present study, we show that berberine up-regulated the expression of two different sets of C/EBP inhibitors, CHOP and DEC2, while down-modulating C/EBPalpha, PPARgamma and other adipogenic markers and effectors in differentiating 3T3-L1 preadipocytes and mature adipocytes.	Berberine	35-44	CCAAT enhancer binding protein alpha	Homo sapiens	153-163
21893041-6	2011	Together, up-regulation of C/EBP inhibitors appears to underlie the berberine-induced repression of C/EBPalpha and PPARgamma and, so, the inhibition of adipogenesis.	Berberine	68-77	CCAAT enhancer binding protein alpha	Homo sapiens	27-32
21893041-6	2011	Together, up-regulation of C/EBP inhibitors appears to underlie the berberine-induced repression of C/EBPalpha and PPARgamma and, so, the inhibition of adipogenesis.	Berberine	68-77	CCAAT enhancer binding protein alpha	Homo sapiens	100-110
21521687-5	2011	Reducing mSin3A/HDAC1 binding to LAP/LAP* and LIP through deletion of this motif reduced the recruitment of HDAC1 to the C/ebpalpha promoter and increased preadipocyte differentiation stimulated by insulin and 1-methyl-3-isobutylxanthine.	1-Methyl-3-isobutylxanthine	210-237	CCAAT enhancer binding protein alpha	Homo sapiens	121-131
21600648-0	2011	C/EBP-alpha and C/EBP-beta-mediated adipogenesis of human mesenchymal stem cells (hMSCs) using PLGA nanoparticles complexed with poly(ethyleneimmine).	poly	129-133	CCAAT enhancer binding protein alpha	Homo sapiens	0-11
21600648-0	2011	C/EBP-alpha and C/EBP-beta-mediated adipogenesis of human mesenchymal stem cells (hMSCs) using PLGA nanoparticles complexed with poly(ethyleneimmine).	ethyleneimmine	134-148	CCAAT enhancer binding protein alpha	Homo sapiens	0-11
21600648-1	2011	In this study, to drive efficient adipogenic differentiation, the adipogenic transcription factors C/EBP-alpha and C/EBP-beta fused to green fluorescent protein (GFP) or red fluorescent protein (RFP) were complexed with poly-ethyleneimine (PEI) coupled with biodegradable PLGA nanospheres and delivered to human mesenchymal stem cell (hMSC).	poly-ethyleneimine	220-238	CCAAT enhancer binding protein alpha	Homo sapiens	99-110
21600648-1	2011	In this study, to drive efficient adipogenic differentiation, the adipogenic transcription factors C/EBP-alpha and C/EBP-beta fused to green fluorescent protein (GFP) or red fluorescent protein (RFP) were complexed with poly-ethyleneimine (PEI) coupled with biodegradable PLGA nanospheres and delivered to human mesenchymal stem cell (hMSC).	pei	240-243	CCAAT enhancer binding protein alpha	Homo sapiens	99-110
21338441-6	2011	The RAS/mitogen-activated protein kinase (MAPK) pathway molecules (in particular MAPK/ERK kinase 1 (MEK1) and C/EBP transcription factors) include tribbles-binding proteins that are involved in leukemogenesis, and the role of Trib1 as a linker between MAPK signaling and C/EBP degradation is proposed.	tribbles	147-155	CCAAT enhancer binding protein alpha	Homo sapiens	110-115
21447826-5	2011	Bortezomib treatment leads to increased binding of C/EBP to previously recognized binding sites in the ZTA promoter.	Bortezomib	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	51-56
21338441-6	2011	The RAS/mitogen-activated protein kinase (MAPK) pathway molecules (in particular MAPK/ERK kinase 1 (MEK1) and C/EBP transcription factors) include tribbles-binding proteins that are involved in leukemogenesis, and the role of Trib1 as a linker between MAPK signaling and C/EBP degradation is proposed.	tribbles	147-155	CCAAT enhancer binding protein alpha	Homo sapiens	271-276
21304902-12	2011	Furthermore, treatment of LY294002 or rapamycin significantly suppressed AA-induced C/EBP alpha DNA-binding activity.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	26-34	CCAAT enhancer binding protein alpha	Homo sapiens	84-95
21291493-11	2011	Overexpression of miR-375 enhanced 3T3-L1 adipocyte differentiation, as evidenced by its ability to increase mRNA levels of both CCAAT/enhancer binding protein-alpha (C/EBPalpha) and peroxisome proliferator-activated receptor-gamma (PPARgamma2), and induction of adipocyte fatty acid-binding protein (aP2) and triglyceride (TG) accumulation.	Fatty Acids	273-283	CCAAT enhancer binding protein alpha	Homo sapiens	129-165
21291493-11	2011	Overexpression of miR-375 enhanced 3T3-L1 adipocyte differentiation, as evidenced by its ability to increase mRNA levels of both CCAAT/enhancer binding protein-alpha (C/EBPalpha) and peroxisome proliferator-activated receptor-gamma (PPARgamma2), and induction of adipocyte fatty acid-binding protein (aP2) and triglyceride (TG) accumulation.	Triglycerides	310-322	CCAAT enhancer binding protein alpha	Homo sapiens	129-165
21291493-11	2011	Overexpression of miR-375 enhanced 3T3-L1 adipocyte differentiation, as evidenced by its ability to increase mRNA levels of both CCAAT/enhancer binding protein-alpha (C/EBPalpha) and peroxisome proliferator-activated receptor-gamma (PPARgamma2), and induction of adipocyte fatty acid-binding protein (aP2) and triglyceride (TG) accumulation.	Triglycerides	324-326	CCAAT enhancer binding protein alpha	Homo sapiens	129-165
21177436-2	2011	We identified 151 (12.8%) patients with CEBPA mutations (91 CEBPA(dm) and 60 CEBPA(sm)).	dm	66-68	CCAAT enhancer binding protein alpha	Homo sapiens	40-45
21177436-4	2011	CEBPA(dm) patients had a lower frequency of concurrent mutations than CEBPA(sm) patients (P &lt; .0001).	dm	6-8	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
21177436-6	2011	However, in multivariable analysis only CEBPA(dm) was a prognostic factor for favorable OS outcome (hazard ratio [HR] 0.36, P &lt; .0001; event-free survival, HR 0.41, P &lt; .0001; relapse-free survival, HR 0.55, P = .001).	dm	46-48	CCAAT enhancer binding protein alpha	Homo sapiens	40-45
21177436-8	2011	Unsupervised and supervised GEP analyses showed that CEBPA(dm) AML (n = 42), but not CEBPA(sm) AML (n = 18), expressed a unique gene signature.	dm	59-61	CCAAT enhancer binding protein alpha	Homo sapiens	53-58
21177436-9	2011	A 25-probe set prediction signature for CEBPA(dm) AML showed 100% sensitivity and specificity.	dm	46-48	CCAAT enhancer binding protein alpha	Homo sapiens	40-45
21177436-10	2011	Based on these findings, we propose that CEBPA(dm) should be clearly defined from CEBPA(sm) AML and considered as a separate entity in the classification of AML.	dm	47-49	CCAAT enhancer binding protein alpha	Homo sapiens	41-46
21596890-7	2011	In addition, CDCA enhanced luciferase gene transcription from the construct containing -1.65-kb GSTA2 promoter, which contained C/EBP response element (pGL-1651).	Chenodeoxycholic Acid	13-17	CCAAT enhancer binding protein alpha	Homo sapiens	128-133
21225391-2	2011	Cross-sectional studies in the pre-HAART era demonstrated that single nucleotide polymorphisms (SNPs) in peripheral blood-derived LTRs (a C-to-T change at position 3 of C/EBP site I (3T) and at position 5 of Sp site III (5T)) increased in frequency as disease severity increased.	TFF2 protein, human	208-210	CCAAT enhancer binding protein alpha	Homo sapiens	169-174
21059469-3	2011	Lamivudine treatment reduced the mRNA levels of PPARgamma and C/EBPalpha.	Lamivudine	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	62-72
20864248-2	2011	Here, we analyzed a role of C/EBPalpha and PU.1 in human acute leukemia cell lines, HL-60 and NB4, in association with a modified chromatin structure by histone deacetylase inhibitors, FK228, sodium phenyl butyrate and vitamin B3.	romidepsin	185-190	CCAAT enhancer binding protein alpha	Homo sapiens	28-38
20864248-2	2011	Here, we analyzed a role of C/EBPalpha and PU.1 in human acute leukemia cell lines, HL-60 and NB4, in association with a modified chromatin structure by histone deacetylase inhibitors, FK228, sodium phenyl butyrate and vitamin B3.	4-phenylbutyric acid	192-214	CCAAT enhancer binding protein alpha	Homo sapiens	28-38
20864248-2	2011	Here, we analyzed a role of C/EBPalpha and PU.1 in human acute leukemia cell lines, HL-60 and NB4, in association with a modified chromatin structure by histone deacetylase inhibitors, FK228, sodium phenyl butyrate and vitamin B3.	Niacinamide	219-229	CCAAT enhancer binding protein alpha	Homo sapiens	28-38
20927134-5	2011	With a median follow-up of 48 months, among the 125 patients receiving standard induction therapy, CEBPA(high-meth) was associated with better treatment response (complete remission rate 93.3% versus 73.6%, P=0.116).	Methamphetamine	110-114	CCAAT enhancer binding protein alpha	Homo sapiens	99-104
20927134-6	2011	In patients with normal karyotype and without CEBPA and NPM1 mutations, the CEBPA(high-meth) had longer overall survival (OS) than the CEBPA(low-meth) (P=0.028).	Methamphetamine	87-91	CCAAT enhancer binding protein alpha	Homo sapiens	76-81
20927134-6	2011	In patients with normal karyotype and without CEBPA and NPM1 mutations, the CEBPA(high-meth) had longer overall survival (OS) than the CEBPA(low-meth) (P=0.028).	Methamphetamine	87-91	CCAAT enhancer binding protein alpha	Homo sapiens	76-81
21687683-4	2011	The binding of CAAT enhancer binding protein alpha (C/EBP alpha) to CTSL promoter and its key role in the transcription from this promoter and conferring responsiveness to acetaldehyde was established by site directed mutagenesis, electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP) assays and siRNA technology.	Acetaldehyde	172-184	CCAAT enhancer binding protein alpha	Homo sapiens	52-63
22039452-5	2011	Treatment with noncytotoxic doses of quercetin inhibited accumulation of intracytoplasmic lipid droplets and resulted in a dose-dependent decrease in expression of peroxisome proliferator-activated receptor gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, and C/EBPbeta proteins.	Quercetin	37-46	CCAAT enhancer binding protein alpha	Homo sapiens	246-258
21687683-7	2011	This decrease by acetaldehyde was attributed to the fall in the liver enriched transcription factor C/EBP alpha levels and it"s binding to the CTSL promoter.	Acetaldehyde	17-29	CCAAT enhancer binding protein alpha	Homo sapiens	100-111
21687683-8	2011	Mutagenesis of C/EBP alpha binding motifs revealed the key role of this factor in CTSL transcription as well as conferring responsiveness to acetaldehyde.	Acetaldehyde	141-153	CCAAT enhancer binding protein alpha	Homo sapiens	15-26
21687683-9	2011	The siRNA mediated silencing of the C/EBP alpha expression mimicked the effect of acetaldehyde on CTSL levels and its promoter activity.	Acetaldehyde	82-94	CCAAT enhancer binding protein alpha	Homo sapiens	36-47
21687683-11	2011	CONCLUSION: Acetaldehyde down regulates the C/EBP alpha mediated CTSL expression in hepatic cell lines.	Acetaldehyde	12-24	CCAAT enhancer binding protein alpha	Homo sapiens	44-55
21147366-3	2010	This study tested the hypothesis that oleanolic acid suppresses the differentiation of 3T3-L1 adipocytes by downregulating cellular induction of peroxisome proliferators-activated receptor gamma (PPARgamma) and cytidine-cytidine-adenosine-adenosine-thymidine (CCAAT) enhancer binding protein alpha (C/EBPalpha).	Oleanolic Acid	38-52	CCAAT enhancer binding protein alpha	Homo sapiens	211-297
21147366-3	2010	This study tested the hypothesis that oleanolic acid suppresses the differentiation of 3T3-L1 adipocytes by downregulating cellular induction of peroxisome proliferators-activated receptor gamma (PPARgamma) and cytidine-cytidine-adenosine-adenosine-thymidine (CCAAT) enhancer binding protein alpha (C/EBPalpha).	Oleanolic Acid	38-52	CCAAT enhancer binding protein alpha	Homo sapiens	299-309
21147366-6	2010	Western blot analysis showed that the induction of PPARgamma and C/EBPalpha was markedly attenuated in differentiated and oleanolic acid-treated adipocytes at their transcriptional messenger RNA levels.	Oleanolic Acid	122-136	CCAAT enhancer binding protein alpha	Homo sapiens	65-75
20412023-5	2010	We examined the effect of 12-(3-hexylureido)dodec-8(Z)-enoic acid, an EET agonist, on MSC-derived adipocytes and demonstrated an increased number of healthy small adipocytes, attenuated fatty acid synthase (FAS) levels (P &lt; 0.01), and reduced PPARgamma, C/EBPalpha, FAS, and lipid accumulation (P &lt; 0.05).	12-(3-hexylureido)dodec-8(Z)-enoic acid	26-65	CCAAT enhancer binding protein alpha	Homo sapiens	257-267
20817090-9	2010	Since the placenta is rich in C/EBPalpha, the findings underscore the multiplicity of mechanisms by which the FRalpha gene is under the exquisite control of steroid hormones.	Steroids	157-173	CCAAT enhancer binding protein alpha	Homo sapiens	30-40
20659895-6	2010	C/EBPalpha activation induced changes in the expression of more cell cycle- and apoptosis-related genes than the other proteins and enhanced Imatinib-induced apoptosis of K562 cells.	Imatinib Mesylate	141-149	CCAAT enhancer binding protein alpha	Homo sapiens	0-10
20624854-7	2010	Mechanistic studies revealed that C/EBPalpha plays an important role in such synergism by directly interacting with PXR; enhancing RIF-mediated recruitment of PXR to the -82T C harboring CYP2B6 promoter; and looping the PXR-bound distal phenobarbital-responsive enhancer module toward the proximal C/EBP binding site.	Phenobarbital	237-250	CCAAT enhancer binding protein alpha	Homo sapiens	34-44
20624854-7	2010	Mechanistic studies revealed that C/EBPalpha plays an important role in such synergism by directly interacting with PXR; enhancing RIF-mediated recruitment of PXR to the -82T C harboring CYP2B6 promoter; and looping the PXR-bound distal phenobarbital-responsive enhancer module toward the proximal C/EBP binding site.	Phenobarbital	237-250	CCAAT enhancer binding protein alpha	Homo sapiens	34-39
19866452-8	2010	Western analysis for proteins which function as TFs in deltanoid-induced monocytic differentiation, such as members of Jun and C/EBP families, surprisingly demonstrated that SIL upregulated all these TFs in the cases tested.	deltanoid	55-64	CCAAT enhancer binding protein alpha	Homo sapiens	127-132
20536385-0	2010	Wild type p53-dependent transcriptional upregulation of cathepsin L expression is mediated by C/EBP&amp;#x03B1; in human glioblastoma cells.	Adenosine Monophosphate	100-103	CCAAT enhancer binding protein alpha	Homo sapiens	94-99
20388794-5	2010	Exogenous PGE2 and EP receptor agonists induced the LANA-1 promoter in 293 cells, and YY1, Sp1, Oct-1, Oct-6, C/EBP, and c-Jun transcription factors seem to be involved in this induction.	Dinoprostone	10-14	CCAAT enhancer binding protein alpha	Homo sapiens	110-115
20416398-9	2010	RT-PCR and Q-rt-PCR analysis revealed that GBx induced hepatic steatosis had significant increases in the expression of lipogenic genes, C/EBP-alpha, SREBP1, ChREBP and PPAR-gamma, which then activate key enzymes of the de novo FA synthesis, ACC1, FAS, SCD1, AGAPT, PAP and DGAT2.	GBX	43-46	CCAAT enhancer binding protein alpha	Homo sapiens	137-148
20146079-6	2010	In addition, C/EBP was upregulated in hepatoma cells after T(3) treatment and ectopic expression of MAT1A inhibited cell migration and invasion in J7 hepatoma cells.	Triiodothyronine	59-63	CCAAT enhancer binding protein alpha	Homo sapiens	13-18
20176111-1	2010	Previously, we identified an arylstibonic acid, NSC13778 that specifically binds to the basic region of the C/EBPalpha B-ZIP domain and disrupts DNA binding.	arylstibonic acid	29-46	CCAAT enhancer binding protein alpha	Homo sapiens	108-118
20032083-0	2010	Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPalpha in human umbilical vein endothelial cells from gestational diabetes.	Nitric Oxide	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	116-126
20179325-5	2010	Using preadipocytes and mesenchymal stem cell models, we show that RA specifically blocks the occupancy of C/EBPbeta of the Cebpa promoter, thereby abrogating the differentiation process.	Tretinoin	67-69	CCAAT enhancer binding protein alpha	Homo sapiens	124-129
20032083-0	2010	Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPalpha in human umbilical vein endothelial cells from gestational diabetes.	Adenosine	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	116-126
20510075-5	2010	The effect of C/EBPalpha overexpression in HL60 cells was assessed by MTT assay, Wright"s staining and flow cytometry before and after NSC67657 transfection.	monooxyethylene trimethylolpropane tristearate	70-73	CCAAT enhancer binding protein alpha	Homo sapiens	14-24
20101026-0	2010	Phosphorylation status of transcription factor C/EBPalpha determines cell-surface poly-LacNAc branching (I antigen) formation in erythropoiesis and granulopoiesis.	poly-lacnac	82-93	CCAAT enhancer binding protein alpha	Homo sapiens	47-57
20101026-4	2010	In the present investigation, the K-562 cell line was used as a model to show that the i-to-I transition is determined by the phosphorylation status of the C/EBPalpha Ser-21 residue, with dephosphorylated C/EBPalpha Ser-21 stimulating the transcription of the IGnTC gene, consequently resulting in I branching.	Serine	167-170	CCAAT enhancer binding protein alpha	Homo sapiens	156-166
20101026-4	2010	In the present investigation, the K-562 cell line was used as a model to show that the i-to-I transition is determined by the phosphorylation status of the C/EBPalpha Ser-21 residue, with dephosphorylated C/EBPalpha Ser-21 stimulating the transcription of the IGnTC gene, consequently resulting in I branching.	Serine	216-219	CCAAT enhancer binding protein alpha	Homo sapiens	156-166
20101026-6	2010	Taken together, these results demonstrate that the regulation of poly-LacNAc branching (I antigen) formation in erythropoiesis and granulopoiesis share a common mechanism, with dephosphorylation of the Ser-21 residue on C/EBPalpha playing the critical role.	poly-lacnac	65-76	CCAAT enhancer binding protein alpha	Homo sapiens	220-230
20101026-6	2010	Taken together, these results demonstrate that the regulation of poly-LacNAc branching (I antigen) formation in erythropoiesis and granulopoiesis share a common mechanism, with dephosphorylation of the Ser-21 residue on C/EBPalpha playing the critical role.	Serine	202-205	CCAAT enhancer binding protein alpha	Homo sapiens	220-230
20137113-5	2010	It is concluded that during ATRA-induced APL cell differentiation, IRF-1 is first upregulated by ATRA, and then IRF-1 increases the protein levels of IRF-9 and STAT2 with the downregulation of C/EBPalpha.	Tretinoin	28-32	CCAAT enhancer binding protein alpha	Homo sapiens	193-203
20038735-1	2010	PURPOSE: CEBPA mutations are found as either biallelic (biCEBPA) or monoallelic (moCEBPA).	bicebpa	56-63	CCAAT enhancer binding protein alpha	Homo sapiens	9-14
20038735-1	2010	PURPOSE: CEBPA mutations are found as either biallelic (biCEBPA) or monoallelic (moCEBPA).	mocebpa	81-88	CCAAT enhancer binding protein alpha	Homo sapiens	9-14
19759245-6	2009	1,2-DT (100 micromol/L) significantly reduced gene expression of PPARgamma2 (-40%), CCAAT/enhancer binding protein-alpha (-25%), lipoprotein lipase (-22%), leptin (-30%), and adiponectin (-15%).	1,2-dt	0-6	CCAAT enhancer binding protein alpha	Homo sapiens	84-120
19800867-6	2009	Overexpression of miR-27b blunted induction of PPARgamma and C/EBPalpha, two key regulators of adipogenesis, during early onset of adipogenesis and repressed adipogenic marker gene expression and triglyceride accumulation at late stages.	Triglycerides	196-208	CCAAT enhancer binding protein alpha	Homo sapiens	61-71
19019668-9	2009	In contrast, 10,12 CLA increased calcium deposition ( approximately 12-60%), ALP activity ( approximately 2.1-fold) and the expression of Wnt10b ( approximately 60-80%) and osteocalcin ( approximately 90%), but decreased oil red O staining ( approximately 30%) and the expression of C/EBPalpha ( approximately 24-38%) and PPARgamma ( approximately 60%) (P&lt;.05).	Linoleic Acids, Conjugated	19-22	CCAAT enhancer binding protein alpha	Homo sapiens	283-293
19617893-6	2009	The in vitro effect of ethanol on the expression of C/EBP alpha, beta and delta was studied in HepG2 cells.	Ethanol	23-30	CCAAT enhancer binding protein alpha	Homo sapiens	52-63
19939245-6	2009	RESULTS: We found that Forskolin increased MMP-2 mRNA in JAR cells within 24 hours, and induced binding to p53, Ets, C/EBP and AP-2.	Colforsin	23-32	CCAAT enhancer binding protein alpha	Homo sapiens	117-122
19939245-7	2009	Transcription factors Ets-2, phospho- p53, C/EBP epsilon, C/EBP lambda and AP-2 alpha bound to their respective binding sequences in response to Forskolin and the expressions of these transcription factors were all elevated in Forskolin- treated cells.	Colforsin	145-154	CCAAT enhancer binding protein alpha	Homo sapiens	43-48
19553330-0	2009	Dexamethasone treatment of calves latently infected with bovine herpesvirus 1 leads to activation of the bICP0 early promoter, in part by the cellular transcription factor C/EBP-alpha.	Dexamethasone	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	172-183
19553330-8	2009	Expression of a cellular transcription factor, C/EBP-alpha, was stimulated by DEX, and C/EBP-alpha expression was necessary for DEX induction of bICP0 early promoter activity.	Dexamethasone	78-81	CCAAT enhancer binding protein alpha	Homo sapiens	47-58
19553330-8	2009	Expression of a cellular transcription factor, C/EBP-alpha, was stimulated by DEX, and C/EBP-alpha expression was necessary for DEX induction of bICP0 early promoter activity.	Dexamethasone	128-131	CCAAT enhancer binding protein alpha	Homo sapiens	87-98
19544470-0	2009	p38 MAP kinase inhibits neutrophil development through phosphorylation of C/EBPalpha on serine 21.	Serine	88-94	CCAAT enhancer binding protein alpha	Homo sapiens	74-84
19544470-6	2009	Inhibitory phosphorylation of CCAAT/enhancer binding protein alpha (C/EBPalpha) on serine 21 was induced upon activation of p38MAPK.	Serine	83-89	CCAAT enhancer binding protein alpha	Homo sapiens	30-66
19544470-6	2009	Inhibitory phosphorylation of CCAAT/enhancer binding protein alpha (C/EBPalpha) on serine 21 was induced upon activation of p38MAPK.	Serine	83-89	CCAAT enhancer binding protein alpha	Homo sapiens	68-78
19939245-7	2009	Transcription factors Ets-2, phospho- p53, C/EBP epsilon, C/EBP lambda and AP-2 alpha bound to their respective binding sequences in response to Forskolin and the expressions of these transcription factors were all elevated in Forskolin- treated cells.	Colforsin	227-236	CCAAT enhancer binding protein alpha	Homo sapiens	43-48
19581927-4	2009	Electrophoretic mobility shift assay (EMSA) analysis of nuclear extracts prepared from ultraviolet B (UVB)- and N-methyl-N"-nitro-N-nitrosoguanidine (MNNG)-treated fibroblasts showed increased binding of C/EBPbeta to a C/EBP consensus sequence and chromatin immunoprecipitation (ChIP) analysis also showed increased C/EBPbeta binding to the C/EBPalpha promoter.	Methylnitronitrosoguanidine	112-148	CCAAT enhancer binding protein alpha	Homo sapiens	204-209
19581927-4	2009	Electrophoretic mobility shift assay (EMSA) analysis of nuclear extracts prepared from ultraviolet B (UVB)- and N-methyl-N"-nitro-N-nitrosoguanidine (MNNG)-treated fibroblasts showed increased binding of C/EBPbeta to a C/EBP consensus sequence and chromatin immunoprecipitation (ChIP) analysis also showed increased C/EBPbeta binding to the C/EBPalpha promoter.	Methylnitronitrosoguanidine	112-148	CCAAT enhancer binding protein alpha	Homo sapiens	341-351
19586877-8	2009	These results suggest that rosiglitazone has a promotive effect on PPARgamma and C/EBPalpha.	Rosiglitazone	27-40	CCAAT enhancer binding protein alpha	Homo sapiens	81-91
19662097-8	2009	Additionally, silencing of C/EBPalpha expression by small interfering RNAs enhanced, while inducible expression of C/EBPalpha inhibited NSC606985/etoposide-induced apoptosis in leukemic cells.	Etoposide	146-155	CCAAT enhancer binding protein alpha	Homo sapiens	115-125
19545899-7	2009	Finally, we demonstrated that transcription factors CREB-1 and C/EBPalpha and C/EBPbeta are translocated to the nucleus following PGE(2) stimulation and bind the potent CCR7 promoter region.	Prostaglandins E	130-133	CCAAT enhancer binding protein alpha	Homo sapiens	63-73
18789670-4	2009	Octanoate and decanoate up-regulated the mRNA expression of peroxisome-proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, fatty-acid-binding protein, sterol-regulatory element binding protein 1c, lipoprotein lipase and hormone-sensitive lipase, and the protein expression of PPARgamma and C/EBPalpha, with decanoate being more effective.	octanoic acid	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	149-161
18789670-4	2009	Octanoate and decanoate up-regulated the mRNA expression of peroxisome-proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, fatty-acid-binding protein, sterol-regulatory element binding protein 1c, lipoprotein lipase and hormone-sensitive lipase, and the protein expression of PPARgamma and C/EBPalpha, with decanoate being more effective.	octanoic acid	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	330-340
18789670-4	2009	Octanoate and decanoate up-regulated the mRNA expression of peroxisome-proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, fatty-acid-binding protein, sterol-regulatory element binding protein 1c, lipoprotein lipase and hormone-sensitive lipase, and the protein expression of PPARgamma and C/EBPalpha, with decanoate being more effective.	Decanoates	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	149-161
19287338-4	2009	In this review, we discuss transcription factors whose activity is regulated by oxygen, including nuclear factor, erythroid 2-related factor 2 (Nrf2), activator protein 1 (AP-1), p53, nuclear factor kappaB (NF-kappaB), signal transducers and activators of transcription protein (STAT), and ccat/enhancer binding protein (CEBP).	Oxygen	80-86	CCAAT enhancer binding protein alpha	Homo sapiens	290-319
19287338-4	2009	In this review, we discuss transcription factors whose activity is regulated by oxygen, including nuclear factor, erythroid 2-related factor 2 (Nrf2), activator protein 1 (AP-1), p53, nuclear factor kappaB (NF-kappaB), signal transducers and activators of transcription protein (STAT), and ccat/enhancer binding protein (CEBP).	Oxygen	80-86	CCAAT enhancer binding protein alpha	Homo sapiens	321-325
19662097-4	2009	METHODOLOGY/PRINCIPAL FINDINGS: Upon onset of apoptosis induced by various kinds of inducers such as NSC606985, etoposide and others, C/EBPalpha expression presented a profound down-regulation in leukemic cell lines and primary cells via induction of protein degradation and inhibition of transcription, as assessed respectively by cycloheximide inhibition test, real-time quantitative RT-PCR and luciferase reporter assay.	Etoposide	112-121	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
19662097-4	2009	METHODOLOGY/PRINCIPAL FINDINGS: Upon onset of apoptosis induced by various kinds of inducers such as NSC606985, etoposide and others, C/EBPalpha expression presented a profound down-regulation in leukemic cell lines and primary cells via induction of protein degradation and inhibition of transcription, as assessed respectively by cycloheximide inhibition test, real-time quantitative RT-PCR and luciferase reporter assay.	Cycloheximide	332-345	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
19332118-0	2009	Oleic acid inhibits hepatic insulin signaling through deregulation of STAT3 activation and C/EBPalpha expression.	Oleic Acid	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	91-101
19332118-5	2009	Moreover, oleic acid enhanced the phosphorylation of signal transducer and activator of transcription (STAT) 3 and induced the expression of CCAAT/enhancer-binding protein alpha (C/EBPalpha).	Oleic Acid	10-20	CCAAT enhancer binding protein alpha	Homo sapiens	141-177
19332118-5	2009	Moreover, oleic acid enhanced the phosphorylation of signal transducer and activator of transcription (STAT) 3 and induced the expression of CCAAT/enhancer-binding protein alpha (C/EBPalpha).	Oleic Acid	10-20	CCAAT enhancer binding protein alpha	Homo sapiens	179-189
19332118-6	2009	The interaction between STAT3 and C/EBPalpha was increased by oleic acid; these proteins subsequently enhanced the promoter activity of SOCS3 in the presence of oleic acid.	Oleic Acid	62-72	CCAAT enhancer binding protein alpha	Homo sapiens	34-44
19332118-6	2009	The interaction between STAT3 and C/EBPalpha was increased by oleic acid; these proteins subsequently enhanced the promoter activity of SOCS3 in the presence of oleic acid.	Oleic Acid	161-171	CCAAT enhancer binding protein alpha	Homo sapiens	34-44
19075268-2	2009	The differentiation-inducing transcription factor CCAAT enhancer binding protein alpha (C/EBPalpha) is required for proper control of adipogenesis, glucose metabolism, granulocytic differentiation, and lung development.	Glucose	148-155	CCAAT enhancer binding protein alpha	Homo sapiens	50-86
18789670-4	2009	Octanoate and decanoate up-regulated the mRNA expression of peroxisome-proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, fatty-acid-binding protein, sterol-regulatory element binding protein 1c, lipoprotein lipase and hormone-sensitive lipase, and the protein expression of PPARgamma and C/EBPalpha, with decanoate being more effective.	Decanoates	14-23	CCAAT enhancer binding protein alpha	Homo sapiens	330-340
19035457-5	2009	Oligonucleotide microarray analysis revealed that 30 genes including UCHL1, C/EBPalpha, TIMP2 and IRF7 were up-regulated after treatment with 5Aza-dC and SAHA in PANC-1.	Decitabine	142-149	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
19035457-5	2009	Oligonucleotide microarray analysis revealed that 30 genes including UCHL1, C/EBPalpha, TIMP2 and IRF7 were up-regulated after treatment with 5Aza-dC and SAHA in PANC-1.	Vorinostat	154-158	CCAAT enhancer binding protein alpha	Homo sapiens	76-86
19035457-8	2009	Chromatin immunoprecipitation assay revealed that histone H3 of the promoter region of C/EBPalpha was acetylated in PANC-1 treated with SAHA; and bisulfate sequencing showed methylation of its promoter region in several pancreatic cancer cell lines.	Vorinostat	136-140	CCAAT enhancer binding protein alpha	Homo sapiens	87-97
19035457-8	2009	Chromatin immunoprecipitation assay revealed that histone H3 of the promoter region of C/EBPalpha was acetylated in PANC-1 treated with SAHA; and bisulfate sequencing showed methylation of its promoter region in several pancreatic cancer cell lines.	hydrogen sulfate	146-155	CCAAT enhancer binding protein alpha	Homo sapiens	87-97
19075268-2	2009	The differentiation-inducing transcription factor CCAAT enhancer binding protein alpha (C/EBPalpha) is required for proper control of adipogenesis, glucose metabolism, granulocytic differentiation, and lung development.	Glucose	148-155	CCAAT enhancer binding protein alpha	Homo sapiens	88-98
19054766-0	2009	CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.	Calcitriol	62-86	CCAAT enhancer binding protein alpha	Homo sapiens	0-36
19059241-4	2009	Butyrate, an intestinal differentiation inducer, increased the protein interaction of CDX1 and C/EBPalpha, thereby resulting in a significant increase in PPARgamma expression.	Butyrates	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	95-105
18765514-0	2008	CCAAT/enhancer binding protein alpha (C/EBPalpha) in adipose tissue regulates genes in lipid and glucose metabolism and a genetic variation in C/EBPalpha is associated with serum levels of triglycerides.	Triglycerides	189-202	CCAAT enhancer binding protein alpha	Homo sapiens	0-36
18801408-4	2008	DHT (0-30 nM) dose-dependently inhibited lipid accumulation in adipocytes differentiated from hMSCs and downregulated expression of aP2, PPARgamma, leptin, and C/EBPalpha.	Dihydrotestosterone	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	160-170
18776924-4	2008	Retinoic acid (RA) induced monocytic differentiation in the myelomonocytic cell lines with MLL-fusion genes, THP-1, MOLM-14 and HF-6 cells, accompanied by monocytic differentiation with the upregulation of C/EBPalpha and C/EBPepsilon.	Tretinoin	15-17	CCAAT enhancer binding protein alpha	Homo sapiens	206-216
18765514-10	2008	CONCLUSIONS: Adipose tissue C/EBPalpha regulates several genes in glucose and lipid metabolism, and a genetic variation in C/EBPalpha is associated with triglycerides in two independent populations.	Glucose	66-73	CCAAT enhancer binding protein alpha	Homo sapiens	28-38
18765514-10	2008	CONCLUSIONS: Adipose tissue C/EBPalpha regulates several genes in glucose and lipid metabolism, and a genetic variation in C/EBPalpha is associated with triglycerides in two independent populations.	Triglycerides	153-166	CCAAT enhancer binding protein alpha	Homo sapiens	123-133
18757096-2	2009	In hematopoietic tumor cell lines, CpG island hypermethylation of the proximal C/EBPalpha promoter region was associated with transcriptional silencing, and treatment with the demethylating agent 5-aza-2"-deoxycytidine resulted in C/EBPalpha reexpression and promoter demethylation.	Decitabine	196-218	CCAAT enhancer binding protein alpha	Homo sapiens	79-89
18757096-2	2009	In hematopoietic tumor cell lines, CpG island hypermethylation of the proximal C/EBPalpha promoter region was associated with transcriptional silencing, and treatment with the demethylating agent 5-aza-2"-deoxycytidine resulted in C/EBPalpha reexpression and promoter demethylation.	Decitabine	196-218	CCAAT enhancer binding protein alpha	Homo sapiens	231-241
19149928-11	2009	Ghrelin of 10(-11) mol/L significantly increased the mRNA expression of PPARgamma and C/EBPalpha in the course of 3T3-L1 preadipocyte differentiation, compared with the normal control group (p&lt;0.05).	Ghrelin	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	86-96
19149928-12	2009	The PPARgamma and C/EBPalpha mRNA expression increased with the prolonged differentiation of preadipocytes induced by ghrelin or INS.	Ghrelin	118-125	CCAAT enhancer binding protein alpha	Homo sapiens	18-28
19149928-16	2009	Ghrelin may promote differentiation of 3T3-L1 preadipocytes by increasing mRNA expression of PPARgamma and C/EBPalpha, thus enhances the sensitivity of adipocytes to INS.	Ghrelin	0-7	CCAAT enhancer binding protein alpha	Homo sapiens	107-117
18801408-8	2008	DHT also inhibited lipid accumulation and downregulated aP2 and C/EBPalpha in human subcutaneous, mesenteric and omental preadipocytes.	Dihydrotestosterone	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	64-74
18776924-4	2008	Retinoic acid (RA) induced monocytic differentiation in the myelomonocytic cell lines with MLL-fusion genes, THP-1, MOLM-14 and HF-6 cells, accompanied by monocytic differentiation with the upregulation of C/EBPalpha and C/EBPepsilon.	Tretinoin	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	206-216
18355828-3	2008	Cilostazol-induced 3T3-L1 fibroblast differentiation into adipocytes in concert with increases in expression of PPARgamma responsive genes such as CCAAT enhancer binding protein alpha (C-EBPalpha), aP2, which were accompanied by increased adiponectin and decreased resistin expressions as did rosiglitazone.	Cilostazol	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	147-183
18355828-3	2008	Cilostazol-induced 3T3-L1 fibroblast differentiation into adipocytes in concert with increases in expression of PPARgamma responsive genes such as CCAAT enhancer binding protein alpha (C-EBPalpha), aP2, which were accompanied by increased adiponectin and decreased resistin expressions as did rosiglitazone.	Cilostazol	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	185-195
18355828-3	2008	Cilostazol-induced 3T3-L1 fibroblast differentiation into adipocytes in concert with increases in expression of PPARgamma responsive genes such as CCAAT enhancer binding protein alpha (C-EBPalpha), aP2, which were accompanied by increased adiponectin and decreased resistin expressions as did rosiglitazone.	Rosiglitazone	293-306	CCAAT enhancer binding protein alpha	Homo sapiens	147-183
18355828-3	2008	Cilostazol-induced 3T3-L1 fibroblast differentiation into adipocytes in concert with increases in expression of PPARgamma responsive genes such as CCAAT enhancer binding protein alpha (C-EBPalpha), aP2, which were accompanied by increased adiponectin and decreased resistin expressions as did rosiglitazone.	Rosiglitazone	293-306	CCAAT enhancer binding protein alpha	Homo sapiens	185-195
18765514-0	2008	CCAAT/enhancer binding protein alpha (C/EBPalpha) in adipose tissue regulates genes in lipid and glucose metabolism and a genetic variation in C/EBPalpha is associated with serum levels of triglycerides.	Triglycerides	189-202	CCAAT enhancer binding protein alpha	Homo sapiens	38-48
18765514-0	2008	CCAAT/enhancer binding protein alpha (C/EBPalpha) in adipose tissue regulates genes in lipid and glucose metabolism and a genetic variation in C/EBPalpha is associated with serum levels of triglycerides.	Triglycerides	189-202	CCAAT enhancer binding protein alpha	Homo sapiens	143-153
18583320-0	2008	Cyclic adenosine 3",5"-monophosphate response element-binding protein and CCAAT/enhancer-binding protein mediate prostaglandin E2-induced steroidogenic acute regulatory protein expression in endometriotic stromal cells.	Dinoprostone	113-129	CCAAT enhancer binding protein alpha	Homo sapiens	74-104
18702507-3	2008	We found that on each strand of the C/EBP site, the wt bZIP recognizes two 4 bp subsites, TTGC and TGCG, which overlap to form the effective 5 bp half-site (TTGCG).	ttgcg	157-162	CCAAT enhancer binding protein alpha	Homo sapiens	36-41
18461556-5	2008	Significantly, we demonstrate that the shRNA-mediated knockdown of endogenous HIF-1alpha expression attenuates the PGF2alpha-induced expression of DEC1, overcomes the inhibitory effects of PGF2alpha on the expression of proadipogenic transcription factors C/EBPalpha and PPARgamma and partially rescues the PGF2alpha-induced inhibition of adipogenesis.	Dinoprost	115-124	CCAAT enhancer binding protein alpha	Homo sapiens	256-266
18583320-4	2008	A promoter activity assay revealed that the cis-element needed for the binding of the CCAAT/enhancer-binding protein (C/EBP) was critical for PGE(2)-induced StAR expression.	Dinoprostone	142-148	CCAAT enhancer binding protein alpha	Homo sapiens	86-116
18583320-4	2008	A promoter activity assay revealed that the cis-element needed for the binding of the CCAAT/enhancer-binding protein (C/EBP) was critical for PGE(2)-induced StAR expression.	Dinoprostone	142-148	CCAAT enhancer binding protein alpha	Homo sapiens	118-123
18362203-5	2008	The consensus sites for C/EBP in the Cox-2 promoter were essential for transcriptional activation of Cox-2 by LPA.	lysophosphatidic acid	110-113	CCAAT enhancer binding protein alpha	Homo sapiens	24-29
18406180-7	2008	In addition to phosphorylation, C/EBP alpha is modified, post-translationally by a small ubiquitin-related modifier (SUMO) at a lysine residue (K159), which lies within the growth inhibitory region of the C/EBP alpha protein.	Lysine	128-134	CCAAT enhancer binding protein alpha	Homo sapiens	32-43
18406180-7	2008	In addition to phosphorylation, C/EBP alpha is modified, post-translationally by a small ubiquitin-related modifier (SUMO) at a lysine residue (K159), which lies within the growth inhibitory region of the C/EBP alpha protein.	Lysine	128-134	CCAAT enhancer binding protein alpha	Homo sapiens	205-216
18467525-5	2008	We demonstrate in vivo C/EBPbeta binding to C/EBP and cAMP response element sites in the PGC-1alpha promoter and show that the C/EBP site is essential for PGC-1alpha activation.	Cyclic AMP	54-58	CCAAT enhancer binding protein alpha	Homo sapiens	23-28
18405381-3	2008	RESULTS: Here, we report that granulocytic differentiation of human PLB-985 cells with DMSO yields cells that are neutrophil-like with respect to surface markers, acquisition of responsiveness to physiological neutrophil stimuli (fMLP, LPS), cytokine expression and production profile, and transcription factor activation profile (NF-kappaB, C/EBP, AP-1, STAT).	Dimethyl Sulfoxide	87-91	CCAAT enhancer binding protein alpha	Homo sapiens	342-347
18302931-4	2008	In this study, using beta-estradiol inducible stable cell lines we show that the point mutation of phosphorylation site S248 in C/EBP disrupts the CD11b and GCSFr expression and subsequently reduces the differentiation of leukemic K562 cells.	Estradiol	21-35	CCAAT enhancer binding protein alpha	Homo sapiens	128-133
18381421-7	2008	Immunocytochemical analysis showed that C/EBP alpha was localized in the nucleus at 21% O(2), but was mostly cytoplasmic under 1% O(2).	o(2)	88-92	CCAAT enhancer binding protein alpha	Homo sapiens	40-51
18226606-6	2008	At the same time, increases in the activating transcription factor-4 and C/EBP homologous protein and reduction in procaspase 12 levels indicated activation of the endoplasmic reticulum (ER) pathway in the arsenite-induced cytotoxicity in DRG explants.	arsenite	206-214	CCAAT enhancer binding protein alpha	Homo sapiens	73-78
18381421-7	2008	Immunocytochemical analysis showed that C/EBP alpha was localized in the nucleus at 21% O(2), but was mostly cytoplasmic under 1% O(2).	o(2)	130-134	CCAAT enhancer binding protein alpha	Homo sapiens	40-51
17493651-5	2007	These actions of EGCG are mediated via activation of a nPKC, Ras, MEKK1, MEK3, p38delta-ERK1/2 signaling cascade which leads to increased activator protein 1 (AP1) and CAATT enhancer binding protein (C/EBP) transcription factor expression, increased binding of these factors to DNA, and increased gene transcription.	epigallocatechin gallate	17-21	CCAAT enhancer binding protein alpha	Homo sapiens	168-198
18195020-9	2008	In summary, our findings constitute the first description of an EPAC-C/EBP pathway that can control cAMP-mediated changes in gene expression independently of protein kinase A.	Cyclic AMP	100-104	CCAAT enhancer binding protein alpha	Homo sapiens	69-74
18182446-6	2008	Reporter constructs of promoter I.3/II deletion and site-directed mutants with selective disruption of cis-regulatory elements in the -517/-16 bp region revealed that five out of seven elements, including three CCAAT/enhancer binding protein (C/EBP) binding sites and two cAMP response elements, were essential for cAMP-induced promoter activity.	Cyclic AMP	272-276	CCAAT enhancer binding protein alpha	Homo sapiens	211-241
18182446-6	2008	Reporter constructs of promoter I.3/II deletion and site-directed mutants with selective disruption of cis-regulatory elements in the -517/-16 bp region revealed that five out of seven elements, including three CCAAT/enhancer binding protein (C/EBP) binding sites and two cAMP response elements, were essential for cAMP-induced promoter activity.	Cyclic AMP	272-276	CCAAT enhancer binding protein alpha	Homo sapiens	243-248
18182446-6	2008	Reporter constructs of promoter I.3/II deletion and site-directed mutants with selective disruption of cis-regulatory elements in the -517/-16 bp region revealed that five out of seven elements, including three CCAAT/enhancer binding protein (C/EBP) binding sites and two cAMP response elements, were essential for cAMP-induced promoter activity.	Cyclic AMP	315-319	CCAAT enhancer binding protein alpha	Homo sapiens	211-241
18182446-6	2008	Reporter constructs of promoter I.3/II deletion and site-directed mutants with selective disruption of cis-regulatory elements in the -517/-16 bp region revealed that five out of seven elements, including three CCAAT/enhancer binding protein (C/EBP) binding sites and two cAMP response elements, were essential for cAMP-induced promoter activity.	Cyclic AMP	315-319	CCAAT enhancer binding protein alpha	Homo sapiens	243-248
18024476-4	2008	Glutathione S-transferase pull-down assay proposed that the protein-protein interaction was direct, and transactivation domains of C/EBPalpha and the basic helix-loop-helix domain of HIF-1alpha were essential for such an interaction.	Glutathione	0-11	CCAAT enhancer binding protein alpha	Homo sapiens	131-141
18172087-15	2008	Expression of C/EBPalpha and C/EBPbeta, downstream of the p38 MAPK signaling pathway, was strongly induced by airlift culture and partially was inhibited by SB203580.	SB 203580	157-165	CCAAT enhancer binding protein alpha	Homo sapiens	14-24
18077580-8	2007	In the ER pathway, NAC suppressed arsenite-induced increases in activating transcription factor 6 and C/EBP homologous protein in the nuclear fraction.	Acetylcysteine	19-22	CCAAT enhancer binding protein alpha	Homo sapiens	102-107
18077580-8	2007	In the ER pathway, NAC suppressed arsenite-induced increases in activating transcription factor 6 and C/EBP homologous protein in the nuclear fraction.	arsenite	34-42	CCAAT enhancer binding protein alpha	Homo sapiens	102-107
17671235-2	2007	Here we assessed the effects of CDDO on CCAAT enhancer-binding protein alpha (CEBPA), a transcription factor critical for granulocytic differentiation.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	32-36	CCAAT enhancer binding protein alpha	Homo sapiens	40-76
17671235-2	2007	Here we assessed the effects of CDDO on CCAAT enhancer-binding protein alpha (CEBPA), a transcription factor critical for granulocytic differentiation.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	32-36	CCAAT enhancer binding protein alpha	Homo sapiens	78-83
17671235-4	2007	Conversely, subapoptotic doses of CDDO promote phagocytic activity and granulocytic-monocytic differentiation of HL60 cells through increased de novo synthesis of p42 CEBPA protein.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	34-38	CCAAT enhancer binding protein alpha	Homo sapiens	167-172
17671235-5	2007	CEBPA translational up-regulation is required for CDDO-induced granulocytic differentiation and depends on the integrity of the CEBPA upstream open reading frame (uORF).	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	50-54	CCAAT enhancer binding protein alpha	Homo sapiens	0-5
17671235-6	2007	Moreover, CDDO increases the ratio of transcriptionally active p42 and the inactive p30 CEBPA isoform, which, in turn, leads to transcriptional activation of CEBPA-regulated genes (eg, GSCFR) and is associated with dephosphorylation of eIF2alpha and phosphorylation of eIF4E.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	10-14	CCAAT enhancer binding protein alpha	Homo sapiens	88-93
17671235-6	2007	Moreover, CDDO increases the ratio of transcriptionally active p42 and the inactive p30 CEBPA isoform, which, in turn, leads to transcriptional activation of CEBPA-regulated genes (eg, GSCFR) and is associated with dephosphorylation of eIF2alpha and phosphorylation of eIF4E.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	10-14	CCAAT enhancer binding protein alpha	Homo sapiens	158-163
17671235-7	2007	In concordance with these results, CDDO induces a CEBPA ratio change and differentiation of primary blasts from patients with acute myeloid leukemia (AML).	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	35-39	CCAAT enhancer binding protein alpha	Homo sapiens	50-55
17951535-7	2007	Moreover, chromatin immunoprecipitation assay and electrophoretic mobility shift assay showed that GR and C/EBPalpha but not C/EBPbeta could bind this promoter region upon cortisol stimulation of amnion fibroblasts.	Hydrocortisone	172-180	CCAAT enhancer binding protein alpha	Homo sapiens	106-116
17951535-8	2007	In conclusion, we demonstrated that GR and C/EBPalpha were involved in cortisol-induced 11beta-HSD1 mRNA expression via binding to 11beta-HSD1 promoter in amnion fibroblasts, which may cast a feed-forward production of cortisol in the fetal membranes at the end of gestation.	Hydrocortisone	71-79	CCAAT enhancer binding protein alpha	Homo sapiens	43-53
17951535-8	2007	In conclusion, we demonstrated that GR and C/EBPalpha were involved in cortisol-induced 11beta-HSD1 mRNA expression via binding to 11beta-HSD1 promoter in amnion fibroblasts, which may cast a feed-forward production of cortisol in the fetal membranes at the end of gestation.	Hydrocortisone	219-227	CCAAT enhancer binding protein alpha	Homo sapiens	43-53
18247123-7	2008	Similarly, the C/EBP-beta isoform liver activating protein and C/EBP-delta-induced C3 promoter activity were upregulated by morphine and IL-1beta.	Morphine	124-132	CCAAT enhancer binding protein alpha	Homo sapiens	15-20
18060476-6	2008	Both LY294002 and rapamycin severely suppressed lipid accumulation, as well as the expression of adipogenic markers, including PPAR gamma 2 and C/EBP alpha, two master adipogenic transcription factors.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	5-13	CCAAT enhancer binding protein alpha	Homo sapiens	144-155
19088398-2	2008	All-trans retinoic acid (RA) induced expression of osteoblast-specific mRNAs encoding Cbfa1/Runx2, osterix, alkaline phosphatase, osteopontin, parathyroid hormone receptor, and osteocalcin in the DFAT cells, but did not induce the expression of adipocyte-specific mRNAs encoding PPARgamma2, C/EBPalpha, and GLUT4.	Tretinoin	10-23	CCAAT enhancer binding protein alpha	Homo sapiens	291-301
18444174-8	2008	Using transient transfections, UDCA inhibited Cox-2 promoter and C/EBP reporter activation by DCA.	Deoxycholic Acid	32-35	CCAAT enhancer binding protein alpha	Homo sapiens	65-70
17493651-5	2007	These actions of EGCG are mediated via activation of a nPKC, Ras, MEKK1, MEK3, p38delta-ERK1/2 signaling cascade which leads to increased activator protein 1 (AP1) and CAATT enhancer binding protein (C/EBP) transcription factor expression, increased binding of these factors to DNA, and increased gene transcription.	epigallocatechin gallate	17-21	CCAAT enhancer binding protein alpha	Homo sapiens	200-205
17880164-6	2007	o-Coumaric acid and rutin also inhibited the expression of PPARgamma, C/EBPalpha and leptin and then up-regulated expression of adiponectin at the protein level.	2-hydroxycinnamic acid	0-15	CCAAT enhancer binding protein alpha	Homo sapiens	70-80
17880164-6	2007	o-Coumaric acid and rutin also inhibited the expression of PPARgamma, C/EBPalpha and leptin and then up-regulated expression of adiponectin at the protein level.	Rutin	20-25	CCAAT enhancer binding protein alpha	Homo sapiens	70-80
17513780-6	2007	Such treated nuclei contain only C/EBPzeta (also known as CHOP10 and GADD153) because the C/EBP-binding consensus oligonucleotide binds to all C/EBP family proteins except C/EBPzeta.	Oligonucleotides	114-129	CCAAT enhancer binding protein alpha	Homo sapiens	90-95
17716978-0	2007	Tamoxifen induction of CCAAT enhancer-binding protein alpha is required for tamoxifen-induced apoptosis.	Tamoxifen	0-9	CCAAT enhancer binding protein alpha	Homo sapiens	23-59
17716978-0	2007	Tamoxifen induction of CCAAT enhancer-binding protein alpha is required for tamoxifen-induced apoptosis.	Tamoxifen	76-85	CCAAT enhancer binding protein alpha	Homo sapiens	23-59
17513780-5	2007	Accordingly, we treated Hep3B nuclear extract with a C/EBP-binding consensus oligonucleotide to generate an extract lacking active C/EBPbeta.	Oligonucleotides	77-92	CCAAT enhancer binding protein alpha	Homo sapiens	53-58
17372916-5	2007	LY294002 and wortmannin, specific inhibitors of PI3 kinase, and PD98059, a specific inhibitor of mitogen-activated protein (MAP) kinase, were used to examine the signaling pathway of C/EBPalpha upregulated by IGF-II.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	183-193
17372916-5	2007	LY294002 and wortmannin, specific inhibitors of PI3 kinase, and PD98059, a specific inhibitor of mitogen-activated protein (MAP) kinase, were used to examine the signaling pathway of C/EBPalpha upregulated by IGF-II.	Wortmannin	13-23	CCAAT enhancer binding protein alpha	Homo sapiens	183-193
17372916-5	2007	LY294002 and wortmannin, specific inhibitors of PI3 kinase, and PD98059, a specific inhibitor of mitogen-activated protein (MAP) kinase, were used to examine the signaling pathway of C/EBPalpha upregulated by IGF-II.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	64-71	CCAAT enhancer binding protein alpha	Homo sapiens	183-193
17372916-7	2007	Actinomycin D was used to analyze half-life of C/EBPalpha mRNA.	Dactinomycin	0-13	CCAAT enhancer binding protein alpha	Homo sapiens	47-57
17372916-11	2007	LY294002 and wortmannin suppressed expression of C/EBPalpha.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	49-59
17372916-11	2007	LY294002 and wortmannin suppressed expression of C/EBPalpha.	Wortmannin	13-23	CCAAT enhancer binding protein alpha	Homo sapiens	49-59
17372916-13	2007	LY294002 and wortmannin suppressed the promoter activity of C/EBPalpha while PD98059 did not, suggesting that activation of the promoter was mediated by PI3 kinase.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	60-70
17372916-13	2007	LY294002 and wortmannin suppressed the promoter activity of C/EBPalpha while PD98059 did not, suggesting that activation of the promoter was mediated by PI3 kinase.	Wortmannin	13-23	CCAAT enhancer binding protein alpha	Homo sapiens	60-70
17712722-6	2007	The induction of CCAAT/enhancer binding protein alpha was reduced by 37% (p&lt;0.05), correlating with a similar reduction in insulin-stimulated IRS-1 tyrosine phosphorylation and glucose transport in DDR2-L1 adipocytes (decreases of 22% and 27%, respectively; p&lt;0.05 for both).	Tyrosine	151-159	CCAAT enhancer binding protein alpha	Homo sapiens	17-53
17712722-6	2007	The induction of CCAAT/enhancer binding protein alpha was reduced by 37% (p&lt;0.05), correlating with a similar reduction in insulin-stimulated IRS-1 tyrosine phosphorylation and glucose transport in DDR2-L1 adipocytes (decreases of 22% and 27%, respectively; p&lt;0.05 for both).	Glucose	180-187	CCAAT enhancer binding protein alpha	Homo sapiens	17-53
17657426-7	2007	The processes of induction of long-term facilitation in the sensory inputs of neurons from chemoreceptors on the head have been shown to involve cAMP and cAMP-dependent transcription factors of the immediate early gene C/EBP (CAAT/enhancer binding protein), while the mechanisms controlling the other sensory input of neurons LPl1 and RPl1--from mechanoreceptors on the head--involve protein kinase C and protein kinase C-dependent transcription factor SRF (serum response factor).	Cyclic AMP	145-149	CCAAT enhancer binding protein alpha	Homo sapiens	219-224
17657426-7	2007	The processes of induction of long-term facilitation in the sensory inputs of neurons from chemoreceptors on the head have been shown to involve cAMP and cAMP-dependent transcription factors of the immediate early gene C/EBP (CAAT/enhancer binding protein), while the mechanisms controlling the other sensory input of neurons LPl1 and RPl1--from mechanoreceptors on the head--involve protein kinase C and protein kinase C-dependent transcription factor SRF (serum response factor).	Cyclic AMP	145-149	CCAAT enhancer binding protein alpha	Homo sapiens	226-255
17657426-7	2007	The processes of induction of long-term facilitation in the sensory inputs of neurons from chemoreceptors on the head have been shown to involve cAMP and cAMP-dependent transcription factors of the immediate early gene C/EBP (CAAT/enhancer binding protein), while the mechanisms controlling the other sensory input of neurons LPl1 and RPl1--from mechanoreceptors on the head--involve protein kinase C and protein kinase C-dependent transcription factor SRF (serum response factor).	Cyclic AMP	154-158	CCAAT enhancer binding protein alpha	Homo sapiens	219-224
17657426-7	2007	The processes of induction of long-term facilitation in the sensory inputs of neurons from chemoreceptors on the head have been shown to involve cAMP and cAMP-dependent transcription factors of the immediate early gene C/EBP (CAAT/enhancer binding protein), while the mechanisms controlling the other sensory input of neurons LPl1 and RPl1--from mechanoreceptors on the head--involve protein kinase C and protein kinase C-dependent transcription factor SRF (serum response factor).	Cyclic AMP	154-158	CCAAT enhancer binding protein alpha	Homo sapiens	226-255
17595889-0	2007	Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion.	Rosuvastatin Calcium	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	113-118
17595889-11	2007	Rosuvastatin (1 microM) attenuated the activation of STAT3 and C/EBP by 48% and 54%, respectively.	Rosuvastatin Calcium	0-12	CCAAT enhancer binding protein alpha	Homo sapiens	63-68
17347301-3	2007	Dimerization required the ZIP motif of each protein and redirected DNA binding of C/EBPepsilon and ATF4 from their respective symmetric consensus sites to asymmetric C/EBP and cAMP response element sites.	Cyclic AMP	176-180	CCAAT enhancer binding protein alpha	Homo sapiens	82-87
17255362-6	2007	RelA-C/EBP interaction is enhanced by phosphorylation of threonine at amino acid 75 and results in increased DNA binding compared with the wild-type nonphosphorylated C/EBP both in vitro and in vivo.	Threonine	57-66	CCAAT enhancer binding protein alpha	Homo sapiens	5-10
17395587-8	2007	Salmeterol caused an augmentation of rhinovirus-induced promoter activation via a mechanism dependent upon the c/EBP and/or CRE (cyclic AMP response element) cis-acting sites.	Salmeterol Xinafoate	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	111-116
17255362-6	2007	RelA-C/EBP interaction is enhanced by phosphorylation of threonine at amino acid 75 and results in increased DNA binding compared with the wild-type nonphosphorylated C/EBP both in vitro and in vivo.	Threonine	57-66	CCAAT enhancer binding protein alpha	Homo sapiens	167-172
17349976-0	2007	ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3.	ros	0-3	CCAAT enhancer binding protein alpha	Homo sapiens	70-80
17349976-8	2007	These results suggest that ROS repress the hepcidin gene by preventing C/EBPalpha and STAT-3 binding to hepcidin promoter during hypoxia.	ros	27-30	CCAAT enhancer binding protein alpha	Homo sapiens	71-81
17510391-7	2007	We found a consistently methylated upstream regulatory region (-1,399 bp to -1,253 bp in relation to the transcription start site) in 68% of the HNSCC tumor samples, and DNA demethylation using 5-aza-2"-deoxycytidine treatment was able to significantly restore C/EBPalpha mRNA expression in the HNSCC cell lines we tested.	Decitabine	194-216	CCAAT enhancer binding protein alpha	Homo sapiens	261-271